Additional Information
Book Details
Abstract
The best drug resource for health professionals and health professions students on the market is back! Mosby's Drug Reference for Health Professions, 6th Edition makes it easy to look up the drugs that patients and clients are taking and understand how those drugs may affect treatment. This new edition has been expertly edited to determine which drugs should be retained, excluded and added, allowing for quick access to over 700 concise drug monographs. The newly revised Precautions and Considerations sections contain key information such as storage and administration written specifically for general health professions markets. Packed with practical resources for everyday use, no student or practitioner should be without this portable drug guide!
- Abbreviated drug monographs organized alphabetically by generic name save you time finding need-to-know details for day-to-day practice.
- Precautions and Considerations sections include key information written specifically for health professions students and practitioners.
- Drug storage information identifies those drugs in which extra care is needed to maintain potency.
- Lifespan content provides the answers needed when working with elderly, pediatric, and adult populations.
- Alphabetical organization of drugs by generic name — and a two-color design — save time in finding need-to-know details for day-to-day practice.
- Icons call attention to special drug information including high alert warnings and IV compatibilities/incompatibilities.
- Useful appendices make it easy to look up topics including normal laboratory values.
- NEW! Updated drug list adds newly approved drugs and deletes drugs that have been recalled or discontinued to ensure that drug information is clinically accurate, relevant, and current.
- NEW! Over 700 drug monographs ensure you have the most current and inclusive drug information.
- NEW! Updated and streamlined outline focuses on the most useful information.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| IFC\r | ES1 | ||
| MOSBY’S DRUG REFERENCE for HEALTH PROFESSIONS | i | ||
| Copyright | ii | ||
| REVIEWERS | iii | ||
| PAST REVIEWERS | iii | ||
| INTRODUCTION | vii | ||
| ESSENTIAL DRUG INFORMATION IN A USER-FRIENDLY FORMAT | vii | ||
| Appendices | ix | ||
| Electronic Resources | ix | ||
| AN IMPORTANT AND PRACTICAL RESOURCE | ix | ||
| ABOUT THE WRITER | x | ||
| CONTENTS | xi | ||
| A | 1 | ||
| Abacavir | 1 | ||
| Mechanism of Action | 1 | ||
| Pharmacokinetics | 1 | ||
| Availability | 1 | ||
| Indications and Dosages | 1 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 1 | ||
| ▸Dosage in hepatic impairment | 1 | ||
| Contraindications | 1 | ||
| Interactions | 1 | ||
| Side Effects | 1 | ||
| Serious Reactions | 1 | ||
| Abatacept | 2 | ||
| Mechanism of Action | 2 | ||
| Pharmacokinetics | 2 | ||
| Availability | 2 | ||
| Indications and Dosages | 2 | ||
| ▸Rheumatoid arthritis | 2 | ||
| Contraindications | 2 | ||
| Interactions | 2 | ||
| Diagnostic Test Effects | 2 | ||
| ?IV Incompatibilities | 3 | ||
| Side Effects | 3 | ||
| Serious Reactions | 3 | ||
| Abciximab | 3 | ||
| Mechanism of Action | 4 | ||
| Pharmacokinetics | 4 | ||
| Availability | 4 | ||
| Indications and Dosages | 4 | ||
| ▸Percutaneous coronary intervention (PCI) | 4 | ||
| ▸Unstable angina when PCI is planned within 24 h | 4 | ||
| Contraindications | 4 | ||
| Interactions | 4 | ||
| Diagnostic Test Effects | 4 | ||
| ?IV Incompatibilities | 4 | ||
| Side Effects | 4 | ||
| Serious Reactions | 4 | ||
| Abiraterone | 5.e1 | ||
| Mechanism of Action | 5.e1 | ||
| Pharmacokinetics | 5.e1 | ||
| Availability | 5.e1 | ||
| Indications and Dosages | 5.e1 | ||
| ▸Metastatic castration-resistant prostatic carcinoma | 5.e1 | ||
| ▸Dosage in hepatic impairment | 5.e1 | ||
| Contraindications | 5.e1 | ||
| Interactions | 5.e1 | ||
| Diagnostic Test Effects | 5.e2 | ||
| Side Effects | 5.e2 | ||
| Serious Reactions | 5.e2 | ||
| Acamprosate | 6 | ||
| Mechanism of Action | 6 | ||
| Pharmacokinetics | 6 | ||
| Availability | 6 | ||
| Indications and Dosages | 6 | ||
| ▸Maintenance of alcohol abstinence in alcohol-dependent patients who are abstinent at initiation of treatment | 6 | ||
| ▸Dosage in renal impairment | 6 | ||
| Contraindications | 6 | ||
| Interactions | 6 | ||
| Diagnostic Test Effects | 6 | ||
| Side Effects | 6 | ||
| Serious Reactions | 6 | ||
| Acarbose | 7 | ||
| Mechanism of Action | 7 | ||
| Pharmacokinetics | 7 | ||
| Availability | 7 | ||
| Indications and Dosages | 7 | ||
| ▸Diabetes Mellitus Type 2 | 7 | ||
| Contraindications | 7 | ||
| Interactions | 7 | ||
| Diagnostic Test Effects | 7 | ||
| Side Effects | 7 | ||
| Serious Reactions | 8 | ||
| Acebutolol | 8 | ||
| Mechanism of Action | 8 | ||
| Pharmacokinetics | 8 | ||
| Availability | 8 | ||
| Indications and Dosages | 8 | ||
| ▸Mild to moderate hypertension | 8 | ||
| ▸Ventricular arrhythmias | 9 | ||
| ▸Dosage in renal impairment | 9 | ||
| Off-Label Uses | 9 | ||
| Contraindications | 9 | ||
| Interactions | 9 | ||
| Diagnostic Test Effects | 9 | ||
| Side Effects | 9 | ||
| Serious Reactions | 9 | ||
| Acetaminophen | 10 | ||
| Mechanism of Action | 10 | ||
| Pharmacokinetics | 10 | ||
| Availability | 11 | ||
| Indications and Dosages | 11 | ||
| ▸Analgesia and antipyresis | 11 | ||
| Contraindications | 11 | ||
| Interactions | 11 | ||
| Diagnostic Test Effects | 11 | ||
| ?IV Incompatibilities | 11 | ||
| Side Effects | 11 | ||
| Serious Reactions | 11 | ||
| Acetazolamide | 13 | ||
| Mechanism of Action | 13 | ||
| Pharmacokinetics | 13 | ||
| Availability | 13 | ||
| Indications and Dosages | 13 | ||
| ▸Chronic simple (open-angle) glaucoma | 13 | ||
| ▸Secondary glaucoma, preop treatment of closed-angle glaucoma (short term) | 13 | ||
| ▸Drug-induced edema | 13 | ||
| ▸Epilepsy | 13 | ||
| ▸Acute mountain sickness | 13 | ||
| ▸Diuresis in CHF | 13 | ||
| ▸Dosage in renal impairment (immediate release products only) | 14 | ||
| Contraindications | 14 | ||
| Interactions | 14 | ||
| Diagnostic Test Effects | 14 | ||
| ?IV Incompatibilities | 14 | ||
| ?IV Compatibilities | 14 | ||
| Side Effects | 14 | ||
| Serious Reactions | 14 | ||
| Acetylcysteine | 15 | ||
| Mechanism of Action | 15 | ||
| Pharmacokinetics | 15 | ||
| Availability | 15 | ||
| Indications and Dosages | 15 | ||
| ▸Adjunctive treatment of viscid mucus secretions from chronic bronchopulmonary disease and for pulmonary complications of cystic... | 15 | ||
| ▸Treatment of viscid mucus secretions in patients with a tracheostomy | 15 | ||
| Mechanism of Action | 15.e1 | ||
| Pharmacokinetics | 15.e1 | ||
| Availability | 15.e1 | ||
| Indications and Dosages | 15.e1 | ||
| ▸Superficial infections of the external auditory canal | 15.e1 | ||
| ▸Dermatologic irrigation | 15.e1 | ||
| ▸Bladder irrigation | 15.e1 | ||
| Contraindications | 15.e1 | ||
| Diagnostic Test Effects | 15.e1 | ||
| Side Effects | 15.e1 | ||
| Serious Reactions | 15.e1 | ||
| ▸Acetaminophen overdose | 16 | ||
| Off-Label Uses | 16 | ||
| Contraindications | 16 | ||
| Diagnostic Test Effects | 16 | ||
| ?IV Incompatibilities | 16 | ||
| ?IV Compatibilities | 16 | ||
| Side Effects | 16 | ||
| Serious Reactions | 16 | ||
| Acitretin | 17 | ||
| Mechanism of Action | 17 | ||
| Pharmacokinetics | 17 | ||
| Availability | 17 | ||
| Indications and Dosages | 17 | ||
| ▸Psoriasis | 17 | ||
| Off-Label Uses | 17 | ||
| Contraindications | 17 | ||
| Interactions | 17 | ||
| Diagnostic Test Effects | 18 | ||
| Side Effects | 18 | ||
| Serious Reactions | 18 | ||
| Aclidinium | 19 | ||
| Mechanism of Action | 19 | ||
| Pharmacokinetics | 19 | ||
| Availability | 19 | ||
| Indications and Dosages | 19 | ||
| ▸Bronchospasm, maintenance treatment, associated with COPD | 19 | ||
| Contraindications | 19 | ||
| Interactions | 19 | ||
| Diagnostic Test Effects | 19 | ||
| Side Effects | 19 | ||
| Serious Reactions | 19 | ||
| Acyclovir | 20 | ||
| Mechanism of Action | 20 | ||
| Pharmacokinetics | 20 | ||
| Availability | 20 | ||
| Indications and Dosages | 21 | ||
| ▸Genital herpes (initial episode) | 21 | ||
| ▸Genital herpes (recurrent) | 21 | ||
| ▸Herpes labialis (cold sores), recurrent | 21 | ||
| ▸Herpes simplex mucocutaneous | 21 | ||
| ▸Herpes simplex neonatal | 21 | ||
| ▸Herpes simplex encephalitis | 21 | ||
| ▸Herpes zoster (caused by varicella) | 21 | ||
| ▸Herpes zoster (shingles) | 21 | ||
| ▸Varicella (chickenpox) | 21 | ||
| ▸Dosage in renal impairment | 21 | ||
| Off-Label Uses | 21 | ||
| Contraindications | 21 | ||
| Interactions | 22 | ||
| Diagnostic Test Effects | 22 | ||
| ?IV Incompatibilities | 22 | ||
| Side Effects | 22 | ||
| Serious Reactions | 22 | ||
| Adalimumab | 23 | ||
| Mechanism of Action | 23 | ||
| Pharmacokinetics | 23 | ||
| Availability | 23 | ||
| Indications and Dosages | 23 | ||
| ▸Ankylosing spondylitis | 23 | ||
| ▸Crohn’s disease and ulcerative colitis | 23 | ||
| ▸Juvenile idiopathic arthritis | 23 | ||
| ▸Plaque psoriasis | 23 | ||
| ▸Psoriatic arthritis | 23 | ||
| ▸Rheumatoid arthritis | 23 | ||
| Contraindications | 23 | ||
| Interactions | 24 | ||
| Diagnostic Test Effects | 24 | ||
| Side Effects | 24 | ||
| Serious Reactions | 24 | ||
| Adapalene | 25 | ||
| Mechanism of Action | 25 | ||
| Pharmacokinetics | 25 | ||
| Availability | 25 | ||
| Indications and Dosages | 25 | ||
| ▸Acne vulgaris | 25 | ||
| Contraindications | 25 | ||
| Interactions | 25 | ||
| Diagnostic Test Effects | 25 | ||
| Side Effects | 25 | ||
| Serious Reactions | 25 | ||
| Adefovir Dipivoxil | 26 | ||
| Mechanism of Action | 26 | ||
| Pharmacokinetics | 26 | ||
| Availability | 26 | ||
| Indications and Dosages | 26 | ||
| ▸Chronic hepatitis B in patients with normal renal function | 26 | ||
| ▸Chronic hepatitis B in patients with impaired renal function (adults) | 26 | ||
| Contraindications | 26 | ||
| Interactions | 26 | ||
| Diagnostic Test Effects | 26 | ||
| Side Effects | 26 | ||
| Serious Reactions | 27 | ||
| Adenosine | 27 | ||
| Mechanism of Action | 27 | ||
| Pharmacokinetics | 27 | ||
| Availability | 27 | ||
| Indications and Dosages | 27 | ||
| ▸Paroxysmal supraventricular tachycardia (PSVT) | 27 | ||
| ▸Diagnostic testing | 28 | ||
| Contraindications | 28 | ||
| Interactions | 28 | ||
| Diagnostic Test Effects | 28 | ||
| ?IV Incompatibilities | 28 | ||
| ?IV Compatibilities | 28 | ||
| Side Effects | 28 | ||
| Serious Reactions | 28 | ||
| Albendazole | 29 | ||
| Mechanism of Action | 29 | ||
| Pharmacokinetics | 29 | ||
| Availability | 29 | ||
| Indications and Dosages | 29 | ||
| ▸Neurocysticercosis | 29 | ||
| ▸Cystic hydatid | 29 | ||
| Off-Label Uses | 29 | ||
| Contraindications | 29 | ||
| Interactions | 29 | ||
| Diagnostic Test Effects | 29 | ||
| Side Effects | 29 | ||
| Afatinib | 29.e1 | ||
| Mechanism of Action | 29.e1 | ||
| Pharmacokinetics | 29.e1 | ||
| Availability | 29.e1 | ||
| Indications and Dosages | 29.e1 | ||
| ▸Metastatic non–small cell lung cancer (NSCLC) whose tumors express certain EGFR mutations | 29.e1 | ||
| ▸Dosage adjustment for toxicities | 29.e1 | ||
| ▸Dosage adjustment for P-gp inhibitor co-use | 29.e1 | ||
| ▸Dosage adjustment for chronic P-gp inducer co-use | 29.e1 | ||
| Contraindications | 29.e1 | ||
| Interactions | 29.e1 | ||
| Diagnostic Test Effects | 29.e1 | ||
| Side Effects | 29.e2 | ||
| Serious Reactions | 29.e2 | ||
| Agalsidase beta | 29.e3 | ||
| Mechanism of Action | 29.e3 | ||
| Pharmacokinetics | 29.e3 | ||
| Availability | 29.e3 | ||
| Indications and Dosages | 29.e3 | ||
| ▸Fabry disease | 29.e3 | ||
| Contraindications | 29.e3 | ||
| Diagnostic Test Effects | 29.e3 | ||
| ?IV Incompatibilities | 29.e3 | ||
| Side Effects | 29.e3 | ||
| Serious Reactions | 29.e3 | ||
| Serious Reactions | 30 | ||
| Albumin, Human | 30 | ||
| Mechanism of Action | 30 | ||
| Pharmacokinetics | 30 | ||
| Availability | 30 | ||
| Indications and Dosages | 30 | ||
| ▸Hypovolemia | 30 | ||
| ▸Hypoproteinemia | 31 | ||
| ▸Burns | 31 | ||
| ▸Cardiopulmonary bypass | 31 | ||
| ▸Acute nephrosis, nephrotic syndrome | 31 | ||
| ▸Hemodialysis | 31 | ||
| ▸Hyperbilirubinemia, erythroblastosis fetalis | 31 | ||
| Contraindications | 31 | ||
| Diagnostic Test Effects | 31 | ||
| ?IV Incompatibilities | 31 | ||
| ?IV Compatibilities | 31 | ||
| Side Effects | 31 | ||
| Serious Reactions | 31 | ||
| Albuterol | 32 | ||
| Mechanism of Action | 32 | ||
| Pharmacokinetics | 32 | ||
| Availability | 32 | ||
| Indications and Dosages | 32 | ||
| ▸Bronchospasm | 32 | ||
| ▸Exercise-induced bronchospasm | 33 | ||
| Off-Label Uses | 33 | ||
| Contraindications | 33 | ||
| Interactions | 33 | ||
| Diagnostic Test Effects | 33 | ||
| Side Effects | 33 | ||
| Serious Reactions | 33 | ||
| Albuterol; Ipratropium | 34 | ||
| Mechanism of Action | 34 | ||
| Pharmacokinetics | 35 | ||
| Availability | 35 | ||
| Indications and Dosages | 35 | ||
| ▸Bronchospasm, maintenance treatment, associated with COPD | 35 | ||
| Off-Label Uses | 35 | ||
| Contraindications | 35 | ||
| Interactions | 35 | ||
| Diagnostic Test Effects | 35 | ||
| Side Effects | 35 | ||
| Serious Reactions | 35 | ||
| Alclometasone | 36 | ||
| Mechanism of Action | 36 | ||
| Pharmacokinetics | 36 | ||
| Availability | 36 | ||
| Indications and Dosages | 36 | ||
| ▸Corticosteroid-responsive dermatoses: atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, e... | 36 | ||
| Contraindications | 36 | ||
| Diagnostic Test Effects | 36 | ||
| Side Effects | 36 | ||
| Alcaftadine | 36.e1 | ||
| Mechanism of Action | 36.e1 | ||
| Pharmacokinetics | 36.e1 | ||
| Availability | 36.e1 | ||
| Indications and Dosages | 36.e1 | ||
| ▸Allergic conjunctivitis | 36.e1 | ||
| Contraindications | 36.e1 | ||
| Interactions | 36.e1 | ||
| Side Effects | 36.e1 | ||
| Serious Reactions | 36.e1 | ||
| Aldesleukin | 36.e2 | ||
| Mechanism of Action | 36.e2 | ||
| Pharmacokinetics | 36.e2 | ||
| Availability | 36.e2 | ||
| Indications and Dosages | 36.e2 | ||
| ▸Metastatic melanoma, metastatic renal cell carcinoma | 36.e2 | ||
| Off-Label Uses | 36.e2 | ||
| Contraindications | 36.e2 | ||
| Interactions | 36.e2 | ||
| Diagnostic Test Effects | 36.e3 | ||
| ?IV Incompatibilities | 36.e3 | ||
| ?IV Compatibilities | 36.e3 | ||
| Serious Reactions | 36.e3 | ||
| Alendronate | 37 | ||
| Mechanism of Action | 37 | ||
| Pharmacokinetics | 37 | ||
| Availability | 37 | ||
| Indications and Dosages | 37 | ||
| ▸Osteoporosis (in men) | 37 | ||
| ▸Glucocorticoid-induced osteoporosis | 37 | ||
| ▸Postmenopausal osteoporosis | 37 | ||
| Alefacept | 37.e1 | ||
| Mechanism of Action | 37.e1 | ||
| Pharmacokinetics | 37.e1 | ||
| Availability | 37.e1 | ||
| Indications and Dosages | 37.e1 | ||
| ▸Plaque psoriasis | 37.e1 | ||
| Contraindications | 37.e1 | ||
| Interactions | 37.e1 | ||
| Diagnostic Test Effects | 37.e1 | ||
| ?IV Incompatibilities | 37.e1 | ||
| Side Effects | 37.e1 | ||
| Serious Reactions | 37.e1 | ||
| Alemtuzumab | 37.e2 | ||
| Mechanism of Action | 37.e2 | ||
| Pharmacokinetics | 37.e2 | ||
| Availability | 37.e2 | ||
| Indications and Dosages | 37.e2 | ||
| ▸B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and failed fludarabine therapy | 37.e2 | ||
| Contraindications | 37.e3 | ||
| Interactions | 37.e3 | ||
| Diagnostic Test Effects | 37.e3 | ||
| ?IV Incompatibilities | 37.e3 | ||
| Side Effects | 37.e3 | ||
| Serious Reactions | 37.e3 | ||
| ▸Paget disease | 38 | ||
| Contraindications | 38 | ||
| Interactions | 38 | ||
| Diagnostic Test Effects | 38 | ||
| Side Effects | 38 | ||
| Serious Reactions | 38 | ||
| Alfuzosin | 39 | ||
| Mechanism of Action | 39 | ||
| Pharmacokinetics | 39 | ||
| Availability | 39 | ||
| Indications and Dosages | 39 | ||
| ▸Benign prostatic hyperplasia | 39 | ||
| Contraindications | 39 | ||
| Interactions | 39 | ||
| Diagnostic Test Effects | 40 | ||
| Side Effects | 40 | ||
| Serious Reactions | 40 | ||
| Aliskiren | 40 | ||
| Mechanism of Action | 40 | ||
| Pharmacokinetics | 40 | ||
| Availability | 40 | ||
| Indications and Dosages | 40 | ||
| ▸Hypertension | 40 | ||
| Contraindications | 40 | ||
| Interactions | 41 | ||
| Diagnostic Test Effects | 41 | ||
| Side Effects | 41 | ||
| Serious Reactions | 41 | ||
| Allopurinol | 41 | ||
| Mechanism of Action | 41 | ||
| Alitretinoin | 41.e1 | ||
| Mechanism of Action | 41.e1 | ||
| Pharmacokinetics | 41.e1 | ||
| Availability | 41.e1 | ||
| Indications and Dosages | 41.e1 | ||
| ▸Kaposi sarcoma skin lesions | 41.e1 | ||
| Off-Label Uses | 41.e1 | ||
| Contraindications | 41.e1 | ||
| Interactions | 41.e1 | ||
| Diagnostic Test Effects | 41.e1 | ||
| Side Effects | 41.e1 | ||
| Serious Reactions | 41.e1 | ||
| Pharmacokinetics | 42 | ||
| Availability | 42 | ||
| Indications and Dosages | 42 | ||
| ▸For primary or secondary gout (tophi, arthritis, uric acid, lithiasis, etc. ) | 42 | ||
| ▸Recurrent calcium oxalate calculi | 42 | ||
| ▸Dosage in renal impairment (adults) | 42 | ||
| Contraindications | 42 | ||
| Interactions | 42 | ||
| Diagnostic Test Effects | 42 | ||
| Side Effects | 42 | ||
| Serious Reactions | 42 | ||
| Almotriptan | 43 | ||
| Mechanism of Action | 43 | ||
| Pharmacokinetics | 43 | ||
| Availability | 43 | ||
| Indications and Dosages | 43 | ||
| ▸Migraine headache | 43 | ||
| ▸Dosage in hepatic or renal impairment (CrCl < 30 mL/min) | 43 | ||
| Contraindications | 43 | ||
| Interactions | 44 | ||
| Diagnostic Test Effects | 44 | ||
| Side Effects | 44 | ||
| Serious Reactions | 44 | ||
| Alogliptin | 44 | ||
| Mechanism of Action | 45 | ||
| Pharmacokinetics | 45 | ||
| Availability | 45 | ||
| Indications and Dosages | 45 | ||
| ▸Type 2 diabetes mellitus | 45 | ||
| ▸Dosage in moderate renal impairment (CrCl 30-59 mL/min) | 45 | ||
| ▸Dosage in severe renal impairment (CrCl < 30 mL/min) | 45 | ||
| Contraindications | 45 | ||
| Interactions | 45 | ||
| Diagnostic Test Effects | 45 | ||
| Side Effects | 45 | ||
| Serious Reactions | 45 | ||
| Alosetron | 46 | ||
| Mechanism of Action | 46 | ||
| Pharmacokinetics | 46 | ||
| Availability | 46 | ||
| Indications and Dosages | 46 | ||
| ▸Irritable bowel syndrome (IBS), diarrhea predominant, severe and unresponsive to other treatments | 46 | ||
| Contraindications | 46 | ||
| Interactions | 46 | ||
| Diagnostic Test Effects | 47 | ||
| Side Effects | 47 | ||
| Serious Reactions | 47 | ||
| Alprazolam | 47 | ||
| Mechanism of Action | 47 | ||
| Pharmacokinetics | 48 | ||
| Availability | 48 | ||
| Indications and Dosages | 48 | ||
| ▸Anxiety disorders | 48 | ||
| ▸Anxiety with depression | 48 | ||
| ▸Panic disorder | 48 | ||
| Contraindications | 48 | ||
| Interactions | 48 | ||
| Diagnostic Test Effects | 49 | ||
| Side Effects | 49 | ||
| Serious Reactions | 49 | ||
| Alteplase | 49 | ||
| Mechanism of Action | 49 | ||
| Alprostadil | 49.e1 | ||
| Mechanism of Action | 49.e1 | ||
| Pharmacokinetics | 49.e1 | ||
| Availability | 49.e1 | ||
| Indications and Dosages | 49.e1 | ||
| ▸Maintain patency of ductus arteriosus | 49.e1 | ||
| ▸Impotence | 49.e1 | ||
| Contraindications | 49.e1 | ||
| Interactions | 49.e1 | ||
| Diagnostic Test Effects | 49.e1 | ||
| ?IV Incompatibilities | 49.e2 | ||
| Side Effects | 49.e2 | ||
| Serious Reactions | 49.e2 | ||
| Pharmacokinetics | 50 | ||
| Availability | 50 | ||
| Indications and Dosages | 50 | ||
| ▸Acute MI | 50 | ||
| ▸Acute pulmonary emboli | 50 | ||
| ▸Acute ischemic stroke | 50 | ||
| ▸Central venous catheter clearance | 50 | ||
| Off-Label Uses | 50 | ||
| Contraindications | 50 | ||
| Interactions | 50 | ||
| Diagnostic Test Effects | 51 | ||
| ?IV Incompatibilities | 51 | ||
| Side Effects | 51 | ||
| Serious Reactions | 51 | ||
| Aluminum Hydroxide | 52 | ||
| Mechanism of Action | 52 | ||
| Availability | 52 | ||
| Indications and Dosages | 52 | ||
| ▸Antacid | 52 | ||
| ▸Hyperphosphatemia | 52 | ||
| Contraindications | 52 | ||
| Interactions | 52 | ||
| Diagnostic Test Effects | 52 | ||
| Side Effects | 52 | ||
| Serious Reactions | 52 | ||
| Aluminum Chloride Hexahydrate | 52.e1 | ||
| Mechanism of Action | 52.e1 | ||
| Pharmacokinetics | 52.e1 | ||
| Availability | 52.e1 | ||
| Indications and Dosages | 52.e1 | ||
| ▸Antiperspirant | 52.e1 | ||
| ▸Hyperhidrosis | 52.e1 | ||
| Contraindications | 52.e1 | ||
| Interactions | 52.e1 | ||
| Diagnostic Test Effects | 52.e1 | ||
| Side Effects | 52.e1 | ||
| Serious Reactions | 52.e1 | ||
| Amantadine Hydrochloride | 53 | ||
| Mechanism of Action | 53 | ||
| Pharmacokinetics | 53 | ||
| Availability | 53 | ||
| Indications and Dosages | 53 | ||
| ▸Prevention and symptomatic treatment of respiratory illness due to influenza A virus | 53 | ||
| Alvimopan | 53.e1 | ||
| Mechanism of Action | 53.e1 | ||
| Pharmacokinetics | 53.e1 | ||
| Availability | 53.e1 | ||
| Indications and Dosages | 53.e1 | ||
| ▸Postoperative ileus: to accelerate GI recovery time following partial large or small bowel resection with primary anastomosis o... | 53.e1 | ||
| Contraindications | 53.e1 | ||
| Interactions | 53.e1 | ||
| Diagnostic Test Effects | 53.e1 | ||
| Side Effects | 53.e1 | ||
| Serious Reactions | 53.e2 | ||
| ▸Parkinson’s disease, extrapyramidal symptoms | 54 | ||
| ▸Dosage in renal impairment | 54 | ||
| Contraindications | 54 | ||
| Interactions | 54 | ||
| Diagnostic Test Effects | 54 | ||
| Side Effects | 54 | ||
| Serious Reactions | 54 | ||
| Amcinonide | 55 | ||
| Mechanism of Action | 55 | ||
| Pharmacokinetics | 55 | ||
| Availability | 55 | ||
| Indications and Dosages | 55 | ||
| ▸Corticosteroid-responsive dermatoses | 55 | ||
| Contraindications | 55 | ||
| Mechanism of Action | 55.e1 | ||
| Pharmacokinetics | 55.e1 | ||
| Availability | 55.e1 | ||
| Indications and Dosages | 55.e1 | ||
| ▸Myasthenia gravis | 55.e1 | ||
| Contraindications | 55.e1 | ||
| Interactions | 55.e1 | ||
| Diagnostic Test Effects | 55.e1 | ||
| Side Effects | 55.e1 | ||
| Serious Reactions | 55.e1 | ||
| Ambrisentan | 55.e2 | ||
| Mechanism of Action | 55.e2 | ||
| Pharmacokinetics | 55.e2 | ||
| Availability | 55.e2 | ||
| Indications and Dosages | 55.e2 | ||
| ▸Pulmonary Arterial Hypertension | 55.e2 | ||
| Contraindications | 55.e2 | ||
| Interactions | 55.e2 | ||
| Diagnostic Test Effects | 55.e3 | ||
| Side Effects | 55.e3 | ||
| Serious Reactions | 55.e3 | ||
| Interactions | 56 | ||
| Diagnostic Test Effects | 56 | ||
| Side Effects | 56 | ||
| Serious Reactions | 56 | ||
| Amikacin | 56 | ||
| Mechanism of Action | 56 | ||
| Pharmacokinetics | 56 | ||
| Mechanism of Action | 56.e1 | ||
| Pharmacokinetics | 56.e1 | ||
| Availability | 56.e1 | ||
| Indications and Dosages | 56.e1 | ||
| ▸To reduce cumulative renal toxicity from repeated administration of cisplatin in patients with advanced ovarian cancer | 56.e1 | ||
| ▸Treatment of postoperative radiation-induced xerostomia in patients with head and neck cancer | 56.e1 | ||
| Contraindications | 56.e1 | ||
| Interactions | 56.e1 | ||
| Diagnostic Test Effects | 56.e1 | ||
| ?IV Incompatibilities | 56.e1 | ||
| ?IV Compatibilities | 56.e1 | ||
| Side Effects | 56.e1 | ||
| Serious Reactions | 56.e2 | ||
| Availability | 57 | ||
| Indications and Dosages | 57 | ||
| ▸Uncomplicated urinary tract infections | 57 | ||
| ▸Moderate to severe infections | 57 | ||
| ▸Dosage in renal impairment | 57 | ||
| ▸Once-daily dose strategy | 57 | ||
| Contraindications | 57 | ||
| Interactions | 57 | ||
| Diagnostic Test Effects | 57 | ||
| ?IV Incompatibilities | 57 | ||
| ?IV Compatibilities | 57 | ||
| Side Effects | 58 | ||
| Serious Reactions | 58 | ||
| Amiloride Hydrochloride | 58 | ||
| Mechanism of Action | 59 | ||
| Pharmacokinetics | 59 | ||
| Availability | 59 | ||
| Indications and Dosages | 59 | ||
| ▸To treat hypertension and congestive heart failure and to counteract potassium loss induced by other diuretics | 59 | ||
| ▸Dosage in renal impairment | 59 | ||
| Off-Label Uses | 59 | ||
| Contraindications | 59 | ||
| Interactions | 59 | ||
| Diagnostic Test Effects | 59 | ||
| Side Effects | 59 | ||
| Serious Reactions | 59 | ||
| Aminocaproic Acid | 60 | ||
| Mechanism of Action | 60 | ||
| Pharmacokinetics | 60 | ||
| Availability | 60 | ||
| Indications and Dosages | 60 | ||
| ▸Acute bleeding | 60 | ||
| Off-Label Uses | 60 | ||
| Contraindications | 61 | ||
| Interactions | 61 | ||
| Diagnostic Test Effects | 61 | ||
| ?IV Incompatibilities | 61 | ||
| Side Effects | 61 | ||
| Serious Reactions | 61 | ||
| Aminophylline | 62 | ||
| Mechanism of Action | 62 | ||
| Pharmacokinetics | 62 | ||
| Availability | 62 | ||
| Indications and Dosages | 62 | ||
| Contraindications | 62 | ||
| Interactions | 62 | ||
| Diagnostic Test Effects | 62 | ||
| ?IV Incompatibilities | 63 | ||
| ?IV Compatibilities | 63 | ||
| Side Effects | 63 | ||
| Serious Reactions | 63 | ||
| Aminosalicylic Acid | 63 | ||
| Mechanism of Action | 63 | ||
| Pharmacokinetics | 64 | ||
| Availability | 64 | ||
| Indications and Dosages | 64 | ||
| ▸Tuberculosis in combination with other agents; most commonly used for multi-drug resistant TB (MDR-TB) | 64 | ||
| Off-Label Uses | 64 | ||
| Contraindications | 64 | ||
| Interactions | 64 | ||
| Diagnostic Test Effects | 64 | ||
| Side Effects | 64 | ||
| Serious Reactions | 64 | ||
| Amiodarone | 65 | ||
| Mechanism of Action | 65 | ||
| Pharmacokinetics | 65 | ||
| Availability | 65 | ||
| Indications and Dosages | 65 | ||
| ▸Life-threatening recurrent ventricular fibrillation or hemodynamically unstable ventricular tachycardia | 65 | ||
| Off-Label Uses | 65 | ||
| Contraindications | 65 | ||
| Interactions | 65 | ||
| Diagnostic Test Effects | 66 | ||
| ?IV Incompatibilities | 66 | ||
| ?IV Compatibilities | 66 | ||
| Side Effects | 66 | ||
| Serious Reactions | 66 | ||
| Amitriptyline | 67 | ||
| Mechanism of Action | 68 | ||
| Pharmacokinetics | 68 | ||
| Availability | 68 | ||
| Indications and Dosages | 68 | ||
| ▸Depression | 68 | ||
| Off-Label Uses | 68 | ||
| Contraindications | 68 | ||
| Interactions | 68 | ||
| Diagnostic Test Effects | 68 | ||
| Side Effects | 68 | ||
| Serious Reactions | 69 | ||
| Amlodipine | 69 | ||
| Mechanism of Action | 69 | ||
| Pharmacokinetics | 70 | ||
| Availability | 70 | ||
| Indications and Dosages | 70 | ||
| ▸Hypertension | 70 | ||
| ▸Angina (chronic stable or vasospastic) | 70 | ||
| ▸Dosage in hepatic impairment | 70 | ||
| Contraindications | 70 | ||
| Interactions | 70 | ||
| Diagnostic Test Effects | 70 | ||
| Side Effects | 70 | ||
| Serious Reactions | 70 | ||
| Amoxapine | 71 | ||
| Mechanism of Action | 71 | ||
| Pharmacokinetics | 71 | ||
| Availability | 71 | ||
| Indications and Dosages | 71 | ||
| ▸Depression | 71 | ||
| Contraindications | 71 | ||
| Interactions | 71 | ||
| Diagnostic Test Effects | 71 | ||
| Side Effects | 71 | ||
| Amobarbital | 71.e1 | ||
| Mechanism of Action | 71.e1 | ||
| Pharmacokinetics | 71.e1 | ||
| Availability | 71.e1 | ||
| Indications and Dosages | 71.e1 | ||
| ▸Treatment of ichthyosis vulgaris and xerosis | 71.e1 | ||
| Contraindications | 71.e1 | ||
| Interactions | 71.e1 | ||
| Diagnostic Test Effects | 71.e1 | ||
| Side Effects | 71.e1 | ||
| Amoxicillin | 72 | ||
| Mechanism of Action | 72 | ||
| Pharmacokinetics | 73 | ||
| Availability | 73 | ||
| Indications and Dosages | 73 | ||
| ▸Ear, nose, throat, genitourinary, skin, and skin-structure infections | 73 | ||
| ▸Lower respiratory tract infections | 73 | ||
| ▸Acute, uncomplicated gonorrhea | 73 | ||
| ▸Sinusitis (high-dose regimen, children) | 73 | ||
| ▸Acute otitis media | 73 | ||
| ▸Helicobacter pylori infection | 73 | ||
| ▸Prevention of endocarditis | 73 | ||
| ▸Usual neonatal and young infant dosage | 73 | ||
| ▸Dosage in renal impairment (adults) | 73 | ||
| Off-Label Uses | 73 | ||
| Contraindications | 73 | ||
| Interactions | 73 | ||
| Diagnostic Test Effects | 74 | ||
| Side Effects | 74 | ||
| Serious Reactions | 74 | ||
| Amoxicillin/Clavulanate | 75 | ||
| Mechanism of Action | 75 | ||
| Pharmacokinetics | 75 | ||
| Availability | 75 | ||
| Indications and Dosages | 75 | ||
| ▸Mild to moderate infections | 75 | ||
| ▸Respiratory tract, sinusitis, and other severe infections | 75 | ||
| ▸Otitis media | 75 | ||
| ▸Usual neonate dosage | 75 | ||
| ▸Dosage in renal impairment (adults) | 75 | ||
| Off-Label Uses | 75 | ||
| Contraindications | 75 | ||
| Interactions | 76 | ||
| Diagnostic Test Effects | 76 | ||
| Side Effects | 76 | ||
| Serious Reactions | 76 | ||
| Amphetamine; Dextroamphetamine | 77 | ||
| Mechanism of Action | 77 | ||
| Pharmacokinetics | 77 | ||
| Availability | 77 | ||
| Indications and Dosages | 77 | ||
| ▸ADHD | 77 | ||
| ▸Extended-release capsules | 77 | ||
| ▸Narcolepsy | 77 | ||
| Off-Label Uses | 78 | ||
| Contraindications | 78 | ||
| Interactions | 78 | ||
| Diagnostic Test Effects | 78 | ||
| Side Effects | 78 | ||
| Serious Reactions | 78 | ||
| Ampicillin Sodium | 79 | ||
| Mechanism of Action | 79 | ||
| Pharmacokinetics | 79 | ||
| Availability | 79 | ||
| Indications and Dosages | 79 | ||
| ▸Respiratory tract, skin, and skin-structure infections | 79 | ||
| Amphotericin B/Amphotericin B Cholesteryl/Amphotericin B Lipid Complex/Liposomal Amphotericin B | 79.e1 | ||
| Mechanism of Action | 79.e1 | ||
| Pharmacokinetics | 79.e1 | ||
| Availability | 79.e1 | ||
| Indications and Dosages | 79.e1 | ||
| ▸Cryptococcosis; blastomycosis; systemic candidiasis; disseminated forms of moniliasis, coccidioidomycosis, and histoplasmosis; ... | 79.e1 | ||
| ▸Invasive fungal infections unresponsive to or intolerant of amphotericin B | 79.e1 | ||
| ▸Empiric treatment of fungal infections in patients with febrile neutropenia; aspergillosis, candidiasis, or cryptococcosis in p... | 79.e2 | ||
| ▸Invasive aspergillosis in patients with renal impairment and those who have experienced toxicity or treatment failure with amph... | 79.e2 | ||
| Contraindications | 79.e2 | ||
| Interactions | 79.e2 | ||
| Diagnostic Test Effects | 79.e2 | ||
| ?IV Incompatibilities | 79.e2 | ||
| Side Effects | 79.e2 | ||
| Serious Reactions | 79.e3 | ||
| ▸Bacterial meningitis, septicemia | 80 | ||
| ▸Uncomplicated gonococcal infections | 80 | ||
| ▸Perioperative prophylaxis | 80 | ||
| ▸Usual neonatal dosage | 80 | ||
| ▸Dosage in renal impairment (adults) | 80 | ||
| Contraindications | 80 | ||
| Interactions | 80 | ||
| Diagnostic Test Effects | 80 | ||
| ?IV Incompatibilities | 80 | ||
| ?IV Compatibilities | 80 | ||
| Side Effects | 80 | ||
| Serious Reactions | 80 | ||
| Ampicillin/Sulbactam | 81 | ||
| Mechanism of Action | 81 | ||
| Pharmacokinetics | 81 | ||
| Availability | 81 | ||
| Indications and Dosages | 81 | ||
| ▸Skin/skin-structure, intra-abdominal, and gynecologic infections | 81 | ||
| ▸Dosage in renal impairment | 82 | ||
| Off-Label Uses | 82 | ||
| Contraindications | 82 | ||
| Interactions | 82 | ||
| Diagnostic Test Effects | 82 | ||
| ?IV Incompatibilities | 82 | ||
| Side Effects | 82 | ||
| Serious Reactions | 82 | ||
| Anakinra | 83 | ||
| Mechanism of Action | 83 | ||
| Pharmacokinetics | 83 | ||
| Availability | 83 | ||
| Indications and Dosages | 83 | ||
| ▸Rheumatoid arthritis | 83 | ||
| ▸Neonatal-onset multisystem inflammatory disease (NOMID) | 83 | ||
| ▸Renal impairment | 83 | ||
| Contraindications | 83 | ||
| Amyl Nitrite | 83.e1 | ||
| Mechanism of Action | 83.e1 | ||
| Pharmacokinetics | 83.e1 | ||
| Availability | 83.e1 | ||
| Indications and Dosages | 83.e1 | ||
| ▸Acute relief of angina pectoris | 83.e1 | ||
| Off-Label Uses | 83.e1 | ||
| Contraindications | 83.e1 | ||
| Interactions | 83.e1 | ||
| Diagnostic Test Effects | 83.e1 | ||
| Side Effects | 83.e1 | ||
| Serious Reactions | 83.e1 | ||
| Anagrelide | 83.e2 | ||
| Mechanism of Action | 83.e2 | ||
| Pharmacokinetics | 83.e2 | ||
| Availability | 83.e2 | ||
| Indications and Dosages | 83.e2 | ||
| ▸Thrombocythemia secondary to myeloproliferative disorders | 83.e2 | ||
| ▸Dose in hepatic impairment | 83.e2 | ||
| Contraindications | 83.e2 | ||
| Interactions | 83.e2 | ||
| Diagnostic Test Effects | 83.e3 | ||
| Side Effects | 83.e3 | ||
| Serious Reactions | 83.e3 | ||
| Interactions | 84 | ||
| Diagnostic Test Effects | 84 | ||
| Side Effects | 84 | ||
| Serious Reactions | 84 | ||
| Anidulafungin | 84 | ||
| Mechanism of Action | 84 | ||
| Anastrozole | 84.e1 | ||
| Mechanism of Action | 84.e1 | ||
| Pharmacokinetics | 84.e1 | ||
| Availability | 84.e1 | ||
| Indications and Dosages | 84.e1 | ||
| ▸First-line, second-line, and adjuvant treatment of hormonally responsive breast cancer | 84.e1 | ||
| Contraindications | 84.e1 | ||
| Interactions | 84.e1 | ||
| Diagnostic Test Effects | 84.e1 | ||
| Side Effects | 84.e1 | ||
| Serious Reactions | 84.e1 | ||
| Pharmacokinetics | 85 | ||
| Availability | 85 | ||
| Indications and Dosages | 85 | ||
| ▸Candidemia | 85 | ||
| ▸Esophageal candidiasis | 85 | ||
| Contraindications | 85 | ||
| Interactions | 85 | ||
| Diagnostic Test Effects | 85 | ||
| ?IV Incompatibilities | 85 | ||
| Side Effects | 85 | ||
| Serious Reactions | 85 | ||
| Apraclonidine Hydrochloride | 86 | ||
| Mechanism of Action | 86 | ||
| Pharmacokinetics | 86 | ||
| Availability | 86 | ||
| Indications and Dosages | 86 | ||
| ▸Glaucoma | 86 | ||
| ▸Intraocular hypertension post laser surgery | 86 | ||
| Contraindications | 86 | ||
| Drug Interactions | 86 | ||
| Diagnostic Test Effects | 86 | ||
| Side Effects | 86 | ||
| Serious Reactions | 86 | ||
| Anthralin | 86.e1 | ||
| Mechanism of Action | 86.e1 | ||
| Pharmacokinetics | 86.e1 | ||
| Availability | 86.e1 | ||
| Indications and Dosages | 86.e1 | ||
| ▸Psoriasis | 86.e1 | ||
| Off-Label Uses | 86.e1 | ||
| Contraindications | 86.e1 | ||
| Interactions | 86.e1 | ||
| Side Effects | 86.e1 | ||
| Serious Reactions | 86.e1 | ||
| Antihemophilic Factor (Factor VIII, AHF) | 86.e2 | ||
| Mechanism of Action | 86.e2 | ||
| Availability | 86.e2 | ||
| Indications and Dosages | 86.e2 | ||
| ▸Treatment and prevention of bleeding in patients with hemophilia A factor VIII deficiency, hypofibrinogenemia, von Willebrand d... | 86.e2 | ||
| Off-Label Uses | 86.e2 | ||
| Contraindications | 86.e2 | ||
| Interactions | 86.e2 | ||
| Diagnostic Test Effects | 86.e2 | ||
| ?IV Incompatibilities | 86.e2 | ||
| Side Effects | 86.e2 | ||
| Serious Reactions | 86.e2 | ||
| Antithymocyte Globulin, Equine | 86.e3 | ||
| Mechanism of Action | 86.e3 | ||
| Pharmacokinetics | 86.e3 | ||
| Availability | 86.e3 | ||
| Indications and Dosages | 86.e3 | ||
| ▸To delay onset of renal graft allograft rejection | 86.e3 | ||
| ▸Treatment of renal allograft rejection | 86.e3 | ||
| ▸Renal allograft recipients | 86.e4 | ||
| ▸Aplastic anemia | 86.e4 | ||
| Off-Label Uses | 86.e4 | ||
| Contraindications | 86.e4 | ||
| Interactions | 86.e4 | ||
| Diagnostic Test Effects | 86.e4 | ||
| ?IV Incompatibilities | 86.e4 | ||
| Side Effects | 86.e4 | ||
| Serious Reactions | 86.e4 | ||
| Apomorphine | 86.e5 | ||
| Mechanism of Action | 86.e5 | ||
| Pharmacokinetics | 86.e5 | ||
| Availability | 86.e5 | ||
| Indications and Dosages | 86.e5 | ||
| ▸Acute, intermittent treatment of hypomobility (“off” episodes) associated with advanced Parkinson’s disease | 86.e5 | ||
| ▸Dose in renal impairment | 86.e6 | ||
| Contraindications | 86.e6 | ||
| Interactions | 86.e6 | ||
| Diagnostic Test Effects | 86.e6 | ||
| Side Effects | 86.e6 | ||
| Serious Reactions | 86.e6 | ||
| Aprepitant | 87 | ||
| Mechanism of Action | 87 | ||
| Pharmacokinetics | 87 | ||
| Availability | 87 | ||
| Indications and Dosages | 87 | ||
| ▸Prevention of chemotherapy-induced nausea and vomiting | 87 | ||
| ▸Prevention of postoperative nausea and vomiting | 87 | ||
| Contraindications | 87 | ||
| Interactions | 87 | ||
| Diagnostic Test Effects | 88 | ||
| Side Effects | 88 | ||
| Serious Reactions | 88 | ||
| Arformoterol Tartrate | 88 | ||
| Mechanism of Action | 88 | ||
| Pharmacokinetics | 88 | ||
| Availability | 88 | ||
| Indications and Dosages | 88 | ||
| ▸COPD | 88 | ||
| Contraindications | 88 | ||
| Drug Interactions | 89 | ||
| Diagnostic Test Effects | 89 | ||
| Side Effects | 89 | ||
| Serious Reactions | 89 | ||
| Argatroban | 89 | ||
| Mechanism of Action | 89 | ||
| Pharmacokinetics | 90 | ||
| Availability | 90 | ||
| Indications and Dosages | 90 | ||
| ▸To prevent and treat heparin-induced thrombocytopenia | 90 | ||
| ▸During percutaneous coronary intervention | 90 | ||
| ▸Dosage in hepatic impairment | 90 | ||
| Contraindications | 90 | ||
| Interactions | 90 | ||
| Diagnostic Test Effects | 90 | ||
| ?IV Incompatibilities | 90 | ||
| Side Effects | 90 | ||
| Serious Reactions | 90 | ||
| Aripiprazole | 91 | ||
| Mechanism of Action | 91 | ||
| Pharmacokinetics | 91 | ||
| Availability | 91 | ||
| Indications and Dosages | 91 | ||
| ▸Acute agitation associated with schizophrenia or bipolar disorder | 91 | ||
| ▸Bipolar disorder | 91 | ||
| ▸Depression, adjunctive therapy | 92 | ||
| ▸Schizophrenia | 92 | ||
| ▸Irritability associated with autistic disorder | 92 | ||
| ▸Dosage adjustments (all populations) | 92 | ||
| Off-Label Uses | 92 | ||
| Contraindications | 92 | ||
| Interactions | 92 | ||
| Diagnostic Test Effects | 92 | ||
| Side Effects | 92 | ||
| Serious Reactions | 93 | ||
| Arsenic Trioxide | 93.e1 | ||
| Mechanism of Action | 93.e1 | ||
| Availability | 93.e1 | ||
| Indications and Dosages | 93.e1 | ||
| ▸Acute promyelocytic leukemia | 93.e1 | ||
| Contraindications | 93.e1 | ||
| Interactions | 93.e1 | ||
| Diagnostic Test Effects | 93.e1 | ||
| ?IV Incompatibilities | 93.e1 | ||
| Side Effects | 93.e1 | ||
| Serious Reactions | 93.e1 | ||
| Mechanism of Action | 94 | ||
| Pharmacokinetics | 94 | ||
| Availability | 94 | ||
| Indications and Dosages | 94 | ||
| ▸Narcolepsy and obstructive sleep apnea/hypopnea syndrome (OSAHS) | 94 | ||
| ▸Shift-work sleep disorder | 94 | ||
| ▸Dosage in hepatic impairment | 94 | ||
| Contraindications | 94 | ||
| Interactions | 94 | ||
| Diagnostic Test Effects | 94 | ||
| Side Effects | 94 | ||
| Serious Reactions | 94 | ||
| Ascorbic Acid (Vitamin C) | 95 | ||
| Mechanism of Action | 95 | ||
| Pharmacokinetics | 95 | ||
| Availability | 95 | ||
| Indications and Dosages | 95 | ||
| ▸Dietary supplement (ranges within Reference Daily Intake) | 95 | ||
| ▸Scurvy | 95 | ||
| Off-Label Uses | 95 | ||
| Mechanism of Action | 95.e1 | ||
| Pharmacokinetics | 95.e1 | ||
| Availability | 95.e1 | ||
| Indications and Dosages | 95.e1 | ||
| ▸Treatment of malaria | 95.e1 | ||
| Contraindications | 95.e1 | ||
| Interactions | 95.e1 | ||
| Diagnostic Test Effects | 95.e2 | ||
| Side Effects | 95.e2 | ||
| Serious Reactions | 95.e2 | ||
| Contraindications | 96 | ||
| Interactions | 96 | ||
| Diagnostic Test Effects | 96 | ||
| ?IV Incompatibilities | 96 | ||
| ?IV Compatibilities | 96 | ||
| Side Effects | 96 | ||
| Serious Reactions | 96 | ||
| Asenapine | 97 | ||
| Mechanism of Action | 97 | ||
| Pharmacokinetics | 97 | ||
| Availability | 97 | ||
| Indications and Dosages | 97 | ||
| ▸Schizophrenia | 97 | ||
| ▸Acute bipolar mania | 97 | ||
| ▸Bipolar Disorder (maintenance adjunct to lithium or valproate) | 97 | ||
| ▸Patients with hepatic impairment | 97 | ||
| Contraindications | 97 | ||
| Interactions | 97 | ||
| Diagnostic Test Effects | 98 | ||
| Side Effects | 98 | ||
| Serious Reactions | 98 | ||
| Aspirin/Acetylsalicylic Acid | 99 | ||
| Mechanism of Action | 99 | ||
| Pharmacokinetics | 99 | ||
| Availability | 99 | ||
| Indications and Dosages | 99 | ||
| ▸Analgesia, fever | 99 | ||
| ▸Anti-inflammatory | 99 | ||
| ▸Juvenile rheumatoid arthritis | 99 | ||
| Mechanism of Action | 99.e1 | ||
| Pharmacokinetics | 99.e1 | ||
| Availability | 99.e1 | ||
| Indications and Dosages | 99.e1 | ||
| ▸Acute lymphocytic leukemia (usual dosages) | 99.e1 | ||
| Contraindications | 99.e1 | ||
| Interactions | 99.e1 | ||
| Diagnostic Test Effects | 99.e1 | ||
| ?IV Incompatibilities | 99.e1 | ||
| Side Effects | 99.e1 | ||
| Serious Reactions | 99.e2 | ||
| ▸Suspected myocardial infarction (MI) | 100 | ||
| ▸Prevention of MI | 100 | ||
| ▸Prevention of stroke after transient ischemic attack | 100 | ||
| ▸Kawasaki disease | 100 | ||
| ▸Coronary artery bypass graft | 100 | ||
| ▸Percutaneous transluminal coronary angioplasty | 100 | ||
| ▸Stent implantation | 100 | ||
| ▸Carotid endarterectomy | 100 | ||
| ▸Acute ischemic stroke | 100 | ||
| Off-Label Uses | 100 | ||
| Contraindications | 100 | ||
| Interactions | 100 | ||
| Diagnostic Test Effects | 100 | ||
| Side Effects | 101 | ||
| Serious Reactions | 101 | ||
| Atazanavir Sulfate | 102 | ||
| Mechanism of Action | 102 | ||
| Pharmacokinetics | 102 | ||
| Availability | 102 | ||
| Indications and Dosages | 102 | ||
| ▸HIV-1 infection (therapy-naïve) | 102 | ||
| ▸HIV-1 infection (therapy-naïve; concurrent therapy with efavirenz, tenofovir, H2 receptor antagonist, or proton-pump inhibitor)... | 102 | ||
| ▸HIV-1 infection (treatment-experienced) | 102 | ||
| ▸HIV-1 infection (treatment-experienced; concurrent therapy with H2 receptor antagonist) | 102 | ||
| ▸HIV-1 infection (treatment-experienced; concurrent therapy with H2 receptor antagonist and tenofovir) | 102 | ||
| ▸HIV-1 infection in patients with moderate hepatic impairment | 102 | ||
| ▸HIV-1 infection in treatment-naïve patients with end-stage renal disease managed with hemodialysis | 103 | ||
| Contraindications | 103 | ||
| Interactions | 103 | ||
| Diagnostic Test Effects | 103 | ||
| Side Effects | 103 | ||
| Serious Reactions | 103 | ||
| Atenolol | 104 | ||
| Mechanism of Action | 104 | ||
| Pharmacokinetics | 104 | ||
| Availability | 104 | ||
| Indications and Dosages | 104 | ||
| ▸Hypertension | 104 | ||
| ▸Angina pectoris | 104 | ||
| ▸Dosage in renal impairment | 104 | ||
| Off-Label Uses | 105 | ||
| Contraindications | 105 | ||
| Interactions | 105 | ||
| Diagnostic Test Effects | 105 | ||
| Side Effects | 105 | ||
| Serious Reactions | 105 | ||
| Atomoxetine | 106 | ||
| Mechanism of Action | 106 | ||
| Pharmacokinetics | 106 | ||
| Availability | 106 | ||
| Indications and Dosages | 106 | ||
| ▸ADHD | 106 | ||
| ▸ADHD with concomitant therapy with CYP2D6 strong inhibitors (fluoxetine, paroxetine, quinidine) or in known poor CYP2D6 metabol... | 106 | ||
| ▸Dosage in hepatic impairment | 107 | ||
| Contraindications | 107 | ||
| Interactions | 107 | ||
| Diagnostic Test Effects | 107 | ||
| Side Effects | 107 | ||
| Serious Reactions | 107 | ||
| Atorvastatin | 108 | ||
| Mechanism of Action | 108 | ||
| Pharmacokinetics | 108 | ||
| Availability | 108 | ||
| Indications and Dosages | 108 | ||
| ▸Hyperlipidemia, reduction of risk of myocardial infarction (MI), angina revascularization procedures, or stroke in patients wit... | 108 | ||
| ▸Familial hypercholesterolemia | 108 | ||
| ▸Dosages in patients taking cyclosporine, clarithromycin, or taking a combination of ritonavir plus saquinavir or lopinavir | 108 | ||
| Contraindications | 108 | ||
| Interactions | 108 | ||
| Diagnostic Test Effects | 109 | ||
| Side Effects | 109 | ||
| Serious Reactions | 109 | ||
| Atovaquone | 109 | ||
| Mechanism of Action | 110 | ||
| Pharmacokinetics | 110 | ||
| Availability | 110 | ||
| Indications and Dosages | 110 | ||
| ▸Pneumocystis carinii pneumonia (PCP) | 110 | ||
| ▸Prevention of PCP | 110 | ||
| Off-Label Uses | 110 | ||
| Contraindications | 110 | ||
| Interactions | 110 | ||
| Diagnostic Test Effects | 110 | ||
| Side Effects | 110 | ||
| Serious Reactions | 110 | ||
| Atropine | 111 | ||
| Mechanism of Action | 111 | ||
| Pharmacokinetics | 111 | ||
| Availability | 111 | ||
| Indications and Dosages | 111 | ||
| ▸Asystole, slow pulseless electrical activity | 111 | ||
| ▸Preanesthetic | 111 | ||
| ▸Bradycardia | 111 | ||
| ▸Cycloplegia/mydriasis | 111 | ||
| ▸Organophosphate nerve agent or insecticide poisoning | 111 | ||
| Contraindications | 112 | ||
| Interactions | 112 | ||
| Diagnostic Test Effects | 112 | ||
| ?IV Incompatibilities | 112 | ||
| ?IV Compatibilities | 112 | ||
| Side Effects | 112 | ||
| Serious Reactions | 112 | ||
| Avanafil | 113 | ||
| Mechanism of Action | 113 | ||
| Availability | 113 | ||
| Indications and Dosages | 113 | ||
| ▸Erectile dysfunction | 113 | ||
| Contraindications | 113 | ||
| Interactions | 113 | ||
| Diagnostic Test Effects | 113 | ||
| Mechanism of Action | 113.e1 | ||
| Pharmacokinetics | 113.e1 | ||
| Availability | 113.e1 | ||
| Indications and Dosages | 113.e1 | ||
| ▸Rheumatoid arthritis | 113.e1 | ||
| Contraindications | 113.e1 | ||
| Interactions | 113.e1 | ||
| Diagnostic Test Effects | 113.e1 | ||
| Side Effects | 113.e1 | ||
| Serious Reactions | 113.e1 | ||
| Side Effects | 114 | ||
| Serious Reactions | 114 | ||
| Azathioprine | 114 | ||
| Mechanism of Action | 114 | ||
| Availability | 114 | ||
| Mechanism of Action | 114.e1 | ||
| Pharmacokinetics | 114.e1 | ||
| Availability | 114.e1 | ||
| Indications and Dosages | 114.e1 | ||
| ▸Advanced renal cell carcinoma | 114.e1 | ||
| ▸Dosage adjustment for toxicities | 114.e1 | ||
| ▸Dosage adjustment for CYP3A4/5 inhibitor co-use or moderate hepatic impairment | 114.e1 | ||
| Contraindications | 114.e1 | ||
| Interactions | 114.e1 | ||
| Diagnostic Test Effects | 114.e2 | ||
| Side Effects | 114.e2 | ||
| Serious Reactions | 114.e2 | ||
| Azacitidine | 114.e3 | ||
| Mechanism of Action | 114.e3 | ||
| Pharmacokinetics | 114.e3 | ||
| Availability | 114.e3 | ||
| Indications and Dosages | 114.e3 | ||
| ▸Myelodysplastic syndrome | 114.e3 | ||
| Off-Label Uses | 114.e3 | ||
| Contraindications | 114.e3 | ||
| Interactions | 114.e3 | ||
| Diagnostic Test Effects | 114.e3 | ||
| Side Effects | 114.e3 | ||
| Serious Reactions | 114.e4 | ||
| Indications and Dosages | 115 | ||
| ▸Adjunct in prevention of renal allograft rejection | 115 | ||
| ▸Rheumatoid arthritis | 115 | ||
| ▸Dosage in renal impairment | 115 | ||
| Off-Label Uses | 115 | ||
| Contraindications | 115 | ||
| Interactions | 115 | ||
| Diagnostic Test Effects | 115 | ||
| ?IV Incompatibilities | 115 | ||
| Side Effects | 115 | ||
| Serious Reactions | 116 | ||
| Azelastine | 116 | ||
| Mechanism of Action | 116 | ||
| Pharmacokinetics | 116 | ||
| Availability | 116 | ||
| Mechanism of Action | 116.e1 | ||
| Pharmacokinetics | 116.e1 | ||
| Availability | 116.e1 | ||
| Indications and Dosages | 116.e1 | ||
| ▸Mild to moderate acne | 116.e1 | ||
| ▸Mild to moderate rosacea | 116.e1 | ||
| Contraindications | 116.e1 | ||
| Drug Interactions | 116.e1 | ||
| Diagnostic Test Effects | 116.e1 | ||
| Side Effects | 116.e1 | ||
| Serious Reactions | 116.e1 | ||
| Indications and Dosages | 117 | ||
| ▸Allergic rhinitis | 117 | ||
| ▸Allergic conjunctivitis | 117 | ||
| Contraindications | 117 | ||
| Interactions | 117 | ||
| Diagnostic Test Effects | 117 | ||
| Side Effects | 117 | ||
| Serious Reactions | 117 | ||
| Azilsartan | 118 | ||
| Mechanism of Action | 118 | ||
| Pharmacokinetics | 118 | ||
| Availability | 118 | ||
| Indications and Dosages | 118 | ||
| ▸Hypertension | 118 | ||
| Contraindications | 118 | ||
| Interactions | 118 | ||
| Diagnostic Test Effects | 118 | ||
| Side Effects | 118 | ||
| Serious Reactions | 118 | ||
| Azithromycin | 119 | ||
| Mechanism of Action | 119 | ||
| Pharmacokinetics | 119 | ||
| Availability | 119 | ||
| Indications and Dosages | 119 | ||
| ▸Respiratory tract, skin, and skin-structure infections | 119 | ||
| ▸Single-dose treatment of community-acquired pneumonia | 119 | ||
| ▸Acute bacterial exacerbations of COPD | 120 | ||
| ▸Otitis media | 120 | ||
| ▸Pharyngitis, tonsillitis | 120 | ||
| ▸Chancroid | 120 | ||
| ▸Treatment of Mycobacterium avium complex (MAC) | 120 | ||
| ▸Prevention of MAC | 120 | ||
| ▸Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis | 120 | ||
| ▸Gonococcal urethritis | 120 | ||
| ▸Bacterial conjunctivitis | 120 | ||
| ▸Usual pediatric dosage | 120 | ||
| ▸Usual parenteral dosage (community-acquired pneumonia, PID) | 120 | ||
| Off-Label Uses | 120 | ||
| Contraindications | 120 | ||
| Interactions | 120 | ||
| Diagnostic Test Effects | 121 | ||
| ?IV Compatibilities | 121 | ||
| Side Effects | 121 | ||
| Serious Reactions | 121 | ||
| Aztreonam | 122 | ||
| Mechanism of Action | 122 | ||
| Pharmacokinetics | 122 | ||
| Availability | 122 | ||
| Indications and Dosages | 122 | ||
| ▸Urinary tract infections | 122 | ||
| ▸Moderate to severe systemic infections | 122 | ||
| ▸Severe or life-threatening infections | 122 | ||
| ▸Cystic fibrosis | 122 | ||
| ▸Mild to severe infections in children | 122 | ||
| ▸Dosage in renal impairment | 122 | ||
| Off-Label Uses | 122 | ||
| Contraindications | 122 | ||
| Interactions | 122 | ||
| Diagnostic Test Effects | 123 | ||
| ?IV Incompatibilities | 123 | ||
| ?IV Compatibilities | 123 | ||
| Side Effects | 123 | ||
| Serious Reactions | 123 | ||
| B | 125 | ||
| Bacitracin | 125 | ||
| Mechanism of Action | 125 | ||
| Pharmacokinetics | 125 | ||
| Availability | 125 | ||
| Indications and Dosages | 125 | ||
| ▸Superficial ocular infections | 125 | ||
| ▸Skin abrasions, superficial skin infections | 125 | ||
| ▸Surgical treatment and prophylaxis | 125 | ||
| Contraindications | 125 | ||
| Interactions | 125 | ||
| Diagnostic Test Effects | 125 | ||
| Side Effects | 125 | ||
| Serious Reactions | 125 | ||
| Baclofen | 126 | ||
| Mechanism of Action | 126 | ||
| Pharmacokinetics | 126 | ||
| Availability | 126 | ||
| Indications and Dosages | 126 | ||
| ▸Spasticity | 126 | ||
| Off-Label Uses | 126 | ||
| Contraindications | 126 | ||
| Interactions | 126 | ||
| Diagnostic Test Effects | 126 | ||
| Side Effects | 127 | ||
| Serious Reactions | 127 | ||
| Balsalazide | 127 | ||
| Mechanism of Action | 128 | ||
| Pharmacokinetics | 128 | ||
| Availability | 128 | ||
| Indications and Dosages | 128 | ||
| ▸Ulcerative colitis | 128 | ||
| ▸Ulcerative colitis in males | 128 | ||
| Contraindications | 128 | ||
| Interactions | 128 | ||
| Side Effects | 128 | ||
| Serious Reactions | 128 | ||
| Beclomethasone Dipropionate | 129 | ||
| Mechanism of Action | 129 | ||
| Pharmacokinetics | 129 | ||
| Availability | 129 | ||
| Indications and Dosages | 129 | ||
| ▸Long-term control of bronchial asthma, reduces need for oral corticosteroid therapy for asthma | 129 | ||
| ▸Relief of seasonal or perennial rhinitis, prevention of nasal polyp recurrence after surgical removal, treatment of nonallergic... | 129 | ||
| Contraindications | 129 | ||
| Interactions | 129 | ||
| Diagnostic Test Effects | 129 | ||
| Side Effects | 129 | ||
| Basiliximab | 129.e1 | ||
| Mechanism of Action | 129.e1 | ||
| Pharmacokinetics | 129.e1 | ||
| Availability | 129.e1 | ||
| Indications and Dosages | 129.e1 | ||
| ▸Prevention of acute organ rejection in patients receiving a kidney transplant, with cyclosporine and corticosteroids | 129.e1 | ||
| Off-Label Uses | 129.e1 | ||
| Contraindications | 129.e1 | ||
| Interactions | 129.e1 | ||
| Diagnostic Test Effects | 129.e1 | ||
| ?IV Incompatibilities | 129.e1 | ||
| Side Effects | 129.e1 | ||
| Serious Reactions | 129.e1 | ||
| BCG, Intravesical | 129.e2 | ||
| Mechanism of Action | 129.e2 | ||
| Availability | 129.e2 | ||
| Indications and Dosages | 129.e2 | ||
| ▸Treatment and prevention of bladder carcinoma in situ; prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors ... | 129.e2 | ||
| Contraindications | 129.e2 | ||
| Interactions | 129.e3 | ||
| Diagnostic Test Effects | 129.e3 | ||
| Side Effects | 129.e3 | ||
| Serious Reactions | 129.e3 | ||
| Becaplermin | 129.e4 | ||
| Mechanism of Action | 129.e4 | ||
| Pharmacokinetics | 129.e4 | ||
| Availability | 129.e4 | ||
| Indications and Dosages | 129.e4 | ||
| ▸Diabetic foot ulcer and decubitus ulcers | 129.e4 | ||
| Contraindications | 129.e4 | ||
| Interactions | 129.e4 | ||
| Diagnostic Test Effects | 129.e4 | ||
| Side Effects | 129.e4 | ||
| Serious Reactions | 129.e4 | ||
| Serious Reactions | 130 | ||
| Bedaquiline | 131 | ||
| Mechanism of Action | 131 | ||
| Pharmacokinetics | 131 | ||
| Availability | 131 | ||
| Indications and Dosages | 131 | ||
| ‣ Pulmonary multi-drug resistant tuberculosis (MDR-TB) | 131 | ||
| Contraindications | 131 | ||
| Interactions | 131 | ||
| Diagnostic Test Effects | 132 | ||
| Side Effects | 132 | ||
| Serious Reactions | 132 | ||
| Belimumab | 133 | ||
| Mechanism of Action | 133 | ||
| Pharmacokinetics | 133 | ||
| Availability | 133 | ||
| Indications and Dosages | 133 | ||
| ▸Systemic Lupus Erythematosus (active, autoantibody-positive patients receiving standard therapy) | 133 | ||
| Contraindications | 133 | ||
| Interactions | 133 | ||
| Diagnostic Test Effects | 133 | ||
| ?IV Incompatibilities | 133 | ||
| Belatacept | 133.e1 | ||
| Mechanism of Action | 133.e1 | ||
| Pharmacokinetics | 133.e1 | ||
| Availability | 133.e1 | ||
| Indications and Dosages | 133.e1 | ||
| ‣ Prophylaxis of renal transplant rejection | 133.e1 | ||
| Contraindications | 133.e1 | ||
| Interactions | 133.e1 | ||
| Diagnostic Test Effects | 133.e1 | ||
| ?IV Incompatibility | 133.e2 | ||
| Side Effects | 133.e2 | ||
| Serious Reactions | 133.e2 | ||
| Side Effects | 134 | ||
| Serious Reactions | 134 | ||
| Belladonna Alkaloids; Phenobarbital | 135 | ||
| Mechanism of Action | 135 | ||
| Pharmacokinetics | 135 | ||
| Availability | 135 | ||
| Indications and Dosages | 135 | ||
| ▸Irritable bowel syndrome, acute enterocolitis | 135 | ||
| Contraindications | 135 | ||
| Interactions | 135 | ||
| Diagnostic Test Effects | 136 | ||
| Side Effects | 136 | ||
| Serious Reactions | 136 | ||
| Belladonna and Opium | 137 | ||
| Mechanism of Action | 137 | ||
| Pharmacokinetics | 137 | ||
| Availability | 137 | ||
| Indications and Dosages | 137 | ||
| ▸Pain associated with ureteral spasm not responsive to conventional analgesics | 137 | ||
| Contraindications | 137 | ||
| Interactions | 137 | ||
| Diagnostic Test Effects | 137 | ||
| Side Effects | 137 | ||
| Serious Reactions | 138 | ||
| Benazepril | 138 | ||
| Mechanism pf Action | 138 | ||
| Pharmacokinetics | 138 | ||
| Availability | 138 | ||
| Indications and Dosages | 138 | ||
| ▸Hypertension (monotherapy) | 138 | ||
| Mechanism of Action | 138.e1 | ||
| Pharmacokinetics | 138.e1 | ||
| Availability | 138.e1 | ||
| Indications and Dosages | 138.e1 | ||
| ▸Chronic lymphocytic leukemia (CLL) | 138.e1 | ||
| ▸Indolent B-cell non-Hodgkin lymphoma | 138.e1 | ||
| ▸Moderate to severe hepatic impairment or renal impairment (CrCl < 40 mL/min) | 138.e1 | ||
| ?IV Incompatibilities | 138.e1 | ||
| Contraindications | 138.e1 | ||
| Interactions | 138.e1 | ||
| Diagnostic Test Effects | 138.e2 | ||
| Side Effects | 138.e2 | ||
| Serious Reactions | 138.e2 | ||
| Bentoquatam | 138.e3 | ||
| Mechanism of Action | 138.e3 | ||
| Pharmacokinetics | 138.e3 | ||
| Availability | 138.e3 | ||
| Indications and Dosages | 138.e3 | ||
| ▸Prophylaxis of contact dermatitis caused by poison oak, ivy, or sumac | 138.e3 | ||
| Contraindications | 138.e3 | ||
| Interactions | 138.e3 | ||
| Diagnostic Test Effects | 138.e3 | ||
| Side Effects | 138.e3 | ||
| Serious Reactions | 138.e3 | ||
| ▸Hypertension (combination therapy) | 139 | ||
| ▸Dosage in renal impairment | 139 | ||
| Off-Label Uses | 139 | ||
| Contraindications | 139 | ||
| Interactions | 139 | ||
| Diagnostic Test Effects | 139 | ||
| Side Effects | 139 | ||
| Serious Reactions | 139 | ||
| Benzocaine | 140 | ||
| Mechanism of Action | 140 | ||
| Pharmacokinetics | 140 | ||
| Availability | 140 | ||
| Indications and Dosages | 141 | ||
| ▸Canker sores | 141 | ||
| ▸Denture irritation | 141 | ||
| ▸General lubrication | 141 | ||
| ▸Otitis externa, otitis media | 141 | ||
| ▸Pain and itching associated with sunburn, insect bites, minor cuts, scrapes, minor burns, minor skin irritations | 141 | ||
| ▸Pharyngitis | 141 | ||
| ▸Toothache/teething pain | 141 | ||
| ▸Anesthesia | 141 | ||
| Contraindications | 141 | ||
| Interactions | 141 | ||
| Diagnostic Test Effects | 141 | ||
| Side Effects | 142 | ||
| Serious Reactions | 142 | ||
| Benzonatate | 142 | ||
| Mechanism of Action | 142 | ||
| Pharmacokinetics | 142 | ||
| Availability | 142 | ||
| Indications and Dosages | 142 | ||
| ▸Antitussive | 142 | ||
| Off-Label Uses | 142 | ||
| Contraindications | 142 | ||
| Interactions | 143 | ||
| Diagnostic Test Effects | 143 | ||
| Side Effects | 143 | ||
| Serious Reactions | 143 | ||
| Benzoyl Peroxide | 143 | ||
| Mechanism of Action | 143 | ||
| Pharmacokinetics | 143 | ||
| Availability | 144 | ||
| Indications and Dosages | 144 | ||
| ▸Acne | 144 | ||
| Off-Label Uses | 144 | ||
| Contraindications | 144 | ||
| Interactions | 144 | ||
| Diagnostic Test Effects | 144 | ||
| Side Effects | 144 | ||
| Serious Reactions | 144 | ||
| Benztropine | 145 | ||
| Mechanism of Action | 145 | ||
| Pharmacokinetics | 145 | ||
| Availability | 145 | ||
| Indications and Dosages | 145 | ||
| ▸Parkinsonism | 145 | ||
| ▸Drug-induced extrapyramidal symptoms | 145 | ||
| ▸Acute dystonic reactions | 145 | ||
| ?IV Incompatibilities | 145 | ||
| Contraindications | 145 | ||
| Interactions | 145 | ||
| Diagnostic Test Effects | 145 | ||
| Side Effects | 145 | ||
| Serious Reactions | 146 | ||
| Betamethasone | 146 | ||
| Mechanism of Action | 146 | ||
| Pharmacokinetics | 146 | ||
| Availability | 146 | ||
| Mechanism of Action | 146.e1 | ||
| Pharmacokinetics | 146.e1 | ||
| Availability | 146.e1 | ||
| Indications and Dosages | 146.e1 | ||
| ▸Head lice | 146.e1 | ||
| Contraindications | 146.e1 | ||
| Interactions | 146.e1 | ||
| Diagnostic Test Effects | 146.e1 | ||
| Side Effects | 146.e1 | ||
| Serious Reactions | 146.e1 | ||
| Bepotastine | 146.e2 | ||
| Mechanism of Action | 146.e2 | ||
| Pharmacokinetics | 146.e2 | ||
| Availability | 146.e2 | ||
| Indications and Dosages | 146.e2 | ||
| ▸Allergic conjunctivitis | 146.e2 | ||
| Contraindications | 146.e2 | ||
| Interactions | 146.e2 | ||
| Side Effects | 146.e3 | ||
| Serious Reactions | 146.e3 | ||
| Beractant | 146.e3 | ||
| Mechanism of Action | 146.e3 | ||
| Pharmacokinetics | 146.e3 | ||
| Availability | 146.e3 | ||
| Indications and Dosages | 146.e3 | ||
| ▸Prevention and rescue treatment of respiratory distress syndrome (RDS) or hyaline membrane disease in premature infants | 146.e3 | ||
| Contraindications | 146.e3 | ||
| Interactions | 146.e4 | ||
| Diagnostic Test Effects | 146.e4 | ||
| Side Effects | 146.e4 | ||
| Serious Reactions | 146.e4 | ||
| Besifloxacin | 146.e4 | ||
| Mechanism of Action | 146.e5 | ||
| Pharmacokinetics | 146.e5 | ||
| Availability | 146.e5 | ||
| Indications and Dosages | 146.e5 | ||
| ▸Bacterial conjunctivitis | 146.e5 | ||
| Contraindications | 146.e5 | ||
| Interactions | 146.e5 | ||
| Side Effects | 146.e5 | ||
| Serious Reactions | 146.e5 | ||
| Indications and Dosages | 147 | ||
| ▸Anti-inflammation, immunosuppression, corticosteroid replacement therapy | 147 | ||
| ▸Relief of inflamed and pruritic dermatoses | 147 | ||
| ▸Rheumatoid arthritis/osteoarthritis | 147 | ||
| ▸Bursitis | 147 | ||
| Off-Label Uses | 147 | ||
| Contraindications | 147 | ||
| Interactions | 147 | ||
| Diagnostic Test Effects | 147 | ||
| Side Effects | 147 | ||
| Serious Reactions | 148 | ||
| Betaxolol | 148 | ||
| Mechanism of Action | 148 | ||
| Pharmacokinetics | 148 | ||
| Mechanism of Action | 148.e1 | ||
| Pharmacokinetics | 148.e1 | ||
| Availability | 148.e1 | ||
| Indications and Dosages | 148.e1 | ||
| ▸Postoperative and postpartum urine retention, neurogenic atony of bladder with retention | 148.e1 | ||
| Off-Label Uses | 148.e1 | ||
| Contraindications | 148.e1 | ||
| Interactions | 148.e1 | ||
| Diagnostic Test Effects | 148.e1 | ||
| Side Effects | 148.e1 | ||
| Serious Reactions | 148.e1 | ||
| Bevacizumab | 148.e2 | ||
| Mechanism of Action | 148.e2 | ||
| Pharmacokinetics | 148.e2 | ||
| Availability | 148.e2 | ||
| Indications and Dosages | 148.e2 | ||
| ▸First-line treatment of metastatic carcinoma of the colon or rectum in combination with 5-fluorouracil (5-FU) | 148.e2 | ||
| ▸Nonsquamous non–small cell lung cancer | 148.e2 | ||
| ▸Renal cell cancer | 148.e2 | ||
| ▸Gliobiastoma | 148.e2 | ||
| Off-Label Uses | 148.e2 | ||
| Contraindications | 148.e2 | ||
| Interactions | 148.e2 | ||
| Diagnostic Test Effects | 148.e3 | ||
| ?IV Incompatibilities | 148.e3 | ||
| Side Effects | 148.e3 | ||
| Serious Reactions | 148.e3 | ||
| Availability | 149 | ||
| Indications and Dosages | 149 | ||
| ▸Hypertension | 149 | ||
| ▸Chronic open-angle glaucoma and ocular hypertension | 149 | ||
| ▸Oral dosage in renal impairment | 149 | ||
| Off-Label Uses | 149 | ||
| Contraindications | 149 | ||
| Interactions | 149 | ||
| Diagnostic Test Effects | 149 | ||
| Side Effects | 149 | ||
| Serious Reactions | 149 | ||
| Bimatoprost | 150 | ||
| Mechanism of Action | 150 | ||
| Pharmacokinetics | 150 | ||
| Availability | 150 | ||
| Mechanism of Action | 150.e1 | ||
| Pharmacokinetics | 150.e1 | ||
| Availability | 150.e1 | ||
| Indications and Dosages | 150.e1 | ||
| ▸Cutaneous T-cell lymphoma refractory to at least one prior systemic therapy | 150.e1 | ||
| Off-Label Uses | 150.e1 | ||
| Contraindications | 150.e1 | ||
| Interactions | 150.e1 | ||
| Diagnostic Test Effects | 150.e1 | ||
| Side Effects | 150.e1 | ||
| Serious Reactions | 150.e2 | ||
| Bicalutamide | 150.e2 | ||
| Mechanism of Action | 150.e2 | ||
| Pharmacokinetics | 150.e2 | ||
| Availability | 150.e2 | ||
| Indications and Dosages | 150.e2 | ||
| ▸Prostatic carcinoma | 150.e2 | ||
| Contraindications | 150.e3 | ||
| Interactions | 150.e3 | ||
| Diagnostic Test Effects | 150.e3 | ||
| Side Effects | 150.e3 | ||
| Serious Reactions | 150.e3 | ||
| Indications and Dosages | 151 | ||
| ▸Glaucoma, ocular hypertension | 151 | ||
| ▸Hypotrichosis of eyelashes | 151 | ||
| Contraindications | 151 | ||
| Diagnostic Test Effects | 151 | ||
| Side Effects | 151 | ||
| Serious Reactions | 151 | ||
| Bisacodyl | 151 | ||
| Mechanism of Action | 152 | ||
| Pharmacokinetics | 152 | ||
| Availability | 152 | ||
| Indications and Dosages | 152 | ||
| ▸For use in bowel preparation regimens | 152 | ||
| ▸Treatment of constipation | 152 | ||
| Contraindications | 152 | ||
| Interactions | 152 | ||
| Diagnostic Test Effects | 152 | ||
| Side Effects | 152 | ||
| Serious Reactions | 152 | ||
| Bismuth Subsalicylate | 153 | ||
| Mechanism of Action | 153 | ||
| Availability | 153 | ||
| Indications and Dosages | 153 | ||
| ▸Diarrhea, gastric distress | 153 | ||
| ▸H. pylori–associated duodenal ulcer, gastritis | 153 | ||
| Off-Label Uses | 153 | ||
| Contraindications | 153 | ||
| Interactions | 154 | ||
| Diagnostic Test Effects | 154 | ||
| Side Effects | 154 | ||
| Serious Reactions | 154 | ||
| Bisoprolol | 154 | ||
| Mechanism of Action | 155 | ||
| Pharmacokinetics | 155 | ||
| Availability | 155 | ||
| Indications and Dosages | 155 | ||
| ▸Hypertension | 155 | ||
| ▸Dosage in renal or hepatic impairment | 155 | ||
| Off-Label Uses | 155 | ||
| Contraindications | 155 | ||
| Interactions | 155 | ||
| Diagnostic Test Effects | 155 | ||
| Side Effects | 155 | ||
| Serious Reactions | 155 | ||
| Bivalirudin | 156 | ||
| Mechanism of Action | 156 | ||
| Pharmacokinetics | 156 | ||
| Availability | 156 | ||
| Indications and Dosages | 157 | ||
| ▸Anticoagulant in patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA) or perc... | 157 | ||
| ▸Dosage in renal impairment | 157 | ||
| Off-Label Use | 157 | ||
| Contraindications | 157 | ||
| Interactions | 157 | ||
| Diagnostic Test Effects | 157 | ||
| ?IV Incompatibilities | 157 | ||
| Side Effects | 157 | ||
| Serious Reactions | 157 | ||
| Bosentan | 158 | ||
| Mechanism of Action | 158 | ||
| Pharmacokinetics | 158 | ||
| Availability | 158 | ||
| Indications and Dosages | 158 | ||
| ▸PAH in those with World Health Organization Class III or IV symptoms | 158 | ||
| Mechanism of Action | 158.e1 | ||
| Pharmacokinetics | 158.e1 | ||
| Availability | 158.e1 | ||
| Indications and Dosages | 158.e1 | ||
| ▸For monotherapy or in combination therapy for testicular carcinoma; lymphomas (including Hodgkin’s disease, choriocarcinoma, re... | 158.e1 | ||
| ▸As a sclerosing agent to treat malignant pleural effusions and prevent recurrent pleural effusions | 158.e1 | ||
| ▸General dose in renal impairment (Adults) | 158.e1 | ||
| Contraindications | 158.e1 | ||
| Interactions | 158.e1 | ||
| Diagnostic Test Effects | 158.e1 | ||
| Boceprevir | 158.e2 | ||
| Mechanism of Action | 158.e2 | ||
| Pharmacokinetics | 158.e2 | ||
| Side Effects | 158.e2 | ||
| Serious Reactions | 158.e2 | ||
| Availability | 158.e3 | ||
| Indications and Dosages | 158.e3 | ||
| ▸Hepatitis C genotype 1 infection (with peginterferon alfa and ribavirin), compensated | 158.e3 | ||
| Contraindications | 158.e3 | ||
| Interactions | 158.e3 | ||
| Dihydroergotamine, ergonovine, ergotamine, methylergonovine: Risk of ergot toxicity; contraindicated | 158.e3 | ||
| Diagnostic Test Effects | 158.e4 | ||
| Side Effects | 158.e4 | ||
| Serious Reactions | 158.e4 | ||
| Bortezomib | 158.e5 | ||
| Mechanism of Action | 158.e5 | ||
| Pharmacokinetics | 158.e5 | ||
| Availability | 158.e5 | ||
| Indications and Dosages | 158.e5 | ||
| ▸Previously untreated multiple myeloma | 158.e5 | ||
| ▸Relapsed multiple myeloma or for mantle cell lymphoma | 158.e5 | ||
| ▸Moderate or severe hepatic impairment (all indications) | 158.e5 | ||
| ▸Dosage adjustment guidelines | 158.e6 | ||
| Contraindications | 158.e6 | ||
| Interactions | 158.e6 | ||
| Side Effects | 158.e6 | ||
| Serious Reactions | 158.e6 | ||
| ▸Moderate to Severe Hepatic Impairment | 159 | ||
| Contraindications | 159 | ||
| Interactions | 159 | ||
| Diagnostic Test Effects | 159 | ||
| Side Effects | 159 | ||
| Serious Reactions | 159 | ||
| Brimonidine | 160 | ||
| Mechanism of Action | 160 | ||
| Pharmacokinetics | 160 | ||
| Availability | 160 | ||
| Indications and Dosages | 160 | ||
| ▸Glaucoma, ocular hypertension | 160 | ||
| Contraindications | 160 | ||
| Interactions | 160 | ||
| Mechanism of Action | 160.e1 | ||
| Pharmacokinetics | 160.e1 | ||
| Availability | 160.e1 | ||
| Indications and Dosages | 160.e1 | ||
| ‣ Chronic, accelerated, or blast phase Ph+ CML | 160.e1 | ||
| ‣ Dosage adjustment for toxicities | 160.e1 | ||
| ‣ Dosage adjustment for renal impairment | 160.e1 | ||
| ‣ Dosage adjustment for hepatic impairment | 160.e1 | ||
| Contraindications | 160.e1 | ||
| Interactions | 160.e1 | ||
| Diagnostic Test Effects | 160.e2 | ||
| Side Effects | 160.e2 | ||
| Serious Reactions | 160.e2 | ||
| Botulism A/B Immune Globulin Intravenous (Human) | 160.e3 | ||
| Mechanism of Action | 160.e3 | ||
| Pharmacokinetics | 160.e3 | ||
| Availability | 160.e3 | ||
| Indications and Dosages | 160.e3 | ||
| ▸Treatment of infant botulism caused by types A or B | 160.e3 | ||
| ▸Dosage in renal impairment | 160.e3 | ||
| Contraindications | 160.e3 | ||
| Interactions | 160.e3 | ||
| Diagnostic Test Effects | 160.e3 | ||
| Side Effects | 160.e3 | ||
| Serious Reactions | 160.e4 | ||
| Side Effects | 161 | ||
| Serious Reactions | 161 | ||
| Brinzolamide | 161 | ||
| Mechanism of Action | 161 | ||
| Pharmacokinetics | 161 | ||
| Availability | 161 | ||
| Indications and Dosages | 161 | ||
| ▸Glaucoma, ocular hypertension | 161 | ||
| Contraindications | 161 | ||
| Interactions | 161 | ||
| Diagnostic Test Effects | 162 | ||
| Side Effects | 162 | ||
| Serious Reactions | 162 | ||
| Bromfenac | 162 | ||
| Mechanism of Action | 162 | ||
| Pharmacokinetics | 162 | ||
| Availability | 163 | ||
| Indications and Dosages | 163 | ||
| ▸Relief of ocular pain and inflammation in patients who have had cataract extraction | 163 | ||
| Contraindications | 163 | ||
| Interactions | 163 | ||
| Diagnostic Test Effects | 163 | ||
| Side Effects | 163 | ||
| Serious Reactions | 163 | ||
| Bromocriptine | 164 | ||
| Mechanism of Action | 164 | ||
| Pharmacokinetics | 164 | ||
| Availability | 164 | ||
| Indications and Dosages | 164 | ||
| ▸Hyperprolactinemia | 164 | ||
| ▸Parkinson disease | 164 | ||
| ▸Acromegaly | 164 | ||
| ▸Diabetes mellitus type 2 | 164 | ||
| Off-Label Uses | 164 | ||
| Contraindications | 164 | ||
| Interactions | 165 | ||
| Diagnostic Test Effects | 165 | ||
| Side Effects | 165 | ||
| Serious Reactions | 165 | ||
| Brompheniramine | 166 | ||
| Mechanism of Action | 166 | ||
| Pharmacokinetics | 166 | ||
| Availability | 166 | ||
| Indications and Dosages | 166 | ||
| ▸Allergic rhinitis, anaphylaxis, urticarial transfusion reactions, urticaria | 166 | ||
| Contraindications | 166 | ||
| Interactions | 166 | ||
| Diagnostic Test Effects | 167 | ||
| Side Effects | 167 | ||
| Serious Reactions | 167 | ||
| Budesonide | 167 | ||
| Mechanism of Action | 167 | ||
| Pharmacokinetics | 168 | ||
| Availability | 168 | ||
| Indications and Dosages | 168 | ||
| ▸Allergic or vasomotor rhinitis | 168 | ||
| ▸Bronchial asthma | 168 | ||
| ▸Crohn’s disease | 168 | ||
| ▸Ulcerative Colitis | 168 | ||
| Contraindications | 168 | ||
| Interactions | 168 | ||
| Diagnostic Test Effects | 168 | ||
| Side Effects | 168 | ||
| Serious Reactions | 168 | ||
| Budesonide; Formoterol | 170 | ||
| Mechanism of Action | 170 | ||
| Pharmacokinetics | 170 | ||
| Availability | 170 | ||
| Indications and Dosages | 170 | ||
| ▸Bronchial asthma | 170 | ||
| ▸COPD | 170 | ||
| Contraindications | 170 | ||
| Interactions | 170 | ||
| Diagnostic Test Effects | 170 | ||
| Side Effects | 171 | ||
| Serious Reactions | 171 | ||
| Bumetanide | 172 | ||
| Mechanism of Action | 172 | ||
| Pharmacokinetics | 172 | ||
| Availability | 172 | ||
| Indications and Dosages | 172 | ||
| ▸Edema | 172 | ||
| ▸Hypertension | 172 | ||
| ▸Usual pediatric dosage | 172 | ||
| Off-Label Uses | 172 | ||
| Contraindications | 172 | ||
| Interactions | 172 | ||
| Diagnostic Test Effects | 173 | ||
| ?IV Incompatibilities | 173 | ||
| ?IV Compatibilities | 173 | ||
| Side Effects | 173 | ||
| Serious Reactions | 173 | ||
| Buprenorphine | 174 | ||
| Mechanism of Action | 174 | ||
| Pharmacokinetics | 174 | ||
| Availability | 174 | ||
| Indications and Dosages | 174 | ||
| ▸Analgesia | 174 | ||
| ▸Chronic analgesia | 174 | ||
| ▸Opioid dependence | 174 | ||
| Contraindications | 174 | ||
| Interactions | 174 | ||
| Bupivacaine | 174.e1 | ||
| Mechanism of Action | 174.e1 | ||
| Pharmacokinetics | 174.e1 | ||
| Availability | 174.e1 | ||
| Indications and Dosages | 174.e1 | ||
| ▸Analgesic, epidural (partial to moderate motor blockade) | 174.e1 | ||
| ▸Analgesic, epidural (moderate to complete motor blockade) | 174.e1 | ||
| ▸Analgesic, epidural (complete motor blockade) | 174.e1 | ||
| ▸Analgesic, intrapleural | 174.e1 | ||
| ▸Analgesic, caudal (moderate to complete blockade) | 174.e2 | ||
| ▸Analgesic, dental | 174.e2 | ||
| ▸Analgesic, peripheral nerve block (moderate to complete motor blockade) | 174.e2 | ||
| ▸Analgesic, retrobulbar (complete motor blockade) | 174.e2 | ||
| ▸Analgesic, sympathetic blockade | 174.e2 | ||
| ▸Analgesic, hyperbaric spinal (obstetric, normal vaginal delivery) | 174.e2 | ||
| ▸Analgesic, hyperbaric spinal (obstetrical, cesarean section) | 174.e2 | ||
| ▸Anesthesia, hyperbaric spinal (surgical, lower extremity, and perineal procedures) | 174.e2 | ||
| ▸Anesthesia, spinal (surgical, lower abdominal procedures) | 174.e2 | ||
| ▸Anesthesia, spinal (surgical, hyperbaric, upper abdominal procedures) | 174.e2 | ||
| ▸Analgesic, local infiltration | 174.e2 | ||
| Contraindications | 174.e2 | ||
| Interactions | 174.e3 | ||
| Diagnostic Test Effects | 174.e3 | ||
| Side Effects | 174.e3 | ||
| Serious Reactions | 174.e3 | ||
| Diagnostic Test Effects | 175 | ||
| Side Effects | 175 | ||
| Serious Reactions | 175 | ||
| Bupropion | 176 | ||
| Mechanism of Action | 176 | ||
| Pharmacokinetics | 176 | ||
| Availability | 176 | ||
| Indications and Dosages | 176 | ||
| ▸Depression | 176 | ||
| ▸Seasonal Affective Disorder (SAD) | 177 | ||
| ▸Smoking cessation | 177 | ||
| Contraindications | 177 | ||
| Interactions | 177 | ||
| Diagnostic Test Effects | 177 | ||
| Side Effects | 177 | ||
| Serious Reactions | 177 | ||
| Buspirone | 178 | ||
| Mechanism of Action | 178 | ||
| Pharmacokinetics | 178 | ||
| Availability | 178 | ||
| Indications and Dosages | 178 | ||
| ▸Generalized anxiety disorders | 178 | ||
| Off-Label Uses | 178 | ||
| Contraindications | 178 | ||
| Interactions | 178 | ||
| Busulfan | 178.e1 | ||
| Mechanism of Action | 178.e1 | ||
| Pharmacokinetics | 178.e1 | ||
| Availability | 178.e1 | ||
| Indications and Dosages | 178.e1 | ||
| ▸Remission induction in chronic myelogenous leukemia (CML) | 178.e1 | ||
| ▸Marrow ablative conditioning for bone marrow transplantation | 178.e1 | ||
| ?IV Incompatibilities | 178.e1 | ||
| Contraindications | 178.e1 | ||
| Interactions | 178.e1 | ||
| Diagnostic Test Effects | 178.e1 | ||
| Side Effects | 178.e2 | ||
| Serious Reactions | 178.e2 | ||
| Butabarbital Sodium | 178.e2 | ||
| Mechanism of Action | 178.e2 | ||
| Pharmacokinetics | 178.e3 | ||
| Availability | 178.e3 | ||
| Indications and Dosages | 178.e3 | ||
| ▸Insomnia, short-term | 178.e3 | ||
| ▸Preoperative sedation | 178.e3 | ||
| ▸Sedation, daytime | 178.e3 | ||
| Contraindications | 178.e3 | ||
| Interactions | 178.e3 | ||
| Diagnostic Test Effects | 178.e3 | ||
| Side Effects | 178.e3 | ||
| Serious Reactions | 178.e3 | ||
| Diagnostic Test Effects | 179 | ||
| Side Effects | 179 | ||
| Serious Reactions | 179 | ||
| Butenafine | 179 | ||
| Mechanism of Action | 179 | ||
| Pharmacokinetics | 179 | ||
| Availability | 179 | ||
| Indications and Dosages | 179 | ||
| ▸Tinea corporis, tinea cruris, tinea versicolor | 179 | ||
| ▸Tinea pedis | 180 | ||
| Contraindications | 180 | ||
| Interactions | 180 | ||
| Diagnostic Test Effects | 180 | ||
| Side Effects | 180 | ||
| Serious Reactions | 180 | ||
| Butoconazole | 180 | ||
| Mechanism of Action | 180 | ||
| Pharmacokinetics | 180 | ||
| Availability | 180 | ||
| Indications and Dosages | 180 | ||
| ▸Treatment of vaginal candidiasis | 180 | ||
| Contraindications | 181 | ||
| Interactions | 181 | ||
| Side Effects | 181 | ||
| Serious Reactions | 181 | ||
| Butorphanol | 181 | ||
| Mechanism of Action | 181 | ||
| Pharmacokinetics | 181 | ||
| Availability | 181 | ||
| Indications and Dosages | 181 | ||
| ▸Analgesia | 181 | ||
| ▸Migraine | 182 | ||
| ▸Patients with hepatic or renal impairment | 182 | ||
| Contraindications | 182 | ||
| Interactions | 182 | ||
| Diagnostic Test Effects | 182 | ||
| ?IV Incompatibilities | 182 | ||
| ?IV Compatibilities | 182 | ||
| Side Effects | 182 | ||
| Serious Reactions | 182 | ||
| C | 184 | ||
| Cabazitaxel | 183.e1 | ||
| MECHANISM OF ACTION | 183.e1 | ||
| PHARMACOKINETICS | 183.e1 | ||
| AVAILABILITY | 183.e1 | ||
| INDICATIONS AND DOSAGES | 183.e1 | ||
| CONTRAINDICATIONS | 183.e1 | ||
| INTERACTIONS | 183.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 183.e2 | ||
| IV INCOMPATIBILITY | 183.e2 | ||
| SIDE EFFECTS | 183.e2 | ||
| SERIOUS REACTIONS | 183.e2 | ||
| Cabergoline | 184 | ||
| MECHANISM OF ACTION | 184 | ||
| PHARMACOKINETICS | 184 | ||
| AVAILABILITY | 184 | ||
| INDICATIONS AND DOSAGES | 184 | ||
| INTERACTIONS | 184 | ||
| DIAGNOSTIC TEST EFFECTS | 184 | ||
| SIDE EFFECTS | 184 | ||
| SERIOUS REACTIONS | 185 | ||
| Caffeine Citrate | 185 | ||
| MECHANISM OF ACTION | 185 | ||
| PHARMACOKINETICS | 185 | ||
| AVAILABILITY | 185 | ||
| INDICATIONS AND DOSAGES | 185 | ||
| CONTRAINDICATIONS | 185 | ||
| INTERACTIONS | 185 | ||
| Cabozantinib | 185.e1 | ||
| MECHANISM OF ACTION | 185.e1 | ||
| PHARMACOKINETICS | 185.e1 | ||
| AVAILABILITY | 185.e1 | ||
| INDICATIONS AND DOSAGES | 185.e1 | ||
| CONTRAINDICATIONS | 185.e1 | ||
| INTERACTIONS | 185.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 185.e2 | ||
| SIDE EFFECTS | 185.e2 | ||
| SERIOUS REACTIONS | 185.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 186 | ||
| IV INCOMPATIBILITIES | 186 | ||
| IV COMPATIBILITIES | 186 | ||
| SIDE EFFECTS | 186 | ||
| SERIOUS REACTIONS | 186 | ||
| Calcipotriene | 186 | ||
| MECHANISM OF ACTION | 186 | ||
| PHARMACOKINETICS | 187 | ||
| AVAILABILITY | 187 | ||
| INDICATIONS AND DOSAGES | 187 | ||
| CONTRAINDICATIONS | 187 | ||
| INTERACTIONS | 187 | ||
| DIAGNOSTIC TEST EFFECTS | 187 | ||
| Calcitonin | 188 | ||
| MECHANISM OF ACTION | 188 | ||
| PHARMACOKINETICS | 188 | ||
| AVAILABILITY | 188 | ||
| INDICATIONS AND DOSAGES | 188 | ||
| OFF-LABEL USES | 188 | ||
| CONTRAINDICATIONS | 188 | ||
| INTERACTIONS | 188 | ||
| DIAGNOSTIC TEST EFFECTS | 188 | ||
| SIDE EFFECTS | 188 | ||
| SERIOUS REACTIONS | 189 | ||
| Calcitriol | 189 | ||
| MECHANISM OF ACTION | 189 | ||
| PHARMACOKINETICS | 190 | ||
| AVAILABILITY | 190 | ||
| INDICATIONS AND DOSAGES | 190 | ||
| CONTRAINDICATIONS | 190 | ||
| INTERACTIONS | 190 | ||
| DIAGNOSTIC TEST EFFECTS | 191 | ||
| SIDE EFFECTS | 191 | ||
| SERIOUS REACTIONS | 191 | ||
| Calcium Acetate | 191 | ||
| MECHANISM OF ACTION | 191 | ||
| PHARMACOKINETICS | 192 | ||
| AVAILABILITY | 192 | ||
| INDICATIONS AND DOSAGES | 192 | ||
| CONTRAINDICATIONS | 192 | ||
| INTERACTIONS | 192 | ||
| DIAGNOSTIC TEST EFFECTS | 192 | ||
| SIDE EFFECTS | 192 | ||
| SERIOUS REACTIONS | 192 | ||
| Calcium Salts | 193 | ||
| MECHANISM OF ACTION | 193 | ||
| PHARMACOKINETICS | 193 | ||
| AVAILABILITY | 193 | ||
| INDICATIONS AND DOSAGES | 194 | ||
| CONTRAINDICATIONS | 194 | ||
| INTERACTIONS | 194 | ||
| DIAGNOSTIC TEST EFFECTS | 194 | ||
| IV COMPATIBILITIES | 195 | ||
| SIDE EFFECTS | 195 | ||
| SERIOUS REACTIONS | 195 | ||
| Canagliflozin | 196 | ||
| MECHANISM OF ACTION | 196 | ||
| PHARMACOKINETICS | 196 | ||
| AVAILABILITY | 196 | ||
| INDICATIONS AND DOSAGES | 196 | ||
| CONTRAINDICATIONS | 196 | ||
| INTERACTIONS | 196 | ||
| DIAGNOSTIC TEST EFFECTS | 197 | ||
| SIDE EFFECTS | 197 | ||
| SERIOUS REACTIONS | 197 | ||
| Candesartan | 198 | ||
| MECHANISM OF ACTION | 198 | ||
| PHARMACOKINETICS | 198 | ||
| AVAILABILITY | 198 | ||
| INDICATIONS AND DOSAGES | 198 | ||
| CONTRAINDICATIONS | 198 | ||
| INTERACTIONS | 198 | ||
| Calfactant | 198.e1 | ||
| MECHANISM OF ACTION | 198.e1 | ||
| PHARMACOKINETICS | 198.e1 | ||
| AVAILABILITY | 198.e1 | ||
| INDICATIONS AND DOSAGES | 198.e1 | ||
| CONTRAINDICATIONS | 198.e1 | ||
| INTERACTIONS | 198.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 198.e1 | ||
| SIDE EFFECTS | 198.e1 | ||
| SERIOUS REACTIONS | 198.e1 | ||
| Capreomycin | 198.e2 | ||
| MECHANISM OF ACTION | 198.e2 | ||
| PHARMACOKINETICS | 198.e2 | ||
| AVAILABILITY | 198.e2 | ||
| INDICATIONS AND DOSAGES | 198.e2 | ||
| OFF-LABEL USES | 198.e2 | ||
| CONTRAINDICATIONS | 198.e2 | ||
| INTERACTIONS | 198.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 198.e2 | ||
| SIDE EFFECTS | 198.e2 | ||
| SERIOUS REACTIONS | 198.e3 | ||
| DIAGNOSTIC TEST EFFECTS | 199 | ||
| SIDE EFFECTS | 199 | ||
| SERIOUS REACTIONS | 199 | ||
| Capsaicin | 199 | ||
| MECHANISM OF ACTION | 199 | ||
| Capecitabine | 199.e1 | ||
| MECHANISM OF ACTION | 199.e1 | ||
| PHARMACOKINETICS | 199.e1 | ||
| AVAILABILITY | 199.e1 | ||
| INDICATIONS AND DOSAGES | 199.e1 | ||
| CONTRAINDICATIONS | 199.e1 | ||
| INTERACTIONS | 199.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 199.e1 | ||
| SIDE EFFECTS | 199.e1 | ||
| SERIOUS REACTIONS | 199.e2 | ||
| PHARMACOKINETICS | 200 | ||
| AVAILABILITY | 200 | ||
| INDICATIONS AND DOSAGES | 200 | ||
| CONTRAINDICATIONS | 200 | ||
| INTERACTIONS | 200 | ||
| DIAGNOSTIC TEST EFFECTS | 200 | ||
| SIDE EFFECTS | 200 | ||
| SERIOUS REACTIONS | 200 | ||
| Captopril | 201 | ||
| MECHANISM OF ACTION | 201 | ||
| PHARMACOKINETICS | 201 | ||
| AVAILABILITY | 201 | ||
| INDICATIONS AND DOSAGES | 201 | ||
| OFF-LABEL USES | 202 | ||
| CONTRAINDICATIONS | 202 | ||
| INTERACTIONS | 202 | ||
| DIAGNOSTIC TEST EFFECTS | 202 | ||
| SIDE EFFECTS | 202 | ||
| SERIOUS REACTIONS | 202 | ||
| Carbachol | 203 | ||
| MECHANISM OF ACTION | 203 | ||
| PHARMACOKINETICS | 203 | ||
| AVAILABILITY | 203 | ||
| INDICATIONS AND DOSAGES | 203 | ||
| CONTRAINDICATIONS | 203 | ||
| INTERACTIONS | 204 | ||
| DIAGNOSTIC TEST EFFECTS | 204 | ||
| SIDE EFFECTS | 204 | ||
| SERIOUS REACTIONS | 204 | ||
| Carbamazepine | 204 | ||
| MECHANISM OF ACTION | 204 | ||
| PHARMACOKINETICS | 204 | ||
| AVAILABILITY | 204 | ||
| INDICATIONS AND DOSAGES | 204 | ||
| OFF-LABEL USES | 205 | ||
| CONTRAINDICATIONS | 205 | ||
| INTERACTIONS | 205 | ||
| DIAGNOSTIC TEST EFFECTS | 205 | ||
| SIDE EFFECTS | 206 | ||
| SERIOUS REACTIONS | 206 | ||
| Carbamide Peroxide | 207 | ||
| MECHANISM OF ACTION | 207 | ||
| PHARMACOKINETICS | 207 | ||
| AVAILABILITY | 207 | ||
| INDICATIONS AND DOSAGES | 207 | ||
| CONTRAINDICATIONS | 207 | ||
| INTERACTIONS | 207 | ||
| DIAGNOSTIC TEST EFFECTS | 207 | ||
| SIDE EFFECTS | 207 | ||
| SERIOUS REACTIONS | 207 | ||
| Carbidopa and Levodopa | 208 | ||
| MECHANISM OF ACTION | 208 | ||
| PHARMACOKINETICS | 208 | ||
| AVAILABILITY | 208 | ||
| INDICATIONS AND DOSAGES | 208 | ||
| Carboprost | 208.e1 | ||
| MECHANISM OF ACTION | 208.e1 | ||
| PHARMACOKINETICS | 208.e1 | ||
| AVAILABILITY | 208.e1 | ||
| INDICATIONS AND DOSAGES | 208.e1 | ||
| OFF-LABEL USES | 208.e1 | ||
| CONTRAINDICATIONS | 208.e1 | ||
| INTERACTIONS | 208.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 208.e1 | ||
| SIDE EFFECTS | 208.e1 | ||
| SERIOUS REACTIONS | 208.e1 | ||
| Carboplatin | 208.e2 | ||
| MECHANISM OF ACTION | 208.e2 | ||
| PHARMACOKINETICS | 208.e2 | ||
| AVAILABILITY | 208.e2 | ||
| INDICATIONS AND DOSAGES | 208.e2 | ||
| OFF-LABEL USES | 208.e2 | ||
| CONTRAINDICATIONS | 208.e3 | ||
| INTERACTIONS | 208.e3 | ||
| DIAGNOSTIC TEST EFFECTS | 208.e3 | ||
| SIDE EFFECTS | 208.e3 | ||
| SERIOUS REACTIONS | 208.e3 | ||
| Carfilzomib | 208.e4 | ||
| MECHANISM OF ACTION | 208.e4 | ||
| PHARMACOKINETICS | 208.e4 | ||
| AVAILABILITY | 208.e4 | ||
| INDICATIONS AND DOSAGES | 208.e4 | ||
| CONTRAINDICATIONS | 208.e5 | ||
| INTERACTIONS | 208.e5 | ||
| DIAGNOSTIC TEST EFFECTS | 208.e5 | ||
| IV INCOMPATIBILITY | 208.e5 | ||
| SIDE EFFECTS | 208.e5 | ||
| SERIOUS REACTIONS | 208.e5 | ||
| CONTRAINDICATIONS | 209 | ||
| INTERACTIONS | 209 | ||
| DIAGNOSTIC TEST EFFECTS | 209 | ||
| SIDE EFFECTS | 209 | ||
| SERIOUS REACTIONS | 209 | ||
| Carisoprodol | 210 | ||
| MECHANISM OF ACTION | 210 | ||
| AVAILABILITY | 210 | ||
| INDICATIONS AND DOSAGES | 210 | ||
| CONTRAINDICATIONS | 210 | ||
| INTERACTIONS | 210 | ||
| DIAGNOSTIC TEST EFFECTS | 210 | ||
| SIDE EFFECTS | 210 | ||
| SERIOUS REACTIONS | 210 | ||
| Carteolol | 211 | ||
| MECHANISM OF ACTION | 211 | ||
| PHARMACOKINETICS | 211 | ||
| AVAILABILITY | 211 | ||
| INDICATIONS AND DOSAGES | 211 | ||
| OFF-LABEL USES | 211 | ||
| CONTRAINDICATIONS | 211 | ||
| INTERACTIONS | 211 | ||
| Carmustine | 211.e1 | ||
| MECHANISM OF ACTION | 211.e1 | ||
| PHARMACOKINETICS | 211.e1 | ||
| AVAILABILITY | 211.e1 | ||
| INDICATIONS AND DOSAGES | 211.e1 | ||
| CONTRAINDICATIONS | 211.e1 | ||
| INTERACTIONS | 211.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 211.e1 | ||
| SIDE EFFECTS | 211.e1 | ||
| SERIOUS REACTIONS | 211.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 212 | ||
| SIDE EFFECTS | 212 | ||
| SERIOUS REACTIONS | 212 | ||
| Carvedilol | 212 | ||
| MECHANISM OF ACTION | 212 | ||
| PHARMACOKINETICS | 212 | ||
| AVAILABILITY | 213 | ||
| INDICATIONS AND DOSAGES | 213 | ||
| OFF-LABEL USES | 213 | ||
| CONTRAINDICATIONS | 213 | ||
| INTERACTIONS | 213 | ||
| DIAGNOSTIC TEST EFFECTS | 214 | ||
| SIDE EFFECTS | 214 | ||
| SERIOUS REACTIONS | 214 | ||
| Caspofungin Acetate | 215 | ||
| MECHANISM OF ACTION | 215 | ||
| PHARMACOKINETICS | 215 | ||
| AVAILABILITY | 215 | ||
| INDICATIONS AND DOSAGES | 215 | ||
| CONTRAINDICATIONS | 215 | ||
| INTERACTIONS | 215 | ||
| DIAGNOSTIC TEST EFFECTS | 216 | ||
| IV INCOMPATIBILITIES | 216 | ||
| SIDE EFFECTS | 216 | ||
| SERIOUS REACTIONS | 216 | ||
| Castor Oil | 216 | ||
| MECHANISM OF ACTION | 216 | ||
| PHARMACOKINETICS | 217 | ||
| AVAILABILITY | 217 | ||
| INDICATIONS AND DOSAGES | 217 | ||
| CONTRAINDICATIONS | 217 | ||
| INTERACTIONS | 217 | ||
| DIAGNOSTIC TEST EFFECTS | 217 | ||
| SIDE EFFECTS | 217 | ||
| SERIOUS REACTIONS | 217 | ||
| Cefaclor | 217 | ||
| MECHANISM OF ACTION | 217 | ||
| PHARMACOKINETICS | 218 | ||
| AVAILABILITY | 218 | ||
| INDICATIONS AND DOSAGES | 218 | ||
| CONTRAINDICATIONS | 218 | ||
| INTERACTIONS | 218 | ||
| DIAGNOSTIC TEST EFFECTS | 218 | ||
| SIDE EFFECTS | 218 | ||
| SERIOUS REACTIONS | 218 | ||
| Cefadroxil | 219 | ||
| MECHANISM OF ACTION | 219 | ||
| PHARMACOKINETICS | 219 | ||
| AVAILABILITY | 219 | ||
| INDICATIONS AND DOSAGES | 219 | ||
| CONTRAINDICATIONS | 220 | ||
| INTERACTIONS | 220 | ||
| DIAGNOSTIC TEST EFFECTS | 220 | ||
| SIDE EFFECTS | 220 | ||
| SERIOUS REACTIONS | 220 | ||
| Cefazolin | 221 | ||
| MECHANISM OF ACTION | 221 | ||
| PHARMACOKINETICS | 221 | ||
| AVAILABILITY | 221 | ||
| INDICATIONS AND DOSAGES | 221 | ||
| CONTRAINDICATIONS | 221 | ||
| INTERACTIONS | 221 | ||
| DIAGNOSTIC TEST EFFECTS | 222 | ||
| IV INCOMPATIBILITIES | 222 | ||
| IV COMPATIBILITIES | 222 | ||
| SIDE EFFECTS | 222 | ||
| SERIOUS REACTIONS | 222 | ||
| Cefdinir | 223 | ||
| MECHANISM OF ACTION | 223 | ||
| PHARMACOKINETICS | 223 | ||
| AVAILABILITY | 223 | ||
| INDICATIONS AND DOSAGES | 223 | ||
| CONTRAINDICATIONS | 224 | ||
| INTERACTIONS | 224 | ||
| SIDE EFFECTS | 224 | ||
| SERIOUS REACTIONS | 224 | ||
| Cefditoren | 225 | ||
| MECHANISM OF ACTION | 225 | ||
| PHARMACOKINETICS | 225 | ||
| AVAILABILITY | 225 | ||
| INDICATIONS AND DOSAGES | 225 | ||
| CONTRAINDICATIONS | 225 | ||
| INTERACTIONS | 226 | ||
| DIAGNOSTIC TEST EFFECTS | 226 | ||
| SIDE EFFECTS | 226 | ||
| SERIOUS REACTIONS | 226 | ||
| Cefepime | 226 | ||
| MECHANISM OF ACTION | 227 | ||
| PHARMACOKINETICS | 227 | ||
| AVAILABILITY | 227 | ||
| INDICATIONS AND DOSAGES | 227 | ||
| CONTRAINDICATIONS | 227 | ||
| INTERACTIONS | 227 | ||
| DIAGNOSTIC TEST EFFECTS | 227 | ||
| IV INCOMPATIBILITIES | 227 | ||
| IV COMPATIBILITIES | 227 | ||
| SIDE EFFECTS | 227 | ||
| SERIOUS REACTIONS | 228 | ||
| Cefixime | 228 | ||
| MECHANISM OF ACTION | 228 | ||
| PHARMACOKINETICS | 229 | ||
| AVAILABILITY | 229 | ||
| INDICATIONS AND DOSAGES | 229 | ||
| CONTRAINDICATIONS | 229 | ||
| INTERACTIONS | 229 | ||
| DIAGNOSTIC TEST EFFECTS | 229 | ||
| SIDE EFFECTS | 229 | ||
| SERIOUS REACTIONS | 229 | ||
| Cefotaxime | 230 | ||
| PHARMACOKINETICS | 230 | ||
| AVAILABILITY | 230 | ||
| INDICATIONS AND DOSAGES | 230 | ||
| OFF-LABEL USES | 231 | ||
| CONTRAINDICATIONS | 231 | ||
| INTERACTIONS | 231 | ||
| DIAGNOSTIC TEST EFFECTS | 231 | ||
| IV INCOMPATIBILITIES | 231 | ||
| IV COMPATIBILITIES | 231 | ||
| SIDE EFFECTS | 231 | ||
| SERIOUS REACTIONS | 231 | ||
| Cefotetan | 232 | ||
| MECHANISM OF ACTION | 232 | ||
| PHARMACOKINETICS | 232 | ||
| AVAILABILITY | 232 | ||
| INDICATIONS AND DOSAGES | 232 | ||
| CONTRAINDICATIONS | 233 | ||
| INTERACTIONS | 233 | ||
| DIAGNOSTIC TEST EFFECTS | 233 | ||
| SIDE EFFECTS | 233 | ||
| SERIOUS REACTIONS | 233 | ||
| Cefoxitin | 234 | ||
| MECHANISM OF ACTION | 234 | ||
| AVAILABILITY | 234 | ||
| INDICATIONS AND DOSAGES | 234 | ||
| CONTRAINDICATIONS | 235 | ||
| INTERACTIONS | 235 | ||
| DIAGNOSTIC TEST EFFECTS | 235 | ||
| SIDE EFFECTS | 235 | ||
| SERIOUS REACTIONS | 235 | ||
| Cefpodoxime | 236 | ||
| MECHANISM OF ACTION | 236 | ||
| PHARMACOKINETICS | 236 | ||
| AVAILABILITY | 236 | ||
| INDICATIONS AND DOSAGES | 236 | ||
| CONTRAINDICATIONS | 237 | ||
| INTERACTIONS | 237 | ||
| DIAGNOSTIC TEST EFFECTS | 237 | ||
| SIDE EFFECTS | 237 | ||
| SERIOUS REACTIONS | 237 | ||
| Cefprozil | 237 | ||
| MECHANISM OF ACTION | 237 | ||
| PHARMACOKINETICS | 238 | ||
| AVAILABILITY | 238 | ||
| INDICATIONS AND DOSAGES | 238 | ||
| CONTRAINDICATIONS | 238 | ||
| INTERACTIONS | 238 | ||
| DIAGNOSTIC TEST EFFECTS | 238 | ||
| SIDE EFFECTS | 238 | ||
| SERIOUS REACTIONS | 238 | ||
| Ceftaroline Fosamil | 239 | ||
| MECHANISM OF ACTION | 239 | ||
| PHARMACOKINETICS | 239 | ||
| AVAILABILITY | 239 | ||
| INDICATIONS AND DOSAGES | 239 | ||
| CONTRAINDICATIONS | 239 | ||
| INTERACTIONS | 239 | ||
| DIAGNOSTIC TEST EFFECTS | 239 | ||
| SIDE EFFECTS | 240 | ||
| SERIOUS REACTIONS | 240 | ||
| Ceftazidime | 240 | ||
| MECHANISM OF ACTION | 240 | ||
| PHARMACOKINETICS | 240 | ||
| AVAILABILITY | 240 | ||
| INDICATIONS AND DOSAGES | 240 | ||
| CONTRAINDICATIONS | 241 | ||
| DIAGNOSTIC TEST EFFECTS | 241 | ||
| SIDE EFFECTS | 241 | ||
| SERIOUS REACTIONS | 242 | ||
| Ceftibuten | 242 | ||
| MECHANISM OF ACTION | 242 | ||
| PHARMACOKINETICS | 242 | ||
| AVAILABILITY | 242 | ||
| INDICATIONS AND DOSAGES | 242 | ||
| CONTRAINDICATIONS | 243 | ||
| INTERACTIONS | 243 | ||
| DIAGNOSTIC TEST EFFECTS | 243 | ||
| SIDE EFFECTS | 243 | ||
| SERIOUS REACTIONS | 243 | ||
| Ceftriaxone | 244 | ||
| MECHANISM OF ACTION | 244 | ||
| PHARMACOKINETICS | 244 | ||
| AVAILABILITY | 244 | ||
| INDICATIONS AND DOSAGES | 244 | ||
| CONTRAINDICATIONS | 244 | ||
| INTERACTIONS | 244 | ||
| DIAGNOSTIC TEST EFFECTS | 245 | ||
| SIDE EFFECTS | 245 | ||
| SERIOUS REACTIONS | 245 | ||
| Cefuroxime | 246 | ||
| MECHANISM OF ACTION | 246 | ||
| PHARMACOKINETICS | 246 | ||
| AVAILABILITY | 246 | ||
| INDICATIONS AND DOSAGES | 246 | ||
| CONTRAINDICATIONS | 247 | ||
| INTERACTIONS | 247 | ||
| DIAGNOSTIC TEST EFFECTS | 247 | ||
| SIDE EFFECTS | 247 | ||
| SERIOUS REACTIONS | 247 | ||
| Celecoxib | 248 | ||
| MECHANISM OF ACTION | 248 | ||
| PHARMACOKINETICS | 248 | ||
| AVAILABILITY | 248 | ||
| INDICATIONS AND DOSAGES | 248 | ||
| CONTRAINDICATIONS | 249 | ||
| INTERACTIONS | 249 | ||
| DIAGNOSTIC TEST EFFECTS | 249 | ||
| SIDE EFFECTS | 249 | ||
| SERIOUS REACTIONS | 249 | ||
| Cephalexin | 250 | ||
| MECHANISM OF ACTION | 250 | ||
| PHARMACOKINETICS | 250 | ||
| AVAILABILITY | 250 | ||
| INDICATIONS AND DOSAGES | 250 | ||
| CONTRAINDICATIONS | 250 | ||
| INTERACTIONS | 250 | ||
| DIAGNOSTIC TEST EFFECTS | 250 | ||
| SIDE EFFECTS | 251 | ||
| SERIOUS REACTIONS | 251 | ||
| Certolizumab Pegol | 251 | ||
| MECHANISM OF ACTION | 251 | ||
| PHARMACOKINETICS | 252 | ||
| AVAILABILITY | 252 | ||
| INDICATIONS AND DOSAGES | 252 | ||
| CONTRAINDICATIONS | 252 | ||
| INTERACTIONS | 252 | ||
| DIAGNOSTIC TEST EFFECTS | 252 | ||
| SIDE EFFECTS | 252 | ||
| SERIOUS REACTIONS | 252 | ||
| Cetirizine | 254 | ||
| MECHANISM OF ACTION | 254 | ||
| AVAILABILITY | 254 | ||
| INDICATIONS AND DOSAGES | 254 | ||
| CONTRAINDICATIONS | 254 | ||
| INTERACTIONS | 254 | ||
| D | 342 | ||
| Dabigatran | 342 | ||
| Mechanism of Action | 342 | ||
| Pharmacokinetics | 342 | ||
| Availability | 342 | ||
| Indications and Dosages | 342 | ||
| ▸Stroke and systemic embolism prophylaxis in nonvalvular AFib | 342 | ||
| ▸Dosage in renal impairment | 342 | ||
| ▸Converting from or to warfarin | 342 | ||
| Off-Label Uses | 342 | ||
| Contraindications | 342 | ||
| Interactions | 342 | ||
| Diagnostic Test Effects | 343 | ||
| Side Effects | 343 | ||
| Serious Reactions | 343 | ||
| Daklinza | 344 | ||
| Mechanism of Action | 344 | ||
| Pharmacokinetics | 344 | ||
| Availability | 344 | ||
| Indications and Dosages | 344 | ||
| Treatment of chronic hepatitis C genotypes 1 and 3 in combination with other antiviral agents | 344 | ||
| Off-label uses | 344 | ||
| Contraindications | 344 | ||
| Interactions | 344 | ||
| Side Effects | 344 | ||
| Dabrafenib | 344.e1 | ||
| Mechanism of Action | 344.e1 | ||
| Pharmacokinetics | 344.e1 | ||
| Availability | 344.e1 | ||
| Indications and Dosages | 344.e1 | ||
| ▸Unresectable or metastatic melanoma with BRAF V600E mutations | 344.e1 | ||
| ▸Dosage adjustment for toxicities | 344.e1 | ||
| Contraindications | 344.e1 | ||
| Interactions | 344.e1 | ||
| Diagnostic Test Effects | 344.e2 | ||
| Side Effects | 344.e2 | ||
| Serious Reactions | 344.e2 | ||
| Dacarbazine | 344.e3 | ||
| Mechanism of Action | 344.e3 | ||
| Pharmacokinetics | 344.e3 | ||
| Availability | 344.e4 | ||
| Indications and Dosages | 344.e4 | ||
| ▸Malignant melanoma | 344.e4 | ||
| ▸Hodgkin’s disease | 344.e4 | ||
| Off-Label Uses | 344.e4 | ||
| Contraindications | 344.e4 | ||
| Interactions | 344.e4 | ||
| Diagnostic Test Effects | 344.e4 | ||
| IV Incompatibilities\r | 344.e4 | ||
| IV Compatibilities\r | 344.e4 | ||
| Side Effects | 344.e4 | ||
| Serious Reactions | 344.e4 | ||
| Serious Reactions | 345 | ||
| Precautions and Considerations | 345 | ||
| Dalfampridine | 345 | ||
| Mechanism of Action | 345 | ||
| Pharmacokinetics | 345 | ||
| Availability | 345 | ||
| Indications and Dosages | 345 | ||
| ▸To improve walking for patients with multiple sclerosis | 345 | ||
| ▸Dosage in renal impairment | 345 | ||
| Contraindications | 345 | ||
| Interactions | 345 | ||
| Diagnostic Test Effects | 345 | ||
| Side Effects | 345 | ||
| Serious Reactions | 346 | ||
| Dalteparin | 346 | ||
| Mechanism of Action | 346 | ||
| Pharmacokinetics | 346 | ||
| Availability | 346 | ||
| Indications and Dosages | 346 | ||
| ▸Prophylaxis of deep vein thrombosis (DVT), low- to moderate-risk abdominal surgery | 346 | ||
| ▸Prophylaxis of DVT, high-risk abdominal surgery | 346 | ||
| ▸Prophylaxis of DVT, total hip surgery | 347 | ||
| ▸Unstable angina, non–Q-wave MI | 347 | ||
| ▸Prophylaxis of DVT or pulmonary embolism in the acutely ill patient | 347 | ||
| ▸Extended treatment of symptomatic venous thromboembolism (VTE) in patients with cancer | 347 | ||
| Contraindications | 347 | ||
| Interactions | 347 | ||
| Diagnostic Test Effects | 347 | ||
| Side Effects | 347 | ||
| Serious Reactions | 348 | ||
| Danazol | 348 | ||
| Mechanism of Action | 349 | ||
| Pharmacokinetics | 349 | ||
| Availability | 349 | ||
| Indications and Dosages | 349 | ||
| ▸Endometriosis | 349 | ||
| ▸Fibrocystic breast disease | 349 | ||
| ▸Hereditary angioedema | 349 | ||
| Off-Label Uses | 349 | ||
| Contraindications | 349 | ||
| Interactions | 349 | ||
| Diagnostic Test Effects | 349 | ||
| Side Effects | 349 | ||
| Serious Reactions | 350 | ||
| Dantrolene | 350 | ||
| Mechanism of Action | 350 | ||
| Pharmacokinetics | 350 | ||
| Availability | 351 | ||
| Indications and Dosages | 351 | ||
| ▸Spasticity | 351 | ||
| ▸Prevention of malignant hyperthermic crisis | 351 | ||
| ▸Management of malignant hyperthermic crisis | 351 | ||
| Off-Label Uses | 351 | ||
| Contraindications | 351 | ||
| Interactions | 351 | ||
| Diagnostic Test Effects | 351 | ||
| IV Incompatibilities\r | 351 | ||
| Side Effects | 351 | ||
| Serious Reactions | 352 | ||
| Dapagliflozin | 352 | ||
| Mechanism of Action | 352 | ||
| Pharmacokinetics | 352 | ||
| Availability | 353 | ||
| Indications and Dosages | 353 | ||
| ▸Type 2 diabetes mellitus | 353 | ||
| ▸Dosage in renal impairment | 353 | ||
| Contraindications | 353 | ||
| Interactions | 353 | ||
| Diagnostic Test Effects | 353 | ||
| Side Effects | 353 | ||
| Serious Reactions | 353 | ||
| Dapsone | 354 | ||
| Mechanism of Action | 354 | ||
| Availability | 354 | ||
| Indications and Dosages | 354 | ||
| ▸Leprosy | 354 | ||
| ▸Dermatitis herpetiformis | 354 | ||
| ▸Pneumocystis carinii pneumonia (PCP) (off-label) | 354 | ||
| ▸Prevention of PCP (off-label) | 354 | ||
| ▸Acne | 354 | ||
| Off-Label Uses | 354 | ||
| Contraindications | 354 | ||
| Interactions | 355 | ||
| Diagnostic Test Effects | 355 | ||
| Side Effects | 355 | ||
| Serious Reactions | 355 | ||
| Daptomycin | 355 | ||
| Mechanism of Action | 355 | ||
| Pharmacokinetics | 356 | ||
| Availability | 356 | ||
| Indications and Dosages | 356 | ||
| ▸Complicated skin and skin-structure infections | 356 | ||
| ▸Bacteremia from Staphylococcus aureus (MSSA or MRSA), including right-sided endocarditis | 356 | ||
| ▸Dosage in renal impairment | 356 | ||
| Off-Label Uses | 356 | ||
| Contraindications | 356 | ||
| Interactions | 356 | ||
| Diagnostic Test Effects | 356 | ||
| IV Incompatibilities\r | 356 | ||
| IV Compatibilities\r | 356 | ||
| Side Effects | 356 | ||
| Serious Reactions | 356 | ||
| Darbepoetin Alfa | 357 | ||
| Mechanism of Action | 357 | ||
| Pharmacokinetics | 357 | ||
| Availability | 357 | ||
| Indications and Dosages | 358 | ||
| ▸Anemia in chronic renal failure | 358 | ||
| ▸Anemia associated with chemotherapy | 358 | ||
| Contraindications | 358 | ||
| Interactions | 358 | ||
| Diagnostic Test Effects | 358 | ||
| IV Incompatibilities\r | 358 | ||
| Side Effects | 358 | ||
| Serious Reactions | 358 | ||
| Darifenacin Hydrobromide | 359 | ||
| Mechanism of Action | 360 | ||
| Availability | 360 | ||
| Indications and Dosages | 360 | ||
| ▸Overactive bladder | 360 | ||
| ▸Dosage in hepatic impairment | 360 | ||
| Contraindications | 360 | ||
| Interactions | 360 | ||
| Diagnostic Test Effects | 360 | ||
| Side Effects | 360 | ||
| Serious Reactions | 360 | ||
| Darunavir | 361 | ||
| Mechanism of Action | 361 | ||
| Pharmacokinetics | 361 | ||
| Availability | 361 | ||
| Indications and Dosages | 361 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 361 | ||
| Contraindications | 362 | ||
| Interactions | 362 | ||
| Diagnostic Test Effects | 362 | ||
| Side Effects | 362 | ||
| Serious Reactions | 363 | ||
| Deferasirox | 363 | ||
| Mechanism of Action | 363 | ||
| Dasatinib | 363.e1 | ||
| Mechanism of Action | 363.e1 | ||
| Pharmacokinetics | 363.e1 | ||
| Availability | 363.e1 | ||
| Indications and Dosages | 363.e1 | ||
| ▸Acute lymphocytic leukemia (ALL), Philadelphia chromosome–positive, resistant or intolerant to prior therapy | 363.e1 | ||
| ▸CML, accelerated, myeloid, or lymphoid blast phase | 363.e1 | ||
| ▸CML, chronic phase | 363.e1 | ||
| Contraindications | 363.e1 | ||
| Interactions | 363.e1 | ||
| Diagnostic Test Effects | 363.e2 | ||
| Side Effects | 363.e2 | ||
| Serious Reactions | 363.e2 | ||
| Pharmacokinetics | 364 | ||
| Availability | 364 | ||
| Indications | 364 | ||
| ▸Chronic iron toxicity secondary to transfusional iron overload | 364 | ||
| ▸Non-transfusion-dependent thalassemia syndromes | 364 | ||
| ▸Adjustment if taking a potent UGT inducer or a bile acid sequestrant | 364 | ||
| ▸Dosage in hepatic impairment | 364 | ||
| ▸Dosage in renal impairment | 364 | ||
| Contraindications | 364 | ||
| Interactions | 364 | ||
| Diagnostic Test Effects | 365 | ||
| Side Effects | 365 | ||
| Serious Reactions | 365 | ||
| Deferoxamine | 366 | ||
| Mechanism of Action | 366 | ||
| Pharmacokinetics | 366 | ||
| Availability | 366 | ||
| Indications and Dosages | 366 | ||
| ▸Acute iron intoxication | 366 | ||
| ▸Chronic iron overload | 366 | ||
| Off-Label Uses | 366 | ||
| Contraindications | 366 | ||
| Interactions | 366 | ||
| Daunorubicin | 366.e1 | ||
| Mechanism of Action | 366.e1 | ||
| Pharmacokinetics | 366.e1 | ||
| Availability | 366.e1 | ||
| Indications and Dosages | 366.e1 | ||
| ▸Acute lymphocytic leukemia (ALL) | 366.e1 | ||
| ▸Acute myeloid leukemia (AML) | 366.e1 | ||
| ▸Acute nonlymphocytic leukemia (ANLL) | 366.e1 | ||
| ▸Kaposi sarcoma (DaunoXome only) | 366.e1 | ||
| ▸Dosage in renal impairment | 366.e1 | ||
| ▸Dosage in hepatic impairment | 366.e1 | ||
| Off-Label Uses | 366.e2 | ||
| Contraindications | 366.e2 | ||
| Interactions | 366.e2 | ||
| Diagnostic Test Effects | 366.e2 | ||
| ?IV Incompatibilities | 366.e2 | ||
| ?IV Compatibilities | 366.e2 | ||
| Side Effects | 366.e2 | ||
| Serious Reactions | 366.e3 | ||
| Decitabine | 366.e4 | ||
| Mechanism of Action | 366.e4 | ||
| Pharmacokinetics | 366.e4 | ||
| Availability | 366.e4 | ||
| Indications and Dosages | 366.e4 | ||
| ▸Myelodysplastic syndrome (MDS) | 366.e4 | ||
| Contraindications | 366.e4 | ||
| Interactions | 366.e4 | ||
| Diagnostic Test Effects | 366.e4 | ||
| ?IV Compatibilities | 366.e4 | ||
| Side Effects | 366.e4 | ||
| Serious Reactions | 366.e4 | ||
| Diagnostic Test Effects | 367 | ||
| ?IV Incompatibilities | 367 | ||
| Side Effects | 367 | ||
| Serious Reactions | 367 | ||
| Delavirdine | 367 | ||
| Mechanism of Action | 367 | ||
| Pharmacokinetics | 368 | ||
| Availability | 368 | ||
| Indications and Dosages | 368 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 368 | ||
| Contraindications | 368 | ||
| Interactions | 368 | ||
| Diagnostic Test Effects | 368 | ||
| Side Effects | 368 | ||
| Serious Reactions | 369 | ||
| Demeclocycline | 369 | ||
| Mechanism of Action | 369 | ||
| Availability | 369 | ||
| Indications and Dosages | 369 | ||
| ▸Mild to moderate infections, including acne, pertussis, chronic bronchitis, and urinary tract infection | 369 | ||
| ▸Uncomplicated gonorrhea | 369 | ||
| ▸Syndrome of inappropriate ADH secretion (SIADH) | 370 | ||
| Contraindications | 370 | ||
| Interactions | 370 | ||
| Diagnostic Test Effects | 370 | ||
| Side Effects | 370 | ||
| Serious Reactions | 370 | ||
| Denosumab\r | 371 | ||
| Mechanism of Action | 371 | ||
| Pharmacokinetics | 371 | ||
| Availability | 371 | ||
| Indications and Dosages | 371 | ||
| ▸To prevent skeletal-related events due to bone metastases from solid tumors | 371 | ||
| ▸Giant cell tumor of bone | 371 | ||
| ▸Osteoporosis prophylaxis | 371 | ||
| Contraindications | 371 | ||
| Interactions | 372 | ||
| Diagnostic Test Effects | 372 | ||
| Side Effects | 372 | ||
| Serious Reactions | 372 | ||
| Desipramine | 373 | ||
| Mechanism of Action | 373 | ||
| Pharmacokinetics | 373 | ||
| Availability | 373 | ||
| Indications and Dosages | 373 | ||
| ▸Depression | 373 | ||
| Off-Label Uses | 373 | ||
| Contraindications | 373 | ||
| Interactions | 373 | ||
| Diagnostic Test Effects | 374 | ||
| Side Effects | 374 | ||
| Serious Reactions | 374 | ||
| Desloratadine | 375 | ||
| Mechanism of Action | 375 | ||
| Pharmacokinetics | 375 | ||
| Availability | 375 | ||
| Indications and Dosages | 375 | ||
| ▸Urticaria | 375 | ||
| ▸Seasonal or perennial allergic rhinitis | 375 | ||
| ▸Dosage in hepatic or renal impairment | 375 | ||
| Contraindications | 375 | ||
| Interactions | 375 | ||
| Diagnostic Test Effects | 375 | ||
| Side Effects | 376 | ||
| Serious Reactions | 376 | ||
| Desmopressin | 376 | ||
| Mechanism of Action | 376 | ||
| Pharmacokinetics | 376 | ||
| Availability | 376 | ||
| Indications and Dosages | 377 | ||
| ▸Primary nocturnal enuresis | 377 | ||
| ▸Central cranial diabetes insipidus | 377 | ||
| ▸Hemophilia A, von Willebrand disease (type I) | 377 | ||
| Contraindications | 377 | ||
| Interactions | 377 | ||
| Diagnostic Test Effects | 377 | ||
| Side Effects | 377 | ||
| Serious Reactions | 377 | ||
| Desonide | 378 | ||
| Mechanism of Action | 378 | ||
| Pharmacokinetics | 378 | ||
| Availability | 379 | ||
| Indications and Dosages | 379 | ||
| ▸Corticosteroid-responsive dermatoses | 379 | ||
| ▸Atopic dermatitis | 379 | ||
| Contraindications | 379 | ||
| Interactions | 379 | ||
| Diagnostic Test Effects | 379 | ||
| Side Effects | 379 | ||
| Serious Reactions | 379 | ||
| Desoximetasone | 379 | ||
| Mechanism of Action | 380 | ||
| Pharmacokinetics | 380 | ||
| Availability | 380 | ||
| Indications and Dosages | 380 | ||
| ▸Corticosteroid-responsive dermatoses, including plaque psoriasis | 380 | ||
| Contraindications | 380 | ||
| Interactions | 380 | ||
| Diagnostic Test Effects | 380 | ||
| Side Effects | 380 | ||
| Serious Reactions | 380 | ||
| Desvenlafaxine | 381 | ||
| Mechanism of Action | 381 | ||
| Pharmacokinetics | 381 | ||
| Availability | 381 | ||
| Indications and Dosages | 381 | ||
| ▸Depression | 381 | ||
| ▸Dosage in renal impairment | 381 | ||
| ▸Dosage in hepatic impairment | 381 | ||
| Contraindications | 381 | ||
| Interactions | 381 | ||
| Diagnostic Test Effects | 381 | ||
| Side Effects | 381 | ||
| Serious Reactions | 382 | ||
| Dexamethasone | 382 | ||
| Mechanism of Action | 383 | ||
| Pharmacokinetics | 383 | ||
| Availability | 383 | ||
| Indications and Dosages | 383 | ||
| ▸Anti-inflammatory | 383 | ||
| ▸Cerebral edema | 383 | ||
| ▸Nausea and vomiting in chemotherapy patients | 383 | ||
| ▸Physiologic replacement | 383 | ||
| ▸Usual ophthalmic dosage, ocular inflammatory conditions | 383 | ||
| ▸Ocular inflammation due to macular edema following retinal vein occlusion | 383 | ||
| Contraindications | 383 | ||
| Interactions | 383 | ||
| Diagnostic Test Effects | 384 | ||
| ?IV Incompatibilities | 384 | ||
| Side Effects | 384 | ||
| Serious Reactions | 384 | ||
| Dexlansoprazole | 386 | ||
| Mechanism of Action | 386 | ||
| Pharmacokinetics | 386 | ||
| Availability | 386 | ||
| Indications and Dosages | 386 | ||
| ▸Healing and maintenance of erosive esophagitis | 386 | ||
| ▸Symptomatic nonerosive gastroesophageal reflux (GERD) | 386 | ||
| ▸Dosage adjustment in hepatic impairment | 386 | ||
| Contraindications | 386 | ||
| Interactions | 386 | ||
| Mechanism of Action | 386.e1 | ||
| Pharmacokinetics | 386.e1 | ||
| Availability | 386.e1 | ||
| Indications and Dosages | 386.e1 | ||
| ▸Sedation before, during, and after intubation and mechanical ventilation while in the intensive care unit (ICU) | 386.e1 | ||
| ▸Procedural sedation | 386.e1 | ||
| ▸Patients with hepatic impairment | 386.e1 | ||
| Contraindications | 386.e1 | ||
| Interactions | 386.e1 | ||
| Diagnostic Test Effects | 386.e1 | ||
| ?IV Incompatibilities | 386.e1 | ||
| ?IV Compatibilities | 386.e1 | ||
| Side Effects | 386.e2 | ||
| Serious Reactions | 386.e2 | ||
| Diagnostic Test Effects | 387 | ||
| Side Effects | 387 | ||
| Serious Reactions | 387 | ||
| Dexmethylphenidate | 387 | ||
| Mechanism of Action | 388 | ||
| Pharmacokinetics | 388 | ||
| Availability | 388 | ||
| Indications and Dosages | 388 | ||
| ▸Attention deficit hyperactivity disorder (ADHD) | 388 | ||
| Contraindications | 388 | ||
| Interactions | 388 | ||
| Diagnostic Test Effects | 388 | ||
| Side Effects | 389 | ||
| Serious Reactions | 389 | ||
| Dextran | 390 | ||
| Mechanism of Action | 390 | ||
| Availability | 390 | ||
| Indications and Dosages | 390 | ||
| ▸Volume expansion, shock | 390 | ||
| ▸Prevention of venous thrombosis/pulmonary embolism | 390 | ||
| Contraindications | 390 | ||
| Interactions | 390 | ||
| Diagnostic Test Effects | 390 | ||
| ?IV Incompatibilities | 390 | ||
| Side Effects | 390 | ||
| Serious Reactions | 390 | ||
| Dextroamphetamine | 391 | ||
| Mechanism of Action | 391 | ||
| Availability | 391 | ||
| Indications and Dosages | 392 | ||
| ▸Narcolepsy | 392 | ||
| ▸Attention deficit hyperactivity disorder (ADHD) | 392 | ||
| Contraindications | 392 | ||
| Interactions | 392 | ||
| Diagnostic Test Effects | 392 | ||
| Side Effects | 392 | ||
| Serious Reactions | 392 | ||
| Dextromethorphan | 393 | ||
| Mechanism of Action | 393 | ||
| Pharmacokinetics | 393 | ||
| Availability | 394 | ||
| Indications and Dosages | 394 | ||
| ▸Cough | 394 | ||
| Contraindications | 394 | ||
| Interactions | 394 | ||
| Diagnostic Test Effects | 394 | ||
| Side Effects | 394 | ||
| Serious Reactions | 394 | ||
| Diazepam | 395 | ||
| Mechanism of Action | 395 | ||
| Pharmacokinetics | 395 | ||
| Availability | 395 | ||
| Indications and Dosages | 395 | ||
| ▸Anxiety, skeletal muscle relaxation | 395 | ||
| ▸Preanesthesia | 395 | ||
| ▸Alcohol withdrawal | 395 | ||
| ▸Status epilepticus | 395 | ||
| ▸Control of increased seizure activity in patients with refractory epilepsy who are on stable regimens of anticonvulsants | 396 | ||
| ▸Dose in hepatic dysfunction (cirrhosis) | 396 | ||
| Off-Label Uses | 396 | ||
| Contraindications | 396 | ||
| Interactions | 396 | ||
| Diagnostic Test Effects | 396 | ||
| ?IV Incompatibilities | 396 | ||
| Side Effects | 396 | ||
| Serious Reactions | 396 | ||
| Diclofenac | 398 | ||
| Mechanism of Action | 398 | ||
| Pharmacokinetics | 398 | ||
| Availability | 398 | ||
| Indications and Dosages | 398 | ||
| ▸Osteoarthritis | 398 | ||
| ▸Rheumatoid arthritis | 398 | ||
| ▸Ankylosing spondylitis | 399 | ||
| ▸Analgesia, primary dysmenorrhea | 399 | ||
| ▸Acute mild or moderate pain | 399 | ||
| ▸Actinic keratoses | 399 | ||
| ▸Cataract surgery | 399 | ||
| ▸Pain, relief of photophobia in patients undergoing corneal refractive surgery | 399 | ||
| ▸Acute pain from sprains, contusions | 399 | ||
| ▸Acute treatment of migraine | 399 | ||
| Off-Label Uses | 399 | ||
| Contraindications | 399 | ||
| Interactions | 399 | ||
| Diagnostic Test Effects | 400 | ||
| Side Effects | 400 | ||
| Serious Reactions | 400 | ||
| Dicloxacillin | 401 | ||
| Mechanism of Action | 401 | ||
| Pharmacokinetics | 401 | ||
| Availability | 401 | ||
| Indications and Dosages | 401 | ||
| ▸Infections due to susceptible penicillinase-producing staphylococci | 401 | ||
| Contraindications | 401 | ||
| Interactions | 401 | ||
| Diagnostic Test Effects | 402 | ||
| Side Effects | 402 | ||
| Serious Reactions | 402 | ||
| Dicyclomine | 402 | ||
| Mechanism of Action | 402 | ||
| Pharmacokinetics | 402 | ||
| Availability | 402 | ||
| Indications and Dosages | 402 | ||
| ▸Functional disturbances of GI motility | 402 | ||
| Contraindications | 403 | ||
| Interactions | 403 | ||
| Diagnostic Test Effects | 403 | ||
| Side Effects | 403 | ||
| Serious Reactions | 403 | ||
| Didanosine (ddI) | 404 | ||
| Mechanism of Action | 404 | ||
| Pharmacokinetics | 404 | ||
| Availability | 404 | ||
| Indications and Dosages | 404 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 404 | ||
| ▸Dosage if taken with tenofovir | 404 | ||
| ▸Dosage in renal impairment | 405 | ||
| Contraindications | 405 | ||
| Interactions | 405 | ||
| Diagnostic Test Effects | 405 | ||
| Side Effects | 405 | ||
| Serious Reactions | 406 | ||
| Diethylpropion | 407 | ||
| Mechanism of Action | 407 | ||
| Pharmacokinetics | 407 | ||
| Availability | 407 | ||
| Indications and Dosages | 407 | ||
| ▸Obesity | 407 | ||
| Contraindications | 407 | ||
| Interactions | 407 | ||
| Diagnostic Test Effects | 407 | ||
| Side Effects | 407 | ||
| Serious Reactions | 407 | ||
| Diflorasone | 408 | ||
| Mechanism of Action | 408 | ||
| Pharmacokinetics | 408 | ||
| Availability | 408 | ||
| Indications and Dosages | 408 | ||
| ▸Corticosteroid-responsive dermatoses | 408 | ||
| Contraindications | 408 | ||
| Interactions | 408 | ||
| Diagnostic Test Effects | 408 | ||
| Side Effects | 408 | ||
| Serious Reactions | 409 | ||
| Diflunisal | 409 | ||
| Mechanism of Action | 409 | ||
| Pharmacokinetics | 409 | ||
| Availability | 409 | ||
| Indications and Dosages | 410 | ||
| ▸Mild to moderate pain | 410 | ||
| ▸Rheumatoid arthritis, osteoarthritis | 410 | ||
| Off-Label Uses | 410 | ||
| Contraindications | 410 | ||
| Interactions | 410 | ||
| Diagnostic Test Effects | 410 | ||
| Side Effects | 410 | ||
| Serious Reactions | 410 | ||
| Digoxin | 411 | ||
| Mechanism of Action | 411 | ||
| Pharmacokinetics | 411 | ||
| Availability | 412 | ||
| Indications and Dosages | 412 | ||
| ▸Rapid loading dose for the management and treatment of CHF; control of ventricular rate in patients with atrial fibrillation; t... | 412 | ||
| ▸Maintenance dosage for CHF; control of ventricular rate in patients with atrial fibrillation; treatment and prevention of recur... | 412 | ||
| ▸Dosage in renal impairment | 412 | ||
| Contraindications | 412 | ||
| Interactions | 412 | ||
| Diagnostic Test Effects | 413 | ||
| ?IV Incompatibilities | 413 | ||
| Side Effects | 413 | ||
| Serious Reactions | 413 | ||
| Mechanism of Action | 415 | ||
| Pharmacokinetics | 415 | ||
| Availability | 415 | ||
| Indications and Dosages | 415 | ||
| ▸Potentially life-threatening digoxin overdose | 415 | ||
| Contraindications | 415 | ||
| Interactions | 415 | ||
| Diagnostic Test Effects | 415 | ||
| ?IV Incompatibilities | 415 | ||
| Side Effects | 415 | ||
| Serious Reactions | 415 | ||
| Mechanism of Action | 416 | ||
| Pharmacokinetics | 416 | ||
| Availability | 417 | ||
| Indications and Dosages | 417 | ||
| ▸Migraine headaches, cluster headaches | 417 | ||
| Off-Label Uses | 417 | ||
| Contraindications | 417 | ||
| Interactions | 417 | ||
| Diagnostic Test Effects | 417 | ||
| Side Effects | 417 | ||
| Serious Reactions | 417 | ||
| Mechanism of Action | 419 | ||
| Pharmacokinetics | 419 | ||
| Availability | 419 | ||
| Indications and Dosages | 419 | ||
| ▸Angina related to coronary artery spasm (Prinzmetal variant), chronic stable angina (effort-associated) | 419 | ||
| ▸Essential hypertension | 419 | ||
| ▸Temporary control of rapid ventricular rate in atrial fibrillation or flutter, rapid conversion of paroxysmal supraventricular ... | 420 | ||
| Off-Label Uses | 420 | ||
| Contraindications | 420 | ||
| Interactions | 420 | ||
| Diagnostic Test Effects | 420 | ||
| ?IV Incompatibilities | 420 | ||
| ?IV Compatibilities | 420 | ||
| Side Effects | 421 | ||
| Serious Reactions | 421 | ||
| Mechanism of Action | 422 | ||
| Availability | 422 | ||
| Indications and Dosages | 422 | ||
| ▸Motion sickness | 422 | ||
| Contraindications | 422 | ||
| Interactions | 422 | ||
| Diagnostic Test Effects | 422 | ||
| Side Effects | 423 | ||
| Serious Reactions | 423 | ||
| Mechanism of Action | 423 | ||
| Pharmacokinetics | 423 | ||
| Mechanism of Action | 423.e1 | ||
| Pharmacokinetics | 423.e1 | ||
| Availability | 423.e1 | ||
| Indications and Dosages | 423.e1 | ||
| ▸Poisoning, arsenic (mild) | 423.e1 | ||
| ▸Poisoning, arsenic (severe) | 423.e1 | ||
| ▸Poisoning, gold (mild) | 423.e1 | ||
| ▸Poisoning, gold (severe) | 423.e1 | ||
| ▸Poisoning, lead (mild) | 423.e1 | ||
| ▸Poisoning, lead (severe) | 423.e1 | ||
| ▸Poisoning, mercury | 423.e1 | ||
| ▸Dosage in renal impairment | 423.e1 | ||
| Off-Label Uses | 423.e1 | ||
| Contraindications | 423.e2 | ||
| Interactions | 423.e2 | ||
| Diagnostic Test Effects | 423.e2 | ||
| ?IV Incompatibilities | 423.e2 | ||
| Side Effects | 423.e2 | ||
| Serious Reactions | 423.e2 | ||
| Availability | 424 | ||
| Indications and Dosages | 424 | ||
| ▸Relapsing forms of multiple sclerosis | 424 | ||
| Contraindications | 424 | ||
| Interactions | 424 | ||
| Diagnostic Test Effects | 424 | ||
| Side Effects | 424 | ||
| Serious Reactions | 424 | ||
| Mechanism of Action | 425 | ||
| Pharmacokinetics | 425 | ||
| Availability | 425 | ||
| Indications and Dosages | 425 | ||
| ▸Moderate to severe allergic reaction | 425 | ||
| ▸Dystonic reaction | 425 | ||
| ▸Motion sickness, minor allergic rhinitis | 426 | ||
| ▸Antitussive | 426 | ||
| ▸Nighttime sleep aid | 426 | ||
| ▸Pruritus | 426 | ||
| Contraindications | 426 | ||
| Interactions | 426 | ||
| Diagnostic Test Effects | 426 | ||
| ?IV Incompatibilities | 426 | ||
| Side Effects | 426 | ||
| Serious Reactions | 426 | ||
| Mechanism of Action | 427 | ||
| Pharmacokinetics | 427 | ||
| Mechanism of Action | 427.e1 | ||
| Pharmacokinetics | 427.e1 | ||
| Availability | 427.e1 | ||
| Indications and Dosages | 427.e1 | ||
| ▸Incomplete miscarriage, hydatidiform mole, or intrauterine fetal death, or for second-trimester pregnancy termination | 427.e1 | ||
| ▸Ripening of unfavorable cervix | 427.e1 | ||
| Contraindications | 427.e1 | ||
| Interactions | 427.e1 | ||
| Diagnostic Test Effects | 427.e1 | ||
| Side Effects | 427.e1 | ||
| Serious Reactions | 427.e2 | ||
| Availability | 428 | ||
| Indications and Dosages | 428 | ||
| ▸Diarrhea (adjunct treatment) | 428 | ||
| Contraindications | 428 | ||
| Interactions | 428 | ||
| Diagnostic Test Effects | 428 | ||
| Side Effects | 428 | ||
| Serious Reactions | 428 | ||
| Mechanism of Action | 429 | ||
| Pharmacokinetics | 429 | ||
| Availability | 429 | ||
| Indications and Dosages | 429 | ||
| ▸Prevention of thromboembolic disorders after cardiac valve replacement | 429 | ||
| ▸Diagnostic aid, coronary artery disease | 429 | ||
| Off-Label Uses | 429 | ||
| Contraindications | 429 | ||
| Interactions | 429 | ||
| Diagnostic Test Effects | 430 | ||
| ?IV Incompatibilities | 430 | ||
| Side Effects | 430 | ||
| Serious Reactions | 430 | ||
| Disopyramide | 430 | ||
| Mechanism of Action | 430 | ||
| Availability | 431 | ||
| Indications and Dosages | 431 | ||
| ▸Suppression and prevention of ventricular ectopy, unifocal or multifocal premature ventricular contractions, paired ventricular... | 431 | ||
| ▸Rapid control of arrhythmias | 431 | ||
| ▸Severe refractory arrhythmias | 431 | ||
| ▸Dosage in renal impairment | 431 | ||
| ▸Dosage in liver impairment | 431 | ||
| ▸Dosage in cardiomyopathy, cardiac decompensation | 431 | ||
| Off-Label Uses | 431 | ||
| Contraindications | 431 | ||
| Interactions | 431 | ||
| Diagnostic Test Effects | 432 | ||
| Side Effects | 432 | ||
| Serious Reactions | 432 | ||
| Disulfiram | 432 | ||
| Mechanism of Action | 432 | ||
| Pharmacokinetics | 433 | ||
| Availability | 433 | ||
| Indications and Dosages | 433 | ||
| ▸Adjunct in management of selected chronic alcoholic patients who want to remain in state of enforced sobriety | 433 | ||
| Contraindications | 433 | ||
| Drug Interactions | 433 | ||
| Diagnostic Test Effects | 433 | ||
| Side Effects | 433 | ||
| Serious Reactions | 433 | ||
| Dobutamine | 434 | ||
| Mechanism of Action | 434 | ||
| Pharmacokinetics | 434 | ||
| Availability | 434 | ||
| Indications and Dosages | 434 | ||
| ▸Short-term management of cardiac decompensation | 434 | ||
| Contraindications | 434 | ||
| Interactions | 434 | ||
| Diagnostic Test Effects | 434 | ||
| ?IV Incompatibilities | 434 | ||
| ?IV Compatibilities | 435 | ||
| Side Effects | 435 | ||
| Serious Reactions | 435 | ||
| Docosanol | 436 | ||
| E | 466 | ||
| Ecallantide | 466 | ||
| Mechanism of Action | 466 | ||
| Pharmacokinetics | 466 | ||
| Availability | 466 | ||
| Indications and Dosages | 466 | ||
| ‣Acute attacks of hereditary angioedema (HAE) | 466 | ||
| Contraindications | 466 | ||
| Interactions | 466 | ||
| Diagnostic Test Effects | 466 | ||
| Side Effects | 466 | ||
| Serious Reactions | 466 | ||
| Econazole | 467 | ||
| Mechanism of Action | 467 | ||
| Pharmacokinetics | 467 | ||
| Availability | 467 | ||
| Indications and Dosages | 467 | ||
| ‣Treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor | 467 | ||
| ‣Treatment of cutaneous candidiasis | 467 | ||
| Contraindications | 467 | ||
| Interactions | 467 | ||
| Diagnostic Test Effects | 467 | ||
| Side Effects | 467 | ||
| Serious Reactions | 467 | ||
| Eculizumab\r | 467.e1 | ||
| Mechanism of Action | 467.e1 | ||
| Pharmacokinetics | 467.e1 | ||
| Availability | 467.e1 | ||
| Indications and Dosages | 467.e1 | ||
| ‣Reduction of hemolysis from paroxysmal nocturnal hemoglobinuria (PNH) | 467.e1 | ||
| ‣Atypical hemolytic uremic syndrome (aHUS) | 467.e1 | ||
| ‣Dosage adjustments for aHUS when supported with plasma exchange or plasmapheresis sessions | 467.e1 | ||
| Contraindications | 467.e1 | ||
| Interactions | 467.e1 | ||
| Diagnostic Test Effects | 467.e1 | ||
| Side Effects | 467.e2 | ||
| Serious Reactions | 467.e2 | ||
| Edetate Calcium Disodium (Calcium EDTA) | 467.e3 | ||
| Mechanism of Action | 467.e3 | ||
| Pharmacokinetics | 467.e3 | ||
| Availability | 467.e3 | ||
| Indications and Dosages | 467.e3 | ||
| ‣Diagnosis of lead poisoning | 467.e3 | ||
| ‣Symptomatic (without encephalopathy), or asymptomatic lead poisoning with blood lead levels > 70 mcg/dL | 467.e3 | ||
| ‣Lead poisoning (with encephalopathy) with or without blood lead levels > 70 mcg/dL | 467.e3 | ||
| ‣Asymptomatic lead poisoning in children with blood lead level 45-69 mcg/dL | 467.e4 | ||
| Contraindications | 467.e4 | ||
| Interactions | 467.e4 | ||
| ?IV Incompatibilities | 467.e4 | ||
| ?IV Compatibilities | 467.e4 | ||
| Side Effects | 467.e4 | ||
| Serious Reactions | 467.e4 | ||
| Edetate Disodium | 467.e5 | ||
| Mechanism of Action | 467.e5 | ||
| Pharmacokinetics | 467.e5 | ||
| Availability | 467.e5 | ||
| Indications and Dosages | 467.e5 | ||
| ‣Digitalis toxicity (ventricular arrhythmia), hypercalcemia | 467.e5 | ||
| Contraindications | 467.e5 | ||
| Interactions | 467.e5 | ||
| Side Effects | 467.e5 | ||
| Serious Reactions | 467.e6 | ||
| Efavirenz | 468 | ||
| Mechanism of Action | 468 | ||
| Pharmacokinetics | 468 | ||
| Availability | 468 | ||
| Indications and Dosages | 468 | ||
| ‣HIV infection (in combination with other antiretrovirals) | 468 | ||
| ‣Dosage adjustment with voriconazole (adults) | 468 | ||
| ‣Dosage adjustment with rifampin (adults and patients ≥ 50 kg) | 468 | ||
| Contraindications | 468 | ||
| Interactions | 468 | ||
| Diagnostic Test Effects | 469 | ||
| Side Effects | 469 | ||
| Serious Reactions | 469 | ||
| Eletriptan | 470 | ||
| Mechanism of Action | 470 | ||
| Mechanism of Action | 470.e1 | ||
| Pharmacokinetics | 470.e1 | ||
| Availability | 470.e1 | ||
| Indications and Dosages | 470.e1 | ||
| ‣For reduction of unwanted facial hair in women | 470.e1 | ||
| Off-Label Uses | 470.e1 | ||
| Contraindications | 470.e1 | ||
| Interactions | 470.e1 | ||
| Diagnostic Test Effects | 470.e1 | ||
| Side Effects | 470.e1 | ||
| Serious Reactions | 470.e1 | ||
| Eltrombopag | 470.e2 | ||
| Mechanism of Action | 470.e2 | ||
| Pharmacokinetics | 470.e2 | ||
| Availability | 470.e2 | ||
| Indications and Dosages | 470.e2 | ||
| ‣Chronic idiopathic thrombocytopenic purpura (ITP) nonresponsive to other treatments | 470.e2 | ||
| Contraindications | 470.e3 | ||
| Interactions | 470.e3 | ||
| Diagnostic Test Effects | 470.e3 | ||
| Side Effects | 470.e3 | ||
| Serious Reactions | 470.e3 | ||
| Pharmacokinetics | 471 | ||
| Availability | 471 | ||
| Indications and Dosages | 471 | ||
| ‣Acute migraine headache with or without aura | 471 | ||
| Contraindications | 471 | ||
| Interactions | 471 | ||
| Diagnostic Test Effects | 471 | ||
| Side Effects | 471 | ||
| Serious Reactions | 471 | ||
| Emedastine | 472 | ||
| Mechanism of Action | 472 | ||
| Pharmacokinetics | 472 | ||
| Availability | 472 | ||
| Indications and Dosages | 472 | ||
| ‣Allergic conjunctivitis | 472 | ||
| Contraindications | 472 | ||
| Drug Interactions | 472 | ||
| Side Effects | 472 | ||
| Serious Reactions | 473 | ||
| Emtricitabine | 473 | ||
| Mechanism of Action | 473 | ||
| Pharmacokinetics | 473 | ||
| Availability | 473 | ||
| Indications and Dosages | 473 | ||
| ‣HIV infection (in combination with other antiretrovirals) | 473 | ||
| ‣Adult dosage in renal impairment | 473 | ||
| ‣Hemodialysis patients (give after hemodialysis) | 474 | ||
| Off-Label Uses | 474 | ||
| Contraindications | 474 | ||
| Interactions | 474 | ||
| Diagnostic Test Effects | 474 | ||
| Side Effects | 474 | ||
| Serious Reactions | 474 | ||
| Enalapril | 475 | ||
| Mechanism of Action | 475 | ||
| Pharmacokinetics | 475 | ||
| Availability | 475 | ||
| Indications and Dosages | 475 | ||
| ‣Hypertension alone or in combination with other antihypertensives | 475 | ||
| ‣Adjunctive therapy for congestive heart failure | 475 | ||
| ‣Adult oral dosage in renal impairment | 475 | ||
| Off-Label Uses | 475 | ||
| Contraindications | 476 | ||
| Interactions | 476 | ||
| Diagnostic Test Effects | 476 | ||
| ?IV Incompatibilities | 476 | ||
| Side Effects | 476 | ||
| Serious Reactions | 476 | ||
| Enfuvirtide | 477 | ||
| Mechanism of Action | 477 | ||
| Pharmacokinetics | 477 | ||
| Availability | 477 | ||
| Indications and Dosages | 477 | ||
| ‣HIV infection (in combination with other antiretrovirals) | 477 | ||
| ‣Pediatric dosing guidelines | 477 | ||
| Contraindications | 477 | ||
| Interactions | 477 | ||
| Diagnostic Test Effects | 477 | ||
| Side Effects | 478 | ||
| Serious Reactions | 478 | ||
| Enoxaparin | 479 | ||
| Mechanism of Action | 479 | ||
| Pharmacokinetics | 479 | ||
| Availability | 479 | ||
| Indications and Dosages | 479 | ||
| ‣Prevention of deep vein thrombosis (DVT) after hip and knee surgery | 479 | ||
| ‣Prevention of DVT after abdominal surgery | 479 | ||
| ‣Prevention of long-term DVT in nonsurgical acute illness | 479 | ||
| ‣Prevention of ischemic complications of unstable angina and non-Q-wave MI (with oral aspirin therapy) | 479 | ||
| ‣Treatment of acute ST-segment elevation myocardial infarction | 479 | ||
| ‣Acute DVT | 480 | ||
| ‣Usual pediatric dosage | 480 | ||
| ‣Dosage in renal impairment | 480 | ||
| ?IV Incompatibilities | 480 | ||
| Off-Label Uses | 480 | ||
| Contraindications | 480 | ||
| Interactions | 480 | ||
| Diagnostic Test Effects | 480 | ||
| Side Effects | 480 | ||
| Serious Reactions | 480 | ||
| Entacapone | 481 | ||
| Mechanism of Action | 482 | ||
| Pharmacokinetics | 482 | ||
| Availability | 482 | ||
| Indications and Dosages | 482 | ||
| ‣Adjunctive treatment of Parkinson’s disease | 482 | ||
| Contraindications | 482 | ||
| Interactions | 482 | ||
| Diagnostic Test Effects | 482 | ||
| Side Effects | 482 | ||
| Serious Reactions | 482 | ||
| Entecavir | 483 | ||
| Mechanism of Action | 483 | ||
| Pharmacokinetics | 483 | ||
| Availability | 483 | ||
| Indications and Dosages | 483 | ||
| ‣Chronic hepatitis B (compensated) | 483 | ||
| ‣Chronic hepatitis B (decompensated liver disease) | 484 | ||
| ‣Dosage in renal impairment (adult and adolescent) | 484 | ||
| Contraindications | 484 | ||
| Interactions | 484 | ||
| Diagnostic Test Effects | 484 | ||
| Side Effects | 484 | ||
| Serious Reactions | 484 | ||
| Ephedrine | 485 | ||
| Mechanism of Action | 485 | ||
| Pharmacokinetics | 485 | ||
| Availability | 485 | ||
| Indications and Dosages | 485 | ||
| ‣Asthma | 485 | ||
| ‣Hypotension | 485 | ||
| Enzalutamide | 485.e1 | ||
| Mechanism of Action | 485.e1 | ||
| Pharmacokinetics | 485.e1 | ||
| Availability | 485.e1 | ||
| Indications and Dosages | 485.e1 | ||
| ‣Metastatic castration-resistant prostate cancer | 485.e1 | ||
| ‣Dosage adjustments based on toxicity | 485.e1 | ||
| ‣Dose adjustment for concomitant strong CYP2C8 inhibitors | 485.e1 | ||
| Contraindications | 485.e1 | ||
| Interactions | 485.e1 | ||
| Diagnostic Test Effects | 485.e2 | ||
| Side Effects | 485.e2 | ||
| Serious Reactions | 485.e2 | ||
| Contraindications | 486 | ||
| Interactions | 486 | ||
| Diagnostic Test Effects | 486 | ||
| ?IV Incompatibilities | 486 | ||
| ?IV Compatibilities | 486 | ||
| Side Effects | 486 | ||
| Serious Reactions | 486 | ||
| Epinastine | 487 | ||
| Mechanism of Action | 487 | ||
| Pharmacokinetics | 487 | ||
| Availability | 487 | ||
| Indications and Dosages | 487 | ||
| ‣Allergic conjunctivitis | 487 | ||
| Contraindications | 487 | ||
| Interactions | 487 | ||
| Diagnostic Test Effects | 487 | ||
| Side Effects | 487 | ||
| Serious Reactions | 488 | ||
| Epinephrine | 488 | ||
| Mechanism of Action | 488 | ||
| Pharmacokinetics | 488 | ||
| Availability | 488 | ||
| Indications and Dosages | 489 | ||
| ‣Asystole | 489 | ||
| ‣Bradycardia | 489 | ||
| ‣Bronchodilation | 489 | ||
| ‣Hypersensitivity reaction | 489 | ||
| Off-Label Uses | 489 | ||
| Contraindications | 489 | ||
| Interactions | 489 | ||
| Diagnostic Test Effects | 489 | ||
| ?IV Incompatibilities | 489 | ||
| ?IV Compatibilities | 490 | ||
| Side Effects | 490 | ||
| Serious Reactions | 490 | ||
| Eplerenone | 490 | ||
| Mechanism of Action | 491 | ||
| Pharmacokinetics | 491 | ||
| Availability | 491 | ||
| Indications and Dosages | 491 | ||
| ‣Hypertension | 491 | ||
| ‣Congestive heart failure following myocardial infarction | 491 | ||
| Contraindications | 491 | ||
| Interactions | 491 | ||
| Diagnostic Test Effects | 492 | ||
| Side Effects | 492 | ||
| Serious Reactions | 492 | ||
| Epoetin Alfa (Erythropoietin)\r | 492 | ||
| Mechanism of Action | 492 | ||
| Pharmacokinetics | 492 | ||
| Availability | 493 | ||
| Indications and Dosages | 493 | ||
| ‣Treatment of anemia in chemotherapy patients | 493 | ||
| ‣Reduction of allogenic blood transfusions in elective surgery | 493 | ||
| ‣Chronic renal failure | 493 | ||
| ‣HIV infection in patients treated with zidovudine (AZT) | 493 | ||
| Off-Label Uses | 493 | ||
| Contraindications | 493 | ||
| Interactions | 494 | ||
| Diagnostic Test Effects | 494 | ||
| ?IV Incompatibilities | 494 | ||
| Side Effects | 494 | ||
| ‣Patients receiving chemotherapy | 494 | ||
| ‣Patients with chronic renal failure | 494 | ||
| ‣Patients with HIV infection treated with AZT | 494 | ||
| Serious Reactions | 494 | ||
| Epoprostenol (Prostacyclin) | 495 | ||
| Mechanism of Action | 495 | ||
| Availability | 495 | ||
| Indications and Dosages | 495 | ||
| ‣Long-term treatment of New York Heart Association Class III and IV primary pulmonary hypertension and pulmonary hypertension as... | 495 | ||
| Off-Label Uses | 496 | ||
| Contraindications | 496 | ||
| Interactions | 496 | ||
| Diagnostic Test Effects | 496 | ||
| ?IV Incompatibilities | 496 | ||
| ?IV Compatibilities | 496 | ||
| Side Effects | 496 | ||
| Serious Reactions | 496 | ||
| Eprosartan | 497 | ||
| Mechanism of Action | 497 | ||
| Pharmacokinetics | 497 | ||
| Availability | 497 | ||
| Indications and Dosages | 497 | ||
| ‣Hypertension | 497 | ||
| Contraindications | 497 | ||
| Interactions | 498 | ||
| Diagnostic Test Effects | 498 | ||
| Side Effects | 498 | ||
| Serious Reactions | 498 | ||
| Eptifibatide | 498 | ||
| Mechanism of Action | 498 | ||
| Availability | 499 | ||
| Indications and Dosages | 499 | ||
| ‣Adjunct to percutaneous coronary intervention (PCI) | 499 | ||
| ‣Acute coronary syndrome | 499 | ||
| ‣Dosage in renal impairment | 499 | ||
| Contraindications | 499 | ||
| Interactions | 499 | ||
| Diagnostic Test Effects | 499 | ||
| ?IV Incompatibilities | 499 | ||
| Side Effects | 499 | ||
| Serious Reactions | 499 | ||
| Ergoloid Mesylates | 500 | ||
| Mechanism of Action | 500 | ||
| Pharmacokinetics | 500 | ||
| Availability | 500 | ||
| Indications and Dosages | 500 | ||
| ‣Age-related decline in mental capacity | 500 | ||
| Contraindications | 500 | ||
| Interactions | 500 | ||
| Side Effects | 501 | ||
| Serious Reactions | 501 | ||
| Ergotamine & Ergotamine-Caffeine | 501 | ||
| Mechanism of Action | 501 | ||
| Pharmacokinetics | 501 | ||
| Availability | 501 | ||
| Indications and Dosages | 501 | ||
| ‣Vascular headaches | 501 | ||
| Eribulin | 501.e1 | ||
| Mechanism of Action | 501.e1 | ||
| Pharmacokinetics | 501.e1 | ||
| Availability | 501.e1 | ||
| Indications and Dosages | 501.e1 | ||
| ‣Breast cancer, metastatic | 501.e1 | ||
| ‣Dosage adjustments for toxicity | 501.e1 | ||
| ‣Dosage in renal impairment | 501.e1 | ||
| ‣Dosage in hepatic impairment | 501.e1 | ||
| Contraindications | 501.e1 | ||
| Interactions | 501.e1 | ||
| Diagnostic Test Effects | 501.e1 | ||
| ?IV Incompatibility | 501.e2 | ||
| Side Effects | 501.e2 | ||
| Serious Reactions | 501.e2 | ||
| Contraindications | 502 | ||
| Interactions | 502 | ||
| Diagnostic Test Effects | 502 | ||
| Side Effects | 502 | ||
| Serious Reactions | 502 | ||
| Ertapenem | 503 | ||
| Mechanism of Action | 503 | ||
| Pharmacokinetics | 503 | ||
| Availability | 503 | ||
| Indications and Dosages | 503 | ||
| ‣Intra-abdominal infection | 503 | ||
| Erlotinib | 503.e1 | ||
| Mechanism of Action | 503.e1 | ||
| Availability | 503.e1 | ||
| Indications and Dosages | 503.e1 | ||
| ‣Locally advanced or metastatic non–small cell lung cancer after failure of first-line therapy | 503.e1 | ||
| ‣Locally advanced, unresectable, or metastatic pancreatic cancer, first-line therapy | 503.e1 | ||
| ‣Concomitant therapy with strong CYP3A4 inhibitor | 503.e1 | ||
| ‣Concomitant therapy with strong CYP3A4 inducer | 503.e1 | ||
| ‣Dosage-hepatic impairment | 503.e1 | ||
| Off-Label Uses | 503.e1 | ||
| Contraindications | 503.e1 | ||
| Interactions | 503.e1 | ||
| Diagnostic Test Effects | 503.e2 | ||
| Side Effects | 503.e2 | ||
| Serious Reactions | 503.e2 | ||
| ‣Skin and skin-structure infection | 504 | ||
| ‣Community-acquired pneumonia, urinary tract infection (UTI) | 504 | ||
| ‣Pelvic/gynecologic infection | 504 | ||
| ‣Prophylaxis of surgical site infection following colorectal surgery | 504 | ||
| ‣Dosage in renal impairment | 504 | ||
| Contraindications | 504 | ||
| Interactions | 504 | ||
| Diagnostic Test Effects | 504 | ||
| ?IV Incompatibilities | 504 | ||
| ?IV Compatibilities | 504 | ||
| Side Effects | 505 | ||
| Serious Reactions | 505 | ||
| Erythromycin | 506 | ||
| Mechanism of Action | 506 | ||
| Pharmacokinetics | 506 | ||
| Availability | 506 | ||
| Indications and Dosages | 506 | ||
| ‣Mild to moderate infections of the upper and lower respiratory tract, pharyngitis, skin infections | 506 | ||
| ‣Preoperative intestinal antisepsis | 506 | ||
| ‣Acne vulgaris | 506 | ||
| ‣Gonococcal ophthalmia neonatorum prevention | 506 | ||
| Off-Label Uses | 507 | ||
| Contraindications | 507 | ||
| Interactions | 507 | ||
| Diagnostic Test Effects | 507 | ||
| ?IV Incompatibilities | 507 | ||
| ?IV Compatibilities | 507 | ||
| Side Effects | 508 | ||
| Serious Reactions | 508 | ||
| Escitalopram | 509 | ||
| Mechanism of Action | 509 | ||
| Pharmacokinetics | 509 | ||
| Availability | 509 | ||
| Indications and Dosages | 509 | ||
| ‣Depression, general anxiety disorder (GAD) | 509 | ||
| ‣Dose adjustment for hepatic impairment | 509 | ||
| Off-Label Uses | 509 | ||
| Contraindications | 509 | ||
| Interactions | 510 | ||
| Diagnostic Test Effects | 510 | ||
| Side Effects | 510 | ||
| Serious Reactions | 510 | ||
| Esmolol | 511 | ||
| Mechanism of Action | 511 | ||
| Availability | 511 | ||
| Indications and Dosages | 511 | ||
| ‣Supraventricular tachyarrhythmias, including sinus tachycardia or paroxysmal supraventricular tachycardia (PSVT) or to control ... | 511 | ||
| ‣Intraoperative tachycardia or hypertension (immediate control) | 511 | ||
| Off-Label Uses | 511 | ||
| Contraindications | 511 | ||
| Interactions | 511 | ||
| Diagnostic Test Effects | 512 | ||
| ?IV Incompatibilities | 512 | ||
| ?IV Compatibilities | 512 | ||
| Side Effects | 512 | ||
| Serious Reactions | 512 | ||
| Esomeprazole | 513 | ||
| Mechanism of Action | 513 | ||
| Pharmacokinetics | 513 | ||
| Availability | 513 | ||
| Indications and Dosages | 513 | ||
| ‣Erosive esophagitis healing | 513 | ||
| ‣To maintain healing of erosive esophagitis | 513 | ||
| ‣Gastroesophageal reflux disease | 514 | ||
| ‣Duodenal ulcer caused by Helicobacter pylori | 514 | ||
| ‣Prevention of NSAID-induced gastric ulcer | 514 | ||
| ‣Hypersecretory conditions (e.g. , Zollinger-Ellison syndrome) | 514 | ||
| ‣Dose in hepatic impairment (Child-Pugh Class C) | 514 | ||
| Contraindications | 514 | ||
| Interactions | 514 | ||
| Diagnostic Test Effects | 514 | ||
| ?IV Incompatibilities | 514 | ||
| Side Effects | 514 | ||
| Serious Reactions | 514 | ||
| Estazolam | 515 | ||
| Mechanism of Action | 515 | ||
| Pharmacokinetics | 515 | ||
| Availability | 516 | ||
| Indications and Dosages | 516 | ||
| ‣Insomnia | 516 | ||
| Contraindications | 516 | ||
| Interactions | 516 | ||
| Side Effects | 516 | ||
| Serious Reactions | 516 | ||
| Estradiol | 517 | ||
| Mechanism of Action | 517 | ||
| Pharmacokinetics | 517 | ||
| Availability | 517 | ||
| Indications and Dosages | 517 | ||
| ‣Prostate cancer (palliative) | 517 | ||
| ‣Breast cancer (palliative) | 517 | ||
| ‣Osteoporosis prophylaxis in postmenopausal females | 517 | ||
| ‣Female hypoestrogenism | 518 | ||
| ‣Vasomotor symptoms associated with menopause | 518 | ||
| ‣Vaginal atrophy | 518 | ||
| ‣Atrophic vaginitis | 518 | ||
| Off-Label Uses | 518 | ||
| Contraindications | 518 | ||
| Interactions | 519 | ||
| Diagnostic Test Effects | 519 | ||
| Side Effects | 519 | ||
| Serious Reactions | 519 | ||
| Estrogens, Conjugated | 520 | ||
| Mechanism of Action | 521 | ||
| Pharmacokinetics | 521 | ||
| Availability | 521 | ||
| Indications and Dosages | 521 | ||
| ‣Vasomotor symptoms associated with menopause, atrophic vaginitis, kraurosis vulvae | 521 | ||
| ‣Female hypogonadism | 521 | ||
| ‣Female castration, primary ovarian failure | 521 | ||
| ‣Osteoporosis | 521 | ||
| ‣Breast cancer palliation | 521 | ||
| ‣Prostate cancer (palliative) | 521 | ||
| ‣Abnormal uterine bleeding | 521 | ||
| Off-Label Uses | 521 | ||
| Contraindications | 521 | ||
| Interactions | 522 | ||
| Diagnostic Test Effects | 522 | ||
| ?IV Incompatibilities | 522 | ||
| ?IV Compatibilities | 522 | ||
| Side Effects | 522 | ||
| Serious Reactions | 522 | ||
| Estrogens, Esterified | 523 | ||
| Mechanism of Action | 523 | ||
| Pharmacokinetics | 523 | ||
| Availability | 524 | ||
| Indications and Dosages | 524 | ||
| ‣Vasomotor symptoms associated with menopause, atrophic vaginitis, kraurosis vulvae | 524 | ||
| ‣Female hypogonadism | 524 | ||
| ‣Female castration, primary ovarian failure | 524 | ||
| ‣Breast cancer palliation | 524 | ||
| ‣Prostate cancer | 524 | ||
| ‣Osteoporosis in postmenopausal women | 524 | ||
| Contraindications | 524 | ||
| Interactions | 524 | ||
| Diagnostic Test Effects | 524 | ||
| Side Effects | 524 | ||
| Serious Reactions | 525 | ||
| Estropipate | 525 | ||
| Mechanism of Action | 525 | ||
| Availability | 526 | ||
| Indications and Dosages | 526 | ||
| ‣Vasomotor symptoms of menopause, atrophic vaginitis, kraurosis vulvae | 526 | ||
| ‣Female hypogonadism, castration, primary ovarian failure | 526 | ||
| ‣Prevention of osteoporosis | 526 | ||
| Contraindications | 526 | ||
| Interactions | 526 | ||
| Diagnostic Test Effects | 526 | ||
| Side Effects | 526 | ||
| Serious Reactions | 527 | ||
| Eszopiclone | 527 | ||
| Mechanism of Action | 528 | ||
| Availability | 528 | ||
| Indications and Dosages | 528 | ||
| ‣Insomnia | 528 | ||
| ‣Severe hepatic impairment | 528 | ||
| Contraindications | 528 | ||
| Interactions | 528 | ||
| Diagnostic Test Effects | 528 | ||
| Side Effects | 528 | ||
| Serious Reactions | 528 | ||
| Etanercept | 529 | ||
| Mechanism of Action | 529 | ||
| Pharmacokinetics | 529 | ||
| Availability | 529 | ||
| Indications and Dosages | 529 | ||
| ‣Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | 529 | ||
| ‣Juvenile rheumatoid arthritis | 529 | ||
| ‣Plaque psoriasis | 529 | ||
| Contraindications | 529 | ||
| Interactions | 529 | ||
| Diagnostic Test Effects | 529 | ||
| Side Effects | 530 | ||
| Serious Reactions | 530 | ||
| Ethambutol | 531 | ||
| Mechanism of Action | 531 | ||
| Pharmacokinetics | 531 | ||
| Availability | 531 | ||
| Indications and Dosages | 531 | ||
| ‣Tuberculosis | 531 | ||
| ‣Dosage in renal impairment | 531 | ||
| Off-Label Uses | 531 | ||
| Contraindications | 531 | ||
| Interactions | 531 | ||
| Diagnostic Test Effects | 532 | ||
| Side Effects | 532 | ||
| Serious Reactions | 532 | ||
| Ethionamide | 532 | ||
| Mechanism of Action | 532 | ||
| Pharmacokinetics | 533 | ||
| Availability | 533 | ||
| Indications and Dosages | 533 | ||
| ‣Tuberculosis | 533 | ||
| Off-Label Uses | 533 | ||
| Contraindications | 533 | ||
| Interactions | 533 | ||
| Diagnostic Test Effects | 533 | ||
| Side Effects | 533 | ||
| Serious Reactions | 533 | ||
| Ethosuximide | 534 | ||
| Mechanism of Action | 534 | ||
| Pharmacokinetics | 534 | ||
| Availability | 534 | ||
| Indications and Dosages | 534 | ||
| ‣Absence seizures | 534 | ||
| Contraindications | 534 | ||
| Interactions | 534 | ||
| Diagnostic Test Effects | 534 | ||
| Side Effects | 534 | ||
| Serious Reactions | 535 | ||
| Etidronate | 535 | ||
| Mechanism of Action | 535 | ||
| Availability | 535 | ||
| Indications and Dosages | 535 | ||
| ‣Paget’s disease | 535 | ||
| ‣Heterotopic ossification caused by spinal cord injury | 535 | ||
| ‣Heterotopic ossification complicating total hip replacement | 535 | ||
| ‣Hypercalcemia associated with malignancy | 535 | ||
| Off-Label Uses | 536 | ||
| Contraindications | 536 | ||
| Interactions | 536 | ||
| Diagnostic Test Effects | 536 | ||
| Side Effects | 536 | ||
| Serious Reactions | 536 | ||
| Etodolac | 536 | ||
| Mechanism of Action | 536 | ||
| Mechanism of Action | 536.e1 | ||
| Pharmacokinetics | 536.e1 | ||
| Availability | 536.e1 | ||
| Indications and Dosages | 536.e1 | ||
| ‣Refractory testicular tumors | 536.e1 | ||
| ‣Acute myelocytic leukemia | 536.e1 | ||
| ‣Malignant glioma | 536.e1 | ||
| ‣Neuroblastoma | 536.e1 | ||
| ‣Small cell lung cancer | 536.e1 | ||
| ‣Dosage in renal impairment | 536.e1 | ||
| Off-Label Uses | 536.e1 | ||
| Contraindications | 536.e1 | ||
| Interactions | 536.e1 | ||
| Diagnostic Test Effects | 536.e2 | ||
| ?IV Incompatibilities | 536.e2 | ||
| Side Effects | 536.e2 | ||
| Serious Reactions | 536.e2 | ||
| Pharmacokinetics | 537 | ||
| Availability | 537 | ||
| Indications and Dosages | 537 | ||
| ‣Osteoarthritis or rheumatoid arthritis | 537 | ||
| ‣Analgesia | 537 | ||
| ‣Juvenile rheumatoid arthritis | 537 | ||
| Off-Label Uses | 537 | ||
| Contraindications | 537 | ||
| Interactions | 537 | ||
| Diagnostic Test Effects | 538 | ||
| Side Effects | 538 | ||
| Serious Reactions | 538 | ||
| Etravirine | 539 | ||
| Mechanism of Action | 539 | ||
| Pharmacokinetics | 539 | ||
| Availability | 539 | ||
| Indications and Dosages | 539 | ||
| ‣HIV infection (in combination with other antiretrovirals) | 539 | ||
| Contraindications | 539 | ||
| Interactions | 539 | ||
| Diagnostic Test Effects | 540 | ||
| Side Effects | 540 | ||
| Serious Reactions | 540 | ||
| Exenatide | 541 | ||
| Mechanism of Action | 541 | ||
| Pharmacokinetics | 541 | ||
| Availability | 541 | ||
| Indications and Dosages | 541 | ||
| ‣Type 2 diabetes mellitus | 541 | ||
| ‣Dosage in renal impairment | 541 | ||
| Everolimus | 541.e1 | ||
| Mechanism of Action | 541.e1 | ||
| Pharmacokinetics | 541.e1 | ||
| Availability | 541.e1 | ||
| Indications and Dosages | 541.e1 | ||
| ‣Prevention of kidney transplant rejection | 541.e1 | ||
| ‣Zortress—Dosage adjustment for hepatic impairment | 541.e1 | ||
| ‣Advanced renal cell carcinoma after failure with sunitinib or sorafenib | 541.e1 | ||
| ‣Subependymal giant cell astrocytoma (SEGA) | 541.e1 | ||
| ‣Progressive pancreatic neuroendocrine tumor (PNET) | 541.e1 | ||
| ‣Afinitor—If moderate inhibitors of CYP3A4 or P-glycoprotein (P-gp) are required | 541.e2 | ||
| ‣Afinitor—If strong inducers of CYP3A4 are required | 541.e2 | ||
| ‣Afinitor—Dosage adjustment for hepatic impairment | 541.e2 | ||
| ‣Afinitor—Dosage adjustment for side effects | 541.e2 | ||
| Off-Label Uses | 541.e2 | ||
| Contraindications | 541.e2 | ||
| Interactions | 541.e2 | ||
| Diagnostic Test Effects | 541.e2 | ||
| Side Effects | 541.e3 | ||
| Serious Reactions | 541.e3 | ||
| Exemestane | 541.e4 | ||
| Mechanism of Action | 541.e4 | ||
| Pharmacokinetics | 541.e4 | ||
| Availability | 541.e4 | ||
| Indications and Dosages | 541.e4 | ||
| ‣Breast cancer, advanced after tamoxifen therapy | 541.e4 | ||
| Contraindications | 541.e4 | ||
| Interactions | 541.e5 | ||
| Diagnostic Test Effects | 541.e5 | ||
| Side Effects | 541.e5 | ||
| Serious Reactions | 541.e5 | ||
| Contraindications | 542 | ||
| Interactions | 542 | ||
| Diagnostic Test Effects | 542 | ||
| Side Effects | 542 | ||
| Serious Reactions | 542 | ||
| Ezetimibe | 544 | ||
| Mechanism of Action | 544 | ||
| Pharmacokinetics | 544 | ||
| Availability | 544 | ||
| Indications and Dosages | 544 | ||
| ‣Adjunct treatment of hypercholesterolemia | 544 | ||
| Contraindications | 544 | ||
| Interactions | 544 | ||
| Diagnostic Test Effects | 545 | ||
| Side Effects | 545 | ||
| Serious Reactions | 545 | ||
| Ezogabine | 545 | ||
| Mechanism of Action | 545 | ||
| Pharmacokinetics | 545 | ||
| Availability | 546 | ||
| Indications and Dosages | 546 | ||
| ‣Adjunctive treatment of partial seizures | 546 | ||
| ‣Dosage in hepatic impairment | 546 | ||
| ‣Dosage in renal impairment | 546 | ||
| Contraindications | 546 | ||
| Interactions | 546 | ||
| Diagnostic Test Effects | 546 | ||
| Side Effects | 546 | ||
| Serious Reactions | 547 | ||
| F | 548 | ||
| Factor IX Complexand Factor IX Concentrates | 547.e1 | ||
| MECHANISM OF ACTION | 547.e1 | ||
| PHARMACOKINETICS | 547.e1 | ||
| AVAILABILITY | 547.e1 | ||
| INDICATIONS AND DOSAGES | 547.e1 | ||
| ▸ Bleeding caused by factor IX deficiency (hemophilia B, Christmas disease) | 547.e1 | ||
| OFF-LABEL USES | 547.e1 | ||
| CONTRAINDICATIONS | 547.e1 | ||
| INTERACTIONS | 547.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 547.e1 | ||
| ?IV INCOMPATIBILITIES\r | 547.e1 | ||
| SIDE EFFECTS | 547.e1 | ||
| SERIOUS REACTIONS\r | 547.e2 | ||
| Famciclovir | 548 | ||
| MECHANISM OF ACTION | 548 | ||
| PHARMACOKINETICS | 548 | ||
| AVAILABILITY | 548 | ||
| INDICATIONS AND DOSAGES | 548 | ||
| ▸ Herpes zoster (shingles) | 548 | ||
| ▸ Suppression of recurrent genital herpes | 548 | ||
| ▸ Recurrent herpes labialis (cold sores) | 548 | ||
| ▸ Recurrent orolabial or genital herpes simplex infection in patients with HIV infection | 548 | ||
| OFF-LABEL USES | 548 | ||
| CONTRAINDICATIONS | 549 | ||
| INTERACTIONS | 549 | ||
| DIAGNOSTIC TEST EFFECTS | 549 | ||
| SIDE EFFECTS | 549 | ||
| Famotidine | 549 | ||
| MECHANISM OF ACTION | 550 | ||
| PHARMACOKINETICS | 550 | ||
| AVAILABILITY | 550 | ||
| INDICATIONS AND DOSAGES | 550 | ||
| INDICATIONS AND DOSAGES▸ Acute treatment of duodenal and gastric ulcers | 550 | ||
| ▸ Duodenal ulcer maintenance | 550 | ||
| ▸ Gastroesophageal reflux disease (GERD) | 550 | ||
| ▸ Esophagitis | 550 | ||
| ▸ Hypersecretory conditions | 550 | ||
| ▸ Acid indigestion, heartburn (OTC) | 550 | ||
| ▸ Usual parenteral dosage | 550 | ||
| ▸ Dosage in renal impairment | 550 | ||
| CONTRAINDICATIONS | 551 | ||
| INTERACTIONS | 551 | ||
| DIAGNOSTIC TEST EFFECTS | 551 | ||
| ?IV INCOMPATIBILITIES\r | 551 | ||
| ?IV COMPATIBILITIES\r | 551 | ||
| SIDE EFFECTS | 551 | ||
| SERIOUS REACTIONS\r | 551 | ||
| Febuxostat | 552 | ||
| MECHANISM OF ACTION | 552 | ||
| PHARMACOKINETICS | 552 | ||
| AVAILABILITY | 552 | ||
| INDICATIONS AND DOSAGES | 552 | ||
| ▸ For chronic management of hyperuricemia due to gout\r | 552 | ||
| CONTRAINDICATIONS | 552 | ||
| INTERACTIONS | 552 | ||
| DIAGNOSTIC TEST EFFECTS | 553 | ||
| SIDE EFFECTS | 553 | ||
| SERIOUS REACTIONS\r | 553 | ||
| Felbamate | 554 | ||
| MECHANISM OF ACTION | 554 | ||
| PHARMACOKINETICS | 554 | ||
| AVAILABILITY | 554 | ||
| INDICATIONS AND DOSAGES | 554 | ||
| ▸ Monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization\r | 554 | ||
| ▸ Adjunctive therapy in the treatment of partial seizures, with and without generalization | 554 | ||
| ▸ Lennox-Gastaut syndrome | 554 | ||
| ▸ Dosage in renal impairment | 554 | ||
| OFF-LABEL USES | 555 | ||
| CONTRAINDICATIONS | 555 | ||
| INTERACTIONS | 555 | ||
| DIAGNOSTIC TEST EFFECTS | 555 | ||
| SIDE EFFECTS | 555 | ||
| SERIOUS REACTIONS | 555 | ||
| Felodipine | 556 | ||
| MECHANISM OF ACTION | 556 | ||
| PHARMACOKINETICS | 556 | ||
| AVAILABILITY | 556 | ||
| INDICATIONS AND DOSAGES | 556 | ||
| ▸ Hypertension | 556 | ||
| OFF-LABEL USES | 556 | ||
| CONTRAINDICATIONS | 556 | ||
| INTERACTIONS | 556 | ||
| SIDE EFFECTS | 557 | ||
| SERIOUS REACTIONS | 557 | ||
| Fenofibrate | 557 | ||
| MECHANISM OF ACTION | 557 | ||
| PHARMACOKINETICS | 557 | ||
| AVAILABILITY | 557 | ||
| INDICATIONS AND DOSAGES | 558 | ||
| ▸ Hypertriglyceridemia | 558 | ||
| OFF-LABEL USES | 558 | ||
| CONTRAINDICATIONS | 558 | ||
| INTERACTIONS | 558 | ||
| DIAGNOSTIC TEST EFFECTS | 558 | ||
| SIDE EFFECTS | 558 | ||
| SERIOUS REACTIONS | 559 | ||
| Fenofibric Acid | 559 | ||
| MECHANISM OF ACTION | 559 | ||
| PHARMACOKINETICS | 559 | ||
| AVAILABILITY | 559 | ||
| INDICATIONS AND DOSAGES | 559 | ||
| ▸ Severe hypertriglyceridemia | 559 | ||
| ▸ Primary hyperlipidemia or mixed dyslipidemia | 560 | ||
| ▸ Dosage in renal impairment | 560 | ||
| CONTRAINDICATIONS | 560 | ||
| INTERACTIONS | 560 | ||
| DIAGNOSTIC TEST EFFECTS | 560 | ||
| SIDE EFFECTS | 560 | ||
| SERIOUS REACTIONS | 560 | ||
| Fenoprofen | 561 | ||
| MECHANISM OF ACTION | 561 | ||
| AVAILABILITY | 561 | ||
| INDICATIONS AND DOSAGES | 561 | ||
| ▸ Mild to moderate pain | 561 | ||
| ▸ Rheumatoid arthritis, osteoarthritis | 561 | ||
| OFF-LABEL USES | 561 | ||
| CONTRAINDICATIONS | 561 | ||
| INTERACTIONS | 561 | ||
| DIAGNOSTIC TEST EFFECTS | 562 | ||
| SIDE EFFECTS | 562 | ||
| SERIOUS REACTIONS | 562 | ||
| Fentanyl | 563 | ||
| MECHANISM OF ACTION | 563 | ||
| PHARMACOKINETICS | 563 | ||
| AVAILABILITY | 563 | ||
| INDICATIONS AND DOSAGES | 564 | ||
| ▸ Premedication | 564 | ||
| ▸ Adjunct to general anesthesia | 564 | ||
| ▸ Adjunct to regional anesthesia | 564 | ||
| ▸ Postoperative pain | 564 | ||
| ▸ Chronic pain management | 564 | ||
| ▸ Breakthrough cancer pain | 564 | ||
| ▸ Continuous analgesia | 565 | ||
| ▸ Dosage in renal impairment | 565 | ||
| CONTRAINDICATIONS | 565 | ||
| INTERACTIONS | 565 | ||
| DIAGNOSTIC TEST EFFECTS | 566 | ||
| ?IV INCOMPATIBILITIES\r | 566 | ||
| ?IV COMPATIBILITIES\r | 566 | ||
| SIDE EFFECTS | 566 | ||
| SERIOUS REACTIONS | 566 | ||
| Ferrous Salts | 569 | ||
| MECHANISM OF ACTION | 569 | ||
| PHARMACOKINETICS | 569 | ||
| AVAILABILITY | 569 | ||
| INDICATIONS AND DOSAGES | 569 | ||
| ▸ Iron deficiency anemia | 569 | ||
| ▸ Prevention of iron deficiency anemia | 570 | ||
| CONTRAINDICATIONS | 570 | ||
| INTERACTIONS | 570 | ||
| DIAGNOSTIC TEST EFFECTS | 570 | ||
| SIDE EFFECTS | 570 | ||
| SERIOUS REACTIONS | 570 | ||
| Fesoterodine | 571 | ||
| MECHANISM OF ACTION | 571 | ||
| PHARMACOKINETICS | 571 | ||
| AVAILABILITY | 571 | ||
| INDICATIONS AND DOSAGES | 571 | ||
| ▸ Overactive bladder | 571 | ||
| ▸ Dosage in severe renal impairment (CrCl < 30 mL/min) or taking strong inhibitors of CYP3A4 | 571 | ||
| ▸ Severe hepatic impairment | 571 | ||
| CONTRAINDICATIONS | 571 | ||
| INTERACTIONS | 571 | ||
| DIAGNOSTIC TEST EFFECTS | 571 | ||
| SIDE EFFECTS | 571 | ||
| SERIOUS REACTIONS | 572 | ||
| Fexofenadine | 572 | ||
| MECHANISM OF ACTION | 572 | ||
| PHARMACOKINETICS | 572 | ||
| AVAILABILITY | 572 | ||
| INDICATIONS AND DOSAGES | 572 | ||
| ▸ Allergic rhinitis, chronic idiopathic urticaria | 572 | ||
| ▸ Dosage in renal impairment | 572 | ||
| ▸ Allergic rhinitis, chronic idiopathic urticaria | 573 | ||
| ▸ Chronic idiopathic urticaria | 573 | ||
| CONTRAINDICATIONS | 573 | ||
| INTERACTIONS | 573 | ||
| DIAGNOSTIC TEST EFFECTS | 573 | ||
| SIDE EFFECTS | 573 | ||
| SERIOUS REACTIONS | 573 | ||
| Fidaxomicin | 573 | ||
| MECHANISM OF ACTION | 574 | ||
| PHARMACOKINETICS | 574 | ||
| AVAILABILITY | 574 | ||
| INDICATIONS AND DOSAGES | 574 | ||
| ▸ Clostridium difficile-associated diarrhea (CDAD) | 574 | ||
| CONTRAINDICATIONS | 574 | ||
| INTERACTIONS | 574 | ||
| DIAGNOSTIC TEST EFFECTS | 574 | ||
| SIDE EFFECTS | 574 | ||
| SERIOUS REACTIONS | 574 | ||
| Filgrastim | 575 | ||
| MECHANISM OF ACTION | 575 | ||
| PHARMACOKINETICS | 575 | ||
| AVAILABILITY | 575 | ||
| INDICATIONS AND DOSAGES | 575 | ||
| ▸ Myelosuppression from chemotherapy | 575 | ||
| ▸ Bone marrow transplant | 575 | ||
| ▸ Mobilization progenitor cells | 575 | ||
| ▸ Chronic neutropenia, congenital neutropenia | 575 | ||
| ▸ Idiopathic or cyclic neutropenia | 575 | ||
| OFF-LABEL USES | 575 | ||
| CONTRAINDICATIONS | 575 | ||
| INTERACTIONS | 575 | ||
| DIAGNOSTIC TEST EFFECTS | 576 | ||
| ?IV INCOMPATIBILITIES\r | 576 | ||
| SIDE EFFECTS | 576 | ||
| SERIOUS REACTIONS | 576 | ||
| Finasteride | 577 | ||
| MECHANISM OF ACTION | 577 | ||
| PHARMACOKINETICS | 577 | ||
| AVAILABILITY | 577 | ||
| INDICATIONS AND DOSAGES | 577 | ||
| Benign prostatic hyperplasia (BPH) | 577 | ||
| Male-pattern hair loss | 577 | ||
| OFF-LABEL USES | 577 | ||
| CONTRAINDICATIONS | 577 | ||
| INTERACTIONS | 577 | ||
| DIAGNOSTIC TEST EFFECTS | 577 | ||
| SIDE EFFECTS | 578 | ||
| SERIOUS REACTIONS | 578 | ||
| Fingolimod | 578 | ||
| MECHANISM OF ACTION | 578 | ||
| PHARMACOKINETICS | 578 | ||
| AVAILABILITY | 578 | ||
| INDICATIONS AND DOSAGES | 579 | ||
| ▸ Relapsing forms of multiple sclerosis | 579 | ||
| ▸ Dosage in hepatic impairment\r | 579 | ||
| Relapsing forms of multiple sclerosis | 579 | ||
| CONTRAINDICATIONS | 579 | ||
| INTERACTIONS | 579 | ||
| DIAGNOSTIC TEST EFFECTS | 579 | ||
| SIDE EFFECTS | 579 | ||
| SERIOUS REACTIONS | 579 | ||
| Flecainide | 580 | ||
| MECHANISM OF ACTION | 580 | ||
| AVAILABILITY | 580 | ||
| INDICATIONS AND DOSAGES | 580 | ||
| ▸ Life-threatening ventricular arrhythmias, sustained ventricular tachycardia | 580 | ||
| Paroxysmal supraventricular tachycardia (PSVT), paroxysmal atrial fibrillation (PAF) | 580 | ||
| CONTRAINDICATIONS | 580 | ||
| INTERACTIONS | 580 | ||
| Flavocoxid\r | 580.e1 | ||
| MECHANISM OF ACTION | 580.e1 | ||
| PHARMACOKINETICS | 580.e1 | ||
| AVAILABILITY | 580.e1 | ||
| INDICATIONS AND DOSAGES | 580.e1 | ||
| ▸ Osteoarthritis | 580.e1 | ||
| CONTRAINDICATIONS | 580.e1 | ||
| INTERACTIONS | 580.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 580.e1 | ||
| SIDE EFFECTS | 580.e1 | ||
| SERIOUS REACTIONS | 580.e1 | ||
| Flavoxate | 580.e2 | ||
| MECHANISM OF ACTION | 580.e2 | ||
| AVAILABILITY | 580.e2 | ||
| INDICATIONS AND DOSAGES | 580.e2 | ||
| ▸ To relieve symptoms of nocturia, incontinence, suprapubic pain, dysuria, frequency and urgency associated with urologic conditions (symptomatic only) | 580.e2 | ||
| CONTRAINDICATIONS | 580.e2 | ||
| INTERACTIONS | 580.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 580.e2 | ||
| SIDE EFFECTS | 580.e2 | ||
| SERIOUS REACTIONS | 580.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 581 | ||
| SIDE EFFECTS | 581 | ||
| SERIOUS REACTIONS | 581 | ||
| Fluconazole | 581 | ||
| MECHANISM OF ACTION | 581 | ||
| PHARMACOKINETICS | 581 | ||
| AVAILABILITY | 582 | ||
| INDICATIONS AND DOSAGES | 582 | ||
| ▸ Oropharyngeal candidiasis | 582 | ||
| ▸ Esophageal candidiasis | 582 | ||
| ▸ Vaginal candidiasis | 582 | ||
| ▸ Prevention of candidiasis in patients undergoing bone marrow transplantation | 582 | ||
| ▸ Systemic candidiasis | 582 | ||
| ▸ Cryptococcal meningitis | 582 | ||
| ▸ Onychomycosis | 582 | ||
| ▸ Dosage in renal impairment (adults) | 582 | ||
| OFF-LABEL USES | 582 | ||
| CONTRAINDICATIONS | 582 | ||
| INTERACTIONS | 582 | ||
| DIAGNOSTIC TEST EFFECTS | 583 | ||
| ?IV INCOMPATIBILITIES\r | 583 | ||
| ?IV COMPATIBILITIES\r | 583 | ||
| SIDE EFFECTS | 583 | ||
| SERIOUS REACTIONS | 583 | ||
| Flucytosine\r | 583.e1 | ||
| MECHANISM OF ACTION | 583.e1 | ||
| PHARMACOKINETICS | 583.e1 | ||
| AVAILABILITY | 583.e1 | ||
| INDICATIONS AND DOSAGES | 583.e1 | ||
| ▸ Fungal infections, candidiasis, cryptococcosis | 583.e1 | ||
| ▸ Dosage in renal function impairment | 583.e1 | ||
| CONTRAINDICATIONS | 583.e1 | ||
| INTERACTIONS | 583.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 583.e1 | ||
| SIDE EFFECTS | 583.e1 | ||
| SERIOUS REACTIONS | 583.e1 | ||
| Fludrocortisone | 584 | ||
| MECHANISM OF ACTION | 584 | ||
| PHARMACOKINETICS | 584 | ||
| AVAILABILITY | 584 | ||
| INDICATIONS AND DOSAGES | 584 | ||
| ▸ Addison’s disease | 584 | ||
| ▸ Salt-losing adrenogenital syndrome | 584 | ||
| ▸ Usual pediatric dosage | 584 | ||
| OFF-LABEL USES | 584 | ||
| CONTRAINDICATIONS | 584 | ||
| INTERACTIONS | 584 | ||
| DIAGNOSTIC TEST EFFECTS | 584 | ||
| SIDE EFFECTS | 585 | ||
| SERIOUS REACTIONS | 585 | ||
| Flumazenil | 585 | ||
| MECHANISM OF ACTION | 585 | ||
| PHARMACOKINETICS | 585 | ||
| AVAILABILITY | 586 | ||
| INDICATIONS AND DOSAGES | 586 | ||
| ▸ Reversal of conscious sedation or general anesthesia | 586 | ||
| ▸ Benzodiazepine overdose | 586 | ||
| CONTRAINDICATIONS | 586 | ||
| INTERACTIONS | 586 | ||
| DIAGNOSTIC TEST EFFECTS | 586 | ||
| ?IV INCOMPATIBILITIES\r | 586 | ||
| ?IV COMPATIBILITIES\r | 586 | ||
| SIDE EFFECTS | 586 | ||
| SERIOUS REACTIONS | 586 | ||
| Flunisolide | 587 | ||
| MECHANISM OF ACTION | 587 | ||
| PHARMACOKINETICS | 587 | ||
| AVAILABILITY | 587 | ||
| INDICATIONS AND DOSAGES | 588 | ||
| ▸ Long-term control of bronchial asthma, assists in reducing or discontinuing oral corticosteroid therapy | 588 | ||
| ▸ Relief of symptoms of perennial and seasonal rhinitis | 588 | ||
| OFF-LABEL USES | 588 | ||
| CONTRAINDICATIONS | 588 | ||
| INTERACTIONS | 588 | ||
| DIAGNOSTIC TEST EFFECTS | 588 | ||
| SIDE EFFECTS | 588 | ||
| SERIOUS REACTIONS | 588 | ||
| MECHANISM OF ACTION | 589 | ||
| PHARMACOKINETICS | 589 | ||
| AVAILABILITY | 589 | ||
| INDICATIONS AND DOSAGES | 590 | ||
| ▸ Corticosteroid-responsive dermatoses | 590 | ||
| ▸ Scalp psoriasis | 590 | ||
| ▸ Seborrheic dermatitis, scalp | 590 | ||
| CONTRAINDICATIONS | 590 | ||
| INTERACTIONS | 590 | ||
| DIAGNOSTIC TEST EFFECTS | 590 | ||
| SIDE EFFECTS | 590 | ||
| SERIOUS REACTIONS | 590 | ||
| Fluoride, Sodium | 590.e1 | ||
| MECHANISM OF ACTION | 590.e1 | ||
| AVAILABILITY | 590.e1 | ||
| INDICATIONS AND DOSAGES | 590.e1 | ||
| ▸ Dietary supplement for prevention of dental caries in children | 590.e1 | ||
| CONTRAINDICATIONS | 590.e1 | ||
| INTERACTIONS | 590.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 590.e1 | ||
| SIDE EFFECTS | 590.e1 | ||
| SERIOUS REACTIONS | 590.e1 | ||
| Fluorescein\r | 590.e2 | ||
| MECHANISM OF ACTION | 590.e2 | ||
| PHARMACOKINETICS | 590.e2 | ||
| AVAILABILITY | 590.e2 | ||
| INDICATIONS AND DOSAGES | 590.e2 | ||
| ▸ Retinal angiography | 590.e2 | ||
| ▸ Applanation tonometry | 590.e2 | ||
| CONTRAINDICATIONS | 590.e2 | ||
| INTERACTIONS | 590.e2 | ||
| ?IV COMPATIBILITIES\r | 590.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 590.e3 | ||
| SIDE EFFECTS | 590.e3 | ||
| SERIOUS REACTIONS | 590.e3 | ||
| Fluoxetine | 591 | ||
| MECHANISM OF ACTION | 591 | ||
| PHARMACOKINETICS | 591 | ||
| AVAILABILITY | 591 | ||
| INDICATIONS AND DOSAGES | 591 | ||
| ▸ Depression, obsessive-compulsive disorder (OCD) | 591 | ||
| ▸ Panic disorder | 591 | ||
| ▸ Bulimia nervosa | 591 | ||
| ▸ Premenstrual dysphoric disorder | 591 | ||
| ▸ Depressive episodes of bipolar1 disorder | 591 | ||
| Fluorouracil, 5-FU | 591.e1 | ||
| MECHANISM OF ACTION | 591.e1 | ||
| PHARMACOKINETICS | 591.e1 | ||
| AVAILABILITY | 591.e1 | ||
| INDICATIONS AND DOSAGES | 591.e1 | ||
| ▸ Cancer of breast, colon, pancreas, rectum, and stomach; in combination with levamisole after surgical resection in patients with Duke’s stage C colon cancer | 591.e1 | ||
| ▸ Multiple actinic or solar keratoses | 591.e1 | ||
| ▸ Basal cell carcinoma | 591.e1 | ||
| CONTRAINDICATIONS | 591.e1 | ||
| INTERACTIONS | 591.e1 | ||
| ?IV INCOMPATIBILITIES\x0B | 591.e1 | ||
| SIDE EFFECTS | 591.e2 | ||
| SERIOUS REACTIONS | 591.e2 | ||
| OFF-LABEL USES | 592 | ||
| CONTRAINDICATIONS | 592 | ||
| INTERACTIONS | 592 | ||
| DIAGNOSTIC TEST EFFECTS | 592 | ||
| SIDE EFFECTS | 592 | ||
| SERIOUS REACTIONS | 592 | ||
| Fluphenazine | 593 | ||
| MECHANISM OF ACTION | 593 | ||
| PHARMACOKINETICS | 593 | ||
| Fluoxymesterone | 593.e1 | ||
| MECHANISM OF ACTION | 593.e1 | ||
| PHARMACOKINETICS | 593.e1 | ||
| AVAILABILITY | 593.e1 | ||
| INDICATIONS AND DOSAGES | 593.e1 | ||
| ▸ Males (hypogonadism) | 593.e1 | ||
| ▸ Males (delayed puberty) | 593.e1 | ||
| ▸ Females (inoperable breast cancer) | 593.e1 | ||
| CONTRAINDICATIONS | 593.e1 | ||
| INTERACTIONS | 593.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 593.e1 | ||
| SIDE EFFECTS | 593.e1 | ||
| SERIOUS REACTIONS | 593.e2 | ||
| AVAILABILITY | 594 | ||
| INDICATIONS AND DOSAGES | 594 | ||
| ▸ Psychosis | 594 | ||
| CONTRAINDICATIONS | 594 | ||
| INTERACTIONS | 594 | ||
| DIAGNOSTIC TEST EFFECTS | 594 | ||
| SIDE EFFECTS | 594 | ||
| SERIOUS REACTIONS | 594 | ||
| Flurandrenolide | 595 | ||
| MECHANISM OF ACTION | 595 | ||
| PHARMACOKINETICS | 595 | ||
| AVAILABILITY | 595 | ||
| INDICATIONS AND DOSAGES | 595 | ||
| ▸ Anti-inflammatory, immunosuppressant, corticosteroid replacement therapy | 595 | ||
| CONTRAINDICATIONS | 595 | ||
| INTERACTIONS | 595 | ||
| DIAGNOSTIC TEST EFFECTS | 596 | ||
| SIDE EFFECTS | 596 | ||
| SERIOUS REACTIONS | 596 | ||
| Flurazepam | 596 | ||
| MECHANISM OF ACTION | 596 | ||
| PHARMACOKINETICS | 596 | ||
| AVAILABILITY | 596 | ||
| INDICATIONS AND DOSAGES | 596 | ||
| ▸ Insomnia | 596 | ||
| CONTRAINDICATIONS | 596 | ||
| INTERACTIONS | 597 | ||
| DIAGNOSTIC TEST EFFECTS | 597 | ||
| SIDE EFFECTS | 597 | ||
| SERIOUS REACTIONS | 597 | ||
| Flurbiprofen | 598 | ||
| MECHANISM OF ACTION | 598 | ||
| PHARMACOKINETICS | 598 | ||
| AVAILABILITY | 598 | ||
| INDICATIONS AND DOSAGES | 598 | ||
| ▸ Rheumatoid arthritis, osteoarthritis | 598 | ||
| ▸ Dysmenorrhea, pain | 598 | ||
| ▸ Intraoperative miosis | 598 | ||
| CONTRAINDICATIONS | 598 | ||
| INTERACTIONS | 598 | ||
| SIDE EFFECTS | 599 | ||
| SERIOUS REACTIONS | 599 | ||
| Fluticasone | 599 | ||
| MECHANISM OF ACTION | 599 | ||
| Flutamide | 599.e1 | ||
| MECHANISM OF ACTION | 599.e1 | ||
| PHARMACOKINETICS | 599.e1 | ||
| AVAILABILITY | 599.e1 | ||
| INDICATIONS AND DOSAGES | 599.e1 | ||
| ▸ Prostatic carcinoma (in combination with leuprolide) | 599.e1 | ||
| CONTRAINDICATIONS | 599.e1 | ||
| INTERACTIONS | 599.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 599.e1 | ||
| SIDE EFFECTS | 599.e1 | ||
| SERIOUS REACTIONS | 599.e1 | ||
| PHARMACOKINETICS | 600 | ||
| AVAILABILITY | 600 | ||
| INDICATIONS AND DOSAGES | 600 | ||
| ▸ Allergic rhinitis | 600 | ||
| ▸ Relief of inflammation and pruritus associated with steroid-responsive disorders, such as contact dermatitis and eczema | 600 | ||
| ▸ Maintenance treatment for asthma for those previously treated with bronchodilators | 600 | ||
| ▸ Maintenance treatment for asthma for those previously treated with inhaled steroids | 600 | ||
| ▸ Maintenance treatment for asthma for those previously treated with oral steroids | 600 | ||
| CONTRAINDICATIONS | 600 | ||
| INTERACTIONS | 601 | ||
| DIAGNOSTIC TEST EFFECTS | 601 | ||
| SIDE EFFECTS | 601 | ||
| SERIOUS REACTIONS | 601 | ||
| Fluticasone; Vilanterol | 602 | ||
| MECHANISM OF ACTION | 602 | ||
| PHARMACOKINETICS | 602 | ||
| AVAILABILITY | 602 | ||
| INDICATIONS AND DOSAGES | 602 | ||
| ▸ COPD | 602 | ||
| CONTRAINDICATIONS | 602 | ||
| INTERACTIONS | 602 | ||
| DIAGNOSTIC TEST EFFECTS | 603 | ||
| SIDE EFFECTS | 603 | ||
| SERIOUS REACTIONS | 603 | ||
| Fluvastatin | 604 | ||
| MECHANISM OF ACTION | 604 | ||
| PHARMACOKINETICS | 604 | ||
| AVAILABILITY | 604 | ||
| INDICATIONS AND DOSAGES | 604 | ||
| ▸ Hyperlipoproteinemia | 604 | ||
| ▸ Dosage in renal impairment | 604 | ||
| CONTRAINDICATIONS | 604 | ||
| INTERACTIONS | 604 | ||
| DIAGNOSTIC TEST EFFECTS | 605 | ||
| SIDE EFFECTS | 605 | ||
| SERIOUS REACTIONS | 605 | ||
| Fluvoxamine | 605 | ||
| MECHANISM OF ACTION | 605 | ||
| AVAILABILITY | 606 | ||
| INDICATIONS AND DOSAGES | 606 | ||
| ▸ Obsessive-compulsive disorder | 606 | ||
| ▸ Social anxiety disorder | 606 | ||
| OFF-LABEL USES | 606 | ||
| CONTRAINDICATIONS | 606 | ||
| INTERACTIONS | 606 | ||
| DIAGNOSTIC TEST EFFECTS | 606 | ||
| SIDE EFFECTS | 606 | ||
| SERIOUS REACTIONS | 606 | ||
| Folic Acid | 607 | ||
| MECHANISM OF ACTION | 607 | ||
| PHARMACOKINETICS | 607 | ||
| AVAILABILITY | 607 | ||
| INDICATIONS AND DOSAGES | 607 | ||
| ▸ Folic acid deficiency | 607 | ||
| ▸ Dietary supplement | 607 | ||
| CONTRAINDICATIONS | 607 | ||
| INTERACTIONS | 607 | ||
| DIAGNOSTIC TEST EFFECTS | 608 | ||
| ?IV INCOMPATIBILITIES\r | 608 | ||
| SIDE EFFECTS | 608 | ||
| SERIOUS REACTIONS | 608 | ||
| Fondaparinux | 608 | ||
| MECHANISM OF ACTION | 608 | ||
| Fomepizole | 608.e1 | ||
| MECHANISM OF ACTION | 608.e1 | ||
| PHARMACOKINETICS | 608.e1 | ||
| AVAILABILITY | 608.e1 | ||
| INDICATIONS AND DOSAGES | 608.e1 | ||
| ▸ Ethylene glycol or methanol intoxication | 608.e1 | ||
| ▸ Dosage in renal impairment | 608.e1 | ||
| OFF-LABEL USES | 608.e1 | ||
| CONTRAINDICATIONS | 608.e1 | ||
| INTERACTIONS | 608.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 608.e1 | ||
| ?IV INCOMPATIBILITIES\r | 608.e1 | ||
| SIDE EFFECTS | 608.e1 | ||
| SERIOUS REACTIONS | 608.e2 | ||
| PHARMACOKINETICS | 609 | ||
| AVAILABILITY | 609 | ||
| INDICATIONS AND DOSAGES | 609 | ||
| ▸ Prevention of venous thromboembolism | 609 | ||
| ▸ Treatment of pulmonary embolism or DVT in conjunction with warfarin | 609 | ||
| ▸ Dosage in renal impairment | 609 | ||
| CONTRAINDICATIONS | 609 | ||
| INTERACTIONS | 609 | ||
| DIAGNOSTIC TEST EFFECTS | 609 | ||
| SIDE EFFECTS | 609 | ||
| SERIOUS REACTIONS | 609 | ||
| Formoterol | 610 | ||
| MECHANISM OF ACTION | 610 | ||
| PHARMACOKINETICS | 610 | ||
| AVAILABILITY | 611 | ||
| INDICATIONS AND DOSAGES | 611 | ||
| ▸ Asthma, chronic obstructive pulmonary disease (COPD), exercise-induced bronchospasm | 611 | ||
| ▸ Exercise-induced bronchospasm | 611 | ||
| CONTRAINDICATIONS | 611 | ||
| INTERACTIONS | 611 | ||
| DIAGNOSTIC TEST EFFECTS | 611 | ||
| SIDE EFFECTS | 611 | ||
| SERIOUS REACTIONS | 611 | ||
| Fosamprenavir | 612 | ||
| MECHANISM OF ACTION | 612 | ||
| PHARMACOKINETICS | 612 | ||
| AVAILABILITY | 612 | ||
| INDICATIONS AND DOSAGES | 612 | ||
| ▸ HIV infection in patients who have not had previous protease inhibitor therapy | 612 | ||
| ▸ HIV infection in patients who have had previous protease inhibitor therapy | 613 | ||
| ▸ Concurrent therapy with efavirenz | 613 | ||
| ▸ Dosage in hepatic impairment | 613 | ||
| CONTRAINDICATIONS | 613 | ||
| INTERACTIONS | 613 | ||
| DIAGNOSTIC TEST EFFECTS | 614 | ||
| SIDE EFFECTS | 614 | ||
| SERIOUS REACTIONS\r | 614 | ||
| Fosaprepitant | 615 | ||
| MECHANISM OF ACTION | 615 | ||
| PHARMACOKINETICS | 615 | ||
| AVAILABILITY | 615 | ||
| INDICATIONS AND DOSAGES | 615 | ||
| ▸ Prevention of chemotherapy-induced nausea and vomiting | 615 | ||
| CONTRAINDICATIONS | 615 | ||
| INTERACTIONS | 615 | ||
| Foscarnet | 615.e1 | ||
| MECHANISM OF ACTION | 615.e1 | ||
| PHARMACOKINETICS | 615.e1 | ||
| AVAILABILITY | 615.e1 | ||
| INDICATIONS AND DOSAGES | 615.e1 | ||
| ▸ Cytomegalovirus (CMV) retinitis | 615.e1 | ||
| ▸ Herpes infection (resistant cases) | 615.e1 | ||
| ▸ Dosage in renal impairment | 615.e1 | ||
| CONTRAINDICATIONS | 615.e1 | ||
| INTERACTIONS | 615.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 615.e1 | ||
| ?IV INCOMPATIBILITIES\r | 615.e1 | ||
| ?IV COMPATIBILITIES\r | 615.e1 | ||
| SIDE EFFECTS | 615.e1 | ||
| SERIOUS REACTIONS | 615.e2 | ||
| ?IV INCOMPATIBILITIES\r | 616 | ||
| DIAGNOSTIC TEST EFFECTS | 616 | ||
| SIDE EFFECTS | 616 | ||
| SERIOUS REACTIONS | 616 | ||
| G\r | 626 | ||
| Mechanism of Action | 626 | ||
| Pharmacokinetics | 626 | ||
| Availability | 626 | ||
| Indications and Dosages | 626 | ||
| ‣Adjunctive therapy for seizure control | 626 | ||
| ‣Postherpetic neuralgia (PHN) | 626 | ||
| ‣Restless legs syndrome (RLS) | 626 | ||
| ‣Dosage in renal impairment | 626 | ||
| Horizant | 627 | ||
| Gralise | 627 | ||
| Off-Label Uses | 627 | ||
| Contraindications | 627 | ||
| Interactions | 627 | ||
| Diagnostic Test Effects | 627 | ||
| Side Effects | 627 | ||
| Serious Reactions | 627 | ||
| Galantamine | 628 | ||
| Mechanism of Action | 628 | ||
| Pharmacokinetics | 629 | ||
| Availability | 629 | ||
| Indications and Dosages | 629 | ||
| ‣Alzheimer’s disease | 629 | ||
| ‣Dosage in renal or hepatic impairment | 629 | ||
| Contraindications | 629 | ||
| Interactions | 629 | ||
| Diagnostic Test Effects | 629 | ||
| Side Effects | 629 | ||
| Serious Reactions | 629 | ||
| Ganciclovir | 630 | ||
| Mechanism of Action | 630 | ||
| Pharmacokinetics | 630 | ||
| Availability | 630 | ||
| Indications and Dosages | 630 | ||
| ‣Cytomegalovirus (CMV) retinitis | 630 | ||
| ‣Prevention of CMV disease in transplant patients | 630 | ||
| ‣Other CMV infections | 630 | ||
| ‣Intravitreal implant | 631 | ||
| ‣Acute herpes simplex keratitis (dendritic keratitis) | 631 | ||
| ‣Adult dosage in renal impairment | 631 | ||
| Off-Label Uses | 631 | ||
| Contraindications | 631 | ||
| Interactions | 631 | ||
| Diagnostic Test Effects | 631 | ||
| ?IV Incompatibilities | 631 | ||
| Diagnostic Test Effects | 632 | ||
| Side Effects | 632 | ||
| Serious Reactions | 632 | ||
| Gatifloxacin | 633 | ||
| Mechanism of Action | 633 | ||
| Availability | 633 | ||
| Indications and Dosages | 633 | ||
| ‣Bacterial conjunctivitis (Zymar) | 633 | ||
| ‣Bacterial conjunctivitis (Zymaxid) | 633 | ||
| Contraindications | 633 | ||
| Interactions | 633 | ||
| Diagnostic Test Effects | 633 | ||
| Side Effects | 633 | ||
| Serious Reactions | 633 | ||
| Gemfibrozil | 634 | ||
| Mechanism of Action | 634 | ||
| Pharmacokinetics | 634 | ||
| Availability | 634 | ||
| Indications and Dosages | 634 | ||
| ‣Hyperlipidemia, hypertriglyceridemia | 634 | ||
| Contraindications | 634 | ||
| Interactions | 634 | ||
| Gefitinib | 634.e1 | ||
| Mechanism of Action | 634.e1 | ||
| Pharmacokinetics | 634.e1 | ||
| Availability | 634.e1 | ||
| Indications and Dosages | 634.e1 | ||
| ‣Non–small cell lung cancer (only in those patients showing benefit from current or past use) | 634.e1 | ||
| Contraindications | 634.e1 | ||
| Interactions | 634.e1 | ||
| Diagnostic Test Effects | 634.e1 | ||
| Side Effects | 634.e1 | ||
| Serious Reactions | 634.e1 | ||
| Gemcitabine | 634.e2 | ||
| Mechanism of Action | 634.e2 | ||
| Pharmacokinetics | 634.e3 | ||
| Availability | 634.e3 | ||
| Indications and Dosages | 634.e3 | ||
| ‣For metastatic breast cancer with paclitaxel | 634.e3 | ||
| ‣For ovarian cancer that has relapsed at least 6 mo after platinum-based treatment | 634.e3 | ||
| ‣For non–small cell lung cancer along with cisplatin | 634.e3 | ||
| ‣For pancreatic cancer as a single agent | 634.e3 | ||
| ‣Dosage modifications | 634.e3 | ||
| Contraindications | 634.e3 | ||
| Interactions | 634.e3 | ||
| Diagnostic Test Effects | 634.e3 | ||
| ?IV Incompatibilities | 634.e4 | ||
| Side Effects | 634.e4 | ||
| Serious Reactions | 634.e4 | ||
| Diagnostic Test Effects | 635 | ||
| Side Effects | 635 | ||
| Serious Reactions | 635 | ||
| Gemifloxacin | 635 | ||
| Mechanism of Action | 635 | ||
| Pharmacokinetics | 635 | ||
| Availability | 636 | ||
| Indications and Dosages | 636 | ||
| ‣Acute bacterial exacerbation of chronic bronchitis | 636 | ||
| ‣Community-acquired pneumonia | 636 | ||
| ‣Dosage in renal impairment | 636 | ||
| Contraindications | 636 | ||
| Interactions | 636 | ||
| Diagnostic Test Effects | 636 | ||
| Side Effects | 636 | ||
| Serious Reactions | 636 | ||
| Gentamicin | 637 | ||
| Mechanism of Action | 637 | ||
| Pharmacokinetics | 637 | ||
| Availability | 638 | ||
| Indications and Dosages | 638 | ||
| ‣Acute pelvic, bone, intra-abdominal, joint, respiratory tract, burn wound, postoperative, and skin or skin-structure infections... | 638 | ||
| ‣Intrathecal (preservative-free injection only) | 638 | ||
| ‣Superficial eye infections | 638 | ||
| ‣Superficial skin infections | 638 | ||
| ‣Dosage in renal impairment (adults) | 638 | ||
| ‣Hemodialysis | 638 | ||
| ‣“Once daily” dose strategy | 638 | ||
| Contraindications | 638 | ||
| Interactions | 638 | ||
| Diagnostic Test Effects | 639 | ||
| ?IV Incompatibilities | 639 | ||
| ?IV Compatibilities | 639 | ||
| Side Effects | 639 | ||
| Serious Reactions | 639 | ||
| Glatiramer | 640 | ||
| Mechanism of Action | 640 | ||
| Pharmacokinetics | 640 | ||
| Availability | 641 | ||
| Indications and Dosages | 641 | ||
| ‣MS | 641 | ||
| Contraindications | 641 | ||
| Interactions | 641 | ||
| Diagnostic Test Effects | 641 | ||
| Side Effects | 641 | ||
| Serious Reactions | 641 | ||
| Glimepiride | 642 | ||
| Mechanism of Action | 642 | ||
| Pharmacokinetics | 642 | ||
| Availability | 642 | ||
| Indications and Dosages | 642 | ||
| ‣Type 2 diabetes mellitus | 642 | ||
| ‣Dosage in renal impairment | 642 | ||
| Contraindications | 642 | ||
| Interactions | 642 | ||
| Diagnostic Test Effects | 642 | ||
| Side Effects | 642 | ||
| Serious Reactions | 643 | ||
| Glipizide | 643 | ||
| Mechanism of Action | 643 | ||
| Pharmacokinetics | 644 | ||
| Availability | 644 | ||
| Indications and Dosages | 644 | ||
| ‣Type 2 diabetes mellitus | 644 | ||
| Contraindications | 644 | ||
| Interactions | 644 | ||
| Diagnostic Test Effects | 644 | ||
| Side Effects | 644 | ||
| Serious Reactions | 644 | ||
| Glucagon Hydrochloride | 645 | ||
| Mechanism of Action | 645 | ||
| Availability | 645 | ||
| Indications and Dosages | 645 | ||
| ‣Hypoglycemia | 645 | ||
| ‣Diagnostic aid | 646 | ||
| Off-Label Uses | 646 | ||
| Contraindications | 646 | ||
| Interactions | 646 | ||
| Diagnostic Test Effects | 646 | ||
| ?IV Incompatibilities | 646 | ||
| Side Effects | 646 | ||
| Serious Reactions | 646 | ||
| Glucarpidase | 646.e1 | ||
| Mechanism of Action | 646.e1 | ||
| Pharmacokinetics | 646.e1 | ||
| Availability | 646.e1 | ||
| Indications and Dosages | 646.e1 | ||
| ‣Treatment of methotrexate toxicity (concentration > 1 micromole/L) in patients with delayed methotrexate clearance due to impai... | 646.e1 | ||
| Contraindications | 646.e1 | ||
| Interactions | 646.e1 | ||
| Diagnostic Test Effects | 646.e1 | ||
| ?IV Incompatibilities | 646.e1 | ||
| Side Effects | 646.e1 | ||
| Serious Reactions | 646.e1 | ||
| Glyburide | 647 | ||
| Mechanism of Action | 647 | ||
| Pharmacokinetics | 647 | ||
| Availability | 647 | ||
| Indications and Dosages | 647 | ||
| ‣Diabetes mellitus type 2 | 647 | ||
| ‣Dosage in renal impairment | 647 | ||
| Contraindications | 647 | ||
| Interactions | 647 | ||
| Diagnostic Test Effects | 648 | ||
| Side Effects | 648 | ||
| Serious Reactions | 648 | ||
| Glycerin | 649 | ||
| Mechanism of Action | 649 | ||
| Pharmacokinetics | 649 | ||
| Availability | 649 | ||
| Indications and Dosages | 649 | ||
| ‣Constipation | 649 | ||
| ‣Dry, irritated eyes | 649 | ||
| ‣Reduction of intraocular pressure (IOP) | 649 | ||
| Contraindications | 649 | ||
| Interactions | 649 | ||
| Diagnostic Test Effects | 650 | ||
| Side Effects | 650 | ||
| Serious Reactions | 650 | ||
| Glycopyrrolate | 651 | ||
| Mechanism of Action | 651 | ||
| Pharmacokinetics | 651 | ||
| Availability | 651 | ||
| Indications and Dosages | 651 | ||
| ‣Preoperative inhibition of salivation and excessive respiratory tract secretions | 651 | ||
| ‣To block the effects of anticholinesterase agents | 651 | ||
| ‣Peptic ulcer disease, adjunct | 651 | ||
| ‣For severe drooling in children with cerebral palsy | 651 | ||
| Off-Label Uses | 651 | ||
| Contraindications | 651 | ||
| Interactions | 651 | ||
| Diagnostic Test Effects | 652 | ||
| ?IV Incompatibilities | 652 | ||
| ?IV Compatibilities | 652 | ||
| Side Effects | 652 | ||
| Serious Reactions | 652 | ||
| Golimumab | 653 | ||
| Mechanism of Action | 653 | ||
| Pharmacokinetics | 653 | ||
| Availability | 653 | ||
| Indications and Dosages | 653 | ||
| ‣Moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, or active ankylosing spondylitis | 653 | ||
| ‣Moderate to severe ulcerative colitis | 653 | ||
| Contraindications | 653 | ||
| Interactions | 653 | ||
| ?IV Incompatibilities | 654 | ||
| Diagnostic Test Effects | 654 | ||
| Side Effects | 654 | ||
| Serious Reactions | 654 | ||
| Granisetron | 655 | ||
| Mechanism of Action | 655 | ||
| Pharmacokinetics | 655 | ||
| Availability | 655 | ||
| Indications and Dosages | 655 | ||
| ‣Prevention of chemotherapy-induced nausea and vomiting | 655 | ||
| Mechanism of Action | 655.e1 | ||
| Availability | 655.e1 | ||
| Indications and Dosages | 655.e1 | ||
| ‣Prostatic cancer | 655.e1 | ||
| ‣Breast cancer, endometriosis | 655.e1 | ||
| Off-Label Uses | 655.e1 | ||
| Contraindications | 655.e1 | ||
| Interactions | 655.e1 | ||
| Diagnostic Test Effects | 655.e1 | ||
| Side Effects | 655.e1 | ||
| Serious Reactions | 655.e1 | ||
| ‣Prevention of radiation-induced nausea and vomiting | 656 | ||
| ‣Postoperative nausea or vomiting | 656 | ||
| Contraindications | 656 | ||
| Interactions | 656 | ||
| Diagnostic Test Effects | 656 | ||
| ?IV Incompatibilities | 656 | ||
| ?IV Compatibilities | 656 | ||
| Side Effects | 656 | ||
| Serious Reactions | 656 | ||
| Griseofulvin | 657 | ||
| Mechanism of Action | 657 | ||
| Availability | 657 | ||
| Indications and Dosages | 657 | ||
| ‣Tinea capitis, tinea corporis, tinea cruris, tinea pedis, tinea unguium | 657 | ||
| Contraindications | 657 | ||
| Interactions | 658 | ||
| Diagnostic Test Effects | 658 | ||
| Side Effects | 658 | ||
| Serious Reactions | 658 | ||
| Mechanism of Action | 659 | ||
| Pharmacokinetics | 659 | ||
| Availability | 659 | ||
| Indications and Dosages | 659 | ||
| ‣Expectorant | 659 | ||
| Contraindications | 659 | ||
| Interactions | 659 | ||
| Diagnostic Test Effects | 659 | ||
| Side Effects | 659 | ||
| Serious Reactions | 659 | ||
| Guanfacine | 660 | ||
| Mechanism of Action | 660 | ||
| Pharmacokinetics | 660 | ||
| Availability | 660 | ||
| Indications and Dosages | 660 | ||
| ‣Hypertension | 660 | ||
| ‣Attention deficit hyperactivity disorder (ADHD) | 660 | ||
| ‣Dosage in hepatic or renal impairment (all patients) | 660 | ||
| Contraindications | 660 | ||
| Interactions | 661 | ||
| Diagnostic Test Effects | 661 | ||
| Side Effects | 661 | ||
| Serious Reactions | 661 | ||
| H | 663 | ||
| Halcinonide | 663 | ||
| Mechanism of Action | 663 | ||
| Pharmacokinetics | 663 | ||
| Availability | 663 | ||
| Indications and Dosages | 663 | ||
| ▸Corticosteroid-responsive dermatoses | 663 | ||
| Contraindications | 663 | ||
| Interactions | 663 | ||
| Diagnostic Test Effects | 663 | ||
| Side Effects | 663 | ||
| Serious Reactions | 663 | ||
| Mechanism of Action | 664 | ||
| Pharmacokinetics | 664 | ||
| Availability | 664 | ||
| Indications and Dosages | 664 | ||
| ▸Dermatoses, corticosteroid-responsive | 664 | ||
| Contraindications | 664 | ||
| Interactions | 664 | ||
| Diagnostic Test Effects | 664 | ||
| Side Effects | 664 | ||
| Serious Reactions | 664 | ||
| Haloperidol | 665 | ||
| Mechanism of Action | 665 | ||
| Pharmacokinetics | 665 | ||
| Availability | 665 | ||
| Indications and Dosages | 665 | ||
| ▸Treatment of psychotic disorders | 665 | ||
| ▸Treatment of nonpsychotic disorders, Tourette’s syndrome | 665 | ||
| Off-Label Uses | 666 | ||
| Contraindications | 666 | ||
| Interactions | 666 | ||
| Diagnostic Test Effects | 666 | ||
| ?IV Incompatibilities | 666 | ||
| ?IV Compatibilities | 666 | ||
| Side Effects | 667 | ||
| Serious Reactions | 667 | ||
| Hepatitis B ImmuneGlobulin (Human) | 671 | ||
| Mechanism of Action | 671 | ||
| Availability | 671 | ||
| Indications and Dosages | 671 | ||
| ▸Prevention of hepatitis B infection | 671 | ||
| ▸Perinatal exposure of infants born to HBsAg-positive mothers | 671 | ||
| ▸For prevention of hepatitis B infection recurrence after liver transplantation in HBsAg-positive liver transplant patients | 671 | ||
| Contraindications | 671 | ||
| Interactions | 671 | ||
| Diagnostic Test Effects | 671 | ||
| Side Effects | 671 | ||
| Serious Reactions | 672 | ||
| Hetastarch | 672 | ||
| Mechanism of Action | 672 | ||
| Pharmacokinetics | 672 | ||
| Availability | 672 | ||
| Indications and Dosages | 672 | ||
| ▸Plasma volume expansion | 672 | ||
| ▸Leukapheresis | 672 | ||
| Contraindications | 673 | ||
| Interactions | 673 | ||
| Diagnostic Test Effects | 673 | ||
| ?IV Incompatibilities | 673 | ||
| ?IV Compatibilities | 673 | ||
| Side Effects | 673 | ||
| Serious Reactions | 673 | ||
| Heparin | 668 | ||
| Mechanism of Action | 668 | ||
| Pharmacokinetics | 668 | ||
| Availability | 668 | ||
| Indications and Dosages | 668 | ||
| ▸Line flushing | 668 | ||
| ▸Treatment of venous thrombosis, pulmonary embolism, peripheral arterial embolism, atrial fibrillation with embolism | 668 | ||
| ▸Prevention of venous thrombosis, pulmonary embolism, peripheral arterial embolism, atrial fibrillation with embolism | 669 | ||
| Contraindications | 669 | ||
| Interactions | 669 | ||
| Diagnostic Test Effects | 669 | ||
| ?IV Incompatibilities | 669 | ||
| ?IV Compatibilities | 669 | ||
| Side Effects | 670 | ||
| Serious Reactions | 670 | ||
| Hydralazine | 674 | ||
| Mechanism of Action | 674 | ||
| Pharmacokinetics | 674 | ||
| Availability | 674 | ||
| Hyaluronan | 674.e1 | ||
| Mechanism of Action | 674.e1 | ||
| Pharmacokinetics | 674.e1 | ||
| Availability | 674.e1 | ||
| Indications and Dosages | 674.e1 | ||
| ▸Knee osteoarthritis | 674.e1 | ||
| Off-Label Uses | 674.e1 | ||
| Contraindications | 674.e1 | ||
| Interactions | 674.e1 | ||
| Diagnostic Test Effects | 674.e1 | ||
| Side Effects | 674.e1 | ||
| Serious Reactions | 674.e1 | ||
| Indications and Dosages | 675 | ||
| ▸Moderate to severe hypertension | 675 | ||
| ▸Dosage in renal impairment | 675 | ||
| Off-Label Uses | 675 | ||
| Contraindications | 675 | ||
| Interactions | 675 | ||
| Diagnostic Test Effects | 675 | ||
| ?IV Incompatibilities | 675 | ||
| Side Effects | 675 | ||
| Serious Reactions | 675 | ||
| Hydrochlorothiazide | 676 | ||
| Mechanism of Action | 676 | ||
| Pharmacokinetics | 676 | ||
| Availability | 676 | ||
| Indications and Dosages | 676 | ||
| ▸Edema, hypertension | 676 | ||
| ▸Usual pediatric dosage | 677 | ||
| Off-Label Uses | 677 | ||
| Contraindications | 677 | ||
| Interactions | 677 | ||
| Diagnostic Test Effects | 677 | ||
| Side Effects | 677 | ||
| Serious Reactions | 677 | ||
| Hydrocodone | 678 | ||
| Mechanism of Action | 678 | ||
| Pharmacokinetics | 679 | ||
| Availability | 679 | ||
| Indications and Dosages | 679 | ||
| ▸Hydrocodone and acetaminophen Analgesia | 679 | ||
| ▸Hydrocodone and chlorpheniramine | 680 | ||
| ▸Hydrocodone and guaifenesin | 680 | ||
| ▸Hydrocodone and homatropine | 680 | ||
| ▸Hydrocodone and ibuprofen | 680 | ||
| ▸Hydrocodone and pseudoephedrine | 680 | ||
| ▸Breakthrough cancer pain or other chronic pain | 680 | ||
| Contraindications | 680 | ||
| Interactions | 680 | ||
| Diagnostic Test Effects | 680 | ||
| Side Effects | 681 | ||
| Serious Reactions | 681 | ||
| Hydrocortisone | 682 | ||
| Mechanism of Action | 682 | ||
| Pharmacokinetics | 682 | ||
| Availability | 682 | ||
| Indications and Dosages | 682 | ||
| ▸Acute adrenal insufficiency | 682 | ||
| ▸Anti-inflammation, immunosuppression | 682 | ||
| ▸Physiologic replacement | 682 | ||
| ▸Corticosteroid responsive dermatoses | 683 | ||
| ▸Status asthmaticus | 683 | ||
| ▸Shock | 683 | ||
| ▸Adjunctive treatment of ulcerative colitis | 683 | ||
| ▸Hemorrhoidal irritation | 683 | ||
| Contraindications | 683 | ||
| Interactions | 683 | ||
| Diagnostic Test Effects | 683 | ||
| ?IV Incompatibilities | 683 | ||
| ?IV Compatibilities | 683 | ||
| Side Effects | 684 | ||
| Serious Reactions | 684 | ||
| Hydromorphone | 685 | ||
| Mechanism of Action | 685 | ||
| Mechanism of Action | 685.e1 | ||
| Pharmacokinetics | 685.e1 | ||
| Availability | 685.e1 | ||
| Indications and Dosages | 685.e1 | ||
| ▸Hyperpigmentation, melanin | 685.e1 | ||
| Off-Label Uses | 685.e1 | ||
| Contraindications | 685.e1 | ||
| Interactions | 685.e1 | ||
| Diagnostic Test Effects | 685.e1 | ||
| Side Effects | 685.e1 | ||
| Serious Reactions | 685.e1 | ||
| Pharmacokinetics | 686 | ||
| Availability | 686 | ||
| Indications and Dosages | 686 | ||
| ▸Analgesia | 686 | ||
| ▸Patient-controlled analgesia (PCA) | 686 | ||
| ▸For moderate to severe pain in opioid-tolerant patients | 686 | ||
| ▸Dose of Exalgo in hepatic impairment | 686 | ||
| ▸Dose of Exalgo in renal impairment | 687 | ||
| Contraindications | 687 | ||
| Interactions | 687 | ||
| Diagnostic Test Effects | 687 | ||
| ?IV Incompatibilities | 687 | ||
| ?IV Compatibilities | 687 | ||
| Side Effects | 687 | ||
| Serious Reactions | 688 | ||
| Hydroxychloroquine | 689 | ||
| Mechanism of Action | 689 | ||
| Pharmacokinetics | 689 | ||
| Availability | 689 | ||
| Indications and Dosages | 689 | ||
| ▸Treatment of acute attack of malaria (dosage in mg base) | 689 | ||
| ▸Suppression of malaria | 690 | ||
| ▸Rheumatoid arthritis | 690 | ||
| ▸Lupus erythematosus | 690 | ||
| Off-Label Uses | 690 | ||
| Contraindications | 690 | ||
| Interactions | 690 | ||
| Diagnostic Test Effects | 690 | ||
| Side Effects | 690 | ||
| Serious Reactions | 690 | ||
| Mechanism of Action | 691 | ||
| Pharmacokinetics | 691 | ||
| Availability | 691 | ||
| Indications and Dosages | 691 | ||
| ▸Prevention of preterm delivery in singleton pregnancies | 691 | ||
| Contraindications | 691 | ||
| Interactions | 691 | ||
| Diagnostic Test Effects | 692 | ||
| Side Effects | 692 | ||
| Serious Reactions | 692 | ||
| Hydroxyzine | 693 | ||
| Mechanism of Action | 693 | ||
| Pharmacokinetics | 693 | ||
| Availability | 693 | ||
| Indications and Dosages | 693 | ||
| ▸Anxiety | 693 | ||
| ▸Nausea and vomiting | 693 | ||
| ▸Pruritus | 693 | ||
| ▸Preoperative sedation | 693 | ||
| ▸Usual pediatric dosage | 693 | ||
| Contraindications | 693 | ||
| Interactions | 693 | ||
| Diagnostic Test Effects | 694 | ||
| Side Effects | 694 | ||
| Serious Reactions | 694 | ||
| Hyoscyamine | 695 | ||
| Mechanism of Action | 695 | ||
| Availability | 695 | ||
| Indications and Dosages | 695 | ||
| ▸GI tract disorders | 695 | ||
| ▸Hypermotility of lower urinary tract | 695 | ||
| ▸Infant colic | 695 | ||
| Contraindications | 695 | ||
| Interactions | 695 | ||
| Diagnostic Test Effects | 696 | ||
| Side Effects | 696 | ||
| Serious Reactions | 696 | ||
| I | 697 | ||
| Ibandronate | 697 | ||
| Mechanism of Action | 697 | ||
| Pharmacokinetics | 697 | ||
| Availability | 697 | ||
| Indications and Dosages | 697 | ||
| ▸Osteoporosis | 697 | ||
| Contraindications | 697 | ||
| Interactions | 697 | ||
| Diagnostic Test Effects | 697 | ||
| Side Effects | 697 | ||
| Serious Reactions | 697 | ||
| Ibuprofen | 698 | ||
| Mechanism of Action | 698 | ||
| Pharmacokinetics | 699 | ||
| Availability | 699 | ||
| Indications and Dosages | 699 | ||
| ▸Acute or chronic rheumatoid arthritis, osteoarthritis, migraine pain, gouty arthritis | 699 | ||
| ▸Mild to moderate pain, primary dysmenorrhea | 699 | ||
| ▸Fever, minor aches or pain | 699 | ||
| ▸Juvenile arthritis | 699 | ||
| ▸Migraine | 699 | ||
| Contraindications | 699 | ||
| Interactions | 699 | ||
| Diagnostic Test Effects | 700 | ||
| Side Effects | 700 | ||
| Serious Reactions | 700 | ||
| Ibuprofen; Oxycodone | 701 | ||
| Mechanism of Action | 701 | ||
| Pharmacokinetics | 701 | ||
| Availability | 701 | ||
| Indications and Dosages | 701 | ||
| ▸Acute moderate to severe pain | 701 | ||
| Contraindications | 701 | ||
| Interactions | 702 | ||
| Diagnostic Test Effects | 702 | ||
| Side Effects | 702 | ||
| Serious Reactions | 702 | ||
| Ibutilide | 704 | ||
| Mechanism of Action | 704 | ||
| Pharmacokinetics | 704 | ||
| Availability | 704 | ||
| Indications and Dosages | 704 | ||
| ▸Rapid conversion of atrial fibrillation or flutter of recent onset to normal sinus rhythm | 704 | ||
| Contraindications | 704 | ||
| Interactions | 704 | ||
| Diagnostic Test Effects | 704 | ||
| ?IV Incompatibilities | 704 | ||
| Side Effects | 704 | ||
| Serious Reactions | 705 | ||
| Icatibant | 705 | ||
| Mechanism of Action | 705 | ||
| Availability | 705 | ||
| Indications and Dosages | 705 | ||
| ▸Acute attacks of hereditary angioedema (HAE) | 705 | ||
| Contraindications | 706 | ||
| Interactions | 706 | ||
| Diagnostic Test Effects | 706 | ||
| Side Effects | 706 | ||
| Serious Reactions | 706 | ||
| Idarucizumab | 706 | ||
| Mechanism of Action | 706 | ||
| Pharmokinetics | 706 | ||
| Availability | 707 | ||
| Indications and Dosages | 707 | ||
| Off-label uses | 707 | ||
| Contraindications | 707 | ||
| Interactions | 707 | ||
| Diagnostic Test Effects | 707 | ||
| ?IV Incompatibilities | 707 | ||
| Side Effects | 707 | ||
| Serious Reactions | 707 | ||
| Iloperidone | 707 | ||
| Mechanism of Action | 707 | ||
| Pharmacokinetics | 708 | ||
| Availability | 708 | ||
| Indications and Dosages | 708 | ||
| ▸Schizophrenia | 708 | ||
| ▸Dosage adjustment if a poor metabolizer of CYP2D6 | 708 | ||
| ▸Dosage adjustment with CYP2D6 inhibitors | 708 | ||
| ▸Dosage adjustment with CYP3A4 inhibitors | 708 | ||
| ▸Hepatic impairment of any degree | 708 | ||
| Contraindications | 708 | ||
| Interactions | 708 | ||
| Diagnostic Test Effects | 708 | ||
| Side Effects | 709 | ||
| Serious Reactions | 709 | ||
| Iloprost | 710 | ||
| Mechanism of Action | 710 | ||
| Availability | 710 | ||
| Indications and Dosages | 710 | ||
| ▸Pulmonary hypertension in patients with New York Heart Association (NYHA) class III or IV symptoms | 710 | ||
| Contraindications | 710 | ||
| Interactions | 710 | ||
| Diagnostic Test Effects | 710 | ||
| Side Effects | 710 | ||
| Serious Reactions | 710 | ||
| Imipenem-Cilastatin | 711 | ||
| Mechanism of Action | 711 | ||
| Pharmacokinetics | 711 | ||
| Availability | 711 | ||
| Indications and Dosages | 711 | ||
| ▸Serious respiratory tract, skin and skin-structure, gynecologic, bone, joint, intra-abdominal, nosocomial, and polymicrobic inf... | 711 | ||
| ▸Mild to moderate respiratory tract, skin and skin-structure, gynecologic, bone, joint, intra-abdominal, and polymicrobic infect... | 711 | ||
| IImatinib | 711.e1 | ||
| Mechanism of Action | 711.e1 | ||
| Pharmacokinetics | 711.e1 | ||
| Availability | 711.e1 | ||
| Indications and Dosages | 711.e1 | ||
| ▸Philadelphia chromosome positive (Ph+) CML | 711.e1 | ||
| ▸Ph+ acute lymphocytic leukemia (ALL) | 711.e1 | ||
| ▸Kit (CD117) positive unresectable or metastatic gastrointestinal stromal tumors (GIST) | 711.e1 | ||
| ▸Kit-positive GIST after complete gross resection | 711.e1 | ||
| ▸Myelodysplastic syndrome (MDS)/myeloproliferative disease (MPD) with PDGFR (platelet-derived growth factor receptor) gene rearr... | 711.e1 | ||
| ▸Hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) positive for FIPL1L1-PDGFR α fusion kinase OR for HES o... | 711.e1 | ||
| ▸Aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation or status unknown | 711.e2 | ||
| ▸Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP) | 711.e2 | ||
| ▸Dosage modifications (all indications) if taking strong CYP3A inducer | 711.e2 | ||
| ▸Dosage adjustments | 711.e2 | ||
| Contraindications | 711.e2 | ||
| Interactions | 711.e2 | ||
| Diagnostic Test Effects | 711.e2 | ||
| Side Effects | 711.e2 | ||
| Serious Reactions | 711.e2 | ||
| Imiglucerase | 711.e3 | ||
| Mechanism of Action | 711.e3 | ||
| Availability | 711.e3 | ||
| Indications and Dosages | 711.e3 | ||
| ▸Gaucher’s disease | 711.e3 | ||
| Contraindications | 711.e3 | ||
| Interactions | 711.e4 | ||
| Diagnostic Test Effects | 711.e4 | ||
| ?IV Incompatibilities | 711.e4 | ||
| Side Effects | 711.e4 | ||
| Serious Reactions | 711.e4 | ||
| ▸Dosage in renal impairment | 712 | ||
| Contraindications | 712 | ||
| Interactions | 712 | ||
| Diagnostic Test Effects | 712 | ||
| ?IV Incompatibilities | 712 | ||
| ?IV Compatibilities | 712 | ||
| Side Effects | 712 | ||
| Serious Reactions | 712 | ||
| Imipramine | 713 | ||
| Mechanism of Action | 713 | ||
| Availability | 713 | ||
| Indications and Dosages | 713 | ||
| ▸Depression | 713 | ||
| ▸Enuresis | 713 | ||
| Off-Label Uses | 714 | ||
| Contraindications | 714 | ||
| Interactions | 714 | ||
| Diagnostic Test Effects | 714 | ||
| Side Effects | 714 | ||
| Serious Reactions | 714 | ||
| Imiquimod | 715 | ||
| Mechanism of Action | 715 | ||
| Pharmacokinetics | 715 | ||
| Availability | 716 | ||
| Indications and Dosages | 716 | ||
| ▸Condyloma acuminata/genital and perianal warts | 716 | ||
| ▸Actinic keratosis | 716 | ||
| ▸Superficial basal cell carcinoma | 716 | ||
| Contraindications | 716 | ||
| Interactions | 716 | ||
| Diagnostic Test Effects | 716 | ||
| Side Effects | 716 | ||
| Serious Reactions | 716 | ||
| Immune Globulin IV (IGIV) | 717 | ||
| Mechanism of Action | 717 | ||
| Pharmacokinetics | 717 | ||
| Availability | 717 | ||
| Indications and Dosages | 717 | ||
| ▸Primary immunodeficiency syndrome | 717 | ||
| ▸Idiopathic thrombocytopenic purpura (ITP) | 717 | ||
| ▸Kawasaki disease | 717 | ||
| ▸Chronic lymphocytic leukemia | 717 | ||
| ▸Bone marrow transplant | 717 | ||
| Off-Label Uses | 717 | ||
| Contraindications | 718 | ||
| Interactions | 718 | ||
| Diagnostic Test Effects | 718 | ||
| ?IV Incompatibilities | 718 | ||
| Side Effects | 718 | ||
| Serious Reactions | 718 | ||
| Indacaterol | 719 | ||
| Mechanism of Action | 719 | ||
| Pharmacokinetics | 719 | ||
| Availability | 719 | ||
| Indications and Dosages | 719 | ||
| ▸Chronic obstructive pulmonary disease (COPD) | 719 | ||
| Contraindications | 719 | ||
| Interactions | 719 | ||
| Diagnostic Test Effects | 719 | ||
| Mechanism of Action | 719.e1 | ||
| Availability | 719.e1 | ||
| Indications and Dosages | 719.e1 | ||
| ▸Cervical dystonia in patients who have previously tolerated botulinum toxin type A | 719.e1 | ||
| ▸Blepharospasm | 719.e1 | ||
| ▸Improvement of brow furrow/glabellar lines | 719.e1 | ||
| Contraindications | 719.e1 | ||
| Interactions | 719.e1 | ||
| Diagnostic Test Effects | 719.e1 | ||
| Side Effects | 719.e1 | ||
| Serious Reactions | 719.e1 | ||
| Side Effects | 720 | ||
| Serious Reactions | 720 | ||
| Indapamide | 720 | ||
| Mechanism of Action | 721 | ||
| Availability | 721 | ||
| Indications and Dosages | 721 | ||
| ▸Edema | 721 | ||
| ▸Hypertension | 721 | ||
| Contraindications | 721 | ||
| Interactions | 721 | ||
| Diagnostic Test Effects | 721 | ||
| Side Effects | 721 | ||
| Serious Reactions | 721 | ||
| Indinavir | 722 | ||
| Mechanism of Action | 722 | ||
| Pharmacokinetics | 722 | ||
| Availability | 722 | ||
| Indications and Dosages | 722 | ||
| ▸HIV infection | 722 | ||
| ▸HIV infection in patients with hepatic insufficiency | 722 | ||
| Off-Label Uses | 722 | ||
| Contraindications | 722 | ||
| Interactions | 722 | ||
| Diagnostic Test Effects | 723 | ||
| Side Effects | 723 | ||
| Serious Reactions | 723 | ||
| Indomethacin | 724 | ||
| Mechanism of Action | 725 | ||
| Pharmacokinetics | 725 | ||
| Availability | 725 | ||
| Indications and Dosages | 725 | ||
| ▸Moderate to severe rheumatoid arthritis, osteoarthritis, ankylosing spondylitis | 725 | ||
| ▸Acute gouty arthritis | 725 | ||
| ▸Acute shoulder pain, bursitis, tendinitis | 725 | ||
| ▸Usual rectal dosage | 725 | ||
| ▸Patent ductus arteriosus | 725 | ||
| Off-Label Uses | 725 | ||
| Contraindications | 725 | ||
| Interactions | 726 | ||
| Diagnostic Test Effects | 726 | ||
| ?IV Incompatibilities | 726 | ||
| ?IV Compatibilities | 726 | ||
| Side Effects | 726 | ||
| Serious Reactions | 726 | ||
| Infliximab | 728 | ||
| Mechanism of Action | 728 | ||
| Pharmacokinetics | 728 | ||
| Availability | 728 | ||
| Indications and Dosages | 728 | ||
| ▸Moderate to severe Crohn’s disease and fistulizing Crohn’s disease | 728 | ||
| ▸RA | 728 | ||
| ▸Ankylosing spondylitis, prosiatic arthritis, plaque psoriasis, and moderate to severe ulcerative colitis | 728 | ||
| Contraindications | 728 | ||
| Interactions | 728 | ||
| Diagnostic Test Effects | 728 | ||
| ?IV Incompatibilities | 728 | ||
| Side Effects | 729 | ||
| Serious Reactions | 729 | ||
| Insulin | 730 | ||
| Mechanism of Action | 730 | ||
| Pharmacokinetics | 730 | ||
| Availability | 730 | ||
| Indications and Dosages | 730 | ||
| ▸Treatment of type 1 (insulin-dependent) or type 2 diabetes mellitus | 730 | ||
| ▸Emergency treatment of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state of type 2 diabetes mellitus (regular ins... | 731 | ||
| Off-Label Uses | 731 | ||
| Contraindications | 731 | ||
| Interactions | 731 | ||
| Diagnostic Test Effects | 731 | ||
| ?IV Incompatibilities | 731 | ||
| Side Effects | 731 | ||
| Serious Reactions | 732 | ||
| Interferon Alfa-2b | 733 | ||
| Mechanism of Action | 733 | ||
| Pharmacokinetics | 733 | ||
| Availability | 734 | ||
| Indications and Dosages | 734 | ||
| ▸Hairy cell leukemia | 734 | ||
| ▸Condyloma acuminatum | 734 | ||
| ▸AIDS-related Kaposi’s sarcoma | 734 | ||
| ▸Chronic hepatitis C | 734 | ||
| ▸Chronic hepatitis B | 734 | ||
| ▸Malignant melanoma | 734 | ||
| ▸Follicular lymphoma | 734 | ||
| Off-Label Uses | 734 | ||
| Contraindications | 734 | ||
| Diagnostic Test Effects | 734 | ||
| ?IV Incompatibilities | 734 | ||
| Side Effects | 735 | ||
| Serious Reactions | 735 | ||
| Interferon Alfa-n3 | 735.e1 | ||
| Mechanism of Action | 735.e1 | ||
| Pharmacokinetics | 735.e1 | ||
| Availability | 735.e1 | ||
| Indications and Dosages | 735.e1 | ||
| ▸Condyloma acuminatum | 735.e1 | ||
| Contraindications | 735.e1 | ||
| Interactions | 735.e1 | ||
| Diagnostic Test Effects | 735.e1 | ||
| Side Effects | 735.e1 | ||
| Serious Reactions | 735.e1 | ||
| Interferon Beta-1a | 736 | ||
| Mechanism of Action | 736 | ||
| Pharmacokinetics | 736 | ||
| Availability | 736 | ||
| Indications and Dosages | 736 | ||
| ▸Relapsing-remitting multiple sclerosis | 736 | ||
| Off-Label Uses | 736 | ||
| Contraindications | 736 | ||
| Interactions | 736 | ||
| Diagnostic Test Effects | 736 | ||
| Side Effects | 736 | ||
| Serious Reactions | 737 | ||
| Interferon Beta-1b | 737 | ||
| Mechanism of Action | 737 | ||
| Pharmacokinetics | 737 | ||
| Availability | 738 | ||
| Indications and Dosages | 738 | ||
| ▸Relapsing-remitting multiple sclerosis | 738 | ||
| Contraindications | 738 | ||
| Interactions | 738 | ||
| Diagnostic Test Effects | 738 | ||
| Side Effects | 738 | ||
| Serious Reactions | 738 | ||
| Iodoquinol | 739 | ||
| Mechanism of Action | 739 | ||
| Pharmacokinetics | 739 | ||
| Availability | 739 | ||
| Indications and Dosages | 739 | ||
| ▸Intestinal amebiasis | 739 | ||
| Off-Label Uses | 739 | ||
| Contraindications | 739 | ||
| Interactions | 739 | ||
| Diagnostic Test Effects | 739 | ||
| Side Effects | 739 | ||
| Serious Reactions | 739 | ||
| Interferon Gamma-1b | 739.e1 | ||
| Mechanism of Action | 739.e1 | ||
| Pharmacokinetics | 739.e1 | ||
| Availability | 739.e1 | ||
| Indications and Dosages | 739.e1 | ||
| ▸Chronic granulomatous disease; severe, malignant osteopetrosis | 739.e1 | ||
| Contraindications | 739.e1 | ||
| Interactions | 739.e1 | ||
| Diagnostic Test Effects | 739.e1 | ||
| Side Effects | 739.e1 | ||
| Serious Reactions | 739.e1 | ||
| Interleukin-2 (Aldesleukin) | 739.e2 | ||
| Mechanism of Action | 739.e2 | ||
| Pharmacokinetics | 739.e2 | ||
| Availability | 739.e2 | ||
| Indications and Dosages | 739.e2 | ||
| ▸Metastatic melanoma, metastatic renal cell carcinoma | 739.e2 | ||
| Off-Label Uses | 739.e2 | ||
| Contraindications | 739.e2 | ||
| Interactions | 739.e3 | ||
| Diagnostic Test Effects | 739.e3 | ||
| ?IV Incompatibilities | 739.e3 | ||
| ?IV Compatibilities | 739.e3 | ||
| Side Effects | 739.e3 | ||
| Serious Reactions | 739.e3 | ||
| Ipratropium | 740 | ||
| Mechanism of Action | 740 | ||
| Pharmacokinetics | 740 | ||
| Availability | 740 | ||
| Indications and Dosages | 740 | ||
| ▸Bronchospasm, acute treatment, adjunctive | 740 | ||
| ▸Bronchospasm, maintenance treatment, associated with COPD | 740 | ||
| ▸Rhinorrhea, common cold | 740 | ||
| ▸Rhinorrhea, allergic or nonallergic perennial | 740 | ||
| Contraindications | 741 | ||
| Interactions | 741 | ||
| Diagnostic Test Effects | 741 | ||
| Side Effects | 741 | ||
| Serious Reactions | 741 | ||
| Irbesartan | 742 | ||
| Mechanism of Action | 742 | ||
| Pharmacokinetics | 742 | ||
| Availability | 742 | ||
| Indications and Dosages | 742 | ||
| ▸Hypertension (alone or in combination with other antihypertensives) | 742 | ||
| ▸Diabetic nephropathy | 742 | ||
| Off-Label Uses | 742 | ||
| Contraindications | 742 | ||
| Interactions | 742 | ||
| Diagnostic Test Effects | 743 | ||
| Side Effects | 743 | ||
| Serious Reactions | 743 | ||
| Iron Dextran | 743 | ||
| Mechanism of Action | 744 | ||
| Pharmacokinetics | 744 | ||
| Availability | 744 | ||
| Indications and Dosages | 744 | ||
| ▸Iron deficiency anemia (no blood loss) | 744 | ||
| ▸Iron replacement secondary to blood loss | 744 | ||
| ▸Maximum daily dosage | 744 | ||
| Contraindications | 744 | ||
| Interactions | 744 | ||
| Diagnostic Test Effects | 744 | ||
| ?IV Incompatibilities | 744 | ||
| Side Effects | 744 | ||
| Serious Reactions | 744 | ||
| Iron Sucrose | 745 | ||
| Mechanism of Action | 745 | ||
| Availability | 745 | ||
| Indications and Dosages | 745 | ||
| ▸Iron deficiency anemia in adult patients on chronic hemodialysis | 745 | ||
| Irinotecan | 745.e1 | ||
| Mechanism of Action | 745.e1 | ||
| Pharmacokinetics | 745.e1 | ||
| Availability | 745.e1 | ||
| Indications and Dosages | 745.e1 | ||
| ▸Advanced colorectal cancer | 745.e1 | ||
| ▸Dosage Adjustments | 745.e1 | ||
| Off-Label Uses | 745.e1 | ||
| Contraindications | 745.e2 | ||
| Interactions | 745.e2 | ||
| Diagnostic Test Effects | 745.e2 | ||
| ?IV Incompatibilities | 745.e2 | ||
| Side Effects | 745.e2 | ||
| Serious Reactions | 745.e2 | ||
| ▸Pediatric patients on chronic hemodialysis for iron maintenance treatment | 746 | ||
| Contraindications | 746 | ||
| Interactions | 746 | ||
| Diagnostic Test Effects | 746 | ||
| ?IV Incompatibilities | 746 | ||
| Side Effects | 746 | ||
| Serious Reactions | 746 | ||
| Isocarboxazid | 747 | ||
| Mechanism of Action | 747 | ||
| Pharmacokinetics | 747 | ||
| Availability | 747 | ||
| Indications and Dosages | 747 | ||
| ▸Depression refractory to other antidepressants or electroconvulsive therapy | 747 | ||
| Off-Label Uses | 747 | ||
| Contraindications | 747 | ||
| Interactions | 747 | ||
| Diagnostic Test Effects | 748 | ||
| Side Effects | 748 | ||
| Serious Reactions | 748 | ||
| Isoniazid (INH) | 749 | ||
| Mechanism of Action | 749 | ||
| Pharmacokinetics | 749 | ||
| Availability | 749 | ||
| Indications and Dosages | 749 | ||
| ▸Tuberculosis (in combination with one or more antituberculars) | 749 | ||
| ▸Prevention of tuberculosis | 749 | ||
| Contraindications | 749 | ||
| Interactions | 749 | ||
| Isoproterenol | 749.e1 | ||
| Mechanism of Action | 749.e1 | ||
| Pharmacokinetics | 749.e1 | ||
| Availability | 749.e1 | ||
| Indications and Dosages | 749.e1 | ||
| ▸Arrhythmias | 749.e1 | ||
| ▸Shock and hypoperfusion | 749.e1 | ||
| Off-Label Uses | 749.e1 | ||
| Contraindications | 749.e1 | ||
| Interactions | 749.e1 | ||
| Diagnostic Test Effects | 749.e1 | ||
| ?IV Incompatibilities | 749.e1 | ||
| ?IV Compatibilities | 749.e1 | ||
| Side Effects | 749.e2 | ||
| Serious Reactions | 749.e2 | ||
| Diagnostic Test Effects | 750 | ||
| Side Effects | 750 | ||
| Serious Reactions | 750 | ||
| Isosorbide Dinitrate/Mononitrate | 751 | ||
| Mechanism of Action | 751 | ||
| Pharmacokinetics | 751 | ||
| Availability | 751 | ||
| Indications and Dosages | 751 | ||
| ▸Angina | 751 | ||
| Off-Label Uses | 751 | ||
| Contraindications | 751 | ||
| Interactions | 751 | ||
| Diagnostic Test Effects | 752 | ||
| Side Effects | 752 | ||
| Serious Reactions | 752 | ||
| Isotretinoin | 753 | ||
| Mechanism of Action | 753 | ||
| Pharmacokinetics | 753 | ||
| Availability | 753 | ||
| Indications and Dosages | 753 | ||
| ▸Recalcitrant cystic acne that is unresponsive to conventional acne therapies | 753 | ||
| Off-Label Uses | 753 | ||
| Contraindications | 753 | ||
| Interactions | 753 | ||
| Diagnostic Test Effects | 753 | ||
| Side Effects | 754 | ||
| Serious Reactions | 754 | ||
| Isradipine | 755 | ||
| Mechanism of Action | 755 | ||
| Pharmacokinetics | 755 | ||
| Availability | 755 | ||
| Indications and Dosages | 755 | ||
| ▸Hypertension | 755 | ||
| Off-Label Uses | 755 | ||
| Contraindications | 755 | ||
| Interactions | 755 | ||
| Diagnostic Test Effects | 756 | ||
| Side Effects | 756 | ||
| Serious Reactions | 756 | ||
| Itraconazole | 756 | ||
| Mechanism of Action | 756 | ||
| Pharmacokinetics | 757 | ||
| Availability | 757 | ||
| Indications and Dosages | 757 | ||
| ▸Blastomycosis, histoplasmosis, and aspergillosis | 757 | ||
| ▸Life-threatening fungal infections | 757 | ||
| ▸Esophageal candidiasis | 757 | ||
| ▸Oropharyngeal candidiasis | 757 | ||
| ▸Onychomycosis of toenails | 757 | ||
| ▸Onychomycosis of fingernails | 757 | ||
| Off-Label Uses | 757 | ||
| Contraindications | 757 | ||
| Interactions | 757 | ||
| Diagnostic Test Effects | 758 | ||
| Side Effects | 758 | ||
| Serious Reactions | 758 | ||
| Ivacaftor | 759 | ||
| Mechanism of Action | 759 | ||
| Pharmacokinetics | 759 | ||
| Availability | 759 | ||
| Indications and Dosages | 759 | ||
| ▸Cystic fibrosis | 759 | ||
| ▸Co-use with CYP3A inhibitors | 760 | ||
| ▸Dosage for hepatic impairment | 760 | ||
| Contraindications | 760 | ||
| Interactions | 760 | ||
| Diagnostic Test Effects | 760 | ||
| Side Effects | 760 | ||
| Serious Reactions | 760 | ||
| Ivermectin (Systemic) | 761 | ||
| Mechanism of Action | 761 | ||
| Pharmacokinetics | 761 | ||
| Availability | 761 | ||
| Indications and Dosages | 761 | ||
| ▸Strongyloidiasis | 761 | ||
| ▸Onchocerciasis (river blindness) | 761 | ||
| ▸Scabies (off-label) | 761 | ||
| ▸Norwegian scabies (crusted scabies infection), superinfected scabies, or resistant scabies (off-label) | 761 | ||
| ▸Pediculosis (resistant cases) (off-label) | 761 | ||
| Off-Label Uses | 761 | ||
| Contraindications | 761 | ||
| Interactions | 762 | ||
| Diagnostic Test Effects | 762 | ||
| Side Effects | 762 | ||
| Serious Reactions | 762 | ||
| Ixabepilone | 762.e1 | ||
| Mechanism of Action | 762.e1 | ||
| Pharmacokinetics | 762.e1 | ||
| Availability | 762.e1 | ||
| Indications and Dosages | 762.e1 | ||
| ▸Metastatic breast cancer | 762.e1 | ||
| ▸With capecitabine | 762.e1 | ||
| ▸Breast cancer resistant to, intolerant of, or progressing despite anthracycline, taxane, or capecitabine | 762.e1 | ||
| ▸Dosage with a strong CYP3A4 inhibitor | 762.e1 | ||
| ▸Dosage adjustments for neuropathy, neutropenia, or hepatic dysfunction | 762.e1 | ||
| Contraindications | 762.e1 | ||
| Interactions | 762.e2 | ||
| Diagnostic Test Effects | 762.e2 | ||
| ?IV Incompatibilities | 762.e2 | ||
| Side Effects | 762.e2 | ||
| Serious Reactions | 762.e2 | ||
| K | 763 | ||
| Ketoconazole | 763 | ||
| Mechanism of Action | 763 | ||
| Pharmacokinetics | 763 | ||
| Availability | 763 | ||
| Indications and Dosages | 763 | ||
| ▸Systemic fungal infections such as histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, chromomycosis | 763 | ||
| ▸Dermatologic conditions such as seborrheic dermatitis, tinea corporsis, tinea capitis, tinea manus, tinea cruris, tinea pedis | 763 | ||
| Off-Label Uses | 763 | ||
| Contraindications | 763 | ||
| Interactions | 763 | ||
| Ketamine Hydrochloride | 763.e1 | ||
| Mechanism of Action | 763.e1 | ||
| Pharmacokinetics | 763.e1 | ||
| Availability | 763.e1 | ||
| Indications and Dosages | 763.e1 | ||
| ▸Sole anesthetic for short diagnostic and surgical procedures that do not require skeletal muscle relaxation, induction of anest... | 763.e1 | ||
| Contraindications | 763.e1 | ||
| Interactions | 763.e1 | ||
| Diagnostic Test Effects | 763.e1 | ||
| ?IV Incompatibilities | 763.e1 | ||
| ?IV Compatibilities | 763.e1 | ||
| Side Effects | 763.e1 | ||
| Serious Reactions | 763.e2 | ||
| Diagnostic Test Effects | 764 | ||
| Side Effects | 764 | ||
| Serious Reactions | 764 | ||
| Ketoprofen | 765 | ||
| Mechanism of Action | 765 | ||
| Pharmacokinetics | 765 | ||
| Availability | 765 | ||
| Indications and Dosages | 765 | ||
| ▸Acute or chronic rheumatoid arthritis and osteoarthritis | 765 | ||
| ▸Mild to moderate pain, dysmenorrhea | 766 | ||
| ▸Dosage in renal impairment | 766 | ||
| Off-Label Uses | 766 | ||
| Contraindications | 766 | ||
| Interactions | 766 | ||
| Diagnostic Test Effects | 766 | ||
| Side Effects | 766 | ||
| Serious Reactions | 766 | ||
| Ketorolac Tromethamine | 767 | ||
| Mechanism of Action | 767 | ||
| Pharmacokinetics | 767 | ||
| Availability | 768 | ||
| Indications and Dosages | 768 | ||
| ▸Short-term relief of moderate pain (multiple doses) | 768 | ||
| ▸Short-term relief of moderate pain (single dose) | 768 | ||
| ▸Allergic conjunctivitis | 768 | ||
| ▸Cataract extraction | 768 | ||
| ▸Refractive surgery | 768 | ||
| Contraindications | 768 | ||
| Interactions | 769 | ||
| Diagnostic Test Effects | 769 | ||
| ?IV Incompatibilities | 769 | ||
| Side Effects | 769 | ||
| Serious Reactions | 769 | ||
| Ketotifen | 770 | ||
| Mechanism of Action | 771 | ||
| Pharmacokinetics | 771 | ||
| Availability | 771 | ||
| Indications and Dosages | 771 | ||
| ▸Allergic conjunctivitis | 771 | ||
| Contraindications | 771 | ||
| Interactions | 771 | ||
| Diagnostic Test Effects | 771 | ||
| Side Effects | 771 | ||
| Serious Reactions | 771 | ||
| L | 772 | ||
| Labetalol Hydrochloride | 772 | ||
| MECHANISM OF ACTION | 772 | ||
| PHARMACOKINETICS | 772 | ||
| OFF-LABEL USES | 772 | ||
| CONTRAINDICATIONS | 772 | ||
| INTERACTIONS | 772 | ||
| DIAGNOSTIC TEST EFFECTS | 773 | ||
| ?INCOMPATIBILITIES | 773 | ||
| ?COMPATIBILITIES | 773 | ||
| SERIOUS REACTIONS | 773 | ||
| Lacosamide | 774 | ||
| MECHANISM OF ACTION | 774 | ||
| PHARMACOKINETICS | 774 | ||
| AVAILABILITY | 774 | ||
| INDICATIONS AND DOSAGES | 775 | ||
| CONTRAINDICATIONS | 775 | ||
| DIAGNOSTIC TEST EFFECTS | 775 | ||
| ?IV INCOMPATIBILITIES | 775 | ||
| SIDE EFFECTS | 775 | ||
| SERIOUS REACTIONS | 775 | ||
| Lactulose | 776 | ||
| MECHANISM OF ACTION | 776 | ||
| PHARMACOKINETICS | 777 | ||
| AVAILABILITY | 777 | ||
| INDICATIONS AND DOSAGES | 777 | ||
| CONTRAINDICATIONS | 777 | ||
| INTERACTIONS | 777 | ||
| DIAGNOSTIC TEST EFFECTS | 777 | ||
| SIDE EFFECTS | 777 | ||
| SERIOUS REACTIONS | 777 | ||
| Lamivudine (3TC) | 778 | ||
| MECHANISM OF ACTION | 778 | ||
| PHARMACOKINETICS | 778 | ||
| AVAILABILITY | 778 | ||
| INDICATIONS AND DOSAGES | 778 | ||
| OFF-LABEL USES | 779 | ||
| CONTRAINDICATIONS | 779 | ||
| INTERACTIONS | 779 | ||
| DIAGNOSTIC TEST EFFECTS | 779 | ||
| SIDE EFFECTS | 779 | ||
| SERIOUS REACTIONS | 779 | ||
| Lamotrigine | 780 | ||
| MECHANISM OF ACTION | 780 | ||
| PHARMACOKINETICS | 780 | ||
| AVAILABILITY | 780 | ||
| INDICATIONS AND DOSAGES | 780 | ||
| EIAED and valproic acid | 781 | ||
| CONTRAINDICATIONS | 782 | ||
| INTERACTIONS | 782 | ||
| DIAGNOSTIC TEST EFFECTS | 782 | ||
| SIDE EFFECTS | 782 | ||
| SERIOUS REACTIONS | 782 | ||
| Lansoprazole | 783 | ||
| MECHANISM OF ACTION | 784 | ||
| PHARMACOKINETICS | 784 | ||
| AVAILABILITY | 784 | ||
| INDICATIONS AND DOSAGES | 784 | ||
| CONTRAINDICATIONS | 784 | ||
| INTERACTIONS | 784 | ||
| DIAGNOSTIC TEST EFFECTS | 785 | ||
| SIDE EFFECTS | 785 | ||
| SERIOUS REATIONS | 785 | ||
| Lanthanum Carbonate | 786 | ||
| MECHANISM OF ACTION | 786 | ||
| PHARMACOKINETICS | 786 | ||
| AVAILABILITY | 786 | ||
| INDICATIONS AND DOSAGES | 786 | ||
| CONTRAINDICATIONS | 786 | ||
| INTERACTIONS | 786 | ||
| DIAGNOSTIC TEST EFFECTS | 786 | ||
| SIDE EFFECTS | 786 | ||
| SERIOUS REACTIONS | 786 | ||
| Lapatinibla | 786.e1 | ||
| MECHANISM OF ACTION | 786.e1 | ||
| PHARMACOKINETICS | 786.e1 | ||
| AVAILABILITY | 786.e1 | ||
| INDICATIONS AND DOSAGES | 786.e1 | ||
| CONTRAINDICATIONS | 786.e1 | ||
| INTERACTIONS | 786.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 786.e2 | ||
| SIDE EFFECTS | 786.e2 | ||
| SERIOUS REACTIONS | 786.e2 | ||
| Latanoprost | 787 | ||
| MECHANISM OF ACTION | 787 | ||
| PHARMACOKINETICS | 787 | ||
| AVAILABILITY | 787 | ||
| INDICATIONS AND DOSAGES | 787 | ||
| CONTRAINDICATIONS | 787 | ||
| DIAGNOSTIC TEST EFFECTS | 787 | ||
| SIDE EFFECTS | 787 | ||
| SERIOUS REACTIONS | 787 | ||
| Leflunomide | 788 | ||
| MECHANISM OF ACTION | 788 | ||
| PHARMACOKINETICS | 788 | ||
| AVAILABILITY | 788 | ||
| INDICATIONS AND DOSAGES | 788 | ||
| CONTRAINDICATIONS | 788 | ||
| INTERACTIONS | 788 | ||
| Lenalidomide\r | 788.e1 | ||
| MECHANISM OF ACTION | 788.e1 | ||
| PHARMACOKINETICS | 788.e1 | ||
| AVAILABILITY | 788.e1 | ||
| INDICATIONS AND DOSAGES | 788.e1 | ||
| OFF-LABEL USES | 788.e2 | ||
| CONTRAINDICATIONS | 788.e2 | ||
| INTERACTIONS | 788.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 788.e2 | ||
| SIDE EFFECTS | 788.e2 | ||
| SERIOUS REACTIONS | 788.e2 | ||
| Letrozole\r | 788.e3 | ||
| MECHANISM OF ACTION | 788.e3 | ||
| PHARMACOKINETICS | 788.e3 | ||
| AVAILABILITY | 788.e3 | ||
| INDICATIONS AND DOSAGES | 788.e3 | ||
| CONTRAINDICATIONS | 788.e4 | ||
| INTERACTIONS | 788.e4 | ||
| DIAGNOSTIC TEST EFFECTS | 788.e4 | ||
| SIDE EFFECTS | 788.e4 | ||
| SERIOUS REACTIONS | 788.e4 | ||
| Leucovorin Calcium(Folinic Acid, CitrovorumFactor) | 788.e4 | ||
| MECHANISM OF ACTION | 788.e5 | ||
| PHARMACOKINETICS | 788.e5 | ||
| AVAILABILITY | 788.e5 | ||
| INDICATIONS AND DOSAGES | 788.e5 | ||
| OTHER USES | 788.e6 | ||
| CONTRAINDICATIONS | 788.e6 | ||
| INTERACTIONS | 788.e6 | ||
| DIAGNOSTIC TEST EFFECTS | 788.e6 | ||
| ?IV INCOMPATIBILITIES | 788.e6 | ||
| ?IV COMPATIBILITIES | 788.e6 | ||
| SIDE EFFECTS | 788.e6 | ||
| SERIOUS REACTIONS | 788.e6 | ||
| DIAGNOSTIC TEST EFFECTS | 789 | ||
| SIDE EFFECTS | 789 | ||
| SERIOUS REACTIONS | 789 | ||
| Leuprolide Acetate | 790 | ||
| MECHANISM OF ACTION | 790 | ||
| PHARMACOKINETICS | 790 | ||
| AVAILABILITY | 790 | ||
| INDICATIONS AND DOSAGES | 790 | ||
| CONTRAINDICATIONS | 790 | ||
| INTERACTIONS | 791 | ||
| DIAGNOSTIC TEST EFFECTS | 791 | ||
| SIDE EFFECTS | 791 | ||
| SERIOUS REACTIONS | 791 | ||
| Levalbuterol | 792 | ||
| MECHANISM OF ACTION | 792 | ||
| PHARMACOKINETICS | 792 | ||
| AVAILABILITY | 792 | ||
| INDICATIONS AND DOSAGES | 792 | ||
| CONTRAINDICATIONS | 792 | ||
| INTERACTIONS | 792 | ||
| DIAGNOSTIC TEST EFFECTS | 793 | ||
| SIDE EFFECTS | 793 | ||
| SERIOUS REACTIONS | 793 | ||
| Levetiracetam | 793 | ||
| MECHANISM OF ACTION | 794 | ||
| PHARMACOKINETICS | 794 | ||
| AVAILABILITY | 794 | ||
| INDICATIONS AND DOSAGES | 794 | ||
| CONTRAINDICATIONS | 794 | ||
| INTERACTIONS | 794 | ||
| DIAGNOSTIC TEST EFFECTS | 795 | ||
| ?IV COMPATIBILITIES | 795 | ||
| SIDE EFFECTS | 795 | ||
| SERIOUS REACTIONS | 795 | ||
| Levocetirizine | 796 | ||
| MECHANISM OF ACTION | 796 | ||
| PHARMACOKINETICS | 796 | ||
| AVAILABILITY | 796 | ||
| INDICATIONS AND DOSAGES | 796 | ||
| CONTRAINDICATIONS | 796 | ||
| INTERACTIONS | 796 | ||
| DIAGNOSTIC TEST EFFECTS | 796 | ||
| SIDE EFFECTS | 797 | ||
| SERIOUS REACTIONS | 797 | ||
| Levofloxacin | 797 | ||
| MECHANISM OF ACTION | 797 | ||
| PHARMACOKINETICS | 797 | ||
| AVAILABILITY | 797 | ||
| Levoleucovorin Calcium | 797.e1 | ||
| MECHANISM OF ACTION | 797.e1 | ||
| PHARMACOKINETICS | 797.e1 | ||
| AVAILABILITY | 797.e1 | ||
| INDICATIONS AND DOSAGES | 797.e1 | ||
| OFF-LABEL USES | 797.e2 | ||
| CONTRAINDICATIONS | 797.e2 | ||
| INTERACTIONS | 797.e2 | ||
| DIAGNOSTIC TEST EFFECTS | 797.e2 | ||
| ?IV INCOMPATIBILITIES | 797.e2 | ||
| SIDE EFFECTS | 797.e2 | ||
| SERIOUS REACTIONS | 797.e2 | ||
| INDICATIONS AND DOSAGES | 798 | ||
| CONTRAINDICATIONS | 798 | ||
| INTERACTIONS | 798 | ||
| DIAGNOSTIC TEST EFFECTS | 799 | ||
| ?IV INCOMPATIBILITIES | 799 | ||
| ?IV COMPATIBILITIES | 799 | ||
| SIDE EFFECTS | 799 | ||
| SERIOUS REACTIONS | 799 | ||
| Levomilnacipran | 800 | ||
| MECHANISM OF ACTION | 800 | ||
| PHARMACOKINETICS | 800 | ||
| AVAILABILITY | 801 | ||
| INDICATIONS AND DOSAGES | 801 | ||
| CONTRAINDICATIONS | 801 | ||
| INTERACTIONS | 801 | ||
| DIAGNOSTIC TEST EFFECTS | 801 | ||
| SIDE EFFECTS | 801 | ||
| SERIOUS REACTIONS | 801 | ||
| Levorphanol | 802 | ||
| MECHANISM OF ACTION | 802 | ||
| PHARMACOKINETICS | 802 | ||
| AVAILABILITY | 802 | ||
| INDICATIONS AND DOSAGES | 802 | ||
| CONTRAINDICATIONS | 803 | ||
| INTERACTIONS | 803 | ||
| DIAGNOSTIC TEST EFFECTS | 803 | ||
| ?IV INCOMPATIBILITIES | 803 | ||
| SIDE EFFECTS | 803 | ||
| SERIOUS REACTIONS | 803 | ||
| Levothyroxine | 804 | ||
| MECHANISM OF ACTION | 804 | ||
| PHARMACOKINETICS | 804 | ||
| AVAILABILITY | 805 | ||
| INDICATIONS AND DOSAGES | 805 | ||
| CONTRAINDICATIONS | 805 | ||
| INTERACTIONS | 805 | ||
| DIAGNOSTIC TEST EFFECTS | 805 | ||
| ?IV INCOMPATIBILITIES | 806 | ||
| SIDE EFFECTS | 806 | ||
| SERIOUS REACTIONS | 806 | ||
| Lidocaine Hydrochloride | 807 | ||
| MECHANISM OF ACTION | 807 | ||
| PHARMACOKINETICS | 807 | ||
| AVAILABILITY | 807 | ||
| INDICATIONS AND DOSAGES | 807 | ||
| CONTRAINDICATIONS | 808 | ||
| INTERACTIONS | 808 | ||
| DIAGNOSTIC TEST EFFECTS | 808 | ||
| ?IV INCOMPATIBILITIES | 808 | ||
| ?IV COMPATIBILITIES | 808 | ||
| SIDE EFFECTS | 808 | ||
| SERIOUS REACTIONS | 809 | ||
| Linaclotide | 810 | ||
| MECHANISM OF ACTION | 810 | ||
| PHARMACOKINETICS | 810 | ||
| AVAILABILITY | 810 | ||
| INDICATIONS AND DOSAGES | 810 | ||
| CONTRAINDICATIONS | 810 | ||
| INTERACTIONS | 810 | ||
| DIAGNOSTIC TEST EFFECTS | 810 | ||
| SIDE EFFECTS | 810 | ||
| SERIOUS REACTIONS | 811 | ||
| Linagliptin | 811 | ||
| MECHANISM OF ACTION | 811 | ||
| PHARMACOKINETICS | 811 | ||
| AVAILABILITY | 811 | ||
| INDICATIONS AND DOSAGES | 811 | ||
| CONTRAINDICATIONS | 812 | ||
| INTERACTIONS | 812 | ||
| DIAGNOSTIC TEST EFFECTS | 812 | ||
| SIDE EFFECTS | 812 | ||
| SERIOUS REACTIONS | 812 | ||
| Lindane (Gamma Benzene Hexachloride) | 813 | ||
| MECHANISM OF ACTION | 813 | ||
| PHARMACOKINETICS | 813 | ||
| AVAILABILITY | 813 | ||
| INDICATIONS AND DOSAGES | 813 | ||
| CONTRAINDICATIONS | 813 | ||
| INTERACTIONS | 813 | ||
| DIAGNOSTIC TEST EFFECTS | 813 | ||
| SIDE EFFECTS | 813 | ||
| SERIOUS REACTIONS | 813 | ||
| Linezolid | 814 | ||
| MECHANISM OF ACTION | 814 | ||
| PHARMACOKINETICS | 814 | ||
| AVAILABILITY | 814 | ||
| INDICATIONS AND DOSAGES | 814 | ||
| CONTRAINDICATIONS | 815 | ||
| INTERACTIONS | 815 | ||
| DIAGNOSTIC TEST EFFECTS | 815 | ||
| ?IV INCOMPATIBILITIES | 815 | ||
| SIDE EFFECTS | 815 | ||
| SERIOUS REACTIONS | 815 | ||
| Liothyronine T3 | 816 | ||
| MECHANISM OF ACTION | 816 | ||
| PHARMACOKINETICS | 816 | ||
| AVAILABILITY | 816 | ||
| INDICATIONS AND DOSAGES | 816 | ||
| CONTRAINDICATIONS | 817 | ||
| INTERACTIONS | 817 | ||
| DIAGNOSTIC TEST EFFECTS | 817 | ||
| SIDE EFFECTS | 817 | ||
| SERIOUS REACTIONS | 817 | ||
| Liraglutide | 818 | ||
| MECHANISM OF ACTION | 818 | ||
| PHARMACOKINETICS | 818 | ||
| AVAILABILITY | 818 | ||
| INDICATIONS AND DOSAGES | 818 | ||
| CONTRAINDICATIONS | 819 | ||
| INTERACTIONS | 819 | ||
| DIAGNOSTIC TEST EFFECTS | 819 | ||
| SIDE EFFECTS | 819 | ||
| SERIOUS REACTIONS | 819 | ||
| Lisdexamfetamine | 820 | ||
| MECHANISM OF ACTION | 821 | ||
| PHARMACOKINETICS | 821 | ||
| AVAILABILITY | 821 | ||
| INDICATIONS AND DOSAGES | 821 | ||
| CONTRAINDICATIONS | 821 | ||
| INTERACTIONS | 821 | ||
| DIAGNOSTIC TEST EFFECTS | 822 | ||
| SIDE EFFECTS | 822 | ||
| SERIOUS REACTIONS | 822 | ||
| Lisinopril | 823 | ||
| MECHANISM OF ACTION | 823 | ||
| PHARMACOKINETICS | 823 | ||
| AVAILABILITY | 823 | ||
| INDICATIONS AND DOSAGES | 823 | ||
| OFF-LABEL USES | 824 | ||
| CONTRAINDICATIONS | 824 | ||
| INTERACTIONS | 824 | ||
| DIAGNOSTIC TEST EFFECTS | 824 | ||
| SIDE EFFECTS | 824 | ||
| SERIOUS REACTIONS | 824 | ||
| Lithium Carbonate/Lithium Citrate | 825 | ||
| MECHANISM OF ACTION | 825 | ||
| PHARMACOKINETICS | 825 | ||
| AVAILABILITY | 826 | ||
| INDICATIONS AND DOSAGES | 826 | ||
| OFF-LABEL USES | 826 | ||
| CONTRAINDICATIONS | 826 | ||
| INTERACTIONS | 826 | ||
| DIAGNOSTIC TEST EFFECTS | 826 | ||
| SIDE EFFECTS | 826 | ||
| SERIOUS REACTIONS | 827 | ||
| Lomitapide | 827 | ||
| MECHANISM OF ACTION | 827 | ||
| PHARMACOKINETICS | 828 | ||
| AVAILABILITY | 828 | ||
| INDICATIONS AND DOSAGES | 828 | ||
| CONTRAINDICATIONS | 828 | ||
| INTERACTIONS | 828 | ||
| DIAGNOSTIC TEST EFFECTS | 829 | ||
| SIDE EFFECTS | 829 | ||
| SERIOUS REACTIONS | 829 | ||
| Loperamide | 830 | ||
| MECHANISM OF ACTION | 830 | ||
| PHARMACOKINETICS | 830 | ||
| AVAILABILITY | 830 | ||
| INDICATIONS AND DOSAGES | 830 | ||
| Lodoxamide Tromethamine | 830.e1 | ||
| MECHANISM OF ACTION | 830.e1 | ||
| PHARMACOKINETICS | 830.e1 | ||
| AVAILABILITY | 830.e1 | ||
| INDICATIONS AND DOSAGES | 830.e1 | ||
| CONTRAINDICATIONS | 830.e1 | ||
| INTERACTIONS | 830.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 830.e1 | ||
| SIDE EFFECTS | 830.e1 | ||
| SERIOUS REACTIONS | 830.e1 | ||
| CONTRAINDICATIONS | 831 | ||
| INTERACTIONS | 831 | ||
| DIAGNOSTIC TEST EFFECTS | 831 | ||
| SIDE EFFECTS | 831 | ||
| SERIOUS REACTIONS | 831 | ||
| Lopinavir/Ritonavir | 832 | ||
| MECHANISM OF ACTION | 832 | ||
| PHARMACOKINETICS | 832 | ||
| AVAILABILITY | 832 | ||
| INDICATIONS AND DOSAGES | 832 | ||
| CONTRAINDICATIONS | 833 | ||
| INTERACTIONS | 833 | ||
| DIAGNOSTIC TEST EFFECTS | 834 | ||
| SIDE EFFECTS | 834 | ||
| SERIOUS REACTIONS | 834 | ||
| Loratadine | 835 | ||
| MECHANISM OF ACTION | 835 | ||
| PHARMACOKINETICS | 835 | ||
| AVAILABILITY | 835 | ||
| INDICATIONS AND DOSAGES | 835 | ||
| CONTRAINDICATIONS | 835 | ||
| DIAGNOSTIC TEST EFFECTS | 836 | ||
| SIDE EFFECTS | 836 | ||
| SERIOUS REACTIONS | 836 | ||
| Lorazepam | 836 | ||
| MECHANISM OF ACTION | 836 | ||
| PHARMACOKINETICS | 836 | ||
| AVAILABILITY | 837 | ||
| INDICATIONS AND DOSAGES | 837 | ||
| OFF-LABEL USES | 837 | ||
| CONTRAINDICATIONS | 837 | ||
| INTERACTIONS | 837 | ||
| DIAGNOSTIC TEST EFFECTS | 837 | ||
| ?IV INCOMPATIBILITIES | 838 | ||
| ?IV COMPATIBILITIES | 838 | ||
| SIDE EFFECTS | 838 | ||
| SERIOUS REACTIONS | 838 | ||
| Lorcaserin | 839 | ||
| MECHANISM OF ACTION | 839 | ||
| PHARMACOKINETICS | 839 | ||
| AVAILABILITY | 839 | ||
| INDICATIONS AND DOSAGES | 839 | ||
| CONTRAINDICATIONS | 839 | ||
| INTERACTIONS | 839 | ||
| DIAGNOSTIC TEST EFFECTS | 840 | ||
| SIDE EFFECTS | 840 | ||
| SERIOUS REACTIONS | 840 | ||
| Losartan | 841 | ||
| MECHANISM OF ACTION | 841 | ||
| PHARMACOKINETICS | 841 | ||
| AVAILABILITY | 841 | ||
| INDICATIONS AND DOSAGES | 841 | ||
| CONTRAINDICATIONS | 841 | ||
| INTERACTIONS | 841 | ||
| DIAGNOSTIC TEST EFFECTS | 842 | ||
| SIDE EFFECTS | 842 | ||
| SERIOUS REACTIONS | 842 | ||
| Lovastatin | 843 | ||
| MECHANISM OF ACTION | 843 | ||
| PHARMACOKINETICS | 843 | ||
| AVAILABILITY | 843 | ||
| INDICATIONS AND DOSAGES | 843 | ||
| CONTRAINDICATIONS | 843 | ||
| INTERACTIONS | 843 | ||
| DIAGNOSTIC TEST EFFECTS | 844 | ||
| SIDE EFFECTS | 844 | ||
| SERIOUS REACTIONS | 844 | ||
| Loxapine | 844 | ||
| MECHANISM OF ACTION | 844 | ||
| PHARMACOKINETICS | 844 | ||
| AVAILABILITY | 845 | ||
| INDICATIONS AND DOSAGES | 845 | ||
| CONTRAINDICATIONS | 845 | ||
| INTERACTIONS | 845 | ||
| DIAGNOSTIC TEST EFFECTS | 845 | ||
| SIDE EFFECTS | 845 | ||
| SERIOUS REACTIONS | 845 | ||
| Lubiprostone | 846 | ||
| MECHANISM OF ACTION | 846 | ||
| PHARMACOKINETICS | 846 | ||
| Lucinactant\r | 846.e1 | ||
| MECHANISM OF ACTION | 846.e1 | ||
| PHARMACOKINETICS | 846.e1 | ||
| AVAILABILITY | 846.e1 | ||
| INDICATIONS AND DOSAGES | 846.e1 | ||
| CONTRAINDICATIONS | 846.e1 | ||
| INTERACTIONS | 846.e1 | ||
| DIAGNOSTIC TEST EFFECTS | 846.e1 | ||
| SIDE EFFECTS | 846.e1 | ||
| SERIOUS REACTIONS | 846.e1 | ||
| AVAILABILITY | 847 | ||
| INDICATIONS AND DOSAGES | 847 | ||
| CONTRAINDICATIONS | 847 | ||
| INTERACTIONS | 847 | ||
| DIAGNOSTIC TEST EFFECTS | 847 | ||
| SIDE EFFECTS | 847 | ||
| SERIOUS REACTIONS | 847 | ||
| Luliconazole | 848 | ||
| MECHANISM OF ACTION | 848 | ||
| PHARMACOKINETICS | 848 | ||
| AVAILABILITY | 848 | ||
| INDICATIONS AND DOSAGES | 848 | ||
| CONTRAINDICATIONS | 848 | ||
| INTERACTIONS | 848 | ||
| DIAGNOSTIC TEST EFFECTS | 848 | ||
| SIDE EFFECTS | 848 | ||
| SERIOUS REACTIONS | 848 | ||
| Lurasidone | 849 | ||
| MECHANISM OF ACTION | 849 | ||
| AVAILABILITY | 849 | ||
| PHARMACOKINETICS | 849 | ||
| INDICATIONS AND DOSAGES | 849 | ||
| CONTRAINDICATIONS | 849 | ||
| INTERACTIONS | 849 | ||
| DIAGNOSTIC TEST EFFECTS | 850 | ||
| SIDE EFFECTS | 850 | ||
| SERIOUS REACTIONS | 850 | ||
| M | 851 | ||
| Macitentan | 851 | ||
| Mechanism of Action | 851 | ||
| Pharmacokinetics | 851 | ||
| Availability | 851 | ||
| Indications and Dosages | 851 | ||
| ▸Pulmonary arterial hypertension | 851 | ||
| Contraindications | 851 | ||
| Interactions | 851 | ||
| Diagnostic Test Effects | 851 | ||
| Side Effects | 851 | ||
| Serious Reactions | 851 | ||
| Mafenide | 852 | ||
| Mechanism of Action | 852 | ||
| Pharmacokinetics | 852 | ||
| Availability | 852 | ||
| Indications and Dosages | 852 | ||
| ▸Burns | 852 | ||
| Contraindications | 852 | ||
| Interactions | 853 | ||
| Diagnostic Test Effects | 853 | ||
| Side Effects | 853 | ||
| Serious Reactions | 853 | ||
| Magnesium Hydroxide, Aluminum Hydroxide, Simethicone | 853 | ||
| Mechanism of Action | 853 | ||
| Pharmacokinetics | 853 | ||
| Availability | 854 | ||
| Indications and Dosages | 854 | ||
| ▸Antacid (with flatulence) | 854 | ||
| Contraindications | 854 | ||
| Interactions | 854 | ||
| Diagnostic Test Effects | 854 | ||
| Side Effects | 854 | ||
| Serious Reactions | 854 | ||
| Magnesium Salts | 855 | ||
| Mechanism of Action | 855 | ||
| Pharmacokinetics | 855 | ||
| Availability | 856 | ||
| Indications and Dosages | 856 | ||
| ▸Dietary supplement (magnesium oxide) | 856 | ||
| ▸Dietary supplement (magnesium chloride) | 856 | ||
| ▸Dietary supplement (magnesium gluconate) | 856 | ||
| ▸Acute hypomagnesemia (usual dosages, magnesium sulfate) | 856 | ||
| ▸Preeclampsia/eclampsia (magnesium sulfate) | 856 | ||
| ▸Hyperalimentation (magnesium sulfate) | 856 | ||
| ▸ACLS protocol use (magnesium sulfate) | 856 | ||
| ▸Cathartic or bowel preparation (magnesium citrate) | 857 | ||
| N | 963 | ||
| Nabumetone | 963 | ||
| Mechanism of Action | 963 | ||
| Pharmacokinetics | 963 | ||
| Availability | 963 | ||
| Indications and Dosages | 963 | ||
| ▸Acute or chronic rheumatoid and osteoarthritis | 963 | ||
| ▸Dosage in renal impairment | 963 | ||
| Contraindications | 963 | ||
| Interactions | 963 | ||
| Diagnostic Test Effects | 963 | ||
| Side Effects | 964 | ||
| Serious Reactions | 964 | ||
| Nadolol | 964 | ||
| Mechanism of Action | 964 | ||
| Pharmacokinetics | 964 | ||
| Availability | 965 | ||
| Indications and Dosages | 965 | ||
| ▸Mild to moderate hypertension or angina | 965 | ||
| ▸Dosage in renal impairment | 965 | ||
| Off-Label Uses | 965 | ||
| Contraindications | 965 | ||
| Interactions | 965 | ||
| Diagnostic Test Effects | 965 | ||
| Side Effects | 965 | ||
| Serious Reactions | 965 | ||
| Nafarelin | 965.e1 | ||
| Mechanism of Action | 965.e1 | ||
| Pharmacokinetics | 965.e1 | ||
| Availability | 965.e1 | ||
| Indications and Dosages | 965.e1 | ||
| ▸Endometriosis | 965.e1 | ||
| ▸ Precocious puberty | 965.e1 | ||
| Contraindications | 965.e1 | ||
| Interactions | 965.e1 | ||
| Diagnostic Test Effects | 965.e2 | ||
| Side Effects | 965.e2 | ||
| Serious Reactions | 965.e2 | ||
| Nafcillin Sodium | 966 | ||
| Mechanism of Action | 966 | ||
| Pharmacokinetics | 966 | ||
| Availability | 966 | ||
| Indications and Dosages | 966 | ||
| ▸Methicillin-sensitive staphylococcal infections (bacteremia, endocarditis, meningitis, skin and tissue, pneumonia, bone and joi... | 966 | ||
| Off-Label Uses | 967 | ||
| Contraindications | 967 | ||
| Interactions | 967 | ||
| Diagnostic Test Effects | 967 | ||
| ?IV Incompatibilities | 967 | ||
| Side Effects | 967 | ||
| Serious Reactions | 967 | ||
| Naftifine | 968 | ||
| Mechanism of Action | 968 | ||
| Pharmacokinetics | 968 | ||
| Availability | 968 | ||
| Indications and Dosages | 968 | ||
| ▸Tinea pedis, tinea cruris, tinea corporis | 968 | ||
| Off-Label Uses | 968 | ||
| Contraindications | 968 | ||
| Interactions | 968 | ||
| Diagnostic Test Effects | 968 | ||
| Side Effects | 968 | ||
| Serious Reactions | 968 | ||
| Nalbuphine | 969 | ||
| Mechanism of Action | 969 | ||
| Pharmacokinetics | 969 | ||
| Availability | 969 | ||
| Indications and Dosages | 969 | ||
| ▸Analgesia (moderate to severe pain, obstetric) | 969 | ||
| ▸Supplement to anesthesia | 969 | ||
| Contraindications | 969 | ||
| Interactions | 969 | ||
| Diagnostic Test Effects | 970 | ||
| ?IV Incompatibilities | 970 | ||
| ?IV Compatibilities | 970 | ||
| Side Effects | 970 | ||
| Serious Reactions | 970 | ||
| Naloxone | 971 | ||
| Mechanism of Action | 971 | ||
| Pharmacokinetics | 971 | ||
| Availability | 971 | ||
| Indications and Dosages | 971 | ||
| ▸Opioid toxicity | 971 | ||
| ▸Opioid toxicity in children | 971 | ||
| ▸Postanesthesia narcotic reversal | 971 | ||
| Contraindications | 971 | ||
| Interactions | 971 | ||
| Diagnostic Test Effects | 972 | ||
| ?IV Incompatibilities | 972 | ||
| ?IV Compatibilities | 972 | ||
| Side Effects | 972 | ||
| Serious Reactions | 972 | ||
| Naltrexone | 972 | ||
| Mechanism of Action | 973 | ||
| Pharmacokinetics | 973 | ||
| Availability | 973 | ||
| Indications and Dosages | 973 | ||
| ▸Treatment of opioid dependence in patients who have been opioid free for at least 7-10 days | 973 | ||
| ▸Adjunctive treatment of alcohol dependence | 973 | ||
| Contraindications | 973 | ||
| Interactions | 973 | ||
| Diagnostic Test Effects | 973 | ||
| Side Effects | 973 | ||
| Serious Reactions | 973 | ||
| Naphazoline | 974 | ||
| Mechanism of Action | 974 | ||
| Pharmacokinetics | 974 | ||
| Availability | 974 | ||
| Indications and Dosages | 975 | ||
| ▸Control of hyperemia in patients with superficial corneal vascularity; relief of congestion and inflammation; for use during oc... | 975 | ||
| Contraindications | 975 | ||
| Interactions | 975 | ||
| Diagnostic Test Effects | 975 | ||
| Side Effects | 975 | ||
| Serious Reactions | 975 | ||
| Naproxen/Naproxen Sodium | 975 | ||
| Mechanism of Action | 975 | ||
| Pharmacokinetics | 976 | ||
| Availability | 976 | ||
| Indications and Dosages | 976 | ||
| ▸Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis | 976 | ||
| ▸Acute gouty arthritis | 976 | ||
| ▸Mild to moderate pain, dysmenorrhea, bursitis, tendinitis | 976 | ||
| ▸Juvenile rheumatoid arthritis | 976 | ||
| Off-Label Uses | 976 | ||
| Contraindications | 976 | ||
| Interactions | 976 | ||
| Diagnostic Test Effects | 977 | ||
| Side Effects | 977 | ||
| Serious Reactions | 977 | ||
| Naratriptan | 978 | ||
| Mechanism of Action | 978 | ||
| Pharmacokinetics | 978 | ||
| Availability | 978 | ||
| Indications and Dosages | 978 | ||
| ▸Acute migraine attack | 978 | ||
| ▸Dosage in mild to moderate renal or hepatic impairment | 978 | ||
| Contraindications | 978 | ||
| Interactions | 979 | ||
| Diagnostic Test Effects | 979 | ||
| Side Effects | 979 | ||
| Serious Reactions | 979 | ||
| Natalizumab | 979.e1 | ||
| Mechanism of Action | 979.e1 | ||
| Pharmacokinetics | 979.e1 | ||
| Availability | 979.e1 | ||
| Indications and Dosages | 979.e1 | ||
| ▸Relapses of multiple sclerosis | 979.e1 | ||
| ▸Crohn’s disease | 979.e1 | ||
| Contraindications | 979.e1 | ||
| Interactions | 979.e1 | ||
| Diagnostic Test Effects | 979.e1 | ||
| ?IV Incompatibilities | 979.e1 | ||
| Side Effects | 979.e1 | ||
| Serious Reactions | 979.e1 | ||
| O | 1028 | ||
| Octreotide | 1028 | ||
| Mechanism of Action | 1028 | ||
| Pharmacokinetics | 1028 | ||
| Availability | 1028 | ||
| Indications and Dosages | 1028 | ||
| ▸Carcinoid tumors | 1028 | ||
| ▸VIPomas | 1028 | ||
| ▸Esophageal varices (off-label use) | 1028 | ||
| ▸Acromegaly | 1028 | ||
| Off-Label Uses | 1028 | ||
| Contraindications | 1028 | ||
| ?IV Incompatibilities | 1028 | ||
| Interactions | 1028 | ||
| Ofatumumab | 1028.e1 | ||
| Mechanism of Action | 1028.e1 | ||
| Pharmacokinetics | 1028.e1 | ||
| Availability | 1028.e1 | ||
| Indications and Dosages | 1028.e1 | ||
| ▸B-cell chronic lymphocytic leukemia in patients failing alemtuzumab and fludarabine | 1028.e1 | ||
| Contraindications | 1028.e1 | ||
| Interactions | 1028.e1 | ||
| Diagnostic Test Effects | 1028.e1 | ||
| ?IV Incompatibilities | 1028.e1 | ||
| Side Effects | 1028.e1 | ||
| Serious Reactions | 1028.e1 | ||
| Diagnostic Test Effects | 1029 | ||
| Side Effects | 1029 | ||
| Serious Reactions | 1029 | ||
| Ofloxacin | 1030 | ||
| Mechanism of Action | 1030 | ||
| Pharmacokinetics | 1030 | ||
| Availability | 1030 | ||
| Indications and Dosages | 1030 | ||
| ▸Uncomplicated urinary tract infection (UTI) | 1030 | ||
| ▸Complicated urinary tract infection (UTIs) | 1030 | ||
| Adults, Elderly. 200 mg q12h for 10 days | 1030 | ||
| ▸Pelvic inflammatory disease (PID) | 1030 | ||
| ▸Lower respiratory tract, skin, and skin-structure infections | 1030 | ||
| ▸Prostatitis, sexually transmitted diseases (cervicitis, urethritis) | 1030 | ||
| ▸Acute, uncomplicated gonorrhea | 1030 | ||
| ▸Bacterial conjunctivitis | 1030 | ||
| ▸Corneal ulcers, bacterial | 1030 | ||
| ▸Acute otitis media with typanostomy tubes | 1030 | ||
| ▸Otitis externa | 1030 | ||
| ▸Dosage in hepatic impairment (adults) | 1030 | ||
| ▸Dosage in renal impairment (adults) | 1031 | ||
| Contraindications | 1031 | ||
| Interactions | 1031 | ||
| Diagnostic Test Effects | 1031 | ||
| Side Effects | 1031 | ||
| Serious Reactions | 1031 | ||
| Olanzapine | 1032 | ||
| Mechanism of Action | 1032 | ||
| Pharmacokinetics | 1033 | ||
| Availability | 1033 | ||
| Indications and Dosages | 1033 | ||
| ▸Schizophrenia | 1033 | ||
| ▸Bipolar mania | 1033 | ||
| ▸Dosage for elderly or debilitated patients and those predisposed to hypotensive reactions | 1033 | ||
| ▸Control of agitation in schizophrenic or bipolar patients | 1033 | ||
| Off-Label Uses | 1033 | ||
| Contraindications | 1033 | ||
| Interactions | 1033 | ||
| Diagnostic Test Effects | 1034 | ||
| Side Effects | 1034 | ||
| Serious Reactions | 1034 | ||
| Olmesartan Medoxomil | 1035 | ||
| Mechanism of Action | 1035 | ||
| Pharmacokinetics | 1035 | ||
| Availability | 1035 | ||
| Indications and Dosages | 1035 | ||
| ▸Hypertension | 1035 | ||
| Contraindications | 1036 | ||
| Interactions | 1036 | ||
| Diagnostic Test Effects | 1036 | ||
| Side Effects | 1036 | ||
| Serious Reactions | 1036 | ||
| Olopatadine | 1037 | ||
| Mechanism of Action | 1037 | ||
| Pharmacokinetics | 1037 | ||
| Availability | 1037 | ||
| Indications and Dosages | 1037 | ||
| ▸Allergic conjunctivitis | 1037 | ||
| ▸Seasonal allergic rhinitis | 1037 | ||
| Contraindications | 1037 | ||
| Interactions | 1037 | ||
| Side Effects | 1037 | ||
| Serious Reactions | 1037 | ||
| Olsalazine Sodium | 1038 | ||
| Mechanism of Action | 1038 | ||
| Pharmacokinetics | 1038 | ||
| Availability | 1038 | ||
| Indications and Dosages | 1038 | ||
| ▸Maintenance of controlled ulcerative colitis | 1038 | ||
| Off-Label Uses | 1038 | ||
| Contraindications | 1038 | ||
| Interactions | 1038 | ||
| Diagnostic Test Effects | 1038 | ||
| Side Effects | 1038 | ||
| Serious Reactions | 1038 | ||
| Omalizumab | 1039 | ||
| Mechanism of Action | 1039 | ||
| Pharmacokinetics | 1039 | ||
| Availability | 1039 | ||
| Indications and Dosages | 1039 | ||
| ▸Chronic idiopathic urticaria | 1039 | ||
| ▸Moderate to severe persistent asthma in patients who are reactive to a perennial allergen and whose asthma symptoms have been i... | 1039 | ||
| Off-Label Uses | 1040 | ||
| Contraindications | 1040 | ||
| Interactions | 1040 | ||
| Diagnostic Test Effects | 1040 | ||
| Side Effects | 1040 | ||
| Serious Reactions | 1040 | ||
| Omega-3 Fatty Acids (Omega-3 Ethyl Esters) | 1041 | ||
| Mechanism of Action | 1041 | ||
| Pharmacokinetics | 1041 | ||
| Availability | 1041 | ||
| Indications and Dosages | 1041 | ||
| ▸Severe (≥ 500 mg/dL) hypertriglyceridemia | 1041 | ||
| Contraindications | 1041 | ||
| Interactions | 1041 | ||
| Diagnostic Test Effects | 1042 | ||
| Side Effects | 1042 | ||
| Serious Reactions | 1042 | ||
| Omeprazole | 1042 | ||
| Mechanism of Action | 1042 | ||
| OnabotulinumtoxinA (formerly BotulinumToxin Type A) | 1042.e1 | ||
| Mechanism of Action | 1042.e1 | ||
| Availability | 1042.e1 | ||
| Indications and Dosages | 1042.e1 | ||
| ▸Cervical dystonia in patients who have previously tolerated botulinum toxin type A | 1042.e1 | ||
| ▸Cervical dystonia in patients who have not previously been treated with botulinum toxin type A | 1042.e1 | ||
| ▸Strabismus | 1042.e1 | ||
| ▸Blepharospasm | 1042.e1 | ||
| ▸Improvement of brow furrow/glabellar lines | 1042.e1 | ||
| ▸Improvement of lateral canthal lines (crow’s-feet) | 1042.e1 | ||
| ▸Axillary hyperhidrosis | 1042.e1 | ||
| ▸Prevention of migraine in chronic cases | 1042.e1 | ||
| ▸Urinary incontinence due to detrusor overactivity caused by neurologic conditions | 1042.e1 | ||
| Off-Label Uses | 1042.e2 | ||
| Contraindications | 1042.e2 | ||
| Interactions | 1042.e2 | ||
| Diagnostic Test Effects | 1042.e2 | ||
| Side Effects | 1042.e2 | ||
| Serious Reactions | 1042.e2 | ||
| Pharmacokinetics | 1043 | ||
| Availability | 1043 | ||
| Indications and Dosages | 1043 | ||
| ▸Erosive esophagitis, poorly responsive gastroesophageal reflux disease (GERD), active duodenal ulcer, prevention and treatment ... | 1043 | ||
| ▸To maintain healing of erosive esophagitis | 1043 | ||
| ▸Pathologic hypersecretory conditions | 1043 | ||
| ▸Duodenal ulcer caused by Helicobacter pylori | 1043 | ||
| ▸Active benign gastric ulcer | 1043 | ||
| ▸Dyspepsia (OTC use) | 1043 | ||
| ▸Usual pediatric dosage | 1043 | ||
| Off-Label Uses | 1043 | ||
| Contraindications | 1043 | ||
| Interactions | 1043 | ||
| Diagnostic Test Effects | 1044 | ||
| Side Effects | 1044 | ||
| Serious Reactions | 1044 | ||
| Ondansetron | 1044 | ||
| Mechanism of Action | 1045 | ||
| Pharmacokinetics | 1045 | ||
| Availability | 1045 | ||
| Indications and Dosages | 1045 | ||
| ▸Prevention of chemotherapy-induced nausea and vomiting | 1045 | ||
| ▸Prevention of radiation-induced nausea and vomiting | 1045 | ||
| ▸Prevention of postoperative nausea and vomiting | 1045 | ||
| Off-Label Uses | 1045 | ||
| Contraindications | 1045 | ||
| Interactions | 1045 | ||
| Diagnostic Test Effects | 1045 | ||
| ?IV Incompatibilities | 1046 | ||
| ?IV Compatibilities | 1046 | ||
| Side Effects | 1046 | ||
| Serious Reactions | 1046 | ||
| Oprelvekin (Interleukin-11 [IL-11]) | 1047 | ||
| Mechanism of Action | 1047 | ||
| Pharmacokinetics | 1047 | ||
| Availability | 1047 | ||
| Indications and Dosages | 1047 | ||
| ▸Prevention of thrombocytopenia as a result of chemotherapy | 1047 | ||
| ▸Dosage in renal impairment | 1047 | ||
| Contraindications | 1047 | ||
| Interactions | 1047 | ||
| Diagnostic Test Effects | 1047 | ||
| Side Effects | 1047 | ||
| Serious Reactions | 1048 | ||
| Orlistat | 1048 | ||
| Mechanism of Action | 1048 | ||
| Pharmacokinetics | 1048 | ||
| Mechanism of Action | 1048.e1 | ||
| Pharmacokinetics | 1048.e1 | ||
| Availability | 1048.e1 | ||
| Indications and Dosages | 1048.e1 | ||
| ▸Musculoskeletal pain | 1048.e1 | ||
| Off-Label Uses | 1048.e1 | ||
| Contraindications | 1048.e1 | ||
| Interactions | 1048.e1 | ||
| Diagnostic Test Effects | 1048.e1 | ||
| ?IV Incompatibilities | 1048.e1 | ||
| ?IV Compatibilities | 1048.e1 | ||
| Side Effects | 1048.e1 | ||
| Serious Reactions | 1048.e1 | ||
| Availability | 1049 | ||
| Indications and Dosages | 1049 | ||
| ▸Weight reduction in patients with body mass index of 27 kg/m2 or over | 1049 | ||
| Contraindications | 1049 | ||
| Interactions | 1049 | ||
| Diagnostic Test Effects | 1049 | ||
| Side Effects | 1049 | ||
| Serious Reactions | 1049 | ||
| Oseltamivir | 1050 | ||
| Mechanism of Action | 1050 | ||
| Pharmacokinetics | 1050 | ||
| Availability | 1050 | ||
| Indications and Dosages | 1050 | ||
| ▸Influenza A or B infection | 1050 | ||
| ▸Prevention of influenza | 1050 | ||
| ▸Dosage in renal impairment | 1050 | ||
| Off-Label Uses | 1051 | ||
| Contraindications | 1051 | ||
| Interactions | 1051 | ||
| Diagnostic Test Effects | 1051 | ||
| Side Effects | 1051 | ||
| Serious Reactions | 1051 | ||
| Ospemifene | 1051 | ||
| Mechanism of Action | 1052 | ||
| Pharmacokinetics | 1052 | ||
| Availability | 1052 | ||
| Indications and Dosages | 1052 | ||
| ▸Moderate to severe dyspareunia (vulvar and vaginal atrophy) due to menopause | 1052 | ||
| Contraindications | 1052 | ||
| Interactions | 1052 | ||
| Diagnostic Test Effects | 1052 | ||
| Side Effects | 1052 | ||
| Serious Reactions | 1052 | ||
| Oxacillin | 1052.e1 | ||
| Mechanism of Action | 1052.e1 | ||
| Pharmacokinetics | 1052.e1 | ||
| Availability | 1052.e1 | ||
| Indications and Dosages | 1052.e1 | ||
| ▸Upper respiratory tract, skin and skin-structure infections | 1052.e1 | ||
| ▸Lower respiratory tract and other serious infections | 1052.e1 | ||
| Contraindications | 1052.e1 | ||
| Interactions | 1052.e1 | ||
| Diagnostic Test Effects | 1052.e1 | ||
| ?IV Incompatibilities | 1052.e1 | ||
| Side Effects | 1052.e1 | ||
| Serious Reactions | 1052.e2 | ||
| Oxandrolone | 1053 | ||
| Mechanism of Action | 1053 | ||
| Pharmacokinetics | 1053 | ||
| Availability | 1053 | ||
| Indications and Dosages | 1053 | ||
| ▸Cachexia | 1053 | ||
| Off-Label Uses | 1053 | ||
| Mechanism of Action | 1053.e1 | ||
| Pharmacokinetics | 1053.e1 | ||
| Availability | 1053.e1 | ||
| Indications and Dosages | 1053.e1 | ||
| ▸Metastatic colon or rectal cancer in patients whose disease has recurred or progressed during or within 6 mo of completing firs... | 1053.e1 | ||
| ▸Dosage adjustments for neurotoxicity, gastrointestinal toxicity, or hematologic toxicity | 1053.e1 | ||
| Off-Label Uses | 1053.e1 | ||
| Contraindications | 1053.e1 | ||
| Drug Interactions | 1053.e1 | ||
| ?IV Incompatibilities | 1053.e1 | ||
| Side Effects | 1053.e1 | ||
| Serious Reactions | 1053.e2 | ||
| Contraindications | 1054 | ||
| Interactions | 1054 | ||
| Diagnostic Test Effects | 1054 | ||
| Side Effects | 1054 | ||
| Serious Reactions | 1054 | ||
| Oxaprozin | 1055 | ||
| Mechanism of Action | 1055 | ||
| Pharmacokinetics | 1055 | ||
| Availability | 1055 | ||
| Indications and Dosages | 1055 | ||
| ▸Osteoarthritis | 1055 | ||
| ▸Rheumatoid arthritis | 1055 | ||
| ▸Juvenile rheumatoid arthritis (6 yr and older) | 1055 | ||
| ▸Dosage in renal impairment | 1055 | ||
| Contraindications | 1055 | ||
| Interactions | 1055 | ||
| Diagnostic Test Effects | 1056 | ||
| Side Effects | 1056 | ||
| Serious Reactions | 1056 | ||
| Oxazepam | 1057 | ||
| Mechanism of Action | 1057 | ||
| Pharmacokinetics | 1057 | ||
| Availability | 1057 | ||
| Indications and Dosages | 1057 | ||
| ▸Mild to moderate anxiety | 1057 | ||
| ▸Severe anxiety | 1057 | ||
| ▸Alcohol withdrawal | 1057 | ||
| Contraindications | 1057 | ||
| Interactions | 1057 | ||
| Diagnostic Test Effects | 1057 | ||
| Side Effects | 1057 | ||
| Serious Reactions | 1057 | ||
| Oxcarbazepine | 1058 | ||
| Mechanism of Action | 1058 | ||
| Pharmacokinetics | 1058 | ||
| Availability | 1058 | ||
| Indications and Dosages | 1058 | ||
| ▸Adjunctive treatment of seizures | 1058 | ||
| ▸Conversion to monotherapy | 1059 | ||
| ▸Initiation of monotherapy | 1059 | ||
| ▸Dosage in renal impairment | 1059 | ||
| ▸Dosage for Oxtellar XR | 1059 | ||
| ▸Oxtellar XR dosage in renal impairment (adults) | 1059 | ||
| ▸Conversion of immediate-release to Oxtellar XR | 1059 | ||
| Off-Label Uses | 1059 | ||
| Contraindications | 1059 | ||
| Interactions | 1059 | ||
| Diagnostic Test Effects | 1059 | ||
| Side Effects | 1060 | ||
| Serious Reactions | 1060 | ||
| Oxiconazole | 1060 | ||
| Mechanism of Action | 1061 | ||
| Pharmacokinetics | 1061 | ||
| Availability | 1061 | ||
| Indications and Dosages | 1061 | ||
| ▸Tinea pedis | 1061 | ||
| ▸Tinea cruris, tinea corporis | 1061 | ||
| Contraindications | 1061 | ||
| Interactions | 1061 | ||
| Diagnostic Test Effects | 1061 | ||
| Side Effects | 1061 | ||
| Serious Reactions | 1061 | ||
| Oxybutynin | 1062 | ||
| Mechanism of Action | 1062 | ||
| Pharmacokinetics | 1062 | ||
| Availability | 1062 | ||
| Indications and Dosages | 1062 | ||
| ▸Neurogenic bladder, overactive bladder | 1062 | ||
| Contraindications | 1062 | ||
| Interactions | 1062 | ||
| Diagnostic Test Effects | 1063 | ||
| Side Effects | 1063 | ||
| Serious Reactions | 1063 | ||
| Oxycodone | 1063 | ||
| Mechanism of Action | 1064 | ||
| Pharmacokinetics | 1064 | ||
| Availability | 1064 | ||
| Indications and Dosages | 1064 | ||
| ▸Analgesia | 1064 | ||
| ▸Analgesia in patients with moderate to severe pain needing the drug for an extended period | 1064 | ||
| ▸Patients with hepatic impairment | 1064 | ||
| Contraindications | 1064 | ||
| Interactions | 1064 | ||
| Diagnostic Test Effects | 1064 | ||
| Side Effects | 1065 | ||
| Serious Reactions | 1065 | ||
| Oxycodone; Acetaminophen | 1066 | ||
| Mechanism of Action | 1066 | ||
| Pharmacokinetics | 1066 | ||
| Availability | 1066 | ||
| Indications and Dosages | 1066 | ||
| ▸Analgesia | 1066 | ||
| Contraindications | 1067 | ||
| Interactions | 1067 | ||
| Diagnostic Test Effects | 1067 | ||
| Side Effects | 1067 | ||
| Serious Reactions | 1067 | ||
| Oxymorphone | 1069 | ||
| Mechanism of Action | 1069 | ||
| Pharmacokinetics | 1069 | ||
| Availability | 1069 | ||
| Indications and Dosages | 1069 | ||
| ▸Analgesic, anxiety, preanesthesia | 1069 | ||
| ▸Acute or chronic moderate to severe pain | 1069 | ||
| ▸Obstetric analgesic | 1069 | ||
| Off-Label Uses | 1069 | ||
| Contraindications | 1069 | ||
| Oxymetholone | 1069.e1 | ||
| Mechanism of Action | 1069.e1 | ||
| Pharmacokinetics | 1069.e1 | ||
| Availability | 1069.e1 | ||
| Indications and Dosages | 1069.e1 | ||
| ▸Anemia, chronic renal failure, acquired aplastic anemia, chemotherapy-induced myelosuppression, Fanconi anemia, red cell aplasi... | 1069.e1 | ||
| Contraindications | 1069.e1 | ||
| Interactions | 1069.e1 | ||
| Diagnostic Test Effects | 1069.e1 | ||
| Side Effects | 1069.e1 | ||
| Serious Reactions | 1069.e2 | ||
| Interactions | 1070 | ||
| Diagnostic Test Effects | 1070 | ||
| ?IV Incompatibilities | 1070 | ||
| ?IV Compatibilities | 1070 | ||
| Side Effects | 1070 | ||
| Serious Reactions | 1070 | ||
| Oxytocin | 1071 | ||
| Mechanism of Action | 1071 | ||
| Pharmacokinetics | 1071 | ||
| Availability | 1071 | ||
| Indications and Dosages | 1072 | ||
| ▸Induction or stimulation of labor | 1072 | ||
| ▸Abortion, adjunct | 1072 | ||
| ▸Control of postpartum bleeding | 1072 | ||
| Contraindications | 1072 | ||
| Interactions | 1072 | ||
| Diagnostic Test Effects | 1072 | ||
| ?IV Incompatibilities | 1072 | ||
| ?IV Compatibilities | 1072 | ||
| Side Effects | 1072 | ||
| Serious Reactions | 1072 | ||
| P | 1074 | ||
| Paliperidone | 1074 | ||
| Mechanism of Action | 1074 | ||
| Pharmacokinetics | 1074 | ||
| Availability | 1074 | ||
| Indications and Dosages | 1074 | ||
| ▸Schizophrenia/schizoaffective disorder | 1074 | ||
| ▸Dosage in renal impairment (oral) | 1074 | ||
| ▸Dosage in renal impairment (IM) (adults) | 1074 | ||
| Mechanism of Action | 1074.e1 | ||
| Pharmacokinetics | 1074.e1 | ||
| Availability | 1074.e1 | ||
| Indications and Dosages | 1074.e1 | ||
| ▸Ovarian cancer | 1074.e1 | ||
| ▸Breast cancer | 1074.e1 | ||
| ▸Non–small cell lung cancer | 1074.e1 | ||
| ▸Kaposi’s sarcoma | 1074.e1 | ||
| ▸Dosage in hepatic impairment | 1074.e1 | ||
| Contraindications | 1074.e1 | ||
| Interactions | 1074.e1 | ||
| ?IV Incompatibilities | 1074.e1 | ||
| Side Effects | 1074.e2 | ||
| Serious Reactions | 1074.e2 | ||
| Palifermin | 1074.e2 | ||
| Mechanism of Action | 1074.e2 | ||
| Pharmacokinetics | 1074.e3 | ||
| Availability | 1074.e3 | ||
| Indications and Dosages | 1074.e3 | ||
| ▸Prevention of oral mucositis | 1074.e3 | ||
| Contraindications | 1074.e3 | ||
| Interactions | 1074.e3 | ||
| Diagnostic Test Effects | 1074.e3 | ||
| ?IV Incompatibilities | 1074.e3 | ||
| Side Effects | 1074.e3 | ||
| Serious Reactions | 1074.e3 | ||
| Contraindications | 1075 | ||
| Interactions | 1075 | ||
| Diagnostic Test Effects | 1075 | ||
| Side Effects | 1075 | ||
| Serious Reactions | 1075 | ||
| Palonosetron | 1076 | ||
| Mechanism of Action | 1076 | ||
| Pharmacokinetics | 1076 | ||
| Availability | 1076 | ||
| Indications and Dosages | 1076 | ||
| ▸Chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy | 1076 | ||
| ▸Post-op nausea/vomiting prevention | 1077 | ||
| Contraindications | 1077 | ||
| Interactions | 1077 | ||
| Diagnostic Test Effects | 1077 | ||
| ?IV Incompatibilities | 1077 | ||
| Side Effects | 1077 | ||
| Serious Reactions | 1077 | ||
| Pamidronate Disodium | 1077 | ||
| Mechanism of Action | 1078 | ||
| Pharmacokinetics | 1078 | ||
| Availability | 1078 | ||
| Indications and Dosages | 1078 | ||
| ▸Hypercalcemia of malignancy | 1078 | ||
| ▸Paget’s disease | 1078 | ||
| ▸Osteolytic bone lesion | 1078 | ||
| Contraindications | 1078 | ||
| Interactions | 1078 | ||
| Q | 1222.e1 | ||
| Quazepam | 1222.e1 | ||
| MECHANISM OF ACTION | 1222.e1 | ||
| Pharmacokinetics | 1222.e1 | ||
| Availability | 1222.e1 | ||
| Indications and Dosages | 1222.e1 | ||
| ▸Insomnia | 1222.e1 | ||
| Contraindications | 1222.e1 | ||
| Interactions | 1222.e1 | ||
| Diagnostic Test Effects | 1222.e1 | ||
| Side Effects | 1222.e1 | ||
| Serious Reactions | 1222.e1 | ||
| Quetiapine | 1223 | ||
| Mechanism of Action | 1223 | ||
| Pharmacokinetics | 1223 | ||
| Availability | 1223 | ||
| Indications and Dosages | 1223 | ||
| ▸Management of manifestations of psychotic disorders and schizophrenia | 1223 | ||
| ▸Adjunctive treatment to antidepressants for depression | 1223 | ||
| ▸Bipolar mania | 1223 | ||
| ▸Depressive episodes associated with bipolar disorder | 1223 | ||
| ▸Dosage in hepatic impairment, elderly or debilitated patients, and those predisposed to hypotensive reactions | 1224 | ||
| Contraindications | 1224 | ||
| Interactions | 1224 | ||
| Diagnostic Test Effects | 1224 | ||
| Side Effects | 1224 | ||
| Serious Reactions | 1224 | ||
| Quinapril | 1225 | ||
| Mechanism of Action | 1225 | ||
| Pharmacokinetics | 1225 | ||
| Availability | 1225 | ||
| Indications and Dosages | 1225 | ||
| ▸Hypertension (monotherapy) | 1225 | ||
| ▸Hypertension (combination therapy) | 1226 | ||
| ▸Adjunct to manage heart failure | 1226 | ||
| ▸Dosage in renal impairment | 1226 | ||
| Off-Label Uses | 1226 | ||
| Contraindications | 1226 | ||
| Interactions | 1226 | ||
| Diagnostic Test Effects | 1226 | ||
| Side Effects | 1226 | ||
| Serious Reactions | 1226 | ||
| Quinidine | 1227 | ||
| Mechanism of Action | 1227 | ||
| Availability | 1227 | ||
| Indications and Dosages | 1227 | ||
| ▸Conversion and reduction of relapse for atrial fib/flutter and suppression of ventricular arrhythmias | 1227 | ||
| ▸Treatment of severe malaria (rare) | 1227 | ||
| Contraindications | 1228 | ||
| Interactions | 1228 | ||
| Diagnostic Test Effects | 1228 | ||
| ?IV Incompatibilities | 1228 | ||
| ?IV Compatibilities | 1228 | ||
| Side Effects | 1228 | ||
| Serious Reactions | 1228 | ||
| Quinine | 1229 | ||
| Mechanism of Action | 1230 | ||
| Pharmacokinetics | 1230 | ||
| Availability | 1230 | ||
| Indications and Dosages | 1230 | ||
| ▸Treatment of malaria | 1230 | ||
| ▸Dosage in renal impairment | 1230 | ||
| ▸Dosage in hepatic impairment | 1230 | ||
| Contraindications | 1230 | ||
| Interactions | 1230 | ||
| Quinupristin/Dalfopristin | 1230.e1 | ||
| Mechanism of Action | 1230.e1 | ||
| Pharmacokinetics | 1230.e1 | ||
| Availability | 1230.e1 | ||
| Indications and Dosages | 1230.e1 | ||
| ▸Serious or life-threatening infections (e.g., bacteremia, endocarditis) associated with vancomycin-resistant E. faecium (VREF) | 1230.e1 | ||
| ▸Complicated skin or skin-structure infections due to methicillin-sensitive Staph aureus or Strep pyogenes | 1230.e1 | ||
| ▸Pediatric dosage (emergency use) | 1230.e1 | ||
| Contraindications | 1230.e1 | ||
| Interactions | 1230.e1 | ||
| Diagnostic Test Effects | 1230.e1 | ||
| ?IV Incompatibilities | 1230.e1 | ||
| ?IV Compatibilities | 1230.e2 | ||
| Side Effects | 1230.e2 | ||
| Serious Reactions | 1230.e2 | ||
| Diagnostic Test Effects | 1231 | ||
| Side Effects | 1231 | ||
| Serious Reactions | 1231 | ||
| R | 1233 | ||
| Rabeprazole | 1233 | ||
| Mechanism of Action | 1233 | ||
| Pharmacokinetics | 1233 | ||
| Availability | 1233 | ||
| Indications and Dosages | 1233 | ||
| ▸Erosive/ulcerative or symptomatic gastroesophageal reflux disease (GERD) | 1233 | ||
| ▸Duodenal ulcer | 1233 | ||
| ▸Pathologic hypersecretory conditions, including Zollinger-Ellison syndrome | 1233 | ||
| ▸Helicobacter pylori infection | 1233 | ||
| Contraindications | 1233 | ||
| Interactions | 1233 | ||
| Diagnostic Test Effects | 1234 | ||
| Side Effects | 1234 | ||
| Serious Reactions | 1234 | ||
| Raloxifene | 1234 | ||
| Mechanism of Action | 1234 | ||
| Pharmacokinetics | 1235 | ||
| Availability | 1235 | ||
| Indications and Dosages | 1235 | ||
| ▸Prevention or treatment of osteoporosis | 1235 | ||
| ▸For invasive breast cancer prophylaxis in postmenopausal women with osteoporosis or in postmenopausal women who are at high ris... | 1235 | ||
| Contraindications | 1235 | ||
| Interactions | 1235 | ||
| Diagnostic Test Effects | 1235 | ||
| Side Effects | 1235 | ||
| Serious Reactions | 1235 | ||
| Raltegravir | 1236 | ||
| Mechanism of Action | 1236 | ||
| Pharmacokinetics | 1236 | ||
| Availability | 1236 | ||
| Indications and Dosages | 1236 | ||
| ▸ HIV infection (in combination with other antiretrovirals) | 1236 | ||
| ▸Dosage in hepatic impairment | 1236 | ||
| Contraindications | 1237 | ||
| Interactions | 1237 | ||
| Diagnostic Test Effects | 1237 | ||
| Side Effects | 1237 | ||
| Serious Reactions | 1237 | ||
| Ramelteon | 1238 | ||
| Mechanism of Action | 1238 | ||
| Pharmacokinetics | 1238 | ||
| Availability | 1239 | ||
| Indications and Dosages | 1239 | ||
| ▸Insomnia | 1239 | ||
| ▸Hepatic impairment | 1239 | ||
| Contraindications | 1239 | ||
| Interactions | 1239 | ||
| Diagnostic Test Effects | 1239 | ||
| Side Effects | 1239 | ||
| Serious Reactions | 1239 | ||
| Ramipril | 1240 | ||
| Mechanism of Action | 1240 | ||
| Pharmacokinetics | 1240 | ||
| Availability | 1240 | ||
| Indications and Dosages | 1240 | ||
| ▸Hypertension (monotherapy) | 1240 | ||
| ▸Hypertension (in combination with other antihypertensives) | 1240 | ||
| ▸Congestive heart failure (CHF) post-myocardial infarction (MI) | 1240 | ||
| ▸Risk reduction for MI, stroke, and death from cardiovascular causes | 1240 | ||
| ▸Dosage in renal impairment | 1241 | ||
| Off-Label Uses | 1241 | ||
| Contraindications | 1241 | ||
| Interactions | 1241 | ||
| Diagnostic Test Effects | 1241 | ||
| Side Effects | 1241 | ||
| Serious Reactions | 1241 | ||
| Ranitidine | 1242 | ||
| Mechanism of Action | 1242 | ||
| Pharmacokinetics | 1242 | ||
| Availability | 1242 | ||
| Indications and Dosages | 1243 | ||
| ▸Duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD) | 1243 | ||
| ▸Erosive esophagitis | 1243 | ||
| ▸Hypersecretory conditions | 1243 | ||
| ▸Usual parenteral dosage | 1243 | ||
| ▸Helicobacter pylori eradication | 1243 | ||
| ▸Prevention of heartburn | 1243 | ||
| ▸Usual neonatal dosage | 1243 | ||
| ▸Dosage in renal impairment | 1243 | ||
| Off-Label Uses | 1243 | ||
| Contraindications | 1243 | ||
| Interactions | 1243 | ||
| Diagnostic Test Effects | 1243 | ||
| ?IV Incompatibilities | 1244 | ||
| ?IV Compatibilities | 1244 | ||
| Side Effects | 1244 | ||
| Serious Reactions | 1244 | ||
| Ranolazine | 1244 | ||
| Mechanism of Action | 1244 | ||
| Pharmacokinetics | 1245 | ||
| Availability | 1245 | ||
| Indications and Dosages | 1245 | ||
| ▸Chronic stable angina | 1245 | ||
| ▸Use with moderate inhibitors of CYP3A4 | 1245 | ||
| ▸Hepatic impairment | 1245 | ||
| ▸Severe renal impairment | 1245 | ||
| Contraindications | 1245 | ||
| Interactions | 1245 | ||
| Diagnostic Test Effects | 1245 | ||
| Side Effects | 1246 | ||
| Serious Reactions | 1246 | ||
| Rasagiline | 1246 | ||
| Mechanism of Action | 1246 | ||
| Pharmacokinetics | 1247 | ||
| Availability | 1247 | ||
| Indications and Dosages | 1247 | ||
| ▸Monotherapy for Parkinson’s disease | 1247 | ||
| ▸Parkinson’s disease with levodopa/carbidopa therapy | 1247 | ||
| ▸Patients taking concomitant CYP1A2 inhibitors or with mild hepatic impairment | 1247 | ||
| Contraindications | 1247 | ||
| Interactions | 1247 | ||
| Diagnostic Test Effects | 1248 | ||
| Side Effects | 1248 | ||
| Serious Reactions | 1248 | ||
| Rasburicase | 1248 | ||
| Mechanism of Action | 1249 | ||
| Pharmacokinetics | 1249 | ||
| Availability | 1249 | ||
| Indications and Dosages | 1249 | ||
| ▸To prevent uric acid nephropathy during chemotherapy | 1249 | ||
| Contraindications | 1249 | ||
| Interactions | 1249 | ||
| Diagnostic Test Effects | 1249 | ||
| ?IV Incompatibilities | 1249 | ||
| Side Effects | 1249 | ||
| Serious Reactions | 1249 | ||
| Repaglinide | 1250 | ||
| Mechanism of Action | 1250 | ||
| Pharmacokinetics | 1250 | ||
| Availability | 1250 | ||
| Mechanism of Action | 1250.e1 | ||
| Pharmacokinetics | 1250.e1 | ||
| Availability | 1250.e1 | ||
| Indications and Dosages | 1250.e1 | ||
| ▸Metastatic colorectal cancer or gastrointestinal stromal tumor (GIST) | 1250.e1 | ||
| ▸Dosage adjustment for toxicities | 1250.e1 | ||
| Contraindications | 1250.e1 | ||
| Interactions | 1250.e1 | ||
| Diagnostic Test Effects | 1250.e2 | ||
| Side Effects | 1250.e2 | ||
| Serious Reactions | 1250.e2 | ||
| Indications and Dosages | 1251 | ||
| ▸Diabetes mellitus type 2 | 1251 | ||
| Contraindications | 1251 | ||
| Interactions | 1251 | ||
| Diagnostic Test Effects | 1251 | ||
| Side Effects | 1251 | ||
| Serious Reactions | 1251 | ||
| Retapamulin | 1252 | ||
| Mechanism of Action | 1252 | ||
| Pharmacokinetics | 1252 | ||
| Availability | 1252 | ||
| Indications and Dosages | 1252 | ||
| ▸Impetigo due to susceptible isolates | 1252 | ||
| Mechanism of Action | 1252.e1 | ||
| Pharmacokinetics | 1252.e1 | ||
| Availability | 1252.e1 | ||
| Indications and Dosages | 1252.e1 | ||
| ▸Hypertension | 1252.e1 | ||
| ▸Psychiatric disorders | 1252.e1 | ||
| Contraindications | 1252.e1 | ||
| Interactions | 1252.e1 | ||
| Diagnostic Test Effects | 1252.e2 | ||
| Side Effects | 1252.e2 | ||
| Serious Reactions | 1252.e2 | ||
| Off-Label Uses | 1253 | ||
| Contraindications | 1253 | ||
| Interactions | 1253 | ||
| Diagnostic Test Effects | 1253 | ||
| Side Effects | 1253 | ||
| Serious Reactions | 1253 | ||
| Reteplase | 1253 | ||
| Mechanism of Action | 1253 | ||
| Pharmacokinetics | 1253 | ||
| Availability | 1253 | ||
| Indications and Dosages | 1254 | ||
| ▸Acute myocardial infarction (MI) | 1254 | ||
| Contraindications | 1254 | ||
| Interactions | 1254 | ||
| Diagnostic Test Effects | 1254 | ||
| ?IV Incompatibilities | 1254 | ||
| Side Effects | 1254 | ||
| Serious Reactions | 1254 | ||
| Ribavirin | 1255 | ||
| Mechanism of Action | 1255 | ||
| Pharmacokinetics | 1255 | ||
| Availability | 1255 | ||
| Indications and Dosages | 1255 | ||
| ▸Chronic hepatitis C | 1255 | ||
| ▸Severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) | 1256 | ||
| Off-Label Uses | 1256 | ||
| Contraindications | 1256 | ||
| Interactions | 1256 | ||
| Diagnostic Test Effects | 1256 | ||
| Side Effects | 1256 | ||
| Serious Reactions | 1256 | ||
| Rifabutin | 1257 | ||
| Mechanism of Action | 1257 | ||
| Pharmacokinetics | 1258 | ||
| Availability | 1258 | ||
| Indications and Dosages | 1258 | ||
| ▸Prevention of MAC disease (first episode or recurrent episodes) in HIV-infected patients with < 50 CD4+ cells/mm3 | 1258 | ||
| ▸Dosage in renal impairment | 1258 | ||
| Off Label Uses | 1258 | ||
| Contraindications | 1258 | ||
| Interactions | 1258 | ||
| Diagnostic Test Effects | 1258 | ||
| Side Effects | 1258 | ||
| Serious Reactions | 1259 | ||
| Rifampin | 1259 | ||
| Mechanism of Action | 1259 | ||
| Pharmacokinetics | 1259 | ||
| Availability | 1259 | ||
| Indications and Dosages | 1259 | ||
| ▸Tuberculosis | 1259 | ||
| ▸Prevention of meningococcal infections | 1260 | ||
| ▸Staphylococcal infections | 1260 | ||
| ▸Staphylococcus aureus infections (in combination with other anti-infectives) | 1260 | ||
| ▸Prevention of Haemophilus influenzae infection | 1260 | ||
| Off-Label Uses | 1260 | ||
| Contraindications | 1260 | ||
| Interactions | 1260 | ||
| Diagnostic Test Effects | 1260 | ||
| ?IV Incompatibilities | 1261 | ||
| Side Effects | 1261 | ||
| Serious Reactions | 1261 | ||
| Rifapentine | 1262 | ||
| Mechanism of Action | 1262 | ||
| Availability | 1262 | ||
| Indications and Dosages | 1262 | ||
| ▸Tuberculosis (in combination with at least one other antituberculosis agent) | 1262 | ||
| Contraindications | 1262 | ||
| Interactions | 1262 | ||
| Diagnostic Test Effects | 1262 | ||
| Side Effects | 1262 | ||
| Serious Reactions | 1262 | ||
| Rifaximin | 1263 | ||
| Mechanism of Action | 1263 | ||
| Pharmacokinetics | 1263 | ||
| Availability | 1263 | ||
| Indications and Dosages | 1263 | ||
| ▸Reduce recurrence of hepatic encephalopathy | 1263 | ||
| ▸Traveler’s diarrhea | 1263 | ||
| Off-Label Uses | 1263 | ||
| Contraindications | 1263 | ||
| Interactions | 1263 | ||
| Diagnostic Test Effects | 1263 | ||
| Side Effects | 1263 | ||
| Serious Reactions | 1263 | ||
| Rilpivirine | 1264 | ||
| Mechanism of Action | 1264 | ||
| Pharmacokinetics | 1264 | ||
| Availability | 1264 | ||
| Indications and Dosages | 1264 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 1264 | ||
| Contraindications | 1264 | ||
| Interactions | 1264 | ||
| Diagnostic Test Effects | 1265 | ||
| Side Effects | 1265 | ||
| Serious Reactions | 1265 | ||
| Riluzole | 1266 | ||
| Mechanism of Action | 1266 | ||
| Pharmacokinetics | 1266 | ||
| Availability | 1266 | ||
| Indications and Dosages | 1266 | ||
| ▸ALS | 1266 | ||
| Contraindications | 1266 | ||
| Interactions | 1266 | ||
| Diagnostic Test Effects | 1267 | ||
| Side Effects | 1267 | ||
| Serious Reactions | 1267 | ||
| Riociguat | 1267 | ||
| Mechanism of Action | 1267 | ||
| Pharmacokinetics | 1267 | ||
| Mechanism of Action | 1267.e1 | ||
| Availability | 1267.e1 | ||
| Indications and Dosages | 1267.e1 | ||
| ▸To reduce the severity of symptoms in patients with cervical dystonia who have previously tolerated rimabotulinumtoxin B | 1267.e1 | ||
| ▸To reduce the severity of symptoms in patients with cervical dystonia who have not previously been treated with rimabotulinumto... | 1267.e1 | ||
| Contraindications | 1267.e1 | ||
| Interactions | 1267.e1 | ||
| Diagnostic Test Effects | 1267.e1 | ||
| Side Effects | 1267.e1 | ||
| Serious Reactions | 1267.e1 | ||
| Availability | 1268 | ||
| Indications and Dosages | 1268 | ||
| ▸Pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) | 1268 | ||
| Contraindications | 1268 | ||
| Interactions | 1268 | ||
| Diagnostic Test Effects | 1268 | ||
| Side Effects | 1268 | ||
| Serious Reactions | 1268 | ||
| Risedronate | 1269 | ||
| Mechanism of Action | 1269 | ||
| Availability | 1269 | ||
| Indications and Dosages | 1269 | ||
| ▸Paget’s disease | 1269 | ||
| ▸Prevention and treatment of postmenopausal osteoporosis | 1269 | ||
| ▸Glucocorticoid-induced osteoporosis | 1270 | ||
| ▸Treatment of male osteoporosis | 1270 | ||
| Contraindications | 1270 | ||
| Interactions | 1270 | ||
| Diagnostic Test Effects | 1270 | ||
| Side Effects | 1270 | ||
| Serious Reactions | 1270 | ||
| Risperidone | 1271 | ||
| Mechanism of Action | 1271 | ||
| Pharmacokinetics | 1271 | ||
| Availability | 1271 | ||
| Indications and Dosages | 1271 | ||
| ▸Schizophrenia | 1271 | ||
| ▸Mania, bipolar | 1271 | ||
| ▸Irritability associated with autistic disorder | 1272 | ||
| ▸Dosage in renal impairment | 1272 | ||
| Off-Label Uses | 1272 | ||
| Contraindications | 1272 | ||
| Interactions | 1272 | ||
| Diagnostic Test Effects | 1272 | ||
| Side Effects | 1272 | ||
| Serious Reactions | 1273 | ||
| Ritonavir | 1274 | ||
| Mechanism of Action | 1274 | ||
| Pharmacokinetics | 1274 | ||
| Availability | 1274 | ||
| Indications and Dosages | 1274 | ||
| ▸HIV infection | 1274 | ||
| Contraindications | 1274 | ||
| Interactions | 1274 | ||
| Mechanism of Action | 1274.e1 | ||
| Pharmacokinetics | 1274.e1 | ||
| Availability | 1274.e1 | ||
| Indications and Dosages | 1274.e1 | ||
| ▸Non-Hodgkin’s lymphoma: different treatment protocols depending on type | 1274.e1 | ||
| ▸CD20+ chronic lymphocytic leukemia | 1274.e1 | ||
| ▸Rheumatoid arthritis | 1274.e1 | ||
| ▸Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA) | 1274.e1 | ||
| Contraindications | 1274.e1 | ||
| Interactions | 1274.e1 | ||
| Diagnostic Test Effects | 1274.e1 | ||
| ?IV Incompatibilities | 1274.e2 | ||
| Side Effects | 1274.e2 | ||
| Serious Reactions | 1274.e2 | ||
| Diagnostic Test Effects | 1275 | ||
| Side Effects | 1275 | ||
| Serious Reactions | 1275 | ||
| Rivaroxaban | 1276 | ||
| Mechanism of Action | 1276 | ||
| Pharmacokinetics | 1277 | ||
| Availability | 1277 | ||
| Indications and Dosages | 1277 | ||
| ▸Prevention of deep vein thrombosis (DVT) in patients undergoing knee or hip replacement | 1277 | ||
| ▸Dosage in renal impairment (joint replacement only) | 1277 | ||
| ▸Stroke and systemic embolism prophylaxis in nonvalvular atrial fibrillation | 1277 | ||
| ▸Dosage in renal impairment (atrial fibrillation only) | 1277 | ||
| ▸Treatment of DVT, pulmonary embolism (PE), and to reduce risk of recurrence | 1277 | ||
| ▸Dosage in renal impairment (DVT/PE only) | 1277 | ||
| ▸Hepatic impairment (all uses) | 1277 | ||
| Contraindications | 1277 | ||
| Interactions | 1277 | ||
| Diagnostic Test Effects | 1278 | ||
| Side Effects | 1278 | ||
| Serious Reactions | 1278 | ||
| Rivastigmine | 1279 | ||
| Mechanism of Action | 1279 | ||
| Pharmacokinetics | 1279 | ||
| Availability | 1280 | ||
| Indications and Dosages | 1280 | ||
| ▸Alzheimer’s disease or Parkinson’s dementia | 1280 | ||
| Contraindications | 1280 | ||
| Interactions | 1280 | ||
| Diagnostic Test Effects | 1280 | ||
| Side Effects | 1280 | ||
| Serious Reactions | 1281 | ||
| Rizatriptan | 1282 | ||
| Mechanism of Action | 1282 | ||
| Pharmacokinetics | 1282 | ||
| Availability | 1282 | ||
| Indications and Dosages | 1282 | ||
| ▸Acute migraine attack | 1282 | ||
| Contraindications | 1282 | ||
| Interactions | 1282 | ||
| Diagnostic Test Effects | 1282 | ||
| Side Effects | 1282 | ||
| Serious Reactions | 1283 | ||
| Roflumilast | 1283 | ||
| Mechanism of Action | 1283 | ||
| Pharmacokinetics | 1283 | ||
| Availability | 1284 | ||
| Indications and Dosages | 1284 | ||
| ▸COPD (exacerbation prevention) | 1284 | ||
| Contraindications | 1284 | ||
| Interactions | 1284 | ||
| Diagnostic Test Effects | 1284 | ||
| Side Effects | 1284 | ||
| Serious Reactions | 1284 | ||
| Ropinirole | 1285 | ||
| Mechanism of Action | 1285 | ||
| Pharmacokinetics | 1285 | ||
| Availability | 1285 | ||
| Indications and Dosages | 1285 | ||
| ▸Parkinson’s disease | 1285 | ||
| ▸Restless legs syndrome | 1285 | ||
| Contraindications | 1285 | ||
| Interactions | 1285 | ||
| Rosiglitazone | 1285.e1 | ||
| Mechanism of Action | 1285.e1 | ||
| Pharmacokinetics | 1285.e1 | ||
| Availability | 1285.e1 | ||
| Indications and Dosages | 1285.e1 | ||
| ▸Diabetes mellitus type 2, monotherapy, or combination therapy | 1285.e1 | ||
| Contraindications | 1285.e1 | ||
| Interactions | 1285.e1 | ||
| Diagnostic Test Effects | 1285.e1 | ||
| Side Effects | 1285.e2 | ||
| Serious Reactions | 1285.e2 | ||
| Diagnostic Test Effects | 1286 | ||
| Side Effects | 1286 | ||
| Serious Reactions | 1286 | ||
| Rosuvastatin | 1287 | ||
| Mechanism of Action | 1287 | ||
| Pharmacokinetics | 1287 | ||
| Availability | 1287 | ||
| Indications and Dosages | 1287 | ||
| ▸Hyperlipidemia, dyslipidemia | 1287 | ||
| ▸Renal impairment (creatinine clearance < 30 mL/min) | 1287 | ||
| ▸Concurrent Iopinavir-ritonavir use | 1287 | ||
| ▸Concurrent cyclosporine use | 1287 | ||
| ▸Concurrent lipid-lowering therapy | 1287 | ||
| Contraindications | 1287 | ||
| Interactions | 1287 | ||
| Diagnostic Test Effects | 1288 | ||
| Side Effects | 1288 | ||
| Serious Reactions | 1288 | ||
| Rufinamide | 1288 | ||
| Mechanism of Action | 1289 | ||
| Pharmacokinetics | 1289 | ||
| Availability | 1289 | ||
| Indications and Dosages | 1289 | ||
| ▸Lennox-Gastaut syndrome | 1289 | ||
| ▸Dosage in hepatic impairment | 1289 | ||
| Contraindications | 1289 | ||
| Interactions | 1289 | ||
| Diagnostic Test Effects | 1289 | ||
| Side Effects | 1289 | ||
| Ruxolitinib | 1289.e1 | ||
| Mechanism of Action | 1289.e1 | ||
| Pharmacokinetics | 1289.e1 | ||
| Availability | 1289.e1 | ||
| Indications and Dosages | 1289.e1 | ||
| ▸Myelofibrosis | 1289.e1 | ||
| ▸Dosage adjustment for toxicities | 1289.e1 | ||
| ▸Dosage adjustment for strong CYP3A4 inhibitor co-use | 1289.e1 | ||
| ▸Dosage adjustment for renal impairment | 1289.e1 | ||
| ▸Dosage adjustment for hepatic impairment | 1289.e2 | ||
| Contraindications | 1289.e2 | ||
| Interactions | 1289.e2 | ||
| Diagnostic Test Effects | 1289.e2 | ||
| Side Effects | 1289.e2 | ||
| Serious Reactions | 1289.e2 | ||
| Serious Reactions | 1290 | ||
| S | 1291 | ||
| Sacubitril and valsartan | 1291 | ||
| Mechanism of action | 1291 | ||
| Pharmacokinetics | 1291 | ||
| Availability | 1291 | ||
| Indications and Dosages | 1291 | ||
| Off-label uses | 1291 | ||
| Contraindications | 1291 | ||
| Interactions | 1291 | ||
| Diagnostic Side Effects | 1291 | ||
| Salicylic Acid | 1291.e1 | ||
| Mechanism of Action | 1291.e1 | ||
| Pharmacokinetics | 1291.e1 | ||
| Availability | 1291.e1 | ||
| Indications and Dosages | 1291.e1 | ||
| ▸Acne | 1291.e1 | ||
| ▸Callus, corn, wart removal | 1291.e1 | ||
| ▸Dandruff, psoriasis, seborrheic dermatitis | 1291.e1 | ||
| Contraindications | 1291.e1 | ||
| Interactions | 1291.e2 | ||
| Diagnostic Test Effects | 1291.e2 | ||
| Side Effects | 1291.e2 | ||
| Serious Reactions | 1291.e2 | ||
| Side Effects | 1292 | ||
| Serious Reactions | 1292 | ||
| Precautions and Considerations | 1292 | ||
| Salmeterol | 1292 | ||
| Mechanism of Action | 1292 | ||
| Pharmacokinetics | 1292 | ||
| Availability | 1292 | ||
| Indications and Dosages | 1292 | ||
| ▸Prevention and maintenance treatment of asthma | 1292 | ||
| ▸Prevention of exercise-induced bronchospasm | 1292 | ||
| ▸Chronic obstructive pulmonary disease (COPD) | 1292 | ||
| Contraindications | 1292 | ||
| Interactions | 1292 | ||
| Diagnostic Test Effects | 1293 | ||
| Side Effects | 1293 | ||
| Serious Reactions | 1293 | ||
| Salmeterol; Fluticasone | 1294 | ||
| Mechanism of Action | 1294 | ||
| Pharmacokinetics | 1294 | ||
| Availability | 1294 | ||
| Indications and Dosages | 1294 | ||
| ▸Bronchial asthma | 1294 | ||
| ▸COPD | 1294 | ||
| Contraindications | 1294 | ||
| Interactions | 1295 | ||
| Diagnostic Test Effects | 1295 | ||
| Side Effects | 1295 | ||
| Serious Reactions | 1295 | ||
| Saquinavir | 1296 | ||
| Mechanism of Action | 1296 | ||
| Pharmacokinetics | 1296 | ||
| Mechanism of Action | 1296.e1 | ||
| Pharmacokinetics | 1296.e1 | ||
| Availability | 1296.e1 | ||
| Indications and Dosages | 1296.e1 | ||
| ▸Phenylketonuria | 1296.e1 | ||
| Contraindications | 1296.e1 | ||
| Interactions | 1296.e1 | ||
| Diagnostic Test Effects | 1296.e1 | ||
| Side Effects | 1296.e1 | ||
| Serious Reactions | 1296.e1 | ||
| Availability | 1297 | ||
| Indications and Dosages | 1297 | ||
| ▸HIV infection in combination with other antiretrovirals | 1297 | ||
| ▸Dosage for severe hepatic impairment | 1297 | ||
| Contraindications | 1297 | ||
| Interactions | 1297 | ||
| Diagnostic Test Effects | 1298 | ||
| Side Effects | 1298 | ||
| Serious Reactions | 1298 | ||
| Sargramostim (Granulocyte MacrophageColony-Stimulating Factor, GM-CSF) | 1299 | ||
| Mechanism of Action | 1299 | ||
| Pharmacokinetics | 1299 | ||
| Availability | 1299 | ||
| Indications and Dosages | 1299 | ||
| ▸Myeloid recovery following bone marrow transplant (BMT) | 1299 | ||
| ▸Bone marrow transplant failure, engraftment delay | 1299 | ||
| ▸Stem cell transplant | 1299 | ||
| ▸Mobilization of peripheral blood progenitor cells (PBPCs) | 1299 | ||
| ▸Postperipheral blood progenitor cell transplantation | 1300 | ||
| ▸Neutrophil recovery following chemotherapy in acute myelogenic leukemia (AML) | 1300 | ||
| Off-Label Uses | 1300 | ||
| Contraindications | 1300 | ||
| Interactions | 1300 | ||
| Diagnostic Test Effects | 1300 | ||
| ?IV Incompatibilities | 1300 | ||
| ?IV Compatibilities | 1300 | ||
| Side Effects | 1300 | ||
| Serious Reactions | 1300 | ||
| Saxagliptin | 1301 | ||
| Mechanism of Action | 1301 | ||
| Pharmacokinetics | 1301 | ||
| Availability | 1301 | ||
| Indications and Dosages | 1301 | ||
| ▸Type 2 diabetes mellitus | 1301 | ||
| ▸Dosage in renal impairment (CrCl < 50 mL/min) or taking strong CYP3A4 inhibitors | 1302 | ||
| Contraindications | 1302 | ||
| Interactions | 1302 | ||
| Diagnostic Test Effects | 1302 | ||
| Side Effects | 1302 | ||
| Serious Reactions | 1302 | ||
| Scopolamine | 1303 | ||
| Mechanism of Action | 1303 | ||
| Availability | 1303 | ||
| Indications and Dosages | 1303 | ||
| ▸Postoperative nausea or vomiting | 1303 | ||
| ▸Motion sickness | 1303 | ||
| ▸Aspiration prophylaxis, sedation induction prior to intubation or for bradycardia during surgery | 1303 | ||
| ▸For cycloplegia or mydriasis induction during eye examination | 1303 | ||
| ▸For iritis or uveitis | 1303 | ||
| Contraindications | 1303 | ||
| Interactions | 1303 | ||
| Diagnostic Test Effects | 1304 | ||
| Side Effects | 1304 | ||
| Serious Reactions | 1304 | ||
| Secobarbital | 1304.e1 | ||
| Mechanism of Action | 1304.e1 | ||
| Pharmacokinetics | 1304.e1 | ||
| Availability | 1304.e1 | ||
| Indications and Dosages | 1304.e1 | ||
| ▸Insomnia | 1304.e1 | ||
| ▸Preoperative sedation | 1304.e1 | ||
| Contraindications | 1304.e1 | ||
| Interactions | 1304.e1 | ||
| Diagnostic Test Effects | 1304.e1 | ||
| Side Effects | 1304.e1 | ||
| Serious Reactions | 1304.e2 | ||
| Mechanism of Action | 1305 | ||
| Pharmacokinetics | 1305 | ||
| Availability | 1305 | ||
| Indications and Dosages | 1305 | ||
| ▸Adjunctive treatment for parkinsonism | 1305 | ||
| ▸Depression | 1305 | ||
| Contraindications | 1305 | ||
| Interactions | 1305 | ||
| Diagnostic Test Effects | 1306 | ||
| Side Effects | 1306 | ||
| Serious Reactions | 1306 | ||
| Senna | 1307 | ||
| Mechanism of Action | 1307 | ||
| Pharmacokinetics | 1307 | ||
| Availability | 1307 | ||
| Indications and Dosages | 1307 | ||
| ▸Constipation | 1307 | ||
| ▸Bowel evacuation | 1307 | ||
| Contraindications | 1307 | ||
| Interactions | 1307 | ||
| Diagnostic Test Effects | 1307 | ||
| Side Effects | 1308 | ||
| Serious Reactions | 1308 | ||
| Sertraline | 1308 | ||
| Mechanism of Action | 1308 | ||
| Pharmacokinetics | 1308 | ||
| Mechanism of Action | 1308.e1 | ||
| Availability | 1308.e1 | ||
| Indications and Dosages | 1308.e1 | ||
| ▸Tinea pedis | 1308.e1 | ||
| Contraindications | 1308.e1 | ||
| Interactions | 1308.e1 | ||
| Diagnostic Test Effects | 1308.e1 | ||
| Side Effects | 1308.e1 | ||
| Serious Reactions | 1308.e1 | ||
| Availability | 1309 | ||
| Indications and Dosages | 1309 | ||
| ▸Depression, obsessive-compulsive disorder (OCD) | 1309 | ||
| ▸Panic disorder, post traumatic stress disorder, social anxiety disorder | 1309 | ||
| ▸Premenstrual dysphoric disorder | 1309 | ||
| Off-Label Uses | 1309 | ||
| Contraindications | 1309 | ||
| Interactions | 1309 | ||
| Diagnostic Test Effects | 1309 | ||
| Side Effects | 1310 | ||
| Serious Reactions | 1310 | ||
| Sevelamer | 1310 | ||
| Mechanism of Action | 1311 | ||
| Pharmacokinetics | 1311 | ||
| Availability | 1311 | ||
| Indications and Dosages | 1311 | ||
| ▸Hyperphosphatemia | 1311 | ||
| Contraindications | 1311 | ||
| Interactions | 1311 | ||
| Diagnostic Test Effects | 1311 | ||
| Side Effects | 1311 | ||
| Serious Reactions | 1311 | ||
| Sildenafil | 1312 | ||
| Mechanism of Action | 1312 | ||
| Availability | 1312 | ||
| Indications and Dosages | 1312 | ||
| ▸Erectile dysfunction | 1312 | ||
| ▸Pulmonary arterial hypertension (PAH) | 1312 | ||
| Off-Label Uses | 1312 | ||
| Contraindications | 1312 | ||
| Interactions | 1312 | ||
| Diagnostic Test Effects | 1313 | ||
| Side Effects | 1313 | ||
| Serious Reactions | 1313 | ||
| Silodosin | 1313 | ||
| Mechanism of Action | 1313 | ||
| Pharmacokinetics | 1313 | ||
| Availability | 1314 | ||
| Indications and Dosages | 1314 | ||
| ▸Benign prostatic hyperplasia | 1314 | ||
| ▸Dosage for renal impairment | 1314 | ||
| ▸Severe hepatic impairment | 1314 | ||
| Off-Label Uses | 1314 | ||
| Contraindications | 1314 | ||
| Interactions | 1314 | ||
| Diagnostic Test Effects | 1314 | ||
| Side Effects | 1314 | ||
| Serious Reactions | 1314 | ||
| Silver Sulfadiazine | 1315 | ||
| Mechanism of Action | 1315 | ||
| Pharmacokinetics | 1315 | ||
| Availability | 1315 | ||
| Indications and Dosages | 1315 | ||
| ▸Burns | 1315 | ||
| Off-Label Uses | 1315 | ||
| Contraindications | 1315 | ||
| Interactions | 1315 | ||
| Diagnostic Test Effects | 1315 | ||
| Side Effects | 1315 | ||
| Simeprevir | 1315.e1 | ||
| Mechanism of Action | 1315.e1 | ||
| Pharmacokinetics | 1315.e1 | ||
| Availability | 1315.e1 | ||
| Indications and Dosages | 1315.e1 | ||
| ▸Hepatitis C genotype 1 infection (with peginterferon alfa and ribavirin), compensated | 1315.e1 | ||
| Contraindications | 1315.e1 | ||
| Interactions | 1315.e1 | ||
| Diagnostic Test Effects | 1315.e2 | ||
| Side Effects | 1315.e2 | ||
| Serious Reactions | 1315.e2 | ||
| Serious Reactions | 1316 | ||
| Simethicone | 1316 | ||
| Mechanism of Action | 1316 | ||
| Pharmacokinetics | 1316 | ||
| Availability | 1316 | ||
| Indications and Dosages | 1317 | ||
| ▸Antiflatulent | 1317 | ||
| Off-Label Uses | 1317 | ||
| Contraindications | 1317 | ||
| Interactions | 1317 | ||
| Diagnostic Test Effects | 1317 | ||
| Side Effects | 1317 | ||
| Serious Reactions | 1317 | ||
| Simvastatin | 1317 | ||
| Mechanism of Action | 1317 | ||
| Pharmacokinetics | 1317 | ||
| Availability | 1318 | ||
| Indications and Dosages | 1318 | ||
| ▸To decrease elevated total and LDL cholesterol in hypercholesterolemia (types IIa and IIb), lower triglyceride levels, and incr... | 1318 | ||
| ▸Dose adjustments for adults taking select drugs concurrently | 1318 | ||
| ▸Dose adjustment for Asian patients (Chinese) taking niacin | 1318 | ||
| ▸Dosage in renal impairment (adults) | 1318 | ||
| Contraindications | 1318 | ||
| Interactions | 1318 | ||
| Diagnostic Test Effects | 1319 | ||
| Side Effects | 1319 | ||
| Serious Reactions | 1319 | ||
| Sirolimus | 1320 | ||
| Mechanism of Action | 1320 | ||
| Availability | 1320 | ||
| Indications and Dosages | 1320 | ||
| ▸Prevention of organ transplant rejection | 1320 | ||
| ▸Dosage in hepatic impairment | 1320 | ||
| Contraindications | 1320 | ||
| Interactions | 1320 | ||
| Diagnostic Test Effects | 1320 | ||
| Side Effects | 1320 | ||
| Serious Reactions | 1321 | ||
| Sitagliptin | 1321 | ||
| Mechanism of Action | 1322 | ||
| Pharmacokinetics | 1322 | ||
| Availability | 1322 | ||
| Indications and Dosages | 1322 | ||
| ▸Type 2 diabetes mellitus | 1322 | ||
| ▸Dosage in renal impairment | 1322 | ||
| Contraindications | 1322 | ||
| Interactions | 1322 | ||
| Diagnostic Test Effects | 1322 | ||
| Side Effects | 1322 | ||
| Serious Reactions | 1322 | ||
| Sodium Bicarbonate | 1323 | ||
| Mechanism of Action | 1323 | ||
| Pharmacokinetics | 1323 | ||
| Availability | 1323 | ||
| Indications and Dosages | 1323 | ||
| ▸Cardiac arrest | 1323 | ||
| ▸Metabolic acidosis (not severe) | 1324 | ||
| ▸Metabolic acidosis (associated with chronic renal failure) | 1324 | ||
| ▸Renal tubular acidosis (distal) | 1324 | ||
| ▸Renal tubular acidosis (proximal) | 1324 | ||
| ▸Urine alkalinization | 1324 | ||
| ▸Antacid | 1324 | ||
| ▸Hyperkalemia | 1324 | ||
| Contraindications | 1324 | ||
| Interactions | 1324 | ||
| Diagnostic Test Effects | 1324 | ||
| ?IV Incompatibilities | 1324 | ||
| Side Effects | 1324 | ||
| Serious Reactions | 1324 | ||
| Sodium Chloride | 1325 | ||
| Mechanism of Action | 1325 | ||
| Pharmacokinetics | 1325 | ||
| Availability | 1325 | ||
| Indications and Dosages | 1326 | ||
| ▸Prevention and treatment of sodium and chloride deficiencies; source of hydration | 1326 | ||
| ▸Prevention of heat prostration and muscle cramps from excessive perspiration | 1326 | ||
| ▸Relief of dry and inflamed nasal membranes | 1326 | ||
| ▸Diagnostic aid in ophthalmoscopic exam, treatment of corneal edema | 1326 | ||
| Contraindications | 1326 | ||
| Interactions | 1326 | ||
| Diagnostic Test Effects | 1326 | ||
| Side Effects | 1326 | ||
| Serious Reactions | 1326 | ||
| Sodium Ferric Gluconate Complex | 1327 | ||
| Mechanism of Action | 1327 | ||
| Availability | 1327 | ||
| Indications and Dosages | 1327 | ||
| ▸Iron deficiency anemia | 1327 | ||
| Contraindications | 1327 | ||
| Interactions | 1327 | ||
| Diagnostic Test Effects | 1327 | ||
| ?IV Incompatibilities | 1327 | ||
| Side Effects | 1328 | ||
| Serious Reactions | 1328 | ||
| Sodium Polystyrene Sulfonate | 1328 | ||
| Mechanism of Action | 1328 | ||
| Pharmacokinetics | 1328 | ||
| Mechanism of Action | 1328.e1 | ||
| Pharmacokinetics | 1328.e1 | ||
| Availability | 1328.e1 | ||
| Indications and Dosages | 1328.e1 | ||
| ▸Cataplexy of narcolepsy | 1328.e1 | ||
| Contraindications | 1328.e1 | ||
| Interactions | 1328.e1 | ||
| Diagnostic Test Effects | 1328.e1 | ||
| Side Effects | 1328.e1 | ||
| Serious Reactions | 1328.e2 | ||
| Availability | 1329 | ||
| Indications and Dosages | 1329 | ||
| ▸Hyperkalemia | 1329 | ||
| Contraindications | 1329 | ||
| Interactions | 1329 | ||
| Diagnostic Test Effects | 1329 | ||
| Side Effects | 1329 | ||
| Serious Reactions | 1329 | ||
| Sofosbuvir | 1330 | ||
| Mechanism of Action | 1330 | ||
| Pharmacokinetics | 1330 | ||
| Availability | 1330 | ||
| Indications and Dosages | 1330 | ||
| ▸Hepatitis C genotype 1, 2, or 3 infection with ribavirin (genotype 2 or 3) or peginterferon alfa/ribavirin (genotype 1 and 4), ... | 1330 | ||
| Contraindications | 1331 | ||
| Interactions | 1331 | ||
| Diagnostic Test Effects | 1331 | ||
| Side Effects | 1331 | ||
| Serious Reactions | 1331 | ||
| Solifenacin | 1332 | ||
| Mechanism of Action | 1332 | ||
| Pharmacokinetics | 1332 | ||
| Availability | 1332 | ||
| Indications and Dosages | 1332 | ||
| ▸Overactive bladder | 1332 | ||
| ▸Dosage in renal or hepatic impairment or taking CYP3A4 inhibitors | 1333 | ||
| Contraindications | 1333 | ||
| Interactions | 1333 | ||
| Diagnostic Test Effects | 1333 | ||
| Side Effects | 1333 | ||
| Serious Reactions | 1333 | ||
| Somatropin, rh-GH | 1334 | ||
| Mechanism of Action | 1334 | ||
| Pharmacokinetics | 1334 | ||
| Availability | 1334 | ||
| Indications and Dosages | 1334 | ||
| ▸Usual dosage, children | 1334 | ||
| ▸Usual dosage, adults with growth hormone deficiency | 1335 | ||
| ▸Short bowel syndrome in patients on specialized nutrition support | 1335 | ||
| ▸HIV or AIDS-associated wasting syndrome or failure to thrive, cachexia | 1335 | ||
| Contraindications | 1335 | ||
| Interactions | 1335 | ||
| Diagnostic Test Effects | 1336 | ||
| Side Effects | 1336 | ||
| Serious Reactions | 1336 | ||
| Sotalol | 1337 | ||
| Mechanism of Action | 1337 | ||
| Pharmacokinetics | 1337 | ||
| Availability | 1337 | ||
| Indications and Dosages | 1337 | ||
| ▸Documented, life-threatening ventricular arrhythmias | 1337 | ||
| ▸Maintenance (delay in time to recurrence) for A Fib/A Flutter currently in sinus rhythm | 1337 | ||
| ▸Conversion from oral to IV dosing if needed | 1337 | ||
| ▸Dosage in renal impairment | 1337 | ||
| Sorafenib | 1337.e1 | ||
| Mechanism of Action | 1337.e1 | ||
| Pharmacokinetics | 1337.e1 | ||
| Availability | 1337.e1 | ||
| Indications and Dosages | 1337.e1 | ||
| ▸Advanced renal cell or hepatocellular cancer or differentiated thyroid cancer | 1337.e1 | ||
| ▸Dosage adjustment if strong CYP3A4 inducers used | 1337.e1 | ||
| ▸Dosage adjustment for toxicity | 1337.e1 | ||
| Contraindications | 1337.e1 | ||
| Interactions | 1337.e1 | ||
| Diagnostic Test Effects | 1337.e2 | ||
| Side Effects | 1337.e2 | ||
| Serious Reactions | 1337.e2 | ||
| Off-Label Uses | 1338 | ||
| Contraindications | 1338 | ||
| Interactions | 1338 | ||
| Diagnostic Test Effects | 1338 | ||
| Side Effects | 1338 | ||
| Serious Reactions | 1338 | ||
| Spinosad | 1339 | ||
| Mechanism of Action | 1339 | ||
| Pharmacokinetics | 1339 | ||
| Availability | 1339 | ||
| Indications and Dosages | 1339 | ||
| ▸Head lice | 1339 | ||
| Contraindications | 1339 | ||
| Interactions | 1339 | ||
| Diagnostic Test Effects | 1339 | ||
| Side Effects | 1339 | ||
| Serious Reactions | 1340 | ||
| Spironolactone | 1340 | ||
| Mechanism of Action | 1341 | ||
| Pharmacokinetics | 1341 | ||
| Availability | 1341 | ||
| Indications and Dosages | 1341 | ||
| ▸Edema or the treatment of ascites due to cirrhosis | 1341 | ||
| ▸CHF, severe with ACEI and loop diuretic | 1341 | ||
| ▸Hypertension | 1341 | ||
| ▸Hypokalemia | 1341 | ||
| ▸Primary aldosteronism | 1341 | ||
| ▸Dosage in renal impairment | 1341 | ||
| Off-Label Uses | 1341 | ||
| Contraindications | 1341 | ||
| Interactions | 1341 | ||
| Diagnostic Test Effects | 1342 | ||
| Side Effects | 1342 | ||
| Serious Reactions | 1342 | ||
| Stavudine (d4T) | 1343 | ||
| Mechanism of Action | 1343 | ||
| Pharmacokinetics | 1343 | ||
| Availability | 1343 | ||
| Indications and Dosages | 1343 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 1343 | ||
| ▸HIV infection in patients with a recent history and complete resolution of peripheral neuropathy or elevated liver function tes... | 1343 | ||
| ▸Dosage in renal impairment (Adults) | 1343 | ||
| Contraindications | 1343 | ||
| Interactions | 1344 | ||
| Diagnostic Test Effects | 1344 | ||
| Side Effects | 1344 | ||
| Serious Reactions | 1344 | ||
| Sucralfate | 1345 | ||
| Mechanism of Action | 1345 | ||
| Pharmacokinetics | 1345 | ||
| Availability | 1345 | ||
| Indications and Dosages | 1345 | ||
| ▸Active duodenal ulcers | 1345 | ||
| ▸Maintenance therapy after healing of acute duodenal ulcers | 1345 | ||
| Off-Label Uses | 1345 | ||
| Contraindications | 1345 | ||
| Interactions | 1345 | ||
| Streptomycin | 1345.e1 | ||
| Mechanism of Action | 1345.e1 | ||
| Availability | 1345.e1 | ||
| Indications and Dosages | 1345.e1 | ||
| ▸Tuberculosis | 1345.e1 | ||
| ▸Dosage in renal impairment | 1345.e1 | ||
| Contraindications | 1345.e1 | ||
| Interactions | 1345.e1 | ||
| Diagnostic Test Effects | 1345.e1 | ||
| Side Effects | 1345.e1 | ||
| Serious Reactions | 1345.e1 | ||
| Succimer | 1345.e2 | ||
| Mechanism of Action | 1345.e2 | ||
| Pharmacokinetics | 1345.e2 | ||
| Availability | 1345.e2 | ||
| Indications and Dosages | 1345.e2 | ||
| ▸Lead poisoning, in pediatric patients with blood lead levels > 45 mcg/dL | 1345.e2 | ||
| Off-Label Uses | 1345.e2 | ||
| Contraindications | 1345.e2 | ||
| Interactions | 1345.e2 | ||
| Diagnostic Test Effects | 1345.e2 | ||
| Side Effects | 1345.e2 | ||
| Serious Reactions | 1345.e3 | ||
| Diagnostic Test Effects | 1346 | ||
| Side Effects | 1346 | ||
| Serious Reactions | 1346 | ||
| Sulfacetamide | 1346 | ||
| Mechanism of Action | 1346 | ||
| Pharmacokinetics | 1346 | ||
| Availability | 1346 | ||
| Indications and Dosages | 1347 | ||
| ▸Treatment of corneal ulcers, conjunctivitis, and other superficial infections of the eye, prophylaxis after injuries to the eye... | 1347 | ||
| ▸Seborrheic dermatitis, seborrheic sicca (dandruff), secondary bacterial skin infections | 1347 | ||
| Off-Label Uses | 1347 | ||
| Contraindications | 1347 | ||
| Interactions | 1347 | ||
| Diagnostic Test Effects | 1347 | ||
| Side Effects | 1347 | ||
| Serious Reactions | 1347 | ||
| Sulfasalazine | 1348 | ||
| Mechanism of Action | 1348 | ||
| Pharmacokinetics | 1348 | ||
| Availability | 1348 | ||
| Indications and Dosages | 1348 | ||
| ▸Ulcerative colitis | 1348 | ||
| ▸Rheumatoid arthritis | 1348 | ||
| ▸Juvenile rheumatoid arthritis | 1348 | ||
| Off-Label Uses | 1348 | ||
| Contraindications | 1348 | ||
| Interactions | 1348 | ||
| Diagnostic Test Effects | 1348 | ||
| Side Effects | 1349 | ||
| Serious Reactions | 1349 | ||
| Sulindac | 1349 | ||
| Mechanism of Action | 1349 | ||
| Pharmacokinetics | 1350 | ||
| Availability | 1350 | ||
| Indications and Dosages | 1350 | ||
| ▸Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis | 1350 | ||
| ▸Acute shoulder pain, gouty arthritis, bursitis, tendinitis | 1350 | ||
| Contraindications | 1350 | ||
| Interactions | 1350 | ||
| Diagnostic Test Effects | 1350 | ||
| Side Effects | 1350 | ||
| Serious Reactions | 1350 | ||
| Sumatriptan | 1351 | ||
| Mechanism of Action | 1351 | ||
| Pharmacokinetics | 1351 | ||
| Availability | 1351 | ||
| Indications and Dosages | 1351 | ||
| ▸Acute migraine attack | 1351 | ||
| Contraindications | 1352 | ||
| Interactions | 1352 | ||
| Diagnostic Test Effects | 1352 | ||
| Side Effects | 1352 | ||
| Serious Reactions | 1352 | ||
| Sunitinib | 1353.e1 | ||
| Mechanism of Action | 1353.e1 | ||
| Pharmacokinetics | 1353.e1 | ||
| Availability | 1353.e1 | ||
| Indications and Dosages | 1353.e1 | ||
| ▸Advanced renal cell cancer or gastrointestinal stromal tumor (GIST) | 1353.e1 | ||
| ▸Advanced pancreatic neuroendocrine tumors (pNET) | 1353.e1 | ||
| ▸Dosage adjustment if strong CYP3A4 inhibitors used | 1353.e1 | ||
| ▸Dosage adjustment for toxicity | 1353.e1 | ||
| Contraindications | 1353.e1 | ||
| Interactions | 1353.e1 | ||
| Diagnostic Test Effects | 1353.e2 | ||
| Side Effects | 1353.e2 | ||
| Serious Reactions | 1353.e2 | ||
| T | 1354 | ||
| Tacrolimus | 1354 | ||
| Mechanism of Action | 1354 | ||
| Pharmacokinetics | 1354 | ||
| Availability | 1354 | ||
| Indications and Dosages | 1354 | ||
| ▸Prevention of cardiac transplant rejection | 1354 | ||
| ▸Prevention of liver transplant rejection | 1354 | ||
| ▸Prevention of kidney transplant rejection | 1354 | ||
| ▸Atopic dermatitis | 1354 | ||
| Off-Label Uses | 1355 | ||
| Contraindications | 1355 | ||
| Interactions | 1355 | ||
| Diagnostic Test Effects | 1355 | ||
| ?IV Incompatibilities | 1355 | ||
| ?IV Compatibilities | 1355 | ||
| Side Effects | 1356 | ||
| Serious Reactions | 1356 | ||
| Tadalafil | 1357 | ||
| Mechanism of Action | 1357 | ||
| Pharmacokinetics | 1357 | ||
| Availability | 1357 | ||
| Indications and Dosages | 1357 | ||
| ▸Erectile dysfunction | 1357 | ||
| ▸Benign prostatic hypertrophy, or concurrent treatment of BPH and ED | 1357 | ||
| Talc Powder, Sterile | 1357.e1 | ||
| Mechanism of Action | 1357.e1 | ||
| Pharmacokinetics | 1357.e1 | ||
| Availability | 1357.e1 | ||
| Indications and Dosages | 1357.e1 | ||
| ▸Pleural effusions | 1357.e1 | ||
| Contraindications | 1357.e1 | ||
| Interactions | 1357.e1 | ||
| Diagnostic Test Effects | 1357.e1 | ||
| Side Effects | 1357.e1 | ||
| Serious Reactions | 1357.e1 | ||
| ▸Dosage for ED in renal impairment | 1358 | ||
| ▸Dosage for ED in mild or moderate hepatic impairment (Child-Pugh class A or B) | 1358 | ||
| ▸Dosage for ED with concurrent inhibitors of CYP3A4 | 1358 | ||
| ▸Pulmonary arterial hypertension (PAH) | 1358 | ||
| ▸Dosage for PAH in renal impairment | 1358 | ||
| ▸Dosage for PAH in mild or moderate hepatic impairment (Child-Pugh class A or B) | 1358 | ||
| Contraindications | 1358 | ||
| Interactions | 1358 | ||
| Diagnostic Test Effects | 1358 | ||
| Side Effects | 1358 | ||
| Serious Reactions | 1358 | ||
| Tamsulosin | 1359 | ||
| Mechanism of Action | 1359 | ||
| Pharmacokinetics | 1359 | ||
| Availability | 1359 | ||
| Indications and Dosages | 1359 | ||
| ▸Benign prostatic hyperplasia | 1359 | ||
| ▸Dosage with CYP3A4 inhibitors or strong CYP2D6 inhibitors | 1359 | ||
| ▸Severe hepatic impairment | 1359 | ||
| Contraindications | 1359 | ||
| Interactions | 1359 | ||
| Tamoxifen | 1359.e1 | ||
| Mechanism of Action | 1359.e1 | ||
| Pharmacokinetics | 1359.e1 | ||
| Availability | 1359.e1 | ||
| Indications and Dosages | 1359.e1 | ||
| ▸Adjunctive treatment of breast cancer | 1359.e1 | ||
| ▸Metastatic breast cancer (males and females) | 1359.e1 | ||
| ▸Prevention of breast cancer in high-risk women | 1359.e1 | ||
| ▸Ductal carcinoma in situ (DCIS) | 1359.e1 | ||
| Off-Label Uses | 1359.e1 | ||
| Contraindications | 1359.e1 | ||
| Interactions | 1359.e1 | ||
| Diagnostic Test Effects | 1359.e2 | ||
| Side Effects | 1359.e2 | ||
| Serious Reactions | 1359.e2 | ||
| Diagnostic Test Effects | 1360 | ||
| Side Effects | 1360 | ||
| Serious Reactions | 1360 | ||
| Tapentadol | 1360 | ||
| Mechanism of Action | 1360 | ||
| Pharmacokinetics | 1361 | ||
| Availability | 1361 | ||
| Indications and Dosages | 1361 | ||
| ▸Diabetic peripheral neuropathy | 1361 | ||
| ▸Moderate to moderately severe pain | 1361 | ||
| ▸Severe renal impairment | 1361 | ||
| ▸Dosage in hepatic impairment | 1361 | ||
| Contraindications | 1361 | ||
| Interactions | 1361 | ||
| Diagnostic Test Effects | 1362 | ||
| Side Effects | 1362 | ||
| Serious Reactions | 1362 | ||
| Tazarotene | 1363 | ||
| Mechanism of Action | 1363 | ||
| Pharmacokinetics | 1363 | ||
| Availability | 1363 | ||
| Indications and Dosages | 1363 | ||
| ▸Psoriasis | 1363 | ||
| ▸Acne vulgaris | 1363 | ||
| ▸Fine facial wrinkles, facial mottled hyperpigmentation (liver spots), hypopigmentation associated with photoaging | 1363 | ||
| Contraindications | 1363 | ||
| Interactions | 1363 | ||
| Diagnostic Test Effects | 1363 | ||
| Side Effects | 1363 | ||
| Tasimelteon | 1363.e1 | ||
| Mechanism of Action | 1363.e1 | ||
| Pharmacokinetics | 1363.e1 | ||
| Availability | 1363.e1 | ||
| Indications and Dosages | 1363.e1 | ||
| ▸Non-24-hour sleep-wake disorder | 1363.e1 | ||
| ▸Hepatic impairment | 1363.e1 | ||
| Contraindications | 1363.e1 | ||
| Interactions | 1363.e1 | ||
| Diagnostic Test Effects | 1363.e1 | ||
| Side Effects | 1363.e2 | ||
| Serious Reactions | 1363.e2 | ||
| Telaprevir | 1364 | ||
| Mechanism of Action | 1364 | ||
| Pharmacokinetics | 1364 | ||
| Availability | 1364 | ||
| Indications and Dosages | 1364 | ||
| ▸Hepatitis C genotype 1 infection (in combination with peginterferon alfa and ribavirin) | 1364 | ||
| Contraindications | 1365 | ||
| Interactions | 1365 | ||
| Diagnostic Test Effects | 1366 | ||
| Side Effects | 1366 | ||
| Serious Reactions | 1366 | ||
| Telavancin | 1367 | ||
| Mechanism of Action | 1367 | ||
| Pharmacokinetics | 1367 | ||
| Availability | 1367 | ||
| Indications and Dosages | 1367 | ||
| ▸Treatment of skin and soft-tissue infections | 1367 | ||
| ▸Nosocomial pneumonia | 1367 | ||
| ▸Dosage for renal impairment | 1367 | ||
| Contraindications | 1367 | ||
| Interactions | 1367 | ||
| Diagnostic Test Effects | 1368 | ||
| ?IV Incompatibilities | 1368 | ||
| Side Effects | 1368 | ||
| Serious Reactions | 1368 | ||
| Telbivudine | 1369 | ||
| Mechanism of Action | 1369 | ||
| Pharmacokinetics | 1369 | ||
| Availability | 1369 | ||
| Indications and Dosages | 1369 | ||
| ▸Chronic hepatitis B | 1369 | ||
| ▸Dosage in renal impairment (adult and adolescent) | 1369 | ||
| Contraindications | 1369 | ||
| Interactions | 1369 | ||
| Diagnostic Test Effects | 1370 | ||
| Side Effects | 1370 | ||
| Serious Reactions | 1370 | ||
| Telmisartan | 1371 | ||
| Mechanism of Action | 1371 | ||
| Pharmacokinetics | 1371 | ||
| Availability | 1371 | ||
| Indications and Dosages | 1371 | ||
| ▸Hypertension | 1371 | ||
| ▸Cardiovascular risk reduction | 1371 | ||
| Off-Label Uses | 1371 | ||
| Contraindications | 1371 | ||
| Interactions | 1371 | ||
| Telithromycin | 1371.e1 | ||
| Mechanism of Action | 1371.e1 | ||
| Pharmacokinetics | 1371.e1 | ||
| Availability | 1371.e1 | ||
| Indications and Dosages | 1371.e1 | ||
| ▸Community-acquired pneumonia | 1371.e1 | ||
| ▸Dosage for severe renal impairment | 1371.e1 | ||
| ▸Dosage for multiple insufficiency | 1371.e1 | ||
| Contraindications | 1371.e1 | ||
| Interactions | 1371.e1 | ||
| Diagnostic Test Effects | 1371.e1 | ||
| Side Effects | 1371.e1 | ||
| Serious Reactions | 1371.e2 | ||
| Diagnostic Test Effects | 1372 | ||
| Side Effects | 1372 | ||
| Serious Reactions | 1372 | ||
| Temazepam | 1372 | ||
| Mechanism of Action | 1373 | ||
| Pharmacokinetics | 1373 | ||
| Availability | 1373 | ||
| Indications and Dosages | 1373 | ||
| ▸Insomnia | 1373 | ||
| Contraindications | 1373 | ||
| Interactions | 1373 | ||
| Diagnostic Test Effects | 1373 | ||
| Side Effects | 1373 | ||
| Serious Reactions | 1373 | ||
| Tenofovir | 1374 | ||
| Mechanism of Action | 1374 | ||
| Pharmacokinetics | 1374 | ||
| Availability | 1374 | ||
| Indications and Dosages | 1374 | ||
| ▸HIV infection (in combination with other antiretrovirals) | 1374 | ||
| ▸Chronic hepatitis B infection | 1374 | ||
| ▸Dosage adjustment for renal impairment (adults) | 1374 | ||
| Contraindications | 1374 | ||
| Interactions | 1374 | ||
| Temozolomide | 1374.e1 | ||
| Mechanism of Action | 1374.e1 | ||
| Pharmacokinetics | 1374.e1 | ||
| Availability | 1374.e1 | ||
| Indications and Dosages | 1374.e1 | ||
| ▸Newly diagnosed glioblastoma multiforme | 1374.e1 | ||
| ▸Anaplastic astrocytoma | 1374.e1 | ||
| Contraindications | 1374.e1 | ||
| Interactions | 1374.e1 | ||
| Diagnostic Test Effects | 1374.e1 | ||
| ?IV Incompatibilities | 1374.e1 | ||
| Side Effects | 1374.e1 | ||
| Serious Reactions | 1374.e2 | ||
| Temsirolimus | 1374.e3 | ||
| Mechanism of Action | 1374.e3 | ||
| Pharmacokinetics | 1374.e3 | ||
| Availability | 1374.e3 | ||
| Indications and Dosages | 1374.e3 | ||
| ▸Advanced renal cell cancer | 1374.e3 | ||
| ▸Dosage adjustments for toxicity | 1374.e3 | ||
| ▸Dosage adjustments for mild hepatic impairment | 1374.e3 | ||
| ▸Dosage for co-use of strong CYP3A4 inhibitor | 1374.e3 | ||
| ▸Dosage for co-use of strong CYP3A4 inducer | 1374.e3 | ||
| Contraindications | 1374.e3 | ||
| Interactions | 1374.e3 | ||
| Diagnostic Test Effects | 1374.e3 | ||
| ?IV Incompatibilities | 1374.e3 | ||
| Side Effects | 1374.e4 | ||
| Serious Reactions | 1374.e4 | ||
| Diagnostic Test Effects | 1375 | ||
| Side Effects | 1375 | ||
| Serious Reactions | 1375 | ||
| Terazosin | 1376 | ||
| Mechanism of Action | 1376 | ||
| Pharmacokinetics | 1376 | ||
| Availability | 1376 | ||
| Indications and Dosages | 1376 | ||
| ▸Mild to moderate hypertension | 1376 | ||
| ▸Benign prostatic hyperplasia | 1376 | ||
| Contraindications | 1376 | ||
| Interactions | 1376 | ||
| Diagnostic Test Effects | 1376 | ||
| Side Effects | 1376 | ||
| Serious Reactions | 1377 | ||
| Terbinafine | 1377 | ||
| Mechanism of Action | 1377 | ||
| Availability | 1377 | ||
| Indications and Dosages | 1377 | ||
| ▸Tinea pedis | 1377 | ||
| ▸Tinea cruris, tinea corporis | 1377 | ||
| ▸Onychomycosis | 1378 | ||
| ▸Tinea versicolor | 1378 | ||
| Contraindications | 1378 | ||
| Interactions | 1378 | ||
| Diagnostic Test Effects | 1378 | ||
| Side Effects | 1378 | ||
| Serious Reactions | 1378 | ||
| Terbutaline | 1379 | ||
| Mechanism of Action | 1379 | ||
| Pharmacokinetics | 1379 | ||
| Availability | 1379 | ||
| Indications and Dosages | 1379 | ||
| ▸Bronchospasm | 1379 | ||
| Contraindications | 1379 | ||
| Interactions | 1379 | ||
| Diagnostic Test Effects | 1380 | ||
| Side Effects | 1380 | ||
| Serious Reactions | 1380 | ||
| Terconazole | 1380 | ||
| Mechanism of Action | 1380 | ||
| Pharmacokinetics | 1381 | ||
| Availability | 1381 | ||
| Indications and Dosages | 1381 | ||
| ▸Vulvovaginal candidiasis | 1381 | ||
| Contraindications | 1381 | ||
| Interactions | 1381 | ||
| Diagnostic Test Effects | 1381 | ||
| Side Effects | 1381 | ||
| Serious Reactions | 1381 | ||
| Teriparatide | 1381 | ||
| Mechanism of Action | 1381 | ||
| Pharmacokinetics | 1382 | ||
| Availability | 1382 | ||
| Indications and Dosages | 1382 | ||
| ▸Osteoporosis | 1382 | ||
| Contraindications | 1382 | ||
| Interactions | 1382 | ||
| Diagnostic Test Effects | 1382 | ||
| Side Effects | 1382 | ||
| Serious Reactions | 1382 | ||
| Tesamorelin | 1382.e1 | ||
| Mechanism of Action | 1382.e1 | ||
| Pharmacokinetics | 1382.e1 | ||
| Availability | 1382.e1 | ||
| Indications and Dosages | 1382.e1 | ||
| ▸To reduce abdominal fat in HIV-infected persons with lipodystrophy | 1382.e1 | ||
| Contraindications | 1382.e1 | ||
| Interactions | 1382.e1 | ||
| Diagnostic Test Effects | 1382.e1 | ||
| Side Effects | 1382.e1 | ||
| Serious Reactions | 1382.e2 | ||
| Testosterone | 1383 | ||
| Mechanism of Action | 1383 | ||
| Pharmacokinetics | 1383 | ||
| Availability | 1383 | ||
| Indications and Dosages | 1383 | ||
| ▸Male hypogonadism | 1383 | ||
| ▸Delayed puberty | 1384 | ||
| ▸Breast carcinoma | 1384 | ||
| Contraindications | 1384 | ||
| Interactions | 1384 | ||
| Diagnostic Test Effects | 1384 | ||
| Side Effects | 1384 | ||
| Serious Reactions | 1384 | ||
| Tetrabenazine | 1385.e1 | ||
| Mechanism of Action | 1385.e1 | ||
| Pharmacokinetics | 1385.e1 | ||
| Availability | 1385.e1 | ||
| Indications and Dosages | 1385.e1 | ||
| ▸For Huntington’s chorea | 1385.e1 | ||
| ▸Dosage adjustment if receiving strong CYP2D6 inhibitors | 1385.e1 | ||
| ▸Dose adjustment for adverse events | 1385.e1 | ||
| Contraindications | 1385.e2 | ||
| Interactions | 1385.e2 | ||
| Diagnostic Test Effects | 1385.e2 | ||
| Side Effects | 1385.e2 | ||
| Serious Reactions | 1385.e2 | ||
| Tetracycline | 1385 | ||
| Mechanism of Action | 1386 | ||
| Pharmacokinetics | 1386 | ||
| Availability | 1386 | ||
| Indications and Dosages | 1386 | ||
| ▸Inflammatory acne vulgaris, Lyme disease, mycoplasmal disease, Legionella infections, Rocky Mountain spotted fever, chlamydial ... | 1386 | ||
| ▸Helicobacter pylori infections | 1386 | ||
| ▸Dosage in renal impairment | 1386 | ||
| Contraindications | 1386 | ||
| Interactions | 1386 | ||
| Diagnostic Test Effects | 1386 | ||
| Side Effects | 1386 | ||
| Serious Reactions | 1387 | ||
| Theophylline | 1387 | ||
| Mechanism of Action | 1387 | ||
| Pharmacokinetics | 1387 | ||
| Mechanism of Action | 1387.e1 | ||
| Availability | 1387.e1 | ||
| Indications and Dosages | 1387.e1 | ||
| ▸AIDS-related muscle wasting (unlabeled) | 1387.e1 | ||
| ▸Leprosy | 1387.e1 | ||
| ▸Multiple myeloma | 1387.e1 | ||
| Off-Label Uses | 1387.e1 | ||
| Contraindications | 1387.e1 | ||
| Interactions | 1387.e1 | ||
| Diagnostic Test Effects | 1387.e1 | ||
| Side Effects | 1387.e1 | ||
| Serious Reactions | 1387.e2 | ||
| Availability | 1388 | ||
| Indications and Dosages | 1388 | ||
| ▸Chronic lung diseases | 1388 | ||
| ▸Maintenance therapy | 1388 | ||
| ▸Dosage adjustment after serum theophylline measurement | 1388 | ||
| Off-Label Uses | 1388 | ||
| Contraindications | 1388 | ||
| Interactions | 1388 | ||
| Diagnostic Test Effects | 1388 | ||
| ?IV Incompatibilities | 1388 | ||
| Side Effects | 1389 | ||
| Serious Reactions | 1389 | ||
| Thiamine (Vitamin B1) | 1389 | ||
| Mechanism of Action | 1389 | ||
| Pharmacokinetics | 1389 | ||
| Availability | 1390 | ||
| Indications and Dosages | 1390 | ||
| ▸Dietary supplement (typical range within RDIs) | 1390 | ||
| ▸Thiamine deficiency | 1390 | ||
| ▸Thiamine deficiency in patients who are critically ill or have malabsorption syndrome | 1390 | ||
| ▸Treatment of Wernicke-Korsakoff syndrome | 1390 | ||
| Contraindications | 1390 | ||
| Interactions | 1390 | ||
| Diagnostic Test Effects | 1390 | ||
| ?IV Incompatibilities | 1390 | ||
| ?IV Compatibilities | 1390 | ||
| Side Effects | 1390 | ||
| Serious Reactions | 1390 | ||
| Thioridazine | 1391 | ||
| Mechanism of Action | 1391 | ||
| Availability | 1391 | ||
| Indications and Dosages | 1391 | ||
| ▸Schizophrenia | 1391 | ||
| Contraindications | 1391 | ||
| Interactions | 1391 | ||
| Diagnostic Test Effects | 1392 | ||
| Side Effects | 1392 | ||
| Serious Reactions | 1392 | ||
| Thiothixene | 1392 | ||
| Mechanism of Action | 1392 | ||
| Pharmacokinetics | 1393 | ||
| Availability | 1393 | ||
| Indications and Dosages | 1393 | ||
| ▸Psychosis | 1393 | ||
| Contraindications | 1393 | ||
| Interactions | 1393 | ||
| Diagnostic Test Effects | 1393 | ||
| Side Effects | 1393 | ||
| Serious Reactions | 1393 | ||
| Thyroid | 1394 | ||
| Mechanism of Action | 1394 | ||
| Pharmacokinetics | 1394 | ||
| Availability | 1394 | ||
| Indications and Dosages | 1394 | ||
| ▸Hypothyroidism | 1394 | ||
| Contraindications | 1395 | ||
| Interactions | 1395 | ||
| Diagnostic Test Effects | 1395 | ||
| Side Effects | 1395 | ||
| Serious Reactions | 1395 | ||
| Tiagabine | 1396 | ||
| Mechanism of Action | 1396 | ||
| Pharmacokinetics | 1396 | ||
| Availability | 1396 | ||
| Indications and Dosages | 1396 | ||
| ▸Adjunctive treatment of partial seizures | 1396 | ||
| Contraindications | 1396 | ||
| Interactions | 1396 | ||
| Diagnostic Test Effects | 1396 | ||
| Side Effects | 1397 | ||
| Serious Reactions | 1397 | ||
| Ticagrelor | 1397 | ||
| Mechanism of Action | 1397 | ||
| Pharmacokinetics | 1397 | ||
| Availability | 1398 | ||
| Indications and Dosages | 1398 | ||
| ▸Acute coronary syndrome (unstable angina or non-Q-wave acute MI), including those who have PCI | 1398 | ||
| Contraindications | 1398 | ||
| Interactions | 1398 | ||
| Diagnostic Test Effects | 1398 | ||
| Side Effects | 1398 | ||
| Serious Reactions | 1398 | ||
| Tigecycline | 1399 | ||
| Mechanism of Action | 1399 | ||
| Pharmacokinetics | 1399 | ||
| Availability | 1399 | ||
| Indications and Dosages | 1399 | ||
| ▸Community-acquired pneumonia, complicated skin and skin-structure infections, complicated intra-abdominal infections | 1399 | ||
| ▸Dosage adjustment for hepatic impairment (Adults) | 1399 | ||
| ▸Suggested Pediatric dosages when medically necessary | 1399 | ||
| Contraindications | 1399 | ||
| Mechanism of Action | 1399.e1 | ||
| Pharmacokinetics | 1399.e1 | ||
| Availability | 1399.e1 | ||
| Indications and Dosages | 1399.e1 | ||
| ▸Skin and skin-structure, bone, joint, and lower respiratory tract infections; septicemia; endometriosis; urinary tract infectio... | 1399.e1 | ||
| ▸Dosage in renal impairment | 1399.e1 | ||
| Contraindications | 1399.e1 | ||
| Interactions | 1399.e1 | ||
| Diagnostic Test Effects | 1399.e1 | ||
| ?IV Incompatibilities | 1399.e1 | ||
| ?IV Compatibilities | 1399.e2 | ||
| Side Effects | 1399.e2 | ||
| Serious Reactions | 1399.e2 | ||
| Ticlopidine | 1399.e3 | ||
| Mechanism of Action | 1399.e3 | ||
| Availability | 1399.e3 | ||
| Indications and Dosages | 1399.e3 | ||
| ▸Prevention of stroke | 1399.e3 | ||
| Off-Label Uses | 1399.e3 | ||
| Contraindications | 1399.e3 | ||
| Interactions | 1399.e3 | ||
| Diagnostic Test Effects | 1399.e3 | ||
| Side Effects | 1399.e3 | ||
| Serious Reactions | 1399.e3 | ||
| Diagnostic Test Effects | 1400 | ||
| Interactions | 1400 | ||
| ?IV Incompatibilities | 1400 | ||
| ?IV Compatibilities | 1400 | ||
| Side Effects | 1400 | ||
| Serious Reactions | 1400 | ||
| Timolol | 1401 | ||
| Mechanism of Action | 1401 | ||
| Mechanism of Action | 1401.e1 | ||
| Pharmacokinetics | 1401.e1 | ||
| Availability | 1401.e1 | ||
| Indications and Dosages | 1401.e1 | ||
| ▸Paget’s disease | 1401.e1 | ||
| Contraindications | 1401.e1 | ||
| Interactions | 1401.e1 | ||
| Diagnostic Test Effects | 1401.e1 | ||
| Side Effects | 1401.e1 | ||
| Serious Reactions | 1401.e1 | ||
| Pharmacokinetics | 1402 | ||
| Availability | 1402 | ||
| Indications and Dosages | 1402 | ||
| ▸Mild to moderate hypertension | 1402 | ||
| ▸Reduction of cardiovascular mortality in definite or suspected acute myocardial infarction (MI) | 1402 | ||
| ▸Migraine prevention | 1402 | ||
| ▸Reduction of IOP in open-angle glaucoma, aphakic glaucoma, ocular hypertension, and secondary glaucoma | 1402 | ||
| Off-Label Uses | 1402 | ||
| Contraindications | 1402 | ||
| Interactions | 1402 | ||
| Diagnostic Test Effects | 1403 | ||
| Side Effects | 1403 | ||
| Serious Reactions | 1403 | ||
| Tinidazole | 1404 | ||
| Mechanism of Action | 1404 | ||
| Pharmacokinetics | 1404 | ||
| Availability | 1404 | ||
| Indications and Dosages | 1404 | ||
| ▸Intestinal amebiasis | 1404 | ||
| ▸Amebic hepatic abscess | 1404 | ||
| ▸Giardiasis | 1404 | ||
| ▸Trichomoniasis | 1404 | ||
| ▸Bacterial vaginosis | 1404 | ||
| ▸Patients on hemodialysis | 1404 | ||
| Contraindications | 1404 | ||
| Interactions | 1405 | ||
| Diagnostic Test Effects | 1405 | ||
| Side Effects | 1405 | ||
| Serious Reactions | 1405 | ||
| Tinzaparin | 1405.e1 | ||
| Mechanism of Action | 1405.e1 | ||
| Pharmacokinetics | 1405.e1 | ||
| Availability | 1405.e1 | ||
| Indications and Dosages | 1405.e1 | ||
| ▸Deep vein thrombosis | 1405.e1 | ||
| Contraindications | 1405.e1 | ||
| Interactions | 1405.e1 | ||
| Diagnostic Test Effects | 1405.e1 | ||
| Side Effects | 1405.e1 | ||
| Serious Reactions | 1405.e1 | ||
| Tioconazole | 1405 | ||
| U | 1454 | ||
| Umeclidinium; Vilanterol | 1454 | ||
| Mechanism of Action | 1454 | ||
| Pharmacokinetics | 1454 | ||
| Availability | 1454 | ||
| Indications and Dosages | 1454 | ||
| ▸COPD | 1454 | ||
| Contraindications | 1454 | ||
| Interactions | 1454 | ||
| Diagnostic Test Effects | 1455 | ||
| Side Effects | 1455 | ||
| Serious Reactions | 1455 | ||
| Ursodiol | 1456 | ||
| Mechanism of Action | 1456 | ||
| Availability | 1456 | ||
| Pharmacokinetics | 1456 | ||
| Indications and Dosages | 1456 | ||
| ▸Dissolution of radiolucent, noncalcified gallstones when cholecystectomy is not recommended | 1456 | ||
| ▸Primary biliary cirrhosis | 1456 | ||
| ▸Prevention of gallstones | 1456 | ||
| Off-Label Uses | 1456 | ||
| Contraindications | 1456 | ||
| Interactions | 1456 | ||
| Diagnostic Test Effects | 1457 | ||
| Side Effects | 1457 | ||
| Serious Reactions | 1457 | ||
| Ustekinumab | 1457 | ||
| Mechanism of Action | 1457 | ||
| Pharmacokinetics | 1457 | ||
| Availability | 1457 | ||
| Indications and Dosages | 1457 | ||
| ▸Moderate to severe plaque psoriasis or psoriatic arthritis | 1457 | ||
| Contraindications | 1458 | ||
| Interactions | 1458 | ||
| Diagnostic Test Effects | 1458 | ||
| Side Effects | 1458 | ||
| Serious Reactions | 1458 | ||
| V | 1460 | ||
| Valacyclovir | 1460 | ||
| Mechanism of Action | 1460 | ||
| Pharmacokinetics | 1460 | ||
| Availability | 1460 | ||
| Indications and Dosages | 1460 | ||
| ▸Herpes zoster (shingles) | 1460 | ||
| ▸Herpes labialis (cold sores) | 1460 | ||
| ▸Initial episode of genital herpes | 1460 | ||
| ▸Recurrent episodes of genital herpes | 1460 | ||
| ▸Prevention of genital herpes | 1460 | ||
| ▸Varicella (chickenpox in immunocompetent patients) | 1460 | ||
| ▸Dosage in renal impairment (adults) | 1460 | ||
| Contraindications | 1460 | ||
| Interactions | 1460 | ||
| Diagnostic Test Effects | 1461 | ||
| Side Effects | 1461 | ||
| Serious Reactions | 1461 | ||
| Valganciclovir | 1462 | ||
| Mechanism of Action | 1462 | ||
| Pharmacokinetics | 1462 | ||
| Availability | 1462 | ||
| Indications and Dosages | 1462 | ||
| ▸Cytomegalovirus (CMV) retinitis in patients with normal renal function | 1462 | ||
| ▸Prevention of CMV after kidney, heart, or kidney-pancreas transplant | 1462 | ||
| ▸Dosage in renal impairment (adults) | 1462 | ||
| Contraindications | 1462 | ||
| Interactions | 1463 | ||
| Diagnostic Test Effects | 1463 | ||
| Side Effects | 1463 | ||
| Serious Reactions | 1463 | ||
| Valproic Acid/Valproate Sodium/Divalproex Sodium | 1464 | ||
| Mechanism of Action | 1464 | ||
| Pharmacokinetics | 1464 | ||
| Availability | 1464 | ||
| Indications and Dosages | 1464 | ||
| ▸Seizures | 1464 | ||
| ▸Manic episodes | 1465 | ||
| ▸Prevention of migraine headaches | 1465 | ||
| Off-Label Uses | 1465 | ||
| Contraindications | 1465 | ||
| Interactions | 1465 | ||
| Diagnostic Test Effects | 1465 | ||
| ?IV Incompatibilities | 1465 | ||
| Side Effects | 1465 | ||
| Serious Reactions | 1466 | ||
| Valsartan | 1467 | ||
| Mechanism of Action | 1467.e1 | ||
| Pharmacokinetics | 1467.e1 | ||
| Availability | 1467.e1 | ||
| Indications and Dosages | 1467.e1 | ||
| ▸Bladder cancer | 1467.e1 | ||
| Contraindications | 1467.e1 | ||
| Interactions | 1467.e1 | ||
| Diagnostic Test Effects | 1467.e1 | ||
| Side Effects | 1467.e1 | ||
| Serious Reactions | 1467.e1 | ||
| Diagnostic Test Effects | 1468 | ||
| Side Effects | 1468 | ||
| Serious Reactions | 1468 | ||
| Mechanism of Action | 1467 | ||
| Pharmacokinetics | 1467 | ||
| Availability | 1467 | ||
| Indications and Dosages | 1467 | ||
| ▸Hypertension | 1467 | ||
| ▸Congestive heart failure (CHF) | 1467 | ||
| ▸Post-myocardial infarction (MI) | 1467 | ||
| ▸Dosage in renal impairment | 1467 | ||
| Contraindications | 1467 | ||
| Interactions | 1467 | ||
| Vancomycin | 1469 | ||
| Mechanism of Action | 1469 | ||
| Pharmacokinetics | 1469 | ||
| Availability | 1469 | ||
| Indications and Dosages | 1469 | ||
| ▸Treatment of bone, respiratory tract, skin, and soft-tissue infections, endocarditis, peritonitis, and septicemia; prevention o... | 1469 | ||
| ▸Staphylococcal enterocolitis, antibiotic-associated pseudomembranous colitis caused by Clostridium difficile | 1469 | ||
| ▸Dosage in renal impairment (intravenous therapy) | 1469 | ||
| Off-Label Uses | 1469 | ||
| Contraindications | 1470 | ||
| Interactions | 1470 | ||
| Diagnostic Test Effects | 1470 | ||
| ?IV Incompatibilities | 1470 | ||
| ?IV Compatibilities | 1470 | ||
| Side Effects | 1470 | ||
| Serious Reactions | 1470 | ||
| Vardenafil | 1471 | ||
| Mechanism of Action | 1471 | ||
| Pharmacokinetics | 1471 | ||
| Availability | 1471 | ||
| Indications and Dosages | 1471 | ||
| ▸Erectile dysfunction | 1471 | ||
| ▸Dosage in moderate hepatic impairment | 1471 | ||
| ▸Dosage with concurrent ritonavir | 1471 | ||
| Vandetanib | 1471.e1 | ||
| Mechanism of Action | 1471.e1 | ||
| Pharmacokinetics | 1471.e1 | ||
| Availability | 1471.e1 | ||
| Indications and Dosages | 1471.e1 | ||
| ▸Medullary thyroid cancer | 1471.e1 | ||
| ▸Dosage adjustment for toxicities | 1471.e1 | ||
| ▸Dosage adjustment for renal impairment | 1471.e1 | ||
| ▸Dosage adjustment for hepatic impairment | 1471.e1 | ||
| Contraindications | 1471.e1 | ||
| Interactions | 1471.e1 | ||
| Diagnostic Test Effects | 1471.e2 | ||
| Side Effects | 1471.e2 | ||
| Serious Reactions | 1471.e2 | ||
| ▸Dosage with concurrent ketoconazole or itraconazole (at 400 mg/day), indinavir, atazanavir, saquinavir, clarithromycin, ketocon... | 1472 | ||
| ▸Dosage with concurrent ketoconazole or itraconazole (at 200 mg/day) or erythromycin | 1472 | ||
| ▸Stable α-adrenergic blocker therapy | 1472 | ||
| Off-Label Uses | 1472 | ||
| Contraindications | 1472 | ||
| Interactions | 1472 | ||
| Diagnostic Test Effects | 1472 | ||
| Side Effects | 1472 | ||
| Serious Reactions | 1472 | ||
| Varenicline | 1473 | ||
| Mechanism of Action | 1474 | ||
| W | 1496 | ||
| Warfarin Sodium | 1496 | ||
| Mechanism of Action | 1496 | ||
| Pharmacokinetics | 1496 | ||
| Availability | 1496 | ||
| Indications and Dosages | 1496 | ||
| ‣Anticoagulant | 1496 | ||
| ‣Usual elderly dosage (maintenance) | 1496 | ||
| ‣Conversion from other anticoagulants | 1496 | ||
| Contraindications | 1496 | ||
| Interactions | 1497 | ||
| Diagnostic Test Effects | 1497 | ||
| Side Effects | 1497 | ||
| Serious Reactions | 1498 | ||
| Z | 1500 | ||
| Zafirlukast | 1500 | ||
| Mechanism of Action | 1500 | ||
| Pharmacokinetics | 1500 | ||
| Availability | 1500 | ||
| Indications and Dosages | 1500 | ||
| ▸For the prevention and chronic treatment of asthma | 1500 | ||
| Off-Label Uses | 1500 | ||
| Contraindications | 1500 | ||
| Interactions | 1500 | ||
| Diagnostic Test Effects | 1500 | ||
| Side Effects | 1500 | ||
| Serious Reactions | 1501 | ||
| Zaleplon | 1501 | ||
| Mechanism of Action | 1501 | ||
| Availability | 1501 | ||
| Pharmacokinetics | 1501 | ||
| Indications and Dosages | 1501 | ||
| ▸Insomnia | 1501 | ||
| ▸Dosage in hepatic impairment (adults) | 1502 | ||
| Contraindications | 1502 | ||
| Interactions | 1502 | ||
| Diagnostic Test Effects | 1502 | ||
| Side Effects | 1502 | ||
| Serious Reactions | 1502 | ||
| Zanamivir | 1503 | ||
| Mechanism of Action | 1503 | ||
| Availability | 1503 | ||
| Pharmacokinetics | 1503 | ||
| Indications and Dosages | 1503 | ||
| ▸Influenza virus infection | 1503 | ||
| ▸Prevention of influenza virus infection | 1503 | ||
| Contraindications | 1503 | ||
| Interactions | 1503 | ||
| Diagnostic Test Effects | 1503 | ||
| Side Effects | 1504 | ||
| Serious Reactions | 1504 | ||
| Zidovudine | 1504 | ||
| Mechanism of Action | 1504 | ||
| Pharmacokinetics | 1505 | ||
| Availability | 1505 | ||
| Indications and Dosages | 1505 | ||
| ▸HIV infection | 1505 | ||
| ▸Reducing maternal-fetal HIV transmission | 1505 | ||
| ▸Dose for neonate once delivered | 1505 | ||
| ▸Usual dose, pediatrics with HIV infection (non-neonatal) | 1505 | ||
| ▸Renal failure | 1505 | ||
| Contraindications | 1505 | ||
| Interactions | 1505 | ||
| Diagnostic Test Effects | 1506 | ||
| ?IV Incompatibilities | 1506 | ||
| Side Effects | 1506 | ||
| Serious Reactions | 1506 | ||
| Zinc Oxide/Zinc Sulfate | 1506 | ||
| Mechanism of Action | 1506 | ||
| rA - FDA PREGNANCY RISK CATEGORIES | 1517 | ||
| FDA PREGNANCY RISK CATEGORIES | 1517 | ||
| A: Adequate and well-controlled studies have failed to show a risk to the fetus in the first trimester of pregnancy (also, no ev... | 1517 | ||
| B: Animal reproduction studies have failed to show a risk to the fetus; no adequate and well-controlled studies have been done i... | 1517 | ||
| C: Animal reproduction studies have shown an adverse effect on the fetus, and no adequate and well-controlled studies have been ... | 1517 | ||
| D: Positive evidence has been found of human fetal risk based on data from investigational or marketing experience or from studi... | 1517 | ||
| X: Animal or human studies have shown fetal abnormalities, and/or there is evidence of human fetal risk based on adverse reactio... | 1517 | ||
| B - Normal Laboratory Values | 1518 | ||
| HEMATOLOGY/COAGULATION | 1518 | ||
| CLINICAL CHEMISTRY (SERUM PLASMA UNLESS OTHERWISE INDICATED) | 1518 | ||
| Index | 1520 | ||
| A | 1520 | ||
| B | 1524 | ||
| C | 1525 | ||
| D | 1528 | ||
| E | 1530 | ||
| F | 1532 | ||
| G | 1533 | ||
| H | 1534 | ||
| I | 1535 | ||
| J | 1536 | ||
| K | 1536 | ||
| L | 1536 | ||
| M | 1538 | ||
| N | 1540 | ||
| O | 1542 | ||
| P | 1543 | ||
| Q | 1545 | ||
| R | 1545 | ||
| S | 1547 | ||
| T | 1549 | ||
| U | 1551 | ||
| V | 1551 | ||
| W | 1552 | ||
| X | 1552 | ||
| Y | 1552 | ||
| Z | 1552 | ||
| IBC | ES2 |